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Zusammenfassung 
Einleitung: Hintergrund und Ziele des Assessments 
In den letzten Jahrzenten wurden international einige Hadronen-Strahlen-
therapiezentren errichtet. Auch in Österreich wurde ein solches Therapiezent-
rum, MedAustron, in den letzten zwei Jahrzenten geplant bzw. in weiterer 
Folge gebaut und 2016 eröffnet. In MedAustron wird Krebsbehandlung mit-
tels Partikeltherapie (mit Protonen und Kohlenstoff-Ionen) angeboten und 
entsprechende Forschung durchgeführt. Derzeit kommt bei MedAustron die 
Protonentherapie bereits zum Einsatz und zusätzlich ist ein Ausbau der Be-
handlung mittels Kohlenstoff-Ionentherapie in Planung. Das Krebstherapie-
zentrum begann mit PatientInnen-Behandlungen etwa vor einem Jahr und 
hat das Ziel ab 2020 ca. 1.000 Krebs-PatientInnen pro Jahr mit Protonen und/ 
oder Kohlenstoff-Ionen zu behandeln. 
Einerseits wird davon ausgegangen, dass die Kohlenstoff-Ionentherapie (engl. 
carbon ion radiotherapy = CIRT) – aufgrund der besseren Dosisverteilung 
und der höheren relativen biologischen Wirksamkeit (RBW) – im Vergleich 
zur herkömmlichen Strahlentherapie sowohl effektiver als auch sicherer ist. 
Es wird vermutet, dass CIRT im Vergleich zur herkömmlichen Strahlenthe-
rapie eine bessere lokale Tumor-Kontrolle ermöglicht, wodurch die Wahr-
scheinlichkeit, umliegendes gesundes Gewebe zu beschädigen, minimiert 
werden kann. Andererseits führt die höhere RBW auch dazu, dass die Ioni-
sationsdichte höher ist als bei herkömmlicher Strahlentherapie und damit 
der lineare Energietransfer (LET) hoch ist. Die Eigenschaften von CIRT im 
Vergleich zur herkömmlichen Strahlentherapie werden deshalb auch als 
„zweischneidiges Schwert“ bezeichnet: Manche dieser Unterschiede könnten 
Vorteile erbringen, während andere mit Nachteilen verbunden sein könnten, 
weil a) die behandelte Fläche größer ist als der Tumor und damit gesundes 
Gewebe der Bestrahlung ausgesetzt ist und b) Tumore in gesundes Gewebe 
eingebettet sind und dieses auch beschädigt wird.  
Es ist also wichtig zu klären, sowohl für welche Indikationen CIRT verwendet 
werden sollte, als auch, ob CIRT effektiver und sicherer als herkömmliche 
Strahlentherapie ist. Ein Ziel des vorliegenden Berichts ist es, mögliche In-
dikationen für die Verwendung der CIRT zu eruieren, indem alle Indikatio-
nen in (publizierten und laufenden) klinischen Studien identifiziert wurden. 
Ein weiteres Ziel ist es, die Evidenz hinsichtlich Wirksamkeit und Sicherheit 
von CIRT bei ausgewählten Indikationen zu prüfen. Es wurde dafür eine sys-
tematische Übersichtsarbeit der Studien zu Effektivität (Mortalität, Morbi-
dität) und Sicherheit von CIRT für 54 onkologische Indikationen in 12 Kör-
perregionen durchgeführt. 
 
Beschreibung der Technologie 
In der Strahlentherapie können Photonen und Hadronen zum Einsatz kom-
men. Allgemein geht es in der Strahlentherapie darum, die DNA eines Tu-
mors zu beschädigen, sodass der Tumor zerstört wird. Während bei der Pho-
tonentherapie Röntgenstrahlung oder Gamma Strahlen zum Einsatz kom-
men, können bei der Hadronentherapie sowohl Protonen als auch Kohlen-
stoff-Ionen zur Bestrahlung verwendet werden.  
MedAustron:  
seit 2016 in Betrieb 
 
Strahkentherapie  
mit Protonen und 
Kohlenstoff-Ionen  
(= CIRT) 
Hoffnung in CIRT 
wegen physikalischer 
Eigenschaften: 
 
präziser und schonender 
 
aber ev. auch 
schädlicher für 
umliegendes gesundes 
Gewebe 
Ziel des  
vorliegenden Berichts: 
 
mögliche  
CIRT-Indikationen 
 
Evidenz zu  
12 Indikationsbereichen 
(54 Sub-Indikationen) 
Hadronentherapie: 
Protonen &  
Kohlenstoff-Ionen 
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Ein Linearbeschleuniger (engl. linear accelerator = LINAC) kommt bei der 
Strahlentherapie zum Einsatz. Bei der CIRT werden Kohlenstoff Ionen durch 
den LINAC – auf gerader Strecke durch elektrische Wechselfelder – beschleu-
nigt bevor es in den sog. Synchrotron injiziert wird. Der Synchrotron – ein 
Kreisbeschleuniger mit einem Umfang von in etwa 80 Metern – beschleunigt 
sodann die Teilchen auf eine Endgeschwindigkeit von ca. 200.000 km/s. Dann 
kommt der Teilchenstrahl über eine sog. Extraktionslinie in einen der 3 Be-
strahlungsräume, die bei MedAustron für die CIRT verwendet werden kön-
nen. Starke Magnetfelder kommen dabei zum Einsatz, um den Teilchenstrahl 
in Vakuumröhren durchführen zu können. 
Hadronentherapie unterscheidet sich von der herkömmlichen Photonenthe-
rapie in der Wirkweise: Das Tiefendosisprofil der Hadronentherapie (der sog. 
Bragg Peak) ermöglicht eine höhere und präzisere Bestrahlung. Kohlenstoff-
Ionen haben eine wesentlich höhere Ionisationsdichte und der lineare Ener-
gietransfer (LET) ist höher als bei der herkömmlichen Photonen und Proto-
nentherapie. CIRT gehört damit zu den hohen LET Strahlentherapien. 
 
Methoden 
Der folgende Bericht widmet sich zwei Forschungsfragen: 
1. Für welche Tumorindikationen wird CIRT derzeit  
(in klinischen Studien) angewendet? und  
2. Welche Evidenz für eine vergleichbare oder höhere Wirksamkeit  
beziehungsweise Sicherheit von CIRT liegt bei 54 onkologischen  
Indikationen in 12 „Regionen“ vor? 
Zur Beantwortung der Forschungsfragen wurde eine systematische  
Literatursuche in folgenden 4 Datenbanken durchgeführt: 
 Cochrane (CENTRAL) 
 Centre for Research and Dissemination (CRD) 
 Embase 
 Ovid MEDLINE 
Es wurden klinische Studien, die die Effektivität und/oder Sicherheit der 
CIRT analysieren, systematisch gesucht. Zusätzlich wurde eine Handsuche 
in Referenzlisten der identifizierten systematischen Übersichtsarbeiten so-
wie im Internet durchgeführt: Die Websites der Krebstherapiezentren sowie 
der Particle Therapy Co-Operative Group (PTCOGC) wurden durchsucht, 
um weitere abgeschlossene und/oder laufende klinische Studien zu finden. 
Für die erste Forschungsfrage wurden alle publizierten Studien mit zumin-
dest prospektivem Fallserien Studiendesign sowie laufende klinische Stu-
dien aufgearbeitet: Studien wurden gescreent und nach Indikationsgruppen 
(Regionen) sortiert. Anschließend erfolgte eine Kategorisierung der Studien 
nach Studiendesign sowie Phase der klinischen Studien und die Extraktion 
der Anzahl der PatientInnen, die an den Studien teilnahmen. Mit Hilfe die-
ser Daten wurde die Anzahl der CIRT-PatientInnen mit spezifischen Tumo-
rindikationen bzw. Tumorregionen geschätzt. 
Für die zweite Forschungsfrage wurden striktere Einschlusskriterien gewählt: 
Die Evidenzsynthese wurde auf 54 onkologische Indikationen in 12 Tumor-
regionen eingeschränkt und auf nur jene Studien, die moderates oder nie-
driges Bias-Risiko aufwiesen sowie nach 2005 publiziert worden sind. 
LINAC und Synchotron 
erzeugen  
 
Teilchenstrahlen  
für Tumor-
Bestrahlungstherapie 
Hadronen- vs. 
Photonentherapie:  
unterschiedliche 
Wirkweise 
CIRT: hochdosierte, 
präzise Bestrahlung 
2 Forschungsfragen: 
Indikationenspektrum in 
klinischen Studien  
Evidenz für 
Wirksamkeit und 
Sicherheit in  
12 (resp. 54 Sub-) 
Indikationsbereichen 
systematische 
Literatursuche in  
4 Datenbanken  
Handsuche in 
Referenzlisten und auf 
Websites (PTCOGC) 
Forschungsfrage 1:  
alle prospektiven Studien  
publizierte und laufende 
Studien 
Forschungsfrage 2:  
nur prospektive Studien 
mit low/moderate RoB, 
publiziert nach 2005 
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Die Studienauswahl sowie die Bewertung der methodischen Qualität der Stu-
dien wurden von zwei WissenschafterInnen (GG, MM) unabhängig vonei-
nander durchgeführt ebenso wie die Datenextraktion von einer Person (GG) 
durchgeführt und von zweiter Person (MM) kontrolliert wurde. 
Auswahl der Endpunkte zur Wirksamkeit  
Im Rahmen der Prüfung der CIRT auf Überlegenheit/Unterlegenheit hin-
sichtlich Wirksamkeit und/oder Sicherheit im Vergleich zur Photonenthera-
pie wurden folgende wesentliche Wirksamkeits-Endpunkte gewählt: 
 Gesamtüberleben [engl. Overall Survival (OS)] 
 Krankheitsspezifisches Überleben [engl. Cause-Specific Survival 
(CSS)/Disease-Specific Survival (DFS)] 
 Rezidivfreies Überleben [engl. Recurrence Free Survival (RFS)] 
 Progressionsfreies Überleben [engl. Progression Free Survival (PFS)] 
 Krankheitsfreies Überleben [engl. Disease Free Survival (DFS)] 
 Gesundheitsbezogene Lebensqualität [engl. Health-related Quality  
of Life (HRQoL)] 
 Die lokale Tumorkontrolle [engl. Local Tumor Control (LCR)] wurde 
(nur) als Surrogat-Endpunkt in diesem Assessment aufgenommen.  
Auswahl der Endpunkte zur Sicherheit  
Zur Bewertung der Sicherheit der CIRT wurden folgende wesentliche  
Endpunkte herangezogen: 
 akute Strahlenbelastung 
 späte Strahlenbelastung 
 
Ergebnisse zur Forschungsfrage 1: Indikationsspektrum  
Weltweit wurden etwa 21.580 PatientInnen, die mit CIRT behandelt wur-
den, bis 2016 dokumentiert. Nach Schätzungen aus den identifizierten klini-
schen Studien nahmen in etwa 5.651 PatientInnen in (zumindest) prospek-
tiven Fallserien teil (retrospektive Fallserien und Einzelfallstudien sind hier 
nicht berücksichtigt). 
In unserer systematischen Suche wurden insgesamt 56 publizierte und 65 
laufende Studien identifiziert und aufbereitet, um die Frage der derzeitigen 
Verwendung von CIRT beantworten zu können. Die Ergebnisse zu den Tu-
morindikationen für CIRT legen nahe, dass diese Therapie bislang bei Tu-
moren im Hirn- und Schädelbasisbereich, der Prostata, der Lunge, im HNO 
Bereich, sowie bei gynäkologischen und gastrointestinalen Tumoren durch-
geführt wurde bzw. derzeit durchgeführt wird. 
Die 56 publizierten klinischen Studien umfassen folgende  
Indikationsbereiche:  
 14 Studien zu Tumoren im Hirn- und Schädelbasis-Bereich  
(mit ca. 543 CIRT-PatientInnen),  
 11 Studien zu Prostata-Krebs (mit ca. 3.206 CIRT-PatientInnen,  
die CIRT erhielten) sowie  
 9 Studien zu Lungenkrebs (mit ca. 631 CIRT-PatientInnen),  
 7 Studien zu HNO Tumoren (mit ca. 489 CIRT-PatientInnen) sowie  
 4 Studien zu GI Tumore (mit ca. 184 CIRT-PatientInnen).  
alle Arbeitsschritte von 
2 WissenschafterInnen 
durchgeführt 
wesentliche  
Endpunkte: 
6 Endpunkte  
zur Wirksamkeit: 
 
Überleben (OS)  
Lebensqualität (HRQoL) 
etc. 
und ein 
Surrogatendpunkt (LCR) 
2 Endpunkte  
zur Sicherheit:  
akute & späte 
Strahlenbelastung 
21.580 PatientInnen  
mit CIRT behandelt  
(bis 2016), davon  
26 % in prospektiven 
Studien erfasst 
56 publizierte 
(prospektive) Studien 
 
65 laufende Studien 
56 publizierte Studien:  
14 Studien: Hirn- und 
Schädelbasis 
11 Studien:Prostata  
9 Studien: Lunge  
7 Studien: HNO 
4 Studien: GI Tumore; 
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 Weniger häufig waren Studien zu Knochen- und Weichteiltumore so-
wie Tumore des Auges (Choroid Melanoma): Es wurden 3 Studien zu 
den beiden letzteren Tumorregionen gefunden, wobei jeweils weniger 
als 100 PatientInnen dokumentiert mit CIRT behandelt wurden. 
 Zusätzlich konnten 2 potentielle Tumorindikationen für CIRT iden-
tifiziert werden, die nicht auf der MedAustron-Liste zu finden waren: 
7 Studien zu gynäkologischen Tumoren (mit ca. 241 PatientInnen) 
und 1 weitere Studie zu Hautkrebs (mit 45 CIRT-PatientInnen). 
Die Suche nach laufenden (zumindest prospektiven) Fallserien resultierte in 
1 Patientenregister und 65 derzeitig laufenden klinischen Studien mit unge-
fähr 6.038 StudienteilnehmerInnen. Davon hatten nur 10 Studien ein kon-
trolliertes Studiendesign: 8 laufende RCTs und 2 laufende CTs wurden iden-
tifiziert. Von den 65 laufenden Studien waren  
 16 Studien zu CIRT bei Tumoren im GI-Bereich (mit 861 Teilneh-
merInnen),  
 jeweils 9 zu Prostatakrebs und HNO Tumore  
(Prostata: 1.858 Teilnehmer, HNO: 612 TeilnehmerInnen),  
 8 Studien zu gynäkologischen Tumoren (mit 197 Teilnehmerinnen),  
 8 Studien zu Knochen- und Weichteiltumore  
(mit 391 TeilnehmerInnen),  
 7 Studien zu Hirn und Schädelbasistumore  
(mit ca. 1.219 StudienteilnehmerInnen) sowie  
 5 Studien zu Lungenkrebs (mit ca. 860 PatientInnen).  
 3 weitere Studien behandelten Nierenkrebs-PatientInnen oder Brust-
krebspatientinnen mit CIRT, jedoch waren in beiden dieser Regionen 
insgesamt weniger als 50 PatientInnen in den Studien inkludiert. 
Die laufenden kontrollierten Studien beinhalten Studienpopulationen  
in folgenden Tumoindikationen 
 5 Studien zu Hirn- und Schädelbasis  
 2 Studien: sakrale Chordome 
 1 Studie zu HNO-Tumore 
 1 Studie zu GI-Tumore 
 1 Studie zu Lungenkrebs 
Es fällt auf, dass die in den publizierten Studien (prospektive Fallserien ohne 
Kontrollgruppe) behandelten Tumorindikationen sich – in der Gewichtung/ 
Häufigkeit – nicht mit jenen der laufenden kontrollierten Studien deckt. So 
konnte kein RCT zu CIRT bei Prostatakrebs, und nur eine kontrollierte Stu-
die zu CIRT bei Lungenkrebs, identifiziert werden.  
Es ist erwähnenswert, dass mit einer Verbesserung der Evidenzbasis im Zu-
ge der nächsten Jahre zu rechnen ist: 4 identifizierte „laufende“ RCTs sind 
bereits abgeschlossen, jedoch nicht publiziert und weitere 6 kontrollierte Stu-
dien werden in den nächsten 4 Jahren abgeschlossen. 
 
2 Studien: Knochen- und 
Weichteiltumore 
1 Studie: Auge 
7 Studien: Gynäkologie 
1 Studie: Hautkrebs 
65 laufende Studien mit 
6.038 Pts &  
1 Patientenregister 
 
davon nur  
10 kontrollierte Studien:  
8 laufende RCTs 
2 laufende CTs 
RCTs/CTs: 
5 Studien zu Hirn- und 
Schädelbasis 
2 Studien: sakrale 
Chordome 
jeweils 1 Studie zu  
HNO-Tumore,  
GI-Tumore und 
Lungenkrebs 
 
 
 
kein RCT zu Prostata 
Verbesserung der 
Evidenz in den nächsten 
Jahren durch Ergebnisse 
der RCTs/CTs 
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Ergebnisse zur Forschungsfrage 2:  
Verfügbare Evidenz zu 54 Indikationen in 12 Körperregionen 
Es wurden 27 prospektive Studien eingeschlossen, um die Evidenz zur Wirk-
samkeit und Sicherheit der CIRT im Vergleich zur Photonentherapie zu über-
prüfen: Es konnte nur 1 randomisierte kontrollierte Studie, die sich vor allem 
der Sicherheit bzw. Durchführbarkeit von CIRT widmete, identifiziert wer-
den. Die restlichen eingeschlossenen Studien waren Beobachtungsstudien: 3 
Fall-Kontrollstudien, die sich vor allem der richtigen Dosis für CIRT/PRT 
widmeten, 3 Vorher-Nachher Studien, und 20 Fallserien.  
Wirksamkeit und Sicherheit der CIRT  
Die Ergebnisse dieses Berichts besagen Folgendes: Es konnte keine Evidenz 
zu 41 (von 54) Indikationen, sowie unzureichende Evidenz zu 13 (von 54) In-
dikationen in 7 Regionen gefunden werden: 
Schädelbasis-Tumore 
Der Schädelbasis-Bereich umfasste in diesem Assessment 13 onkologische 
Indikationen. Insgesamt erfüllten 2 unkontrollierte prospektive Fallserien die 
Einschlusskriterien. 112 PatientInnen (53 PatientInnen mit Chordomen und 
59 PatientInnen mit Chondrosarkomen) wurden in diesen Studien mit CIRT 
– mit einer Dosierung von 45 GyE bis 60.8 GyE – behandelt. Keine Evidenz 
wurde zu den weiteren 11 Schädelbasistumoren gefunden. 
Augenkarzinom 
Für Augentumore wurde die Evidenz zu einer onkologischen Indikation 
(Aderhautmelanom) überprüft. Weitere onkologische Indikationen im Au-
genbereich befinden sich in der MedAustron Liste im Schädelbasisbereich 
sowie im HNO Bereich. Es wurden keine Studien, die CIRT auf Wirksamkeit 
und/oder Sicherheit bei Aderhautmelanomen untersuchten, eingeschlossen. 
Deshalb konnte keine Evidenz hinsichtlich der Überlegenheit/Unterlegenheit 
der CIRT für Aderhautmelanome gefunden werden. 
Hirntumore 
Insgesamt wurden 2 unkontrollierte prospektive Fallserien eingeschlossen. 
In diesen Studien wurden 62 PatientInnen (14 PatientInnen mit WHO II Gli-
ome (diffuse Astrozytome) und 48 PatientInnen mit hochgradigen Hirntu-
moren (WHO Grad III-IV)) mit CIRT – mit einer Dosierung von 16,8 bis 
55,2 GyE – behandelt. Die letztere Patientengruppe bekamen CIRT als Boost 
nach einer Photonenbestrahlung. Co-Interventionen umfassten – vor, während 
oder nach der CIRT – operative Behandlungen, Bestrahlung mittels Röntgen 
sowie Salvage-Therapie (z.B. Chemotherapie).  
In Ermangelung einer Kontrollgruppe wurde unzureichende Evidenz hin-
sichtlich der Überlegenheit/Unterlegenheit der CIRT im Vergleich zur her-
kömmlichen Strahlentherapie für Gliome (WHO grad I-II) und Glioblastome 
(WHO Grad III) gefunden. Keine Evidenz wurde für 3 weitere Hirntumore 
gefunden: Ependymoma, Medulloblastom, „andere kindliche Hirntumore“. 
 
27 prospektive Studien 
erfüllten 
Einschlusskriterien: 
 
1 RCT zu Sicherheit 
26 Beobachtungsstudien 
keine Evidenz zu 41 Ind. 
unzureichende Evidenz 
zu 13 Ind. 
Schädelbasis:  
13 Subindikationen,  
3 Studien, 112 Pts, 
45 GyE bis 60.8 GyE 
unzureichende Evidenz 
für Chordome & 
Chondrosarkome 
keine Evidenz für 
weitere 11 Indikationen  
 
Auge:  
keine Evidenz für 
Aderhautmelanome 
Hirn:  
5 Subindikationen 
2 Studien ohne 
Vergleich, 62 Pts,  
16.8-55.2 GyE 
unzureichende Evidenz 
für Gliome (Grad I-II) 
und Glioblastome 
keine Evidenz für 
weitere 3 Indikationen 
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Tumoren im Hals-Nase-Ohr (HNO) Bereich 
Der HNO Bereich umfasste in diesem Assessment 11 onkologische Indikati-
onen. Für Tumore im Hals-Nase-Ohr (HNO) Bereich wurden 5 Studien ein-
geschlossen: 1 Fall-Kontrollstudie und 4 Fallserien von 3 Krebstherapiezen-
tren in Japan und Deutschland. Es nahmen insgesamt 415 PatientInnen an 
diesen Studien Teil, von welchen 381 mit CIRT (Dosisierung: 18 GyE bis 72 
GyE) bekamen. Co-Interventionen umfassten, unter anderem, Photonenthe-
rapie, Salvage-Therapie (insb. Re-Bestrahlung), sowie Post-Chemotherapie. 
In Ermangelung einer Kontrollgruppe wurde unzureichende Evidenz hin-
sichtlich der Überlegenheit/Unterlegenheit der CIRT im Vergleich zur her-
kömmlichen Strahlentherapie für folgende Indikationen gefunden: Tumore 
der Nasenhöhle und Nasennebenhöhle, adenoidzystische Speicheldrüsenkar-
zinome und Sarkome im HNO-Bereich (inkl. Ewing Sarkome). Keine Evidenz 
wurde für die restlichen 8 onkologischen Indikationen im HNO Bereich ge-
funden. 
Lungenkarzinome 
In der „Lungen-Region“ wurden folgende onkologische Indikationen in diesem 
Assessment berücksichtigt: Das nicht-kleinzellige Lungenkarzinom (NSCLC), 
mediastinale Tumore sowie pleurale Mesotheliome. Es wurden nur für NS-
CLC Studien identifiziert: 2 Fall-Kontrollstudien sowie 4 Fallserien, in de-
nen insgesamt in etwa 559 PatientInnen teilnahmen. 459 PatientInnen erhiel-
ten CIRT mit einer Dosierung von 52.8 GyE bis 76 GyE. 100 PatientInnen 
erhielten PRT mit einer Dosis-Schwankung von 60-80 GyE. 
In Ermangelung einer Kontrollgruppe wurde unzureichende Evidenz hin-
sichtlich der Überlegenheit/Unterlegenheit der CIRT im Vergleich zur kon-
ventionellen Strahlentherapie für das NSCLC. Es wurden keine Studien für 
mediastinale Tumore und pleurale Mesotheliome identifiziert: keine Evidenz. 
Gastroinestinale (GI) Tumore 
Es wurden 2 Fallserien mit 215 PatientInnen eingeschlossen: 184 PatientIn-
nen hatten Rektumkarzinome und 31 PatientInnen Ösophaguskarzinome. Sie 
erhielten CIRT mit einer Dosis von 67,2 GyE-73,6 GyE (RektumCa), resp. 
28,8 GyE bis 36,8 GyE ÖsophagusCa). 
In Ermangelung einer Kontrollgruppe wurde unzureichende Evidenz hin-
sichtlich der Überlegenheit/Unterlegenheit der CIRT im Vergleich zur kon-
ventionellen Strahlentherapie für Ösophaguskarzinome und Rektumkarzino-
me ohne distante Metastasen gefunden. Es wurde keine Evidenz zu folgen-
den Indikationen gefunden: Pankreaskarzinom, Leberkarzinom, Schwanno-
me/maligne Schwannome und Ewing Sarkome.  
Knochen- und Weichteiltumore 
Es wurde eine Fallserie mit 17 PatientInnen mit primären Sarkomen der Ex-
tremitäten eingeschlossen. Die PatientInnen erhielten CIRT mit einer Dosis 
zwischen 52,8 GyE und 70,4 GyE. 
In Ermangelung einer Kontrollgruppe wurde unzureichende Evidenz hin-
sichtlich der Überlegenheit/Unterlegenheit der CIRT im Vergleich zur kon-
ventionellen Strahlentherapie für Weichteilsarkome (lokalisierte primäre Sar-
kome der Extremitäten) gefunden. Es wurde keine Evidenz zu folgenden In-
dikationen gefunden: Osteosarkome, Sakrale Chordome, sakrale Chondro-
sarkome sowie spinale Meningeome. 
HNO:  
11 Subindikationen 
5 Studien, 415 Pts,  
18-72 GyE 
unzureichende Evidenz 
für 3 Indikationen  
 
keine Evidenz für  
8 Indikationen  
Lunge: 
3 Subindikationen 
 
6 Studien, 559 Pts  
(459 CIRT, 100 PRT), 
52.8 - 76 GyE 
unzureichende Evidenz 
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mediastinale Tumore, 
pleurale Mesotheliome 
GI: 6 Subindikationen 
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Rektumkarzinome:  
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Ösophaguskarzinome: 
31 Pts, 28,8-36,8 GyE 
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4 weiteren Indikationen 
Knochen- & Weichteile:  
5 Subindikationen 
1 Studie, 17 Pts  
(Sarkome-Extremitäten),  
52.8-70.4 GyE 
 
 
unzureichende Evidenz 
für Weichteilsarkome 
keine Evidenz für 
weitere 4 Indikationen 
Zusammenfassung 
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Prostatakarzinom 
Es wurden 8 Studien eingeschlossen: 1 randomisierte Kontrollstudie (Fokus: 
vor allem Durchführbarkeit, Sicherheit der CIRT) und 3 Vorher-Nachher 
Studien (Fokus: Lebensqualität) sowie 4 Fallserien (Fokus: Wirksamkeit und/ 
oder Sicherheit der CIRT). Insgesamt nahmen ca. 2.715 PatientInnen an die-
sen Studien teil, von welchen 2.668 CIRT bekamen (Dosis: 51,6 GyE–72.0 
GyE). Co-Interventionen waren vor allem Hormonenbehandlung und neo-
adjuvante Hormonenbehandlung. 14 der Patienten bekamen CIRT als Boost 
nach der Intenstitätsmodulierten Strahlentherapie (IMRT). 
In Ermangelung einer Kontrollgruppe, die mit Photonentherapie behandelt 
wurde, wurde unzureichende Evidenz hinsichtlich der Überlegenheit/Unter-
legenheit der CIRT im Vergleich zur konventionellen Strahlentherapie für 
Prostatakarzinome (mit unterschiedlichen Risikogruppen) gefunden. 
Mammakarzinom 
Es wurde keine Evidenz hinsichtlich der Überlegenheit/Unterlegenheit der 
CIRT im Vergleich zur konventionellen Strahlentherapie für das Mamma-
karzinom gefunden. 
Nierenkarzinom 
Es wurde keine Evidenz hinsichtlich der Überlegenheit/Unterlegenheit der 
CIRT im Vergleich zur konventionellen Strahlentherapie für Nephroblastome 
gefunden. 
Tumore des zentralen Nervensystems (ZNS) 
Es wurde keine Evidenz hinsichtlich der Überlegenheit/Unterlegenheit der 
CIRT im Vergleich zur konventionellen Strahlentherapie für Neuroblastome 
gefunden. 
Hämatologische Tumore 
Es wurde keine Evidenz hinsichtlich der Überlegenheit/Unterlegenheit der 
CIRT im Vergleich zur konventionellen Strahlentherapie für Non-Hodgkin’s 
Lymphome und Hodgkin’s Lymphome gefunden. 
Andere onkologische Indikationen 
Es wurde keine Evidenz hinsichtlich der Überlegenheit/Unterlegenheit der 
CIRT im Vergleich zur konventionellen Strahlentherapie für solitäre Leber-
metastasen bei kolorektalen Tumoren, retroperitonealen Metastasen bei kon-
trollierten Primärtumoren sowie Oligo-Metastasen bei kontrollierten Primär-
tumoren bei ausgesuchten Indikationen gefunden. 
  
Prostata:  
8 Studien, 1 RCT primär 
zu Sicherheitsendpunkte 
7 Beobachtungsstudien 
ca. 2.715 Patienten 
(2.668 CIRT-Pts) 
51,6-72,0 GyE 
unzureichende Evidenz 
Brust: keine Evidenz 
Niere: keine Evidenz 
ZNS: keine Evidenz 
Hämatologische 
Tumore: keine Evidenz 
andere Indikationen: 
keine Evidenz 
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Diskussion 
In Anbetracht der Studienlage fällt auf, dass es eine Vielzahl an nicht rand-
omisierten und unkontrollierten publizierten sowie laufenden Studien zur 
CIRT gibt. Ethische Barrieren werden häufig in Debatten zur Hadronenthe-
rapie erwähnt, diese greifen aber im Kontext der CIRT nicht, weil es eine 
Vielzahl an anderen vielversprechenden neuen Behandlungsmöglichkeiten 
(z. B. CyberKnife oder intensitätsmodulierte Strahlentherapie bei ProstataCa) 
gibt. Deshalb ist es unabdingbar, vergleichende Studien durchzuführen, um 
eruieren zu können, für welche onkologischen Indikationen CIRT tatsächlich 
patientenrelevante Vorteile im Vergleich zu anderen Behandlungsmodalitä-
ten bringt. 
Neben ethischen Barrieren könnte es noch andere bedeutende strukturelle 
Faktoren geben, die hinderlich für die Generierung von fundierter wissen-
schaftlicher Forschung im Hinblick auf Überlegenheit/Unterlegenheit der 
CIRT im Vergleich zur herkömmlichen Photonentherapie sind. Die Zusam-
menarbeit zwischen den Krebstherapiezentren in der EU und weltweit ist 
derzeit wenig ausgeprägt. Entsprechende Rahmenbedingungen für die Evi-
denzgenerierung sollten geschaffen bzw. gefördert werden.  
Die Kooperation sollte jedoch nicht auf die Primärforschung eingeschränkt 
werden. Vielmehr sind auch Fragen der Versorgungsforschung sowie der öko-
nomischen Evaluation (insb. jene mit gesellschaftlicher Perspektive) in sol-
chen Krebstherapiezentren zu stellen, um die wissenschaftliche Basis für Pa-
tienten-zentrierte Entscheidungen zu schaffen.  
 
Schlussfolgerung  
In Anbetracht der Evidenzlage sind keine Aussagen zur Überlegenheit/Un-
terlegenheit der CIRT im Vergleich zur herkömmlichen Photonentherapie – 
auf Basis der gewählten Wirksamkeitsendpunkte (OS, CSS, DFS, RFS, PFS, 
LCR, HRQoL) und Sicherheitsendpunkte (akute Strahlenbelastung, späte 
Strahlenbelastung) – möglich. 
Die Ergebnisse dieses Berichts zeigen, dass es damit derzeit kein abgesicher-
tes Wissen darüber gibt, ob die vielversprechenden theoretischen Vorteile der 
CIRT tatsächlich auch mit patientenrelevanten Vorteilen (längeres Überle-
ben, verbesserte Lebensqualität, geringere Nebenwirkungen) einhergehen. 
CIRT ist deshalb derzeit als experimentelle Therapie anzusehen. 
Ergebnisse aus (randomisierten) Kontrollstudien sind notwendig, um Vor- 
oder Nachteile der CIRT im Vergleich zur herkömmlichen Photonenthera-
pie einschätzen zu können. Ziel muss es sein, die Evidenzbasis für CIRT zu 
stärken.  
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Executive summary 
Introduction 
Background and aims 
In recent decades, many cancer therapy centres, using large and costly accel-
erators, were constructed internationally to implement a new form of cancer 
treatment using charged particles. In Austria, MedAustron – planned approx-
imately 2 decades ago – aimed at focusing on cancer treatment using charged 
particles (proton and carbon ion radiotherapy) and research. The centre start-
ed treating cancer patients with proton radiotherapy a year ago, with approx-
imately 30 treated patients as of September 2017, and has ambitious plans 
for the future: MedAustron aims at treating 1,000 patients per year with pro-
tons and carbon ions by 2020. 
Carbon ion radiotherapy (CIRT) is claimed to be both more effective and 
safer than conventional radiotherapy due to its physical dose distribution and 
its higher relative biological effectiveness (RBE). Moreover, CIRT is expected 
to have a higher local control of the tumour than conventional radiotherapy 
while minimising the probability of damaging the surrounding healthy tis-
sues. On the contrary, the higher RBE to be found in CIRT leads to a higher 
ionisation density, generating high linear energy transfer (LET), and can be 
described as a two-edged sword: some of those differences may constitute ad-
vantages, while others may be disadvantages. That is to say: CIRT may also 
have its negative aspects for certain indications, since a) the treated volume 
extends the gross tumour volume and thus, healthy tissues may be affected by 
high LET and b) tumours may be intertwined with, or embedded in, healthy 
tissues. Thus, it is necessary to elaborate for which indications CIRT should 
be used, as well as whether CIRT is more effective and safer than conven-
tional cancer radiotherapy. 
The project aims at elaborating possible cancer types, being an indication for 
carbon ion therapy. As such, clinical studies, analysing the use of CIRT for 
specific cancer types, will be identified through a systematic literature search 
and will be reviewed and reported in this project. 
Furthermore, a systematic analysis of the literature on the effectiveness (mor-
tality, morbidity) and safety of CIRT for 54 oncologic indications in 12 regions 
(i.e., skull base, eye, brain, ear-nose-throat, lung, gastrointestinal, bone and 
soft tissue, prostate, breast, kidney, nervous system, hematologic cancer) will 
be conducted. 
Description of technology 
Carbon ion radiotherapy (CIRT) is a type of radiation therapy and belongs, 
together with other charged particles such as protons, helium or neon, to the 
“family” of hadron therapy. The physical properties to be found in CIRT are 
different to those of conventional radiotherapy (i.e., photons). That is, a peak 
energy delivery (Bragg peak) enables a large fraction of the energy of CIRT 
to be deposited at the target while being less invasive to surrounding tissues 
due to a low entrance dose affecting healthy tissues. That is, the ionisation 
density and the relative biological effectiveness (RBE) increase with depth, 
meaning when travelling deeper into the body. 
Hadron-therapy  
in MedAustron  
since 2016/17: 
proton and carbon ion 
radiotherapy (CIRT) 
expectation in CIRT: 
higher relative 
biological effectiveness 
(RBE) – more effective 
and safer therapy 
 
but also 
ev. destroying 
surrounding  
healthy tissues 
2 research questions 
(RQ): 
potential CIRT 
indications 
evidence for indications 
physical properties  
of CIRT:  
peak energy delivery  
– large fraction of the 
energy at target 
 
precision 
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Methods 
A systematic search was conducted in 4 databases, Cochrane [Cochrane (CEN-
TRAL), Centre for Research and Dissemination (CRD), Embase and Ovid 
MEDLINE]. Studies focusing on the efficacy or safety of carbon ion radio-
therapy (CIRT) were searched for. Moreover, a hand-search was conducted 
on the websites of the cancer therapy centres currently offering CIRT, and 
the particle therapy co-operative group (PTCOG) to identify further relevant 
published and ongoing studies respectively. 
All prospectively conducted primary studies were reviewed, and ongoing con-
trolled studies were identified to elaborate potential current indications for 
CIRT. For the evidence synthesis regarding the efficacy and safety of CIRT, 
all primary studies with low or moderate risk of bias, published between 2005 
and 2017, were eligible to be included in this assessment. 
 
Results 
Available evidence 
Until 2016, 21,580 patients were recorded to have been treated with CIRT 
worldwide. According to the identified studies in this assessment, approxi-
mately 5,651 patients were enrolled in at least prospective case series studies 
and received CIRT.  
Overall, 56 studies elaborating on the efficacy and/or safety of CIRT have 
been identified: The majority of the studies chose samples with CIRT patients 
suffering from tumours in the brain and skull base, prostate and lung region, 
with 14, 11 and 9 identified studies in those regions respectively. Ear-nose-
throat cancer was another significant cluster, consisting of 7 clinical studies. 
Less frequent clusters were in the bone and soft tissue and gastrointestinal 
(GI) region, with 2 and 4 clinical studies assessing the efficacy and safety of 
CIRT in those regions respectively. In addition, 1 study was identified in-
cluding patients with choroid melanomas (eye) in their sample.  
Of those 56 studies, 27 clinical studies were eligible for the qualitative syn-
thesis of the efficacy and safety of CIRT when compared to standard irradia-
tion: 1 randomised controlled trial focusing on toxicity and feasibility of 
CIRT/PRT with a high risk of bias using a historical control and no other 
controlled study was found. The other 26 included studies were either pro-
spective case series (n=20) or – less frequently – case-control studies (n=3) 
or single-arm before-after studies (n=3), focusing on HRQoL. When assessing 
the superiority/inferiority of CIRT in comparison to standard irradiation re-
garding efficacy and safety on the basis of the selected oncologic endpoints, 
no scientific evidence was found for 41 indications, and insufficient scientific 
evidence was found for 13 indications in 7 regions: skull base: chordomas, 
chondrosarcomas; brain: glioma grade II, glioma grade III; glioblastoma; ear-
nose-throat: sarcomas in the head and neck, tumours in the nasal cavity and 
paranasal sinus, adenoid cystic salivary gland carcinoma; bone and soft tis-
sue: soft tissue sarcoma; lung: non-small cell lung carcinoma; prostate: pros-
tate carcinoma; gastrointestinal: oesophageal carcinoma, rectum carcinoma. 
 Skull base: insufficient scientific evidence indicating superiority/infe-
riority of CIRT for chordomas and low-grade chondrosarcoma when 
compared to conventional radiotherapy (evidence base: 3 uncontrolled 
prospective case series studies). No scientific evidence was found for 
11 other skull base tumours. 
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of CIRT centres 
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 Eye: no scientific evidence indicating superiority/inferiority of CIRT 
for eye tumours when compared to conventional radiotherapy. 
 Brain: insufficient scientific evidence indicating superiority/inferior-
ity of CIRT for WHO grade II and WHO grade III-IV brain tumours 
when compared to conventional radiotherapy (evidence base: 2 stud-
ies). No scientific evidence regarding inferiority/superiority of CIRT 
was found for ependymoma, medulloblastoma, and “other childhood 
brain tumours”. 
 Ear-Nose-Throat (ENT): insufficient scientific evidence indicating su-
periority/inferiority of CIRT regarding efficacy or safety for sarcomas 
in the head and neck, tumours in the nasal cavity and paranasal sinus 
and adenoid cystic salivary gland carcinomas (evidence base: 1 case-
control study and 4 prospective case series). No scientific evidence re-
garding superiority/inferiority of CIRT when compared to standard 
irradiation was found for 8 other specific indications in the ENT re-
gion: orbital tumours, maxillary sinus carcinoma, nasopharyngeal car-
cinoma, oropharyngeal carcinoma, tonsil carcinoma, tongue base car-
cinoma, pleomorphic salivary gland carcinoma, rhabdomyosarcoma.  
 Lung: insufficient scientific evidence indicating superiority/inferior-
ity of CIRT for non-small cell lung cancer (NSCLC) when compared 
to conventional radiotherapy (evidence base: 2 case-control studies and 
4 prospective case series).  
 Gastrointestinal tumours: insufficient scientific evidence indicating 
superiority/inferiority of CIRT regarding efficacy or safety for thora-
cic oesophageal squamous cell carcinoma and rectal cancer without 
distant metastases when compared to conventional radiotherapy (evi-
dence base: 1 prospective case series respectively). No scientific evi-
dence indicating superiority/inferiority of CIRT regarding efficacy or 
safety when compared to standard irradiation was found for pancreatic 
cancer, liver carcinoma, schwannomas/malignant schwannomas, and 
Ewing’s sarcomas. 
 Bone and soft tissue sarcoma: insufficient scientific evidence indicat-
ing superiority/inferiority of CIRT regarding efficacy or safety was 
found for soft tissue sarcoma (localised primary sarcoma of the extrem-
ities) when compared to conventional radiotherapy (evidence base: 1 
prospective case series study). No scientific evidence indicating supe-
riority/inferiority of CIRT regarding efficacy or safety when compared 
to standard irradiation was found for osteosarcoma, sacral chordoma, 
sacral chondrosarcoma and spinal meningioma. 
 Prostate: insufficient scientific evidence indicating superiority/infe-
riority of CIRT regarding efficacy or safety (evidence base: 1 RCT fo-
cusing on feasibility and toxicity, 3 before-after studies focusing on 
HRQoL and 4 prospective case series). 
 Breast: no scientific evidence indicating superiority/inferiority regard-
ing efficacy or safety of CIRT when compared to conventional radio-
therapy. 
 Kidney: no scientific evidence indicating superiority/inferiority regard-
ing efficacy or safety of CIRT when compared to conventional radio-
therapy for nephroblastoma. 
 Central nervous system: no scientific evidence indicating superiority/ 
inferiority regarding efficacy or safety of CIRT when compared to con-
ventional radiotherapy for neuroblastoma. 
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 Hematologic cancer: no scientific evidence indicating superiority/in-
feriority regarding efficacy or safety of CIRT when compared to con-
ventional radiotherapy for Non-Hodgkin’s lymphoma and Hodgkin’s 
lymphoma. 
 “Other oncologic indications”: no scientific evidence indicating supe-
riority/inferiority regarding efficacy or safety of CIRT when compared 
to conventional radiotherapy for solitary liver metastases in colorectal 
cancer, retroperitoneal metastases in controlled primary tumours, and 
oligo-metastasis in controlled primary tumours in selected indications. 
Upcoming evidence 
The search for ongoing studies revealed that the great majority of currently 
undertaken studies are uncontrolled: 65 ongoing studies were identified of 
which 10 were at least controlled studies, with enrolled patients suffering from 
tumours in the following regions: brain and skull base, bone and soft tissue, 
gastrointestinal, and ENT as well as lung. Interestingly, no randomised con-
trolled trials were found in the prostate or lung region, and only 1 controlled 
study enrolled lung cancer patients in their study.  
In addition, results from (randomised) controlled trials are expected to arise 
in the following years: the primary completion date of 4 of the ongoing RCTs 
has already passed (region: brain and skull base). The primary completion 
date of the other controlled and randomised controlled trials is in the next 4 
years. 
 
Discussion and conclusion 
In 2018, neither superiority nor inferiority on the basis of the selected end-
points regarding efficacy (OS, CSS, DFS, RFS, PFS, LCR, HRQoL) or safety 
(acute radiation morbidity, late radiation morbidity) can be concluded from 
the currently (un)available evidence for 54 oncologic indications.  
While plans of many cancer therapy centres in the European Union exist to 
increase patient treatment with CIRT, sound scientific evidence to show su-
periority or inferiority of CIRT when compared to photon, or other forms of, 
radiotherapy is absent. Suffice to say that results from (randomised) con-
trolled studies are urgently needed to clarify whether CIRT is more effective 
than or as effective as, or safer than or as safe as standard irradiation. 
As a treatment modality, CIRT can be described as a potentially less inva-
sive cancer treatment due to its physical properties. Due to the lack of con-
trolled trials, no conclusions may be drawn on the comparative effectiveness 
of CIRT when compared to conventional photon therapy. 
As of today, CIRT must be considered as experimental treatment. 
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1 Introduction 
1.1 Carbon ion therapy centres 
Internationally, the Lawrence Berkeley National Laboratory (BEVALAC) in 
the United States was the first cancer therapy centre experimenting treat-
ment with heavy ions [1]: patient treatment started in 1975. In 1992 – after 
treatment of approximately 433 patients – it was closed again [2]. Japan was 
the first country to introduce carbon ion radiotherapy (CIRT) at the Heavy 
Ion Medical Accelerator in Chiba (HIMAC), starting CIRT treatment in 1994. 
In 1997, the “Gesellschaft für Schwerionenforschung” (GSI) in Darmstadt 
(Germany) was the next facility to start treating cancer patients with CIRT. 
However, the GSI – similar to the BEVALAC – had a considerably short his-
tory of patient treatment and was closed in 2009, with 440 patients treated 
with CIRT at this cancer therapy centre [2] [1]. In the next 2 decades, addi-
tional facilities using CIRT for cancer treatment were constructed in Asia 
(Japan, China) and Europe (Germany, Italy and Austria) [2]. Table 1-1 gives 
an overview of the cancer therapy centres and the documented number of 
treated patients as of the end of 2016. 
Table 1-1: Patients treated with C-ions (per end of 2016) [2] 
CIRT Centre Country Start of the treatment Total patients treated 
CNAO, Pavia Italy 2012 816 
GHMC, Gunma Japan 2010 2,231 
GSI, Darmstadt Germany 1997 (-2009) 440 
HIBMC, Hyoga Japan 2002 2,527 
HIMAC, Chiba Japan 1994 10,692 
HIMAT, Saga Japan 2013 1,776 
HIT, Heidelberg Germany 2009 2,430 
IMP-CAS, Lanzhou China 2006 213 
I-rock, Kanagawa Japan 2015 105 
SPHIC Fudan University Shanghai CC  China 2014 350 
Sum  1994-2016 21,580 
Data retrieved from PTOGC website [2], last updated: December 2017,  
Abbreviations: C-ion – carbon ion; MeV – Mega electron volt; 
 
To date, 11 cancer therapy centres worldwide offer CIRT, with the majority 
of these being located in Asia (5 in Japan, 2 in China) and a few in Europe (2 
in Germany, 1 in Italy and 1 in Austria) (see Table 1-2 with more specific in-
formation regarding beam direction, max. energy). In addition, 4 new facili-
ties aiming at offering CIRT in the near future, are under construction [3] 
and 1 is in the planning stage [4]: 2 facilities are under construction in China 
(HITFIL, Lanzhou and the Heavy Ion Cancer Treatment Center in Wuwei), 
and 1 facility is under construction in South Korea (KIRAMS, Busan) and in 
Japan (Yamagata University Hospital, Yamagata) respectively. The cancer 
therapy centres under construction plan to start patient treatments between 
2018 and 2020. In addition, 1 further facility in South Korea (Yonsei Univer-
sity Hospital in Seoul) is currently in the planning stage and is estimated to 
start treating cancer patients by 2022 (see Table 1-3).  
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In addition, 2 cancer therapy treatment centres in France planning to use 
CIRT for cancer therapy are mentioned in the literature, but are not among 
the centres listed by the PTCOG (Particle Therapy Co-Operative Group): 
the ETOILLE (Espace de Traitement Oncologique par Ions Légers dans le 
cadre Européen), with an unknown status regarding patient treatment1, and 
the Advanced Resource Center for Hadrontherapy in Europe (ARCHADE), 
having received permission for the construction of a proton therapy centre 
in 2014. On the website of this centre, it is stated that the accelerator will be 
used for therapeutic applications and will deliver both protons and C-ions2. 
Until end of 2016, approximately 21,580 patients were recorded to have been 
treated with C-ions, with the majority of patients treated at HIMAC, in Chiba, 
Japan (10,692) followed by HIT, in Heidelberg, Germany (2,430) and HIBMC, 
in Hyogo, Japan (2,527) (see Table 1-1). 
Table 1-2: CIRT facilities in operation [7] 
Country CIRT Centre 
S/C/SC*  
Max. Energy (MeV) Beam directions 
Start of 
treatment 
Austria MedAustron, Wiener Neustadt S 430/u 2 fixed beams** 2017 
China IMP-CAS, Lanzhou S 400/u 1 fixed beam 2006 
China SPHIC, Shanghai S 430/u 3 fixed beams** 2014 
Germany HIT, Heidelberg S 430/u 2 fixed beams,  
1 gantry** 
2009, 2012 
Germany MIT, Marburg S 430/u 3 horiz.,  
1 45-deg. fixed 
beams** 
2015 
Italy CNAO, Pavia S 480/u 3 horiz., 1 vertical,  
fixed beams 
2012 
Japan HIMAC, Chiba S 800/u horiz.***, vertical***, 
fixed beams, 1 gantry 
1994, 2017 
Japan HIBMC, Hyogo S 320/u horiz.,vertical,  
fixed beams 
2002 
Japan GHMC, Gunma S 400/u 3 horiz., 1 vertical,  
fixed beams 
2010 
Japan SAGA-HIMAT, Tosu S 400/u 3 horiz., vertical,  
45-deg., fixed beams 
2013 
Japan i-Rock Kanagawa Cancer Center, 
Yokohama 
S 430/u 4 horiz., 2 vertical, 
fixed beams 
2015 
Data retrieved from the PTOGC website [7], last updated: February 2018.  
* S/C/SC = Synchrotron (S) or Cyclotron (C) or SynchroCyclotron (SC);  
** with pencil beam scanning;  
*** with spread beam and pencil beam scanning;  
Abbreviations: C-ion – carbon ion; MeV – Mega electron volt. 
                                                             
1 ETOILLE aimed to become the national centre for light ion hadrontherapy in France 
[5], but some of their projects were abandoned in 2015 [6]. 1 ongoing randomised 
controlled trial with 250 enrolled patients at the ETOILLE was identified through 
hand-searching (NCT02838602). 
2 See https://www.france-hadron.fr/en/nodes/archade-caen.html  
(accessed on 15/02/2018). 
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Table 1-3: CIRT facilities under construction or in the planning stage [3, 4] 
Country CIRT Centre Particle 
Max Energy  
Accelerator 
type (S*) Beam Directions 
N of 
treatment 
rooms 
Start of 
Treatment 
China HITFil, Lanzhou C-ion S 400/u 4 horiz, vertical, 
oblique, 
4 2018 
China Heavy Ion Cancer 
Treatment Center, 
Wuwei, Gansu 
C-ion S 400/u 4 horiz, vertical, 
oblique, 
fixed beams 
4 2018 
Japan Yamagata 
University Hospital, 
Yamagata 
C-ion S 430/u, 1 gantry, 1 horiz. & 
vertical fixed beam 
2 2020 
South 
Korea 
KIRAMS, Busan C-ion, p S 430/u, 230 2 vertical and horiz. 
fixed beams,  
1 horiz. fixed beam 
3 2019 
South 
Korea 
Yonsei Univ. 
Hospital,Seoul 
C-Ion S 430/u, 2 gantries 2 2022 
Data retrieved from the PTOGC website [7] (downloaded Oct 2017, last updated: January 2017),  
S* = Synchrotron (S);  
Abbreviations: C-ion – carbon ion; MeV – Mega electron volt. 
 
 
1.2 MedAustron 
In Austria, MedAustron – planned approximately 2 decades ago – aimed at 
focusing on treating cancer patients with charged particles (using protons and 
C-ions) and on research [8, 9]. The centre started treating cancer patients with 
proton therapy a year ago, with approximately 30 treated patients as of Sep-
tember 2017, and has ambitious plans for the future: MedAustron aims at 
treating 1,000 patients per year with protons and carbon-ions by 2020 [8, 10]. 
In 2017, MedAustron issued a list of potential indications for CIRT (see Table 
1-4): it consists of 56 different oncologic indications.  
The 56 oncologic indications of the issued list were partly already structured 
by anatomical regions. The following further regions were added by the au-
thors to structure those oncologic indications: lung region, bone and soft tis-
sue region, kidney, nervous system, hematologic cancer, “other”. In addition, 
orbital tumours was originally in the brain region on the provided list, but 
was changed to be in the ENT tumour region in this assessment. 
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Table 1-4: MedAustron list of potential indications for CIRT 
Region Indication 
Skull base tumours Skull base tumours 
 Chordoma 
Chondrosarcoma 
Meningioma grade II/grade III 
Meningioma grade I (complex) 
Craniopharyngioma 
Pituitary adenoma (not suitable for stereotaxy) 
Acoustic neuroma 
Other neurinomas 
Glomus tumour 
Retinoblastoma 
Lacrimal gland tumours 
Sarcomas incl. Ewing’s sarcoma 
Rhabdomyosarcomas of the skull base and orbit 
Brain Brain tumours 
 Glioma grade II 
Glioma grade III  
Glioblastoma  
Ependymoma 
Medulloblastoma 
Other childhood brain tumours 
Ear-Nose-Throat (ENT) Ear-Nose-Throat (ENT) 
 Orbital tumours 
Tumor of the nasal cavity and paranasal sinus 
Maxillary sinus carcinoma 
Nasopharyngeal carcinoma 
Oropharyngeal carcinoma 
Tonsil carcinoma 
Tongue base carcinoma 
Salivary gland carcinoma (pleomorphic) 
Salivary gland carcinoma (adenoid cystic)  
Sarcoma in the ENT area including Ewing's sarcoma 
Rhabdomyosarcoma 
Lung Non-small cell lung carcinomas 
 Stage I and II  
Stage III 
Mediastinal tumours (including thymoma) 
Pleural mesothelioma 
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Region Indication 
Gastrointestinal tumours Gastrointestinal tumours 
 Esophageal carcinoma 
 Pancreatic cancer 
 Liver carcinoma 
 Rectal carcinoma recurrence presacral 
 Schwannomas/malignant schwannomas 
 Ewing’s sarcoma 
Bone and soft tissue Osteosarcoma 
 Soft tissue sarcoma 
 Chordoma WS/sacral 
 Chondrosarcoma WS/sacral 
 Spinal meningiomas 
Prostate Prostate cancer 
 Low/intermediate risk 
 high risk 
 with metastases 
Breast Breast cancer 
Kidney Nephroblastoma 
Nervous system Neuroblastoma 
Hematologic cancer Non-Hodgkin's lymphoma (in exceptional cases) 
 Hodgkin’s lymphoma 
Other Solitary liver metastases in colorectal cancer 
 Retroperitoneal metastases in controlled primary tumours 
 Oligometastasis in controlled primary tumours in selected indications 
 
 
1.3 Research question 
This report aims at answering 2 research questions: 
1. For which tumour types is carbon ion radiotherapy (CIRT) currently 
in research (ongoing clinical trial)? 
The aim of this research question is to provide an overview of the main 
indications in both ongoing and published trials with CIRT and to 
give an estimation of the number of patients enrolled in those studies.  
2. What is the evidence that CIRT is more or equally effective, or safer 
than standard radiotherapy in selected oncologic indications?  
The aim of this research question is to provide an overview of the evi-
dence regarding efficacy (mortality, morbidity, HRQOL) and safety of 
CIRT for selected indications. 
 
2 Forschungsfragen 
Indikationen in 
klinischen Studien und 
Anzahl der PatientInnen  
Evidenz zu Wirksamkeit 
und Sicherheit von CIRT  
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2 Methodology 
2.1 Scope 
The EUnetHTA Core Model® for Rapid Relative Effectiveness Assessment 
was used for structuring this report. The Model organises HTA information 
according to pre-defined generic research questions. Based on these generic 
questions, the following research questions were answered in the assessment. 
However, due to its broad scope, the questions regarding the health burden 
of the specific indications are found in the chapter on efficacy and safety of 
CIRT.  
 
Description of the technology 
Element ID Research question 
B0001 What is the technology and the comparator(s)? 
A0020 For which indications has the technology received marketing authorisation or CE marking? 
B0002 What is the claimed benefit of the technology in relation to the comparators? 
B0003 What is the phase of development and implementation of the technology and  
the comparator(s)? 
B0004 Who administers the technology and the comparators and in what context and  
level of care are they provided? 
B0008 What kind of special premises are needed to use the technology and the comparator(s)? 
B0009 What supplies are needed to use the technology and the comparator(s)? 
A0021 What is the reimbursement status of the technology? 
Clinical effectiveness 
D0001 What is the expected beneficial effect of the technology on mortality? 
D0003 What is the effect of the technology on the mortality due to causes other than  
the target disease? 
D0005 How does the technology affect symptoms and findings (severity, frequency) of the disease 
or health condition? 
D0006 How does the technology affect progression (or recurrence) of the disease or health condition? 
D0011 What is the effect of the technology on patients’ body functions? 
D0016 How does the use of technology affect activities of daily living? 
D0012 What is the effect of the technology on generic health-related quality of life? 
D0013 What is the effect of the technology on disease-specific quality of life? 
D0017 Was the use of the technology worthwhile? 
Safety 
C0008 How safe is the technology in comparison to the comparator(s)? 
C0002 Are the harms related to dosage or frequency of applying the technology? 
C0004 How does the frequency or severity of harms change over time or in different settings? 
C0005 What are the susceptible patient groups that are more likely to be harmed through the use  
of the technology? 
C0007 Are the technology and comparator(s) associated with user-dependent harms? 
B0010 What kind of data/records and/or registry is needed to monitor the use of the technology  
and the comparator? 
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2.2 Inclusion criteria 
Inclusion criteria for relevant studies are summarised in Table 2-1.  
For research question 1 – overview of indications in research and number of 
patients in clinical trials – all prospective studies were analysed. 
For research question 2 – synthesis of evidence on efficacy and safety of 
CIRT in selected oncologic indications – only prospective studies published 
after 2005 and with at least moderate risk of bias were included. 
Table 2-1: Inclusion criteria 
Population Patients with tumours as defined in Table 1-4 in the following areas: 
 Skull base 
 Eye 
 Brain 
 Ear-Nose-Throat (ENT) 
 Lung 
 Gastrointestinal (GI) 
 Bone and soft tissue 
 Prostate 
 Breast 
 Kidney 
 “Nervous system” 
 “Hematologic cancer” 
Intervention Carbon ion radiotherapy (CIRT) 
Control  Photon radiation therapy 
 Secondary: Proton radiotherapy, all other forms of radiotherapy, surgery 
Outcomes  
Efficacy  Overall Survival (OS) 
 Cause-Specific Survival (CSS)/Disease-Specific Survival (DSS) 
 Disease-Free Survival (DFS) 
 Recurrence-Free Survival (RFS) 
 Progression-Free Survival (PFS) 
 Local Control Rate (LCR) 
 Health-Related Quality of Life (HRQoL) 
Safety Toxicity: Acute and late radiation morbidity 
Study design  
Efficacy Randomised controlled trials 
Non-randomised controlled trials 
Prospective case series with more than 10 patients 
Safety Randomised controlled trials 
Prospective non-randomised controlled trials 
Prospective case-series with more than 10 patients 
Publication period  
Language German/English/French 
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RQ1: alle prospektiven 
Studien 
RQ2: nur prospektive 
Studien mit low/ 
moderate RoB 
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2.3 Exclusion criteria 
 Population: pathologies not listed in Table 1-1 (for RQ2) 
 Intervention: other forms of radiotherapy, surgery 
 Comparator: no restriction 
 Outcomes: all other outcomes not depicted in Table 2-1 
 Study design: retrospective case series, case reports, commentaries, 
prospective case series with less than, or equal to, 10 patients;  
studies only publicised as an abstract. 
 Language: All languages other than German/English/French. 
In addition, studies were screened for overlapping samples in other, more re-
cent publications by the same authors using the same endpoints: older studies 
with the same population were then excluded. 
 
 
2.4 Systematic literature search 
The systematic literature search was conducted between  
the 5th and 7th of September, 2017 in the following databases:  
 Medline via Ovid 
 Embase  
 The Cochrane Library 
 CRD (DARE, NHS-EED, HTA) 
The systematic search was limited to randomised controlled trials and con-
trolled trials as well as prospective case series and articles published in Eng-
lish, German or French. After deduplication, a total of 408 citations were in-
cluded. The specific search strategy employed can be found in the Appendix 
(Section: Literature search strategies). 
The reference list of 5 systematic reviews on the use of hadron therapy 
(CIRT and PRT) [11-15] was also reviewed by hand search to identify poten-
tially further eligible studies: 4 additional studies were identified. In addi-
tion, the websites of the cancer therapy centres currently offering CIRT were 
reviewed to identify further published studies. No further studies were here-
by identified. 
Furthermore, a hand-search in 3 clinical trial registries [42 (ClinicalTrials. 
gov); 33 (WHO-ICTRP); 2 (EU Clinical Trials)] was conducted to identify 
ongoing and unpublished controlled studies on 19 September 2017, resulting 
in 77 relevant hits. An update of the search to identify ongoing studies was 
conducted on 8 February 2018 on the clinicaltrials.gov, EU Clinical trials and 
WHO-ICTRP websites: 5 further studies and 1 patient registry were identi-
fied. 
In addition, a rigorous hand-search was conducted: on the Particle Therapy 
Co-Operative Group (PTCOG, https://www.ptcog.ch/) website and on the 
MedAustron website (https://www.medaustron.at/) to identify further on-
going and unpublished controlled studies, leading to further 305 potentially 
relevant hits. An additional hand-search on the National Cancer Institute 
(NCI) website complemented the searches. 
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Finally, the systematic search and the hand-search to identify published and 
ongoing studies resulted in 802 hits overall. 
For information on the selected oncologic indications and for the description 
and epidemiology of the selected oncologic indications, a hand search on the 
websites of the following institutions:  
 National Cancer Institute (NCI, https://www.cancer.gov/) 
 Deximed (https://deximed.de/intro) 
 UpToDate (https://www.uptodate.com/home) 
 Surveillance, Epidemiology and End Results Program (SEER) 
(https://seer.cancer.gov) 
 Statistics Austria (http://www.statistik.at/) 
In addition, a radio-oncological expert reviewed the treatment modalities de-
scribed in this assessment: The most common treatment for each indication 
in Austria was added in case those clinical treatment modalities differed to 
the ones identified according to the reviewed websites. 
 
  
Informationen und 
Quellen zu 
onkologischen 
Indikationen 
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2.5 Flowchart of study selection 
Overall, 414 hits were identified. The references were screened by 2 independ-
ent researchers, and in case of disagreement, a third researcher was involved 
in solving the differences. The selection process is displayed in Figure 2-1. 
 
Figure 2-1: Flowchart of study selection (PRISMA Flow Diagram) 
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2.6 Analysis 
For research question 1, the identified (published) studies were screened and 
sorted by broad indication groups (regions). The studies were categorised by 
study design and were reviewed for reporting on patients in multiple indica-
tions. Those patients were then included in the samples of the respective in-
dication. The indication list issued by MedAustron was then revised (reduced) 
to 54 (instead of 56) specific tumour entities: prostate and non-small cell lung 
cancer was judged as being 1 indication respectively. Choroid melanoma was 
also added to the potential indications.  
Data on the sample size and number of patients was extracted in order to as-
sess which tumour indications CIRT is currently being studied for. The num-
ber of patients refers to the total number of enrolled patients. For specific 
tumour indications, data on the number of patients was additionally extract-
ed alongside the issued revised MedAustron list including 54 potential CIRT 
indications. In case the same sample was published in multiple studies – for 
instance, if studies were judged to use the same sample but reported on dif-
ferent outcomes – the studies were not excluded, but those samples were on-
ly counted once in the analysis. The results of the Potential indications for 
the use of carbon ion radiotherapy (CIRT) according to clinical studiescan 
be found in the Appendix and in Section 4.1: CIRT indications in published 
clinical trials. 
For research question 2, the internal validity of the included studies was 
assessed by 2 independent researchers (GG, MM) applying the EUnetHTA 
guidelines [16, 17]. For case series, the risk of bias (RoB) was assessed using 
the IHE-18 checklist (checklist and instructions: see Appendix Table A-9): a 
high score indicates a low risk of bias and a low score indicates a higher risk 
of bias (RoB). A cut-off for the inclusion of only those studies with low or 
moderate RoB was pre-defined. Thresholds used were:  
Table 2-2: Cut-off criteria for the risk of bias (RoB) assessment 
Criteria Points 
Low risk 14.5/18 to 18/18 
Moderate 11/18 to 14/18 
High risk ≤ 10.5/18 
Table 2-3: RoB point system for the risk of bias (RoB) assessment 
Answers to specific questions of the IHE-18 checklist Points 
No 0 
Unclear 0.5 
Partial 0.5 
Yes 1 
 
Data was then extracted from the included studies (low/moderate RoB) by 1 
researcher (GG) and controlled by another researcher (MM). In the case of 
studies reporting about several different indications, these studies were only 
eligible if more than 10 patients, and at least 40% of the total sample, suf-
fered from the specific indication. 
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2.7 Synthesis 
Based on the MedAustron list of indications, the evidence was finally synthe-
sised based on the data extraction tables (see Appendix Table A-1 to Table A-
8) for both the 12 tumour “regions” and the 54 specific oncologic indications. 
In this assessment, prostate and non-small cell lung cancer was judged as 
being 1 indication respectively. The evidence for risk group-specific cancer 
forms for those diseases were not separated due to the broad scope of the as-
sessment, leading to an evidence synthesis of CIRT for 54 oncologic indica-
tions. However, in the qualitative synthesis of those 2 indications, reference 
was made to the stage of the diseases. 
In addition, 1 indication was added: choroid melanoma. 
Some sub-indications (i.e., meningioma grade I and grade II-III, pleomorphic 
and adenoid cystic carcinomas) were also described in 1 section respectively 
for practical reasons. However, the synthesis was – if applicable – conducted 
independently for each of those sub-indications. 
The evidence is reported systematically along the pre-defined crucial outcomes 
in Chapter 5. 
 
 
2.8 Quality assurance  
This report was reviewed by an internal reviewer and an external reviewer. 
The latter was asked for the assessment of the following quality criteria: 
 How do you rate the overall quality of the report? 
 Are the therapy options in the current treatment section used in 
clinical practice and are the presented standard therapies correct? 
 Is the data regarding prevalence, incidence and amount of eligible 
patients correct? 
 Are the investigated studies correctly analysed and presented  
(data extraction was double-checked by a second scientist)? 
 Was the existing evidence from the present studies correctly 
interpreted? 
 Does the current evidence support the final conclusion? 
 Were all important points mentioned in the report? 
The LBI-HTA considers the external assessment by scientific experts from 
different disciplines a method of quality assurance of scientific work. The 
final version and the policy recommendations are under full responsibility 
of the LBI-HTA. 
 
Zusammenfassung  
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und 
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3 Description and technical 
characteristics of technology 
Features of the technology and comparators 
B0001 – What are carbon ion radiotherapy (CIRT)  
and photon radiotherapy? 
Both carbon ion radiotherapy and photon radiotherapy are forms of external 
beam radiation therapy methods. Radiation therapy is used to destroy cancer 
by damaging their DNA. If the DNA of the irradiated cancer cells is damaged, 
they either die or stop dividing [18]. A photon can be described as the basic 
unit of light and consists of either x-rays or gamma rays. Photon radiation 
therapy is the most common form of radiation therapy. The amount of energy 
to be used for irradiation varies, and the dosages are expressed in gray cobalt 
(Gy) [18]. 
CIRT belongs – together with other charged particles such as protons, helium 
or neon – to the family of hadron therapy. Hadron therapy has several biolog-
ical differences when compared to photon radiotherapy. Therefore, the irra-
diation dose cannot be expressed with Gy but with gray cobalt equivalents 
(GyE) [19]. Hadron therapy is characterised by a peak energy delivery (Bragg 
peak): a large fraction of the energy of hadron therapy is deposited at the tar-
get while being less invasive to surrounding tissues due to a low entrance dose 
affecting healthy tissues. The ionisation density and the relative biological ef-
fectiveness (RBE) increases with depth; that is when travelling deeper in the 
body [20]. 
 
Figure 3-1: Illustration of the Bragg peak [20] 
Hadron therapy enables a higher precision of irradiating tumours due to the 
ability of hadron therapy to adjust both the beam’s energy and the intensity. 
The physical properties are different in hadron therapy: the cell killing is 
more efficient due to charged particles damaging a cell DNA differently 
than photons. As such, hadron therapy has a higher relative biological effec-
tiveness (RBE) than photons. That is, proton irradiation leads, for instance, 
to approximately 10% more biological damage than photons (per unit) [19].  
Hadronen  
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eingesetzt 
Hadronen und 
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The radiobiological properties of CIRT differ to the ones of protons as well, 
leading to higher RBE, a higher ionisation density and a considerably high 
linear energy transfer (LET) when compared to proton and photon radiother-
apy [21]. Photons and protons can thus be described as forms of low-LET 
radiotherapies, while CIRT is a form of high LET radiation therapy [20]. 
B0002 – What is the claimed benefit of CIRT  
in relation to photon radiotherapy? 
Carbon ion radiotherapy (CIRT) is claimed to be both more effective and saf-
er than conventional radiotherapy due to its physical dose distribution and 
its higher relative biological effectiveness (RBE). The physical distribution to 
be found in CIRT is promising due to its different radiobiological properties: 
the high ionisation density generates higher linear energy transfer (LET) and 
leads to an increase in radiobiological efficiency. CIRT is, therefore, expected 
to have a higher local control of a tumour than conventional radiotherapy 
while minimising the probability of damaging the surrounding healthy tis-
sues [22]. 
C-ions are, therefore, considered to have the right balance between the phys-
ical dose distribution and the biological effect. That is, the peak-to-plateau 
ratio to be found in CIRT is considered to be superior when compared to oth-
er ion species [20]. 
Within hadron therapy, a superiority of CIRT when compared to proton ther-
apy is anticipated as well, due to its different biological properties. However, 
for soft tissue parameters, the biological advantage of CIRT may not be as sta-
ble [23]. That is to say, the higher ionisation density, resulting in high LET, 
can be described as a two-edged sword [24]: some of those differences may 
constitute advantages, while others may be disadvantages depending on the 
application. As such, CIRT could potentially also have its downside since a) 
the treated volume may not be limited to the volume of the gross tumour, 
thus, healthy tissues may be affected by high LET, as well as b) some sub-
strates of the surrounding healthy tissues may be affected by a tumour, i.e., 
if a tumour is intertwined with, or embedded in healthy tissues [19]. 
B0003 – What is the phase of development  
and implementation of carbon ion radiotherapy (CIRT)? 
In Austria, hadron therapy is a new form of cancer therapy. Patient treatment 
started at the end of 2016 using protons [8]. As of September 2017, approxi-
mately 30 patients were treated at the MedAustron, and radiation therapy 
using both proton and C-ions is currently being offered by the MedAustron 
[10]. 
CIRT is technically not a novel technique; cancer therapy centres started of-
fering this therapy approximately 2 decades ago, and the first cancer therapy 
started experimenting with radiotherapy using heavy ion radiotherapy in 1975 
[1]. Within the last decades, however, many cancer therapy centres started 
offering cancer therapy using C-ions in Europe and Asia. Historically speak-
ing, some cancer therapy centres also stopped treating patients with CIRT 
and other types of heavy ion radiotherapy [2]. 
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Administration, investments, personnel  
and tools required to use CIRT and photon radiotherapy 
B0004 – Who administers CIRT and in what context and level of care  
is CIRT provided? 
Carbon ion radiotherapy (CIRT) is provided in the tertiary, highly special-
ised level of care: in Austria, the treatment occurs in the outpatient setting at 
the MedAustron cancer therapy centre. The use of hadron therapy is to be 
approved by a chief physician [25]. 
B0008 – What kind of special premises are needed to use CIRT  
and standard radiotherapy? B0009 – What supplies are needed to use 
CIRT and photon radiotherapy? 
A so-called linear accelerator (LINAC) can be used for the delivery of exter-
nal beam radiation therapy. Electricity is used by the LINAC to form a stream 
of fast-moving subatomic particles. In so doing, high-energy radiation is cre-
ated and can be used for cancer treatment. A LINAC is necessary for both 
photon radiotherapy and other more experimental, newer methods of radia-
tion therapy, such as CIRT [18]. 
At the MedAustron [26], protons or carbon ions are generated by 3 ion 
sources: charged particles are first pre-accelerated in a LINAC on a straight 
line through alternating electric fields. Then, the ion beams are injected in a 
synchrotron – a circular accelerator with a circumference of approximately 
80 metres. The synchrotron accelerates those particles to their final speed 
(approximately 200,000km/s). Lastly, the ion beam is led into 1 of the irra-
diation rooms through a so-called extraction line. A vacuum tube is used to 
hold particles in place using strong magnetic fields. In addition, there are 4 
treatment rooms at MedAustron [27]: 1 gantry for proton radiotherapy (PRT) 
solely and 3 rooms in which both PRT and CIRT can be used. In the latter, 1 
room uses a horizontal and vertical fixed beam, 1 room uses a horizontal fixed 
beam, and another treatment room is only for non-clinical research for PRT/ 
CIRT using a horizontally fixed beam technique. In all of the latter 3 treat-
ment rooms, C-ions can be accelerated to up to 120-400 MeV/n. 
 
Regulatory and reimbursement status 
A0021 – What is the reimbursement status of proton therapy  
and of CIRT? 
Reimbursement for proton therapy was approved by the Main Association of 
the Austrian Social Security Institutions in June 2017 [8]. However, only se-
lected oncologic indications are currently being reimbursed [28]: 
 Melanoma in the eye (if brachytherapy using iodine or ruthenium 
application is not suitable),  
 Chordoma and chondrosarcoma of the skull base, 
 Adenoid cystic salivary gland carcinoma (if inoperable or macroscopic 
disease residues after surgery are prevalent),  
 Paediatric tumours in children younger than 16 years old,  
 Meningioma (if they cause neurological symptoms and neurosurgical 
measures are likely to increase the risk of additional damage). 
The decisions for the selection of the mentioned indications for protonther-
apy was based on the LBI-HTA report [9]. A decision on the reimbursement 
of CIRT indications is pending. 
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4 Current use of CIRT in published 
and ongoing clinical trials 
In order to assess, for which indications carbon ion radiotherapy (CIRT) is 
currently being used in clinical trials – randomised clinical trials, non-ran-
domised controlled trials and prospective case series –, published as well as 
ongoing studies were searched for and reviewed. This chapter will provide 
an overview of 
a. the main “regions” and specific indications on which trials have been 
conducted (and are published) and  
b. the specific indications on which clinical studies are currently being 
undertaken (ongoing controlled clinical studies).  
The reader is reminded that all of the estimations calculated in this chapter 
are based on data retrieved from published studies and identified ongoing 
studies. Thus, the results must be interpreted with caution, since all the re-
sults depicted in this chapter might not reflect the true number of patients 
having been treated with CIRT, but only patients documented in published 
and ongoing clinical studies.  
 
 
4.1 CIRT indications in published clinical trials 
In this section, the identified studies for research question 1 are summarised 
using the MedAustron list of potential “regions”. Of the 12 “regions” on the 
list, no publications were found for 4 tumour indications (breast, kidney, 
nervous system and hematologic cancer). However, the search was not lim-
ited to the list of the issued list of MedAustron in this chapter. 
Overall, 56 studies elaborating on the efficacy and/or safety of CIRT have 
been identified: the majority of the studies chose samples with CIRT patients 
suffering from tumours in the brain and skull base, prostate and lung region, 
with 14, 11 and 9 identified studies in those regions respectively. Ear-nose-
throat cancer was another significant cluster, consisting of 7 clinical studies. 
Less frequent clusters were in the gastrointestinal region (GI) and bone and 
soft tissue region, with 4 and 2 clinical studies assessing the efficacy and safe-
ty of CIRT in those regions respectively. In addition, 1 study was identified 
with choroid melanomas (eye), and 1 further study was identified with skin 
cancer patients, in their sample.  
In addition, 8 further studies were found for 2 cancer regions not being on 
the issued list of the MedAustron were: 7 studies with gynecologic cancer 
types and 1 study with skin cancer were identified. 
Table 4-1 gives a broad overview of the 56 identified studies according to re-
gions, phases of clinical research and numbers of enrolled patients in those 
clinical studies. It is noticeable that none of the studies were higher than in 
phase II and no controlled trial was undertaken, elaborating on the efficacy 
of CIRT for any of the regions. Only for safety parameters, 1 randomised con-
trolled, pilot study, was identified. 
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However, the numbers of patients treated with CIRT in the published stud-
ies may be less since a) many of the included studies have an overlapping 
sample, and b) the number of patients suffering from specific tumour enti-
ties refer to the total number of enrolled patients and some studies enrolled 
(and reported) both CIRT and PRT patients. 
Table 4-1: Published studies on CIRT in specific tumour regions: phase of clinical trial, number of studies  
and number of patients treated 
Region of cancer 
The phase of clinical research n of 
studies 
identified 
n of pts 
receiving CIRT 
in studies 
n of pts 
in studies Ph 1/23 Ph 2 Ph 3 NR 
Bone and soft tissue 2 0 0 0 2 74 74 
Brain and skull base 5 0 0 9 14 543 763 
Breast 0 0 0 0 0 0 0 
Ear-Nose-Throat 2 2 0 3 7 489 523 
Eye 1 0 0 0 1 59 59 
Gastrointestinal 
(GI) 
Oesophagus 1 0 0 0 1 31 31 
Liver 1 0 0 1 2 148 148 
Rectum 0 0 0 1 1 184 184 
Gynaecologic  6 0 0 1 7 241 241 
Hematologic cancer 0 0 0 0 0 0 0 
Kidney 0 0 0 0 0 0 0 
Lung 4 0 0 5 9 631 731 
Nervous system 0 0 0 0 0 0 0 
Prostate 2 2 0 7 11 3,206 3,253 
Skin 1 0 0 0 1 45 45 
Total 25 4 0 27 56 5,651 6,052 
Abbreviations: ENT – Ear-Nose-Throat; NR – not reported; Ph – phase. 
 
For tumours in the brain and skull base region, 14 studies were identified, 
with approximately 763 enrolled patients, of which 543 patients received 
CIRT. 5 studies were in Phase 1/2 and 9 studies did not report on the clini-
cal phase of their studies. No Phase 2 or Phase 3 studies have been identified 
for this region. 
The most frequent skull base tumours of all enrolled patients were chordo-
mas and chondrosarcomas, with 299 patients suffering from those diseases in 
all identified studies. In addition, 190 enrolled patients suffered from men-
ingiomas. Craniopharyngiomas, pituitary adenomas and tumours of the lac-
rimal gland were less frequent skull base tumours in the identified studies, 
with 5, 14 and 21 patients with those diseases enrolled in all identified studies. 
For more information on the specific studies including skull base tumours, 
the reader is referred to Table A-19 in the Appendix. 
In addition, 194 patients suffered from brain tumours, with 70, 45 and 79 
patients suffering from WHO grade II gliomas, WHO grade III gliomas and 
glioblastomas respectively. For more information on the specific studies in-
cluding brain tumours in their sample, the reader is referred to the Table A-
20 in the Appendix. 
                                                             
3 Phase 1 or a combination of Phase 1/2. 
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For prostate cancer (see Table A-21 in the Appendix), 11 studies were iden-
tified: 2 studies were in phase 1/2, and 2 other studies were phase 2 clinical 
studies. 7 of the identified studies did not report on the phase of the clinical 
research. Of those, 1 randomised controlled trial focusing on safety-related 
endpoints solely, and several case series and 3 before-after studies focusing 
on efficacy-related endpoints were identified: in total, the sum of the sam-
ples lead to 3,253 patients, of which 3,206 were treated with CIRT. However, 
it is assumed that a significant proportion of those patients were enrolled in 
multiple studies: 1 multi-institutional case series study (n=2,157) may have 
included many of patients from other identified studies in this assessment, 
leading to uncertainty of the true number of prostate cancer patients having 
been treated with CIRT according to those studies.  
For lung cancer, 9 clinical studies were identified: 4 were phase 1/2 clinical 
studies, and 5 studies did not report on the phase of clinical research. Approx-
imately 731 patients4 were enrolled in those studies, and 631 patients have 
been treated with CIRT. 8 out of 9 identified studies had patients with non-
small cell cancer (NSCLC) in their sample, and 1 study included 91 patients 
with oligo-recurrence in the lung. The reader is referred to Table A-22 in the 
Appendix for more information on the identified studies. 
For the Ear-Nose-Throat region (see Table A-23 in the Appendix), 7 clinical 
studies were identified: 2 studies and 2 studies were phase 1/2 and phase 2 
respectively. The other 3 clinical studies did not report on the phase of clini-
cal research. Approximately 523 patients were enrolled. Of those, 489 patients 
received CIRT. From all enrolled patients, 215 patients had tumours in the 
nasal cavity and paranasal sinus, and 142 enrolled patients had adenoid cyst-
ic salivary gland tumours. Less frequent indications in those studies were 
pharynx carcinomas5, sarcomas in the head and neck region, orbita tumours, 
and maxillary sinus carcinomas, with 34, 27, 20 and 13 patients with those 
indications included in the identified studies respectively. The rest of the en-
rolled patients had other ENT tumour types not within the list of the selected 
indications. 
For bone and soft tissue tumours (see Table A-24 in the Appendix), 2 phase 
1/2 studies with 74 enrolled patients receiving CIRT were identified. Of those, 
29 patients had soft tissue sarcomas, and 18 had osteosarcomas. In addition, 
patients with sacral chordomas and sacral chondrosarcomas were enrolled in 
the identified studies, with 11 and 7 patients suffering from those cancer types 
respectively. The rest of the enrolled patients (n=9) had tumour types not 
within the list of the selected indications. 
For gastrointestinal tumours (see Table A-25 in the Appendix), 4 studies were 
identified: 2 phase 1/2 studies and 2 further clinical studies did not report 
on the phase of clinical research. 363 patients were enrolled in those clinical 
studies, of which all patients received CIRT in different forms (e.g., dosages). 
Of all enrolled patients, cancer was prevalent in the following indications: 
rectum carcinoma, liver carcinoma and oesophagus carcinoma, with 184, 148 
and 31 patients with those indications respectively. 
                                                             
4 2 studies [29, 30] are assumed to have reported on the same 81 patients in their stud-
ies. It was found out considerably late in the assessment and both of the studies were 
excluded from the qualitative synthesis because of high risk of bias. Therefore, those 
patients were only counted once in the analysis (see Table A-22). 
5 In the studies [31-33], it was not specified whether the patients suffered from naso- or 
oropharyngeal cancer. 
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In the eye region (see Table A-26 in the Appendix), only 1 study was identi-
fied, with 59 patients with choroid melanomas in their sample.  
In addition, 2 further regions on which trials have been conducted were found 
(and are published): 7 case series studies with an estimated 241 patients, receiv-
ing CIRT, were found for gynecologic cancer types. 1 further study, with 45 
CIRT patients suffering from cancer in the skin region, was also identified. 
 
 
4.2 CIRT indications in ongoing studies 
For the analysis of ongoing studies, studies were categorised by region, and 
phase of clinical research. Only controlled studies are described in this sec-
tion (see Table A-17 in the Appendix). However, the phase of clinical research 
and the number of patients enrolled was extracted for all identified studies 
and are depicted in Table 4-2. It was noticeable during the hand-searches 
that numerous uncontrolled studies are currently being undertaken. 
In total, the search for ongoing studies resulted in 382 hits [305 (PTCOG), 
42 (ClinicalTrials.gov); 33 (WHO-ICTRP); 2 (EU Clinical Trials)]. After de-
duplication and excluding those studies focusing on other forms of hadron 
therapy, 60 clinical studies remained, of which only 10 studies are controlled 
trials, evaluating the efficacy or safety of CIRT for 9 different indications. 
The update on 8 February 2018 of those registries led to the identification of 
further 5 uncontrolled studies and 1 patient registry from the MedAustron 
with 800 patients planned to be included in the next 10 years, receiving pro-
ton or C-ion therapy.  
The following table gives an overview of the identified 65 ongoing studies for 
CIRT. The weighting of studies and enrolled patients according to regions 
may be different, but is still similar to the 1 of published studies to a certain 
extent: it appears that many studies (phase 1-2) are currently undertaken for 
tumours in the prostate, brain and skull base, and lung region.  
Table 4-2: Ongoing clinical trials on CIRT in specific tumour regions: phase of clinical trial, number of patients enrolled 
Region of cancer 
The phase of clinical research n of studies  
identified 
n of pts  
in studies Ph 1 Ph 1/2 Ph 2 Ph 3 NR 
Bone & soft tissue tumour 1 3 3 0 1 8 391 
Brain & skull base 0 2 3 2 0 7 1,219 
Breast 0 1 0 0 0 1 20 
ENT 1 3 4 0 1 9 612 
GI tumours 7 1 6 0 2 16 861 
Hematologic cancer 0 0 0 0 0 0 0 
Kidney 0 2 0 0 0 2 20 
Lung 1 0 3 0 1 5 860 
Nervous system 0 0 0 0 0 0 0 
Gynecologic 1 4 0 0 3 8 197 
Prostate 0 2 5 0 2 9 1,858 
Total 11 18 24 2 10 65 6,038 
Abbreviations: ENT – Ear-Nose-Throat; NR – not reported; Ph – phase 
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Of the 10 controlled studies, 2 are phase 3 clinical trials, and 3 and 2 clinical 
trials are either phase 2 or a combination of phase 1 and phase 2 respective-
ly. In addition, 1 clinical trial is in phase 1. 8 (of 10) studies are randomised 
trials and 2 studies did not report the phase of clinical research. The studies 
investigate the efficacy or safety of CIRT in 5 different regions and 9 differ-
ent oncologic indications. Overall, 2,162 patients were enrolled in the identi-
fied ongoing clinical studies. However, the primary completion date of 4 stud-
ies has already passed, leading to approximately 1,129 patients currently en-
rolled in at least controlled clinical studies evaluating the efficacy or safety 
of CIRT. 
The following indications are investigated in the 10 ongoing controlled stud-
ies: tumours in bone and soft tissue (2 studies included patients with sacral 
chordomas); in the brain and skull base region, patients suffering from chor-
domas, meningiomas, chondrosarcoma, primary glioblastomas and recurrent 
gliomas are enrolled, with 1 study for each of those indications respectively; 
for tumours in the ENT region, patients with cystic carcinomas and sarcomas 
are enrolled in another study. 1 further study included patients with tumours 
in the gastrointestinal region (hepatocellular carcinoma), and 1 study includ-
ed lung cancer patients (small-sized peripheral, non-small cell lung carci-
noma).  
The most frequent control interventions are other types of radiotherapy: 4 
studies use proton radiotherapy (PRT) solely as a control intervention, and 
the following control interventions are being used in 1 study respectively: PRT 
in combination with CIRT, x-rays/protons, photon radiotherapy, and fraction-
ated stereotactic radiotherapy (FSRT). In addition, surgery is also used as a 
control intervention in 2 studies: 1 study used surgery alone, and another 
study used surgery in combination with radiotherapy, as a control interven-
tion. 
Surprisingly, the proportions of patients enrolled in the respective indication 
groups (clusters) for controlled, or randomised groups do not correspond with 
the distribution of the identified published and ongoing studies. That is to 
say, numerous uncontrolled studies were, and are currently being undertaken 
for many indications.  
The reader is referred to Table A-17 in the Appendix for more information 
on the characteristics of the ongoing controlled studies identified through the 
hand-search. 
 
(R)CTs: 
insg. 2.162 
StudienteilnehmerInnen 
zu 9 onkologischen 
Indikationen: 
2 Studien:  
sakrale Chordome 
Hirn- und Schädelbasis: 
1 Studie: Chordome  
1 Studie: Meningeom 
1 Studie: 
Chondrosarkom  
1 Studie: Glioblastom 
1 Studie: Gliom 
HNO Bereich: 1 Studie: 
adenoidzystisches 
Karzinom und Sarkom;  
GI: 1 Studie: 
Leberzellkarzinom; 
Lunge: 1 Studie: 
Kleinzelliges 
Lungenkarzinom 

 LBI-HTA | 2018 43 
5 Efficacy and safety of carbon ion 
radiotherapy (CIRT) for 54 indications 
5.1 Outcomes 
To answer the question whether CIRT is more or equally effective as the 
standard irradiation, mortality, and mortality-related endpoints, as well as 
other patient-relevant endpoints, were used to evaluate the evidence regard-
ing the efficacy of CIRT. For efficacy, the following outcomes were defined 
as crucial to derive a conclusion: 
 Overall survival (OS)  
 Cause-specific survival (CSS)/Disease-specific survival (DSS) 
 Recurrence-free survival (RFS) 
 Progression-free survival (PFS) 
 Disease-free survival (DFS) 
 Change in Health-Related Quality of Life (HRQoL) 
Overall survival (OS) refers to the rate or probability of surviving a specified 
time period typically from a specified date (i.e., cancer diagnosis, start of can-
cer treatment) – to death. All causes, leading to death, are hereby included in 
the analysis [34, 35]. The endpoint is reported at 1, 2, 3, 4, 5 and 10 years. 
Cause-specific survival (CSS)/Disease-specific survival (DSS) can be de-
scribed as a “corrected” survival excluding deaths from other causes than the 
patient’s disease. In so doing, several strengths can be observed: the ability to 
compare patient groups, inter alia, with different age distribution, increases. 
Moreover, the (excess) death rate being attributable to certain cancer may be 
shown with this endpoint [34]. The endpoint is reported at 1, 2, 3, 4, 5 and 
10 years. 
Disease-free survival (DFS) refers to the survival of patients until the date 
of recurrence (loco-regional or systemic) [36]. This endpoint is reported at 1, 
2, 3, 4, 5 and 10 years. 
Within the term recurrence-free survival (RFS), related endpoints were 
judged as crucial and summed up within the endpoint RFS accordingly. 
RFS can be described as the period from therapy (e.g., CIRT) until a recur-
rent disease is detected. Typically, second, or other primary cancers are ex-
cluded in the analysis [36]. In this assessment, biochemical recurrence-free 
survival (BRFS) or biochemical relapse-free survival (BNED) were extracted 
and described within the endpoint RFS. The endpoint was seen as crucial at 
1, 2, 3, 4, 5 and 10 years. 
Progression-free survival (PFS) can be described as the “(…) time from ran-
domisation to first radiological or clinical observation of disease progression 
or any-cause death” [9]. Disease progression can be measured using the Re-
sponse Evaluation Criteria in Solid Tumours (RECIST) and includes recur-
rence (loco-regional or systemic), second malignancy, or any deaths from any 
cause. However, late deaths not attributable to cancer are typically excluded 
[36]. The endpoint is reported at 1, 2, 3, 4, 5 and 10 years. 
In addition, the local control rate (LCR) was considered to be relevant and 
was seen as a surrogate endpoint in this assessment. Other forms of local 
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control, such as the loco-regional control (LRC), were also extracted within 
this endpoint. The endpoint is reported at 1, 2, 3, 4, 5 and 10 years. 
Besides survival rates, improvements in Health-Related Quality of Life 
(HRQoL) was used as a crucial outcome since patient-reported outcomes 
(PRO) are important measures in oncology [37]. There are several instruments 
available to measure HRQoL and data was extracted pre- and post-interven-
tional, short-term (<6 weeks), mid-term (>6weeks – ≤6 months) and longer-
term (> 6 months). In this assessment, no restriction was set to specific ques-
tionnaires. 1 or more of the following questionnaires was used in 6 of the 
included studies: the European Organisation for Research and Treatment of 
Cancer Quality of Life Questionnaire (EORTC-QLQ); the Functional Assess-
ment of Cancer Therapy-General (FACT-G) questionnaire, including sub-
scales and summary indexes such as the Trial Outcome Index (TOI); the 
Functional Assessment of Cancer Therapy-Prostate (FACT-P); the UCLA 
Prostate Cancer Index (UCLA-PCI); and the Japanese Version of the SF-8 
questionnaire [38]. 
For safety, the following outcomes were defined as crucial to derive  
a recommendation: 
 Acute radiation morbidities 
 Late radiation morbidities 
Acute radiation morbidities are analysed using the Radiation Therapy On-
cology Group (RTOG) criteria or the Common Terminology Criteria for Ad-
verse Events (CTCAE). Acute radiation morbidities are defined as those mor-
bidities occurring between the start (day 1) of the therapy until 3 months (90 
days) after the therapy was initiated by both the CTCAE [39] and RTOG 
[40] criteria. 
Late radiation morbidities are analysed using the Radiation Therapy Oncolo-
gy Group (RTOG)/European Organisation for Research and Cancer (EORTC) 
and the CTCAE criteria. Late radiation morbidities are defined as radiation 
morbidities occurring 90 days after the start of the therapy by both the CTC-
AE [39] and RTOG [40] criteria. 
 
 
5.2 Included studies 
In order to assess efficacy-, and safety-related outcomes of CIRT, all pro-
spectively conducted studies with more than 10 patients, with low or moder-
ate risk of bias (RoB) were eligible to answer the research question. Overall, 
27 studies were identified and reviewed in this systematic review: of those 27 
studies, only 1 randomised, open-label, pilot study focusing on toxicity/feasi-
bility of CIRT for prostate cancer was identified. Moreover, 26 non-random-
ised, uncontrolled studies met the inclusion criteria. That is; 3 case-control 
studies and 23 case series studies reported on the efficacy and/or safety of 
CIRT in the following regions: prostate (n=7), lung (n=6), ear-nose-throat 
(n=5), skull base (n=3), brain (n=2), bone and soft tissue (n=1), gastro-
intestinal (n=2). Study characteristics and results of included studies are 
displayed in the Appendix (Table A-1 to Table A-8). 
The results will be reported separately for each of the 54 indications. 
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5.3 Results 
In the following section, the body of the evidence of the included studies fo-
cusing on efficacy and/or safety of carbon ion radiotherapy (CIRT) in 54 in-
dications in 12 regions (according to the MedAustron list for potential indi-
cations) are reported. In addition, background information on the specific 
indications will be described and – if applicable – an evidence synthesis will 
be conducted.  
 
5.3.1 Skull base tumours 
Definition 
“Skull base tumours” refers hereby to 13 different oncologic indications: skull 
base chordoma, skull base chondrosarcoma, meningioma (grade II-III), men-
ingioma (grade I, complex), craniopharyngioma, pituitary adenoma, acoustic 
neuroma, other neurinomas, glomus tumours, retinoblastomas, lacrimal gland 
tumours, sarcomas (incl. Ewing’s sarcoma), rhabdomyosarcomas of the skull 
base and orbit. In the medical literature, however, some of the sub-indications 
may be categorised differently. As such, meningiomas are, for instance, tech-
nically brain tumours [41], and many of the other tumours may be catego-
rised as pediatric (e.g., rhabdomyosarcoma) and/or eye tumours (e.g., lacrimal 
gland tumours, retinoblastomas) [41]6. 
Epidemiology, current treatment regimens and prognosis 
Due to the broad variety of specific tumour entities to be found in this chap-
ter, the reader is referred to each specific indication to gain more information 
on current treatment approaches and prognosis of the specific oncologic in-
dications. 
Included studies 
For skull base tumours, 3 case series studies from 2 cancer therapy centres, 
located in Germany and Japan, were included in this assessment. That is, 2 
studies [42, 43] were conducted at the Heidelberg Ion Beam Therapy Centre 
(HIT) in Germany, and 1 study [44] was conducted at the Heavy Ion Medical 
Accelerator in Chiba (HIMAC) in Japan. 
In total, 112 patients suffering from chordomas or chondrosarcomas of the 
skull base or paracervical spine were enrolled in the included studies. Of 
those, 53 and 59 patients suffered from chordomas and chondrosarcomas re-
spectively. 79 patients received CIRT in a raster scanning technique; of those, 
25 patients had recurrent tumours and were receiving CIRT as a re-irradia-
tion. The total dose of CIRT ranged from 48 GyE to 60.8 GyE. Additional 
treatment – counting previous treatments – included, inter alia, photon irra-
diation, proton irradiation, CIRT, and surgery.  
The reader is referred to the evidence synthesis for the specific indication 
and the data extraction table (see Table A-8) for more information on the in-
cluded studies. 
                                                             
6 The structure of the MedAustron list was not changed as conducting the evidence 
synthesis alongside the MedAustron list was judged to be more helpful in guiding 
the decision-making process 
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Conclusion: Efficacy and safety 
Due to the heterogeneity of the different tumours (e.g., different prognosis) 
captured with the term “skull base tumours”, the evidence synthesis for spe-
cific indications can be found in the respective sections. 
For skull base tumours, 3 studies were included in this assessment: none of 
the studies were controlled for comparing CIRT to standard irradiation. In-
direct comparisons were not conducted in any of the included studies. 13 
oncologic “skull base” indications were assessed regarding superiority/infe-
riority of CIRT on the basis of the selected endpoints regarding efficacy (OS, 
CSS, DFS, RFS, PFS, LCR, HRQoL) or safety (acute radiation morbidity, 
late radiation morbidity): no evidence was found for 11 oncologic skull base 
indications, and insufficient scientific evidence was found for 2 oncologic in-
dications (chordomas and chondrosarcomas). 
Thus, neither superiority nor inferiority on the basis of the selected endpoints 
regarding efficacy or safety can be concluded from the evidence. That is to 
say, (randomised) controlled studies are needed to clarify whether CIRT is 
more effective than or as effective as, or safer than or as safe as standard ir-
radiation in patients with skull base tumours. 
In the following section results from specific skull base tumours are presented. 
 
5.3.1.1 Chordoma in the skull base  
Definition and epidemiology 
A skull base chordoma is a rare tumour occurring in the bone of the skull 
base, being locally invasive and an aggressive tumour type [45]. Epidemio-
logic data on the incidence and prevalence of chordomas of the skull base in 
Austria was not found. Data from the Surveillance, Epidemiology, and End 
Results (SEER) Program of the National Cancer Institute (NCI) of the Unit-
ed States (1973–2009) of patients suffering from skull base chordomas sug-
gests that the overall incidence of intra- and extracranial skull base chordomas 
is 8.4 per 10 million persons [46]. The TNM system can be used to stage chor-
domas of the skull base even though the prognostic value may be limited [47]. 
Current treatment regimens and prognosis 
The optimal treatment may not be fully clarified yet. However, combinations 
of surgery and radiation therapy using photons or charged particles are po-
tential treatment modalities [47]. Data from the Surveillance, Epidemiology, 
and End Results (SEER) Program of the National Cancer Institute (NCI) of 
the United States (1983-2009) including 416 patients suffering from skull base 
chordomas showed a relative survival at 5 and 10 years of 65% and 32.3% re-
spectively [48]. 
Included studies 
For skull base chordomas, 2 studies were included in this assessment: 1 dose-
escalation case series, pilot study [44] at the Heavy Ion Medical Accelerator 
in Chiba (HIMAC) in Japan and 1 case series study [42] at the Heidelberg 
Ion Beam Therapy Centre (HIT) in Germany. 
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In total, 58 patients were enrolled in the included studies: 53 patients with 
chordomas of the skull base or paracervical spine and 5 patients with low-
grade chondrosarcomas received CIRT. In the dose escalation, case series 
study [44], patients with chordomas of the skull base or paracervical spine 
(n=33) were irradiated with CIRT at a total dose ranging from 45 GyE/16 fr. 
to 60.8 GyE/16 fr. over 4 weeks. In the other included study [42], patients 
with chordomas and low-grade chondrosarcomas (n=25) received CIRT as a 
re-irradiation – after photon irradiation – in an active raster scanning tech-
nique at a total dose of 51 GyE (range: 45-50 GyE). Patients received surgery 
in both of the included studies before CIRT. 
The specific tumour stage was not reported by any of the studies [42, 44]. 
The median age of the patients was 47 years and 50 years in the included 
studies respectively. All patients were aged between 16 and 76 years at the 
start of the enrolment in the clinical trials [42, 44]. The loss to follow-up was 
not adequately reported in any of the included studies [42, 44]. 
Study characteristics, i.e., information on patient population, intervention, 
control and study design of the included studies, can be found in the Appen-
dix (see Table A-8 in the Appendix). 
Efficacy 
Overall survival (OS) 
Overall, 1 out of 2 included studies [44] measured overall survival (OS) at dif-
ferent time points. None of the included studies compared the OS of CIRT 
patients to the OS of patients undergoing conventional radiotherapy. 
1-year OS was not reported in any of the included studies. 
2-year OS was not reported in any of the included studies. 
3-year OS was not reported in any of the included studies. 
4-year OS was not reported in any of the included studies. 
5-year OS was reported in 1 study: the dose escalation study [44], including 
34 cases of chordomas of the skull base and the paracervical spine in 33 pa-
tients undergoing CIRT at a total dose ranging from 48 GyE/16 fr. to 60.8 
GyE/16 fr., observed an OS of 87.7% (95% CI: NR, SE: 7%) at 5 years. 
10-year OS was reported in 1 study: the dose escalation study [44], including 
34 cases of chordomas of the skull base and the paracervical spine in 33 pa-
tients undergoing CIRT at a total dose ranging from 48 GyE/16 fr. to 60.8 
GyE/16 fr., observed an OS of 67% (95% CI: NR, SE: 14%) at 10 years. 
Cause-specific survival (CSS)/Disease-specific survival (DSS) 
The endpoint cause-specific survival (CSS)/disease-specific survival (DSS) 
was not measured by any of the included studies.  
Disease-free survival (DFS) 
The endpoint disease-free survival (DFS) was not measured by the included 
study. 
Recurrence-free survival (RFS) 
The endpoint recurrence-free survival (RFS) was not measured by any of the 
included studies. 
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Progression-free survival (PFS) 
Overall, 1 out of 2 included studies [42] measured progression-free survival 
(PFS) 2 years after irradiation with photons and C-ions in an active raster 
scanning technique. None of the included studies compared the PFS of CIRT 
patients to the PFS of patients undergoing conventional radiotherapy. 
1-year PFS was not reported in any of the included studies. 
2-year PFS was reported in 1 study [42]: the 2-year-local progression-free 
survival (LPFS) was 79.3% (95 CI: NR) for 25 patients with recurrent chor-
domas or chondrosarcomas having been irradiated with a combined therapy 
of photon radiotherapy and CIRT in an active raster scanning technique. 
3-year PFS was not reported in any of the included studies. 
4-year PFS was not reported in any of the included studies. 
5-year PFS was not reported in any of the included studies. 
10-year PFS was not reported in any of the included studies. 
Local control rate (LCR) 
Overall, 1 out of 2 included studies [44] measured the local control rate (LCR) 
at different time points. None of the included studies compared the LCR of 
CIRT patients to the LCR of patients undergoing conventional radiotherapy. 
1-year LCR was not reported in any of the included studies. 
2-year LCR was not reported in any of the included studies. 
3-year LCR was not reported in any of the included studies. 
4-year LCR was not reported in any of the included studies. 
5-year LCR was reported in 1 study: the dose escalation study [44], including 
34 cases of chordomas of the skull base and the paracervical spine in 33 pa-
tients undergoing CIRT at a total dose ranging from 48 GyE/16 fr. to 60.8 
GyE/16 fr., observed an LCR of 85.1% (95 CI: NR, SE: 8%) at 5 years.  
10-year LCR was reported in 1 study: the dose escalation study [44], includ-
ing 34 cases of chordomas of the skull base and the paracervical spine in 33 
patients undergoing CIRT at a total dose ranging from 48 GyE/16 fr. to 60.8 
GyE/16 fr., observed an LCR of 63.8% (95 CI: NR, SE: 19%) at 10 years. 
Health-Related Quality of Life (HRQoL) 
The endpoint Health-Related Quality of Life was not measured by any of the 
included studies. 
Safety 
All 2 included studies measured radiation morbidities [42, 44]: toxicities of 
CIRT occurred in the mucosa, skin and brain.  
Acute radiation morbidity 
All 2 included studies measured acute radiation morbidities using the RTOG 
[44] or CTCAE [42]. No acute radiation morbidity higher than grade 3 oc-
curred in any of the included studies. 1 study did not consistently and ex-
haustively report on acute radiation morbidities according to the severity 
(grades) [42].  
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Grade 1 acute radiation morbidities were reported in 2 studies [42, 44]: the 
dose escalation study [44] observed several grade 1 acute radiation morbidi-
ties in the mucosa and skin, occurring in 6 (17.6%) and 12 (35.3%) out of 33 
cases of chordomas respectively. Another study [42] did not report on acute 
grade 1 morbidities in the skin or mucosa, but observed 5 out of 25 patients 
(20%) developing grade 1 asymptomatic temporal lobe reactions. The same 
study may have selectively reported on acute radiation morbidities since grade 
1 acute radiation morbidities in the mucosa and skin were not reported. 
Grade 2 acute radiation morbidities were reported in both included studies 
[42, 44]: 1 study [44] observed several grade 2 acute radiation morbidities in 
the mucosa and skin, occurring in 6 (17.6%) and 1 (2.9%) out of 33 cases of 
chordomas respectively. Another study (n=25) [42] observed grade 2 mucosi-
tis and hypacasis, occurring in 1 patient (4%) and 3 patients (12%) respec-
tively. 
Grade 3 acute radiation morbidities were reported in both studies: 1 study 
(n=25) [42] observed 1 grade 3 osteoradionecrosis (4%) and another study 
[44] observed no grade 3 acute radiation morbidities. 
Grade 4 acute radiation morbidities were reported in both, and observed in 
none of the included studies [42, 44]. 
Late radiation morbidity 
Overall, 1 out of 2 included studies measured late radiation morbidities using 
the RTOG/EORTC criteria [44]. Another study [42] did not report on wheth-
er late radiation morbidities occurred. 
Grade 1 late radiation morbidities were reported in 1 study [44]: toxicities 
were observed in the mucosa, skin and brain, with 2 (5.9%), 2 (5.9%) and 5 
(14.7%) cases developing grade 2 late radiation morbidities in those areas re-
spectively. 
Grade 2 late radiation morbidities were reported in 1 study [44]: 1 grade 2 
radiation morbidity occurred in 1 out of 34 cases of chordomas (2.9%). 
Grade 3 late radiation morbidities were reported in 1 study [44]: no grade 3 
late radiation morbidity occurred in 34 cases of chordomas in this study. 
Grade 4 late radiation morbidities were reported in 1 study [44]: no grade 4 
late radiation morbidity occurred in 34 cases of chordomas in this study. 
Conclusion 
For chordomas of the skull base, 2 studies were included to assess the effica-
cy and safety of CIRT: none of the studies were controlled, comparing CIRT 
to standard irradiation. Thus, neither inferiority nor superiority of CIRT on 
the basis of the selected endpoints regarding efficacy (OS, CSS, DFS, RFS, 
PFS, LCR, HRQoL) or safety (acute radiation morbidity, late radiation mor-
bidity) can be concluded from the evidence. That is to say, (randomised) con-
trolled studies are needed to clarify whether CIRT is more effective than or 
as effective as, or safer than or as safe as standard irradiation in patients with 
chordomas of the skull base. 
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5.3.1.2 Chondrosarcoma of the skull base 
Definition and epidemiology 
Chondrosarcoma of the skull base is a rarely occurring malignant tumour [47]. 
Chondrosarcomas are the second most frequent malignant tumours and have 
a peak age of occurrence between 50 and 70 years [41]. Epidemiologic data on 
the incidence and prevalence of chordomas of the skull base in Austria was 
not found. The TNM system can be used to stage chondrosarcomas of the 
skull base, even though the prognostic value may be limited [47]. 
Current treatment regimens and prognosis 
Current treatment modalities of chondrosarcomas include one of the follow-
ing: radical compartmentalised resection or intensity-modulated stereotactic 
radiation therapy (IMSRT) [41]. Data from the Surveillance, Epidemiology, 
and End Results (SEER) Program of the National Cancer Institute (NCI) of 
the United States (1983–2009) including 269 patients suffering from skull base 
chondrosarcomas showed a 5-year and 10-year relative survival of 81.8% and 
49.5% respectively [48]. 
Included studies 
For chondrosarcomas of the skull base, 1 clinical study [43] from the Heidel-
berg Ion Beam Therapy (HIT) Centre was included in this assessment. In to-
tal, 54 patients with low-grade and intermediate-grade chondrosarcomas of 
the skull base were enrolled in the included clinical study. The patients were 
treated with CIRT, after surgery, using a raster scan technique at a median 
dose of 60 Cobalt Gray Equivalents (CGE) in 7 fractions at 3.0 CGE per frac-
tion. 
Of the 54 tumours, 37 (68.5%) and 12 (22.2%) were staged as grade 1 and 
grade 2 tumours respectively. Also, 5 (9.3%) of the tumours were staged as 
grade 1 but had focal grade 2 areas. The median age of the patients was 46 
years, and all patients were aged between 6 and 74 at the start of the enrol-
ment. The median follow-up time was 33 months (range: 3–84) and loss to 
follow-up was not reported in the included study. 
Study characteristics, i.e., information on patient population, intervention 
and study design of the included study, can be found in the Appendix (see 
Table A-8 in the Appendix). 
Efficacy 
Overall survival (OS) 
The included study measured overall survival (OS) of 54 patients with low-
grade and intermediate-grade chondrosarcomas of the skull base having un-
dergone carbon ion therapy (CIRT) at 3 and 4 years after CIRT [43]. No com-
parison between OS of CIRT patients and OS of patients undergoing conven-
tional radiotherapy was undertaken. 
1-year OS was not reported in the included study. 
2-year OS was not reported in the included study. 
3-year OS was reported in the included study [43]: the case series study ob-
served a 3-year OS of 98.2% (95% CI: 94.6–100%) for 54 CIRT patients with 
chondrosarcomas having undergone CIRT in a raster scan technique at a 
median dose of 60 Cobalt Gray Equivalents (CGE) in 7 fractions. 
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4-year OS was reported in the included study [43]: the case series study ob-
served a 4-year OS of 98.2% (95% CI: 94.6–100%) for 54 CIRT patients with 
chondrosarcomas having undergone CIRT in a raster scan technique at a 
median dose of 60 Cobalt Gray Equivalents (CGE) in 7 fractions.  
5-year OS was not reported in the included study7. 
10-year OS was not reported in the included study. 
Cause-specific survival (CSS)/Disease-specific survival (DSS) 
The endpoint cause-specific survival (CSS)/disease-specific survival (DSS) 
was not measured by the included studies. 
Disease-free survival (DFS) 
The endpoint disease-free survival (DFS) was not measured  
by the included study. 
Recurrence-free survival (RFS) 
The endpoint recurrence-free survival (RFS) was not measured  
by the included study. 
Progression-free survival (PFS) 
The endpoint progression-free survival (PFS) was not measured  
by the included study. 
Local control rate (LCR) 
The included study [43] measured the local control rate (LCR) of 54 patients 
with low-grade and intermediate-grade chondrosarcomas of the skull base 
having undergone carbon ion therapy (CIRT) patients at 3 and 4 years. 
1-year LCR was not reported in the included study. 
2-year LCR was not reported in the included study. 
3-year LCR was reported in the included study [43]: the case series study ob-
served a 3-year cumulative local control rate of 96.2% (95% CI: 88.8–100%) 
for 54 CIRT patients with chondrosarcomas having undergone CIRT in a 
raster scan technique at a median dose of 60 Cobalt Gray Equivalents (CGE) 
in 7 fractions. 
4-year LCR was reported in the included study [43]: the case series study ob-
served a 4-year cumulative local control rate of 89.8% (95% CI, 75.6–100%) 
at 4 years for 54 CIRT patients with chondrosarcomas having undergone 
CIRT in a raster scan technique at a median dose of 60 Cobalt Gray Equiva-
lents (CGE) in 7 fractions. 
5-year LCR was not reported in the included study. 
10-year LCR was not reported in the included study. 
 
                                                             
7 The included study stated that in the abstract that the 5-year OS for 54 patients with 
chondrosarcomas was 98.2% (CI: NR). In the results section, this rate is referred to 
be for 3 and 4 years respectively. It is also stated that only 9 patients survived 5 years 
potentially without having calculated the respective 5-year OS. 
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Health-Related Quality of Life (HRQoL) 
The endpoint Health-Related Quality of Life (HRQoL) was not measured by 
the included studies. 
Safety 
Acute radiation morbidity 
The included study [43] did report on acute radiation morbidities using the 
CTCAE v3.0 criteria8. No grade 4, and 1 grade 3, acute radiation morbidities 
occurred. Some grade 1-2 acute radiation morbidities were also observed. 
Grade 1 acute radiation morbidities were reported in the included study [43]: 
the case series study observed 2 patients (3.7%) developing grade 1 acute ra-
diation morbidities in the mucosa.  
Grade 2 acute radiation morbidities were not reported in the included study. 
Grade 3 acute radiation morbidities were reported in the included study [43]: 
the case series study included 54 patients and observed 1 patient (1.9%) de-
veloping grade 3 mucositis. 
Grade 4 acute radiation morbidities were reported in the included study [43]: 
the case series study observed no grade 4 acute radiation morbidities. 
Moreover, the same study observed parotitis (grade: NR) occurring in the 
acute phase in 1 (1.9%) out of 54 CIRT patients. 
Late radiation morbidity 
The included study [43] did report on late radiation morbidities using the 
RTOG/EORTC criteria8.  
Grade 1 late radiation morbidities and grade 2 late radiation morbidities 
were reported in 1 study, but not separated from each other: the case series 
study [43] with 54 patients with chondrosarcomas observed 5 patients (9.3%) 
developing grade 1 or 2 late radiation morbidities. 
Grade 3 late radiation morbidities were reported in 1 study: the case series 
[43] of 54 patients with chondrosarcomas observed 1 grade 3 late radiation 
morbidity (1.9%). 
Grade 4 late radiation morbidities were reported in 1 study: the case series 
[43] of 54 patients with chondrosarcomas observed no grade 4 late radiation 
morbidities. 
Conclusion 
For chondrosarcoma of the skull base, 1 study [43] was included: the study 
was not controlled, comparing CIRT to standard irradiation. Thus, neither 
inferiority nor superiority of CIRT on the basis of the selected endpoints re-
garding efficacy (OS, CSS, DFS, RFS, PFS, LCR, HRQoL) or safety (acute 
radiation morbidity, late radiation morbidity) can be concluded from the ev-
idence. That is to say, (randomised) controlled studies are needed to clarify 
whether CIRT is more effective than or as effective as, or safer than or as 
safe as standard irradiation in chondrosarcoma of the skull base. 
                                                             
8 However, the study did not consistently and exhaustively report on acute radiation 
morbidities according to the severity (grades).  
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5.3.1.3  Meningioma 
Definition and epidemiology 
In this section, the evidence regarding the use of CIRT for 2 indications ac-
cording to the list of potential CIRT indications will be described: meningi-
oma grade I and meningioma grade II-III. A meningioma is a tumour arising 
from the meninges of the brain or the spinal cord [41]. Epidemiologic data 
on the incidence and prevalence of meningioma of the skull base in Austria 
was not found. 
Data from the Surveillance, Epidemiology, and End Results (SEER) Program 
of the National Cancer Institute (NCI) of the United States (2004 and 2011) 
show that the average age-adjusted incidence rate of meningioma was 7.62 per 
100,000 annually [49]. 
The World Health Organisation (WHO) scheme is used to classify meningi-
oma. One can distinguish between the following grades of meningiomas: 
WHO grade I (benign meningiomas without a higher grade lesion to be elab-
orated using morphologic criteria), WHO grade II (e.g., atypical, choroid 
meningiomas) and WHO grade III (including anaplastic, rhabdoid as well as 
papillary meningiomas) [50]. 
Current treatment regimens and prognosis 
The treatment of meningiomas depends on the WHO grade of the disease and 
may include watchful observation, neurosurgery and/or radiation therapy [41]. 
Data from the Surveillance, Epidemiology, and End Results (SEER) Program 
of the National Cancer Institute (NCI) of the United States (2004 and 2011) 
shows 5-year relative survival rates of benign, borderline malignant and ma-
lignant meningiomas of 85.6% 82.3% and 66.0% respectively [49]. 
Included studies, efficacy and safety 
For meningiomas, no study was eligible to be included in the qualitative 
synthesis. No evidence was found to answer the research question. 
Conclusion 
At present, there is no scientific evidence indicating superiority or inferiority 
of CIRT regarding efficacy or safety for meningiomas. 5 case series studies 
were identified, but none of those studies met the inclusion criteria for the 
qualitative synthesis. 
 
5.3.1.4 Craniopharyngioma 
Definition and epidemiology 
Craniopharyngiomas are rare tumours arising in the remnants of the so-called 
Rathke’s pouch (on a line between the nasopharynx and the diencephalon). 
Usually, these tumours occur in the pituitary stalk – to be found in the supra-
sellar region – and adjacently located to the optic chiasm. However, a small 
proportion of craniopharyngiomas also occur in the optic system, third ven-
tricle or the sella [51]. 
Epidemiologic data on the incidence and prevalence of craniopharyngioma in 
Austria was not found. 
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A recent study [52] using data from the Surveillance, Epidemiology, and End 
Results (SEER) Program of the National Cancer Institute (NCI) of the Unit-
ed States (2004 and 2008) calculated the age-adjusted incidence rate to be 
1.7 cases per 1,000,000 persons. However, the study found a bimodal age dis-
tribution regarding the incidence rate of craniopharyngiomas. That is, peaks 
regarding the incidence rate were observed in children (aged 0-19 years) and 
adults (aged 40-79 years), with an incidence rate of 1.9 and 2.1 cases per 
1,000,000 persons in those age groups respectively. 
Current treatment regimens and prognosis 
The treatment of craniopharyngiomas includes surgery (in almost all cases). 
Moreover, radiation therapy (RT) may be indicated if patients underwent 
partial surgical resection or if disease-recurrence occurred followed by a treat-
ment aimed to be a gross total resection. The treatment modalities of RT in-
clude, inter alia, intensity-modulated radiation therapy (IMRT), stereotactic 
radiotherapy, and proton beam therapy [51]. 
A recent study [52] using data from the Surveillance, Epidemiology, and End 
Results (SEER) Program of the National Cancer Institute (NCI) of the Unit-
ed States (2004 and 2008) calculated the 1- and 3-year overall survival of 644 
patients with a craniopharyngioma-diagnosis, with an OS of 91.5% (95% CI, 
88.9%–93.5%) and 86.2% (95% CI, 82.7%–89.0%) at 1 and 3 years respec-
tively. 
Included studies, efficacy and safety 
For craniopharyngioma, no study was eligible to be included in this assess-
ment. Thus, no evidence was found to answer the research question. 
Conclusion 
At present, there is no scientific evidence indicating superiority or inferiority 
regarding the use of carbon ion radiotherapy (CIRT) for craniopharyngioma. 
 
5.3.1.5  Pituitary adenoma 
Pituitary adenomas are intracranial neoplasms that constitute, besides car-
cinomas, the largest proportion of all pituitary neoplasms. Those tumours can 
be either benign or invasive [53]. Epidemiologic data on the incidence and 
prevalence of pituitary adenomas was not found. 
Included studies, efficacy and safety 
For pituitary adenoma, no study was eligible to be included in this assessment. 
Thus, no evidence was found to answer the research question. 
Conclusion 
At present, there is no scientific evidence indicating superiority or inferiority 
regarding the use of carbon ion radiotherapy (CIRT) for pituitary adenomas. 
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5.3.1.6 Acoustic neuroma 
Definition and epidemiology 
Acoustic neurinomas are Schwann cell-derived tumours arising in the cranial 
nerve [54]. Epidemiologic data on the incidence and prevalence of acoustic 
neurinomas was not found. 
Current treatment regimens and prognosis 
For acoustic neurinomas, one, or a combination of the following treatment 
options may be used: surgery, radiation therapy (RT), and observation [54]. 
Survival rates for acoustic neurinomas were not found. 
Included studies, efficacy and safety 
For acoustic neurinoma, no study was included in this assessment. Thus, no 
evidence was found to answer the research question. 
Conclusion 
At present, there is no scientific evidence indicating superiority or inferiority 
regarding the use of carbon ion radiotherapy (CIRT) for acoustic neuroma. 
 
5.3.1.7 Other neurinomas 
Due to the lack of precision of this indication, no further information (i.e., 
epidemiological data) on “other neurinomas” is presented in this section. 
Included studies, efficacy and safety 
For “other neurinomas”, no study was included in this assessment. Thus, no 
evidence was found to answer the research question. 
Conclusion 
At present, there is no scientific evidence indicating superiority or inferiority 
regarding the use of carbon ion radiotherapy (CIRT) for “other neurinomas”. 
 
5.3.1.8 Glomus tumour 
Definition and epidemiology 
Glomus tumours are rare tumours arising from the “glomus body”: there are 
solitary and multiple glomus tumours [55]. Epidemiologic data on the inci-
dence and prevalence of glomus tumours was not found for Austria. 
Current treatment regimens and prognosis 
Resection can be described as a treatment modality for solitary glomus tu-
mours [55]. No information regarding the prognosis of glomus tumours was 
found. 
Included studies, efficacy and safety 
For glomus tumours, no study was included in this assessment. Thus, no 
evidence was found to answer the research question. 
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Conclusion 
At present, there is no scientific evidence indicating superiority or inferiority 
regarding the use of carbon ion radiotherapy (CIRT) for glomus tumours. 
 
5.3.1.9 Retinoblastoma 
Definition and epidemiology 
Retinoblastoma are relatively rare paediatric tumour arising in the retina [56]. 
In Austria, the age-adjusted incidence rate of retinoblastomas was 1.5 cases 
per 1,000,000 children and adolescents (0-19 years old) between 2002 and 
2012 [57]. 
Current treatment regimens and prognosis 
The current treatment modalities may include one, or more of the following: 
radiation therapy, local treatment (i.e., cryotherapy, laser therapy, brachy-
therapy), and chemotherapy [56]. Epidemiologic data on the survival specif-
ically for this tumour was neither found for Austria nor in the Surveillance 
Epidemiology and End Results (SEER) database. According to recent data 
from Statistics Austria, the 5-year survival of all paediatric tumour patients 
is 84.3% for children (0-14 years old) and 83.8% for adolescents (15-19 years 
old) [58]. 
Included studies, efficacy and safety 
For retinoblastomas, no study was included in this assessment. Thus, no ev-
idence was found to answer the research question. 
Conclusion 
At present, there is no scientific evidence indicating superiority or inferiority 
regarding the use of carbon ion radiotherapy (CIRT) for retinoblastomas. 
 
5.3.1.10 Lacrimal gland tumours 
Definition and epidemiology 
Lacrimal gland tumours are rare types of eye tumours [59]. Epidemiological 
data regarding the incidence and prevalence specifically for lacrimal gland 
tumours was not found.  
Current treatment regimens and prognosis 
The treatment of lacrimal gland tumours is dependent on the tumour type 
[59]. Epidemiological data regarding the survival specifically for lacrimal 
gland tumours was not found. 
Included studies, efficacy and safety 
For lacrimal gland tumours, no study was eligible to be included in this as-
sessment. Thus, no evidence was found to answer the research question. 
Conclusion 
At present, there is no scientific evidence indicating superiority or inferiority 
regarding the use of carbon ion radiotherapy (CIRT) for lacrimal gland tu-
mours. 
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5.3.1.11 Sarcomas incl. Ewing’s sarcoma in the skull base 
Definition and epidemiology 
Sarcomas in the head and neck area are rare tumours and include, inter alia, 
osteosarcomas, rhabdomyosarcomas, chondrosarcomas, and soft tissue sarco-
mas. Within sarcomas in the head and neck region, Ewing’s sarcomas are less 
commonly occurring [60]. Epidemiologic data regarding the incidence and 
prevalence specifically of sarcomas in the ENT area in Austria was not found. 
Current treatment regimens and prognosis 
Treatment modalities may depend on the histologic subtype of a tumour and 
include one, or a combination of the following treatments: surgery, adjuvant 
radiotherapy or adjuvant chemotherapy [60]. Epidemiologic data regarding 
the prognosis of sarcomas in the ENT area in Austria was not found.  
Included study, efficacy and safety 
For skull base sarcomas, no study was included in this assessment. Thus, no 
evidence was found to answer the research question. 
Conclusion 
At present, there is no scientific evidence indicating superiority or inferiority 
regarding the use of carbon ion radiotherapy (CIRT) for sarcomas of the skull 
base (incl. Ewing’s sarcoma). 
 
5.3.1.12 Rhabdomyosarcomas of the skull base and orbit 
Definition and epidemiology 
Rhabdomyosarcomas are rare, malignant and considered to be paediatric tu-
mours [61]. Approximately 25% of all rhabdomyosarcomas occur in the head 
and neck region [62]. Epidemiologic data regarding the incidence and preva-
lence specifically for rhabdomyosarcomas in the skull base area in Austria 
was not found. 
Current treatment regimens and prognosis 
Treatment modalities may include one, or a combination of the following 
treatments: surgery, radiation therapy, chemotherapy [62]. Epidemiologic 
data regarding survival specifically for rhabdomyosarcomas in the skull base 
area in Austria was not found. 
Included study, efficacy and safety 
For rhabdomyosarcoma of the skull base and orbit, no study was included in 
this assessment. Thus, no evidence was found to answer the research ques-
tion. 
Conclusion 
At present, there is no scientific evidence indicating superiority or inferiority 
regarding the use of carbon ion radiotherapy (CIRT) for rhabdomyosarcoma 
of the skull base and orbit. 
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5.3.2 Eye tumours 
In this section, one will find an evidence synthesis for choroid melanoma. 
Evidence synthesises for other tumours near the eye may be found in Section 
5.3.1 Skull base tumours. 
 
5.3.2.1 Choroid melanoma  
Definition and epidemiology  
Choroid melanoma is a rare cancer type to be found in the choroidea of the 
uvea (middle eye skin) [63]. A study [64] using data from the Surveillance, 
Epidemiology and End Results (SEER) database measured the mean age-ad-
justed incidence of uveal melanoma to be 5.1 per 1,000,000 (95% CI: 4.2-6.1) 
based on 7,516 patients with uveal melanomas in the United States (1973–
2012). 
Current treatment regimens and prognosis 
According to the National Cancer Institute [63] (NCI), the management of 
uveal melanomas depends on the histology: small choroid melanomas are, 
for instance, poorly understood, leading to doubt whether treatment of this 
disease has a preventive effect of metastases. Radiation therapy may be used 
to treat larger choroid melanomas: brachytherapy is most commonly used to 
treat intraocular melanomas, but newer forms of RT using charged particles 
can also be described as another current treatment form. In the past, eye re-
moval (enucleation) was the standard treatment for primary choroid mela-
noma [63]. A study [64] using data from the Surveillance, Epidemiology and 
End Results (SEER) database measured the mean overall 5-year relative sur-
vival rate to be 79.8% (±5.8) (1973–2012). 
Included study, efficacy and safety 
For choroid melanoma, no study was eligible to be included in this assess-
ment. Thus, no evidence was found to answer the research question.  
Conclusion 
At present, there is no scientific evidence indicating superiority or inferiority 
regarding the use of carbon ion radiotherapy (CIRT) for choroid melanoma.  
 
5.3.3 Brain tumours 
Definition and epidemiology 
The evidence regarding efficacy and safety of CIRT was assessed for the fol-
lowing 6 brain tumours: WHO grade II gliomas, WHO grade III glioma, gli-
oblastoma (WHO grade IV), ependymoma, medulloblastoma, and “other child-
hood brain tumours”9. 
Typically, brain tumours are classified using the WHO Classification of Cen-
tral Nervous System (CNS) tumours [65]. Brain tumours can be localised, 
regional, distant and unstaged (unknown): localised cancer refers to the stage 
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when the cancer is only found in the part of the body in which the cancer 
started. Cancer is regional if the cancer already spread to (an)other part(s) of 
the body and distant if cancer has metastasised as well [66]. 
Data from Statistics Austria, including all tumours in the brain and central 
nervous system (CNS) in Austria, shows an age-adjusted incidence rate of 
9.0 per 100,000 persons in 2015. In addition, those tumours were prevalent 
in 1,948 men and 2,043 women in the same year [67]. Data from the Surveil-
lance, Epidemiology, and End Results (SEER) Program of the National Can-
cer Institute (NCI) of the United States (2010-2014) calculated that 6.4 per 
100,000 persons developed cancer within the brain and another nervous sys-
tem [66]. 
Current treatment regimens and prognosis 
Epidemiologic data from Statistics Austria regarding relative survival (RS) of 
all tumours in the brain and nervous system between 2003 and 2007 shows a 
1-, 3-, 5- and 10-year RS of 59.8%, 39.1%, 33.9% and 28.7% in Austria re-
spectively [67]. Data from the Surveillance, Epidemiology, and End Results 
(SEER) Program of the National Cancer Institute (NCI) of the United States 
(2007–2013) shows a 5-year relative survival of 33.6%. Moreover, the 5-year 
RS for localised, regional, distant and unstaged brain and nervous system tu-
mours was 36.5%, 21.4%, 33.9% and 25.7% respectively [66]. 
Included studies 
For brain tumours, 2 studies [68, 69] conducted at the Heavy Ion Medical 
Accelerator in Chiba (HIMAC) in Japan were included in this assessment: 
1 case series study and 1 dose-escalation, case series study. 
In total, 62 patients suffered from low grade and high grade gliomas: 14 pa-
tients suffered from WHO grade II glioma (diffuse astrocytomas), and the 
other 48 patients suffered from high-grade brain tumours, with 16 and 32 
patients suffering from anaplastic astrocytoma (WHO grade III) and glio-
blastoma multiforme (WHO grade IV) respectively. 48 patients received 
carbon ion boost after x-ray radiotherapy and 14 received CIRT as the main 
therapy. The dose ranged from 16.8 to 55.2 GyE. Additional treatment – be-
fore, during, or after the irradiation – included, inter alia, surgery, x-ray ra-
diotherapy, and salvage treatment (e.g., chemotherapy). 
The reader is referred to the evidence synthesis for the specific indication 
and the data extraction table in the Appendix (Table A-3) for more informa-
tion on the included studies and the efficacy and safety for CIRT for the spe-
cific indications. 
Conclusion, efficacy & safety 
Due to the heterogeneity of the different tumours (e.g., different prognosis) 
captured with the term brain tumours, the evidence synthesis for specific 
indications can be found in the respective sections. 
2 studies on brain tumours were included in this assessment. None of the 
studies were controlled, comparing CIRT to standard irradiation. In adddi-
tion, no indirect comparisons were conducted by any of the included studies. 
6 oncologic indications were assessed regarding superiority/inferiority of 
CIRT on the basis of the selected endpoints regarding efficacy (OS, CSS, 
DFS, RFS, PFS, LCR, HRQoL) or safety (acute radiation morbidity, late 
radiation morbidity): insufficient scientific evidence was found for WHO 
grade II gliomas, WHO grade III gliomas, and glioblastomas (WHO grade 
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IV gliomas). No scientific evidence was found for the remaining 3 indications 
(ependymoma, medulloblastoma, and “other childhood brain tumours”). 
Thus, neither superiority nor inferiority on the basis of the selected endpoints 
regarding efficacy (OS, CSS, DFS, RFS, PFS, LCR, HRQoL) or safety (acute 
radiation morbidity, late radiation morbidity) can be concluded from the ev-
idence. That is to say, that (randomised) controlled trials are needed to clari-
fy whether CIRT is more effective than or as effective as, or safer than or as 
safe as standard irradiation in patients. 
In the following section results from specific brain tumours are presented. 
 
5.3.3.1 Low-grade glioma (WHO grade II brain tumours) 
Definition and epidemiology 
A glioma is a primary brain tumour arising within the parenchyma of the 
brain. The histologic features of gliomas are similar to the ones of normal 
glial cells, such as – inter alia – astrocytes or oligodendrocytes [65]. The stage 
of gliomas can be classified along the WHO Classification of Central Nerv-
ous System tumours [65]. In this context, histopathologic appearance as well 
as “well-established molecular parameters” will be decisive for tumour stage 
grading [65]: one can distinguish between low-grade glioma (WHO grade II) 
[70] or high-grade glioma (WHO grade III-IV) [71]. 
Epidemiologic data regarding the incidence and prevalence of low-grade gli-
oma was not found. However, data from Statistics Austria including all tu-
mours in the brain and central nervous system in Austria shows an age-ad-
justed incidence rate of 9.0 per 100,000 persons in 2015. Those tumours were 
prevalent in 1,948 men and 2,043 women in the same year [67]. Data from 
the Surveillance, Epidemiology, and End Results (SEER) Program of the 
National Cancer Institute (NCI) of the United States (2010-2014) calculated 
that 6.4 per 100,000 persons developed cancer within the brain and another 
nervous system [66].  
Current treatment regimens and prognosis 
Generally speaking, the aim of treating low-grade gliomas is to prolong sur-
vival while minimising morbidities. Surgery, radiotherapy (RT) as well as 
chemotherapy may be treatment modalities even though controversies are 
existent when it comes to both the role/timing of certain therapies (i.e. RT, 
chemotherapy) and the treatment approach of surgeries (i.e. aggressive treat-
ment vs. delayed intervention if disease is at an early stage with limited symp-
toms) [72].  
Epidemiologic data on survival rates specifically for gliomas was not found 
in Austria. However, epidemiologic data regarding relative survival (RS) of 
all tumours in the brain and nervous system between 2003 and 2007 shows a 
1-, 3-, 5- and 10-year RS of 59.8%, 39.1%, 33.9% and 28.7% in Austria re-
spectively [67]. No data was found on the prognosis specifically for gliomas. 
Data from the Surveillance, Epidemiology, and End Results (SEER) Program 
of the National Cancer Institute (NCI) of the United States (2007–2013) shows 
a 5-year relative survival of 33.6% for all brain and nervous system tumours 
[66]. 
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Included studies 
For low-grade gliomas (WHO grade II), 1 study [69] was eligible to be includ-
ed in this assessment: a phase I/II dose-escalation study at the Heavy Ion 
Medical Accelerator in Chiba (HIMAC). In total, 14 patients with diffuse as-
trocytoma (WHO grade II) were enrolled in the included study and treated 
with CIRT at a total dose, ranging from 46.2-55.2 GyE in 24 fractions (6 
weeks). The patients received surgery before, and salvage treatment consist-
ed of chemotherapy (n=2), operation (n=6) and RT (n=1). 
The median age was 32.5 years, and all patients were aged between 18 and 66 
years in the included clinical trial. The patients were followed for 62 months 
(range: 10-152), and loss to follow-up was not reported in the included study. 
Study characteristics, i.e. information on patient population, intervention, 
control and study design of the included studies, can be found in the Ap-
pendix (Table A-3). 
Efficacy 
Overall survival (OS) 
The included study [69] reported on the overall survival (OS) of CIRT pa-
tients with WHO grade II gliomas at 5 and 10 years. No comparison between 
the OS of CIRT patients and the OS of patients undergoing conventional 
therapy was undertaken. 
1-year OS was not reported in the included study. 
2-year OS was not reported in the included study. 
3-year OS was not reported in the included study. 
4-year OS was not reported in the included study. 
5-year OS was reported in the included study [69], and an OS of 43% (95% 
CI: NR; SEM: 13%) for 14 patients with WHO grade II gliomas, undergoing 
CIRT was observed at 5 years. 
10-year OS was reported in the included study [69] and an OS of 36% (95% 
CI: NR, SEM: 13%) for 14 patients with WHO grade II gliomas, undergoing 
CIRT was observed at 5 years. 
Cause-specific survival (CSS)/Disease-specific survival (DSS) 
The endpoint cause-specific survival (CSS)/disease-specific survival (DSS) 
was not measured by the included study. 
Disease-free survival (DFS) 
The endpoint disease-free survival (DFS) was not measured  
by the included study. 
Recurrence-free survival (RFS) 
The endpoint recurrence-free survival (RFS) was not measured  
by the included study. 
Progression-free survival (PFS) 
The included study [69] reported on the progression-free survival (PFS) of 
CIRT patients with WHO grade II gliomas at 5 years. No comparison be-
tween the PFS of CIRT patients and the PFS of patients undergoing conven-
tional therapy was undertaken. 
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1-year PFS was not reported in the included study. 
2-year PFS was not reported in the included study. 
3-year PFS was not reported in the included study. 
4-year PFS was not reported in the included study. 
5-year PFS was reported in the included study [69]: the dose-escalation study 
observed a PFS of 36% (95% CI: NR; SE: 13%) for 14 patients with WHO 
grade II gliomas at 5 years (low-dose group: 11%; high-dose group: 80%).10 
10-year PFS was not reported in the included study. 
Local control rate (LCR) 
The endpoint local control rate (LCR) was not measured  
by the included study. 
Health-Related Quality of Life (HRQoL) 
The endpoint Health-Related Quality of Life (HRQoL) was not measured  
by the included study. 
Safety 
Acute radiation morbidity 
The included study [69] measured acute radiation morbidities using the 
RTOG criteria. Several grade 0-1 acute radiation morbidities and 2 grade 2 
acute radiation morbidities occurred. 
Grade 1 acute radiation morbidities were measured by the included study [69]. 
However, it was summed up with grade 0 acute radiation morbidities and, 
thus, the exact data regarding grade 1 acute radiation morbidities could not 
be retrieved from the study. Grade 0-1 acute radiation morbidities occurred 
in 12 out of 14 patients (86%). 
Grade 2 acute radiation morbidities were measured by the included study [69]: 
2 out of 14 patients (14%) developed grade 2 acute radiation morbidities in 
this dose-escalation study including patients with WHO grade II diffuse as-
trocytomas. 
Grade 3 acute radiation morbidities were measured by the included study [69]: 
no grade 3 acute radiation morbidities were observed in the 14 patients with 
diffuse astrocytomas (WHO grade II) having undergone CIRT. 
Grade 4 acute radiation morbidities were measured by the included study [69]: 
no grade 4 acute radiation morbidities were observed in the 14 patients with 
diffuse astrocytomas (WHO grade II) having undergone CIRT. 
Late radiation morbidity 
The included study measured late radiation morbidities using the RTOG/ 
EORTC criteria. Several grade 1 radiation morbidities occurred in the skin 
and brain, and 2 patients developed grade 2 late radiation morbidities in the 
brain. 
                                                             
10 In addition, the same study [69] measured the median progression-free survival time 
(m-PFS) and observe an m-PFS of 33 months (low dose: 18; high dose: 91). 
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Grade 1 late radiation morbidities were measured by the included study [69]: 
grade 1 late radiation morbidities were observed in the skin and brain region, 
with 1 (7%) and 8 (66.7%) out of 12 CIRT patients with diffuse astrocytomas 
(WHO grade II) developing those radiation morbidities in those regions re-
spectively. 
Grade 2 late radiation morbidities was measured by the included study [69]: 
grade 2 late radiation morbidities were observed in the brain region, with 2 
out of 12 CIRT patients (16.7%). 
Grade 3 late radiation morbidities were measured by the included study [69]: 
no grade 3 late radiation morbidities were observed. 
Grade 4 late radiation morbidities were measured by the included study [69]: 
no grade 4 late radiation morbidities were observed. 
Conclusion 
For low-grade gliomas (WHO grade II), 1 study was eligible to be included 
in the assessment: the study was not controlled, comparing CIRT to stand-
ard irradiation. Thus, neither inferiority nor superiority of CIRT on the basis 
of the selected endpoints regarding efficacy (OS, CSS, DFS, RFS, PFS, LCR, 
HRQoL) or safety (acute radiation morbidity, late radiation morbidity) can 
be concluded from the evidence. That is to say, (randomised) controlled stud-
ies are needed to clarify whether CIRT is more effective than or as effective 
as, or safer than or as safe as standard irradiation in patients with low-grade 
gliomas. 
 
5.3.3.2 High-grade glioma (WHO grade III-IV) 
Definition and epidemiology 
In this assessment, high-grade gliomas consist of all WHO grade III-IV brain 
and nervous system tumours: both gliomas (WHO grade III) and glioblasto-
mas (WHO grade IV) [71]. A glioma is a primary brain tumour arising with-
in the parenchyma of the brain. The histologic features of gliomas are simi-
lar to the ones of normal glial cells, such as – inter alia – astrocytes or oligo-
dendrocytes [65]. 
The stage of gliomas can be classified along the WHO Classification of Cen-
tral Nervous System tumours [65]. In this context, histopathologic appear-
ance as well as “well-established molecular parameters” will be decisive for 
tumour stage grading [65]. Epidemiologic data regarding the incidence and 
prevalence of gliomas was not found. However, data from Statistics Austria 
including all tumours in the brain and central nervous system shows an age-
adjusted incidence rate of 9.0 per 100,000 persons in Austria in 2015. More-
over, those tumours were prevalent in 1,948 men and 2,043 women in the 
same year [67]. Data from the Surveillance, Epidemiology, and End Results 
(SEER) Program of the National Cancer Institute (NCI) of the United States 
(2010–2014) calculated that 6.4 per 100,000 persons developed cancer within 
the brain and other nervous system [66]. 
In addition, the high-grade gliomas can be localised, regional, distant and un-
staged (unknown): localised cancer refers to the stage when the cancer is only 
found in the part of the body in which the cancer started. Cancer is regional 
if cancer already spread to another part of the body and distant if cancer has 
metastasised as well. Two-thirds of all brain and nervous system cancer 
(77.1%) are diagnosed when the cancer is localised [66].  
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Current treatment regimens and prognosis 
The treatment of high-grade gliomas may include – depending on the tumour-
subtype – the following modalities: surgical resection, adjuvant RT, intensi-
ty-modulated RT (other non-established therapies: interstitial brachythera-
py, heavy particle RT) [71, 73]. Epidemiologic data on survival rates specifi-
cally for gliomas was not found in Austria. However, epidemiologic data re-
garding relative survival (RS) of all tumours in the brain and nervous system 
between 2003 and 2007 shows a 1-, 3-, 5- and 10-year RS of 59.8%, 39.1%, 
33.9% and 28.7% in Austria respectively [67]. 
No data regarding the prognosis specifically for high-grade gliomas was found. 
Data from the Surveillance, Epidemiology, and End Results (SEER) Program 
of the National Cancer Institute (NCI) of the United States (2007–2013) shows 
a 5-year relative survival of 33.6% for all brain and nervous system tumours 
[66]. 
Included studies 
For high-grade gliomas (WHO grade III-IV), 1 case series study [68] from 
the Heavy Ion Medical Accelerator in Chiba (HIMAC) was identified and el-
igible to be included in this assessment. In total, 48 patients were enrolled in 
the included study and were treated with a combined treatment of x-ray ra-
diotherapy (50 GyE in 25 fractions), chemotherapy (ACNU) and carbon ion 
radiotherapy (CIRT: 16.8-24.8 GyE in 8 fractions over 2 weeks). Of the 48 
patients, patients had either glioblastomas multiforme (GBM) or anaplastic 
astrocytomas (AA), with 32 patients (67%) and 16 patients (33%) with those 
tumours respectively. The median age was 53 years, and all patients were aged 
between 18 and 78 years at the start of the clinical trial. The length of, and 
loss to follow-up was not reported in the included study. Study characteris-
tics, i.e., information on patient population, intervention, control and study 
design of the included study, can be found in the Appendix (Table A-3). 
Efficacy 
Overall survival (OS) 
The included study [68] did not measure the overall survival (OS) rate  
at different time points11.  
Cause-specific survival (CSS)/Disease-specific survival (DSS) 
The endpoint cause-specific survival (CSS)/disease-specific survival (DSS) 
was not measured by the included study [68]. 
Disease-free survival (DFS) 
The endpoint disease-free survival (DFS) was not measured  
by the included study [68]. 
Recurrence-free survival (RFS) 
The endpoint recurrence-free survival (RFS) was not measured  
by the included study [68]. 
                                                             
11 However, the median survival time (MST) was measured: AA patients and GBM 
patients had an MST of 35 and 17 months respectively. 
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Progression-free survival (PFS) 
The included study [68] did not measure the progression-free survival (PFS) 
rate12. 
Local control rate (LCR) 
The endpoint local control rate (LCR) was not measured  
by the included study [68]. 
Health-Related Quality of Life (HRQoL) 
The endpoint Health-Related Quality of Life (HRQoL) was not measured  
by the included study [68]. 
Safety 
Acute radiation morbidity 
The included study [68] measured acute radiation morbidities using the RTOG 
criteria. Radiation morbidities were observed in the skin (≤grade 2), the white 
blood cells (≤grade 4), the platelet (≤grade 4) and the brain (≤ grade 1). 
Grade 1 acute radiation morbidities were reported by the included study [68]: 
the case series study (n=48) observed 27 (56%), 6 (13%), 7 (15%) and 6 (13%) 
acute radiation morbidities in the skin, white blood cells (WBC), platelet and 
brain region respectively. 
Grade 2 acute radiation morbidities were reported by the included study [68]: 
the case series study observed 9 (19%), 11 (23%), 17 (35%) acute radiation 
morbidities in the skin, white blood cells and platelet region respectively. 
No grade 2 acute radiation morbidities were observed in the brain. 
Grade 3 acute radiation morbidities were reported by the included study [68]: 
the case series study observed 17 (35%) and 6 (13%) acute radiation morbid-
ities in the white blood cells and platelet region respectively. No grade 3 acute 
radiation morbidities were observed in the skin or brain. 
Grade 4 acute radiation morbidities were reported by the included study [68]: 
the case series study observed 3 (6%) and 3 (6%) acute radiation morbidities 
in the white blood cells and platelet region respectively. No grade 4 acute ra-
diation morbidities were observed in the skin or brain. 
Late radiation morbidity 
The included study measured late radiation morbidities using the RTOG/ 
EORTC criteria. Late radiation morbidities were observed in the brain and 
skin. 
Grade 1 late radiation morbidities were reported by the included study [68]: 
the case series study (n=48) observed 1 (2%) and 7 (15%) grade 1 radiation 
morbidities in the skin and brain respectively. 
Grade 2 late radiation morbidities were reported by the included study [68]: 
the case series study observed 4 patients (8%), developing late radiation mor-
bidities in the brain. In the skin region, no grade 2 late radiation morbidities 
were observed in the same study. 
                                                             
12 However, the median progression-free survival (m-PFS) was measured in months 
by 1 study [68]: AA patients and GBM patients had an m-PFS of 18 and 7 months 
respectively. 
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Grade 3 late radiation morbidities were reported by the included study [68]: 
the case series study observed no grade 3 late radiation morbidities. 
Grade 4 late radiation morbidities were reported by the included study [68]: 
the case series study observed no grade 4 late radiation morbidities. 
Moreover, the same study reported on late radiation morbidities using the 
LENT-SOMA criteria in the brain: the late radiation morbidities were iden-
tical except for grade 1 late radiation morbidities. 10 patients (21%) had brain 
late radiation morbidities according to the LENT-SOMA criteria, with slight-
ly more grade 1 late radiation morbidities in the brain compared to the fre-
quency elaborated with the RTOG/EORTC criteria. 
Conclusion 
For high-grade gliomas (WHO grade III-IV), 1 study [68] was eligible to be 
included in the assessment: the study was not controlled, comparing CIRT 
to standard irradiation. Thus, neither inferiority nor superiority of CIRT on 
the basis of the selected endpoints regarding efficacy (OS, CSS, DFS, RFS, 
PFS, LCR, HRQoL) or safety (acute radiation morbidity, late radiation mor-
bidity) can be concluded from the evidence. That is to say, (randomised) 
controlled studies are needed to clarify whether CIRT is more effective than 
or as effective as, or safer than or as safe as standard irradiation in patients 
with high-grade gliomas (WHO grade III-IV). 
 
5.3.3.3 Ependymoma 
Definition and epidemiology 
Ependymoma is a paediatric tumour to be found in the brain and spinal cord 
[74]. Between 2002 and 2012, 53 cases of ependymoma and plexus-chorideus 
tumours in the central nervous system occurred in children and adolescents, 
with an age-adjusted incidence rate of 2.8 per 1,000,000 children and adoles-
cents (0-19 years of age) in Austria [57]. 
Current treatment regimens and prognosis 
According to the National Cancer Institute (NCI) of the United States, there 
are currently 4 standard treatment options: surgery, radiation therapy (RT), 
chemotherapy and observation [74]. Statistics Austria calculated the 5-year 
relative survival of ependymoma and plexus-chorideus tumours of the nerv-
ous system to be 90.6% (95% CI: 73.7-96.9) for children aged between 0 and 
14 years based on 32 patients diagnosed with this disease in Austria between 
2002 and 2009. 
Included studies, efficacy and safety 
For ependymomas, no studies were included in this assessment. Thus, no 
evidence was found to answer the research question. 
Conclusion 
At present, there is no scientific evidence indicating superiority or inferiority 
regarding the use of carbon ion radiotherapy (CIRT) for ependymoma. 
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5.3.3.4 Medulloblastoma 
Definition and epidemiology 
A medulloblastoma is a malignant embryonal tumour in the brain (WHO 
grade IV). The incidence of medulloblastomas is approximately 1–5:1,000,000 
[75]. Statistics Austria measured the incidence of all intracranial and intra-
spinal embryonal tumours to be 7.3 cases per 1,000,000 children (aged 0-14 
years) [57]. 
Current treatment regimens and prognosis 
Current treatment of medulloblastomas includes surgery (exstirpation) and 
postoperative chemotherapy and/or radiation therapy. In addition, radiother-
apy using a boost concept or adjuvant chemotherapy may be used in some 
circumstances. Additional therapies treating the symptoms may also be in-
dicated (e.g., glucocorticoide) [75]. The prognosis of medulloblastomas is de-
pendent on the localisation [75]. Statistics Austria measured the 5-year rela-
tive survival of all intracranial and intraspinal embryonal tumours to be 70% 
(95% CI: 58.7-78.8) based on data of 80 cases in Austria (2002-2009) [58]. 
Included studies, efficacy and safety 
For medulloblastomas, no studies were included in this assessment. Thus, 
no evidence was found to answer the research question. 
Conclusion 
At present, there is no scientific evidence indicating superiority or inferiority 
regarding the use of carbon ion radiotherapy (CIRT) for medulloblastomas. 
 
5.3.3.5 Other childhood brain tumours 
Besides medulloblastomas and ependymomas, pilocytic astrocytomas and 
other embryonal tumours may be considered as “other childhood brain tu-
mours” [76]. Due to the lack of precision of this indication, no epidemiolog-
ical data on “other childhood brain tumours” is presented in this section. 
Included studies, efficacy and safety 
For “other childhood brain tumours”, no studies were included in this as-
sessment. Thus, no evidence was found to answer the research question. 
Conclusion 
At present, there is no scientific evidence indicating superiority or inferiority 
regarding the use of carbon ion radiotherapy (CIRT) for “other childhood 
brain tumours”. 
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5.3.4 Tumours in the ear-nose-throat (ENT) 
Definition and epidemiology 
Tumours in the ear-nose-throat (ENT) region cover a variety of different 
tumours. In this assessment, the term “ENT tumours” is used interchangea-
bly with “head and neck” tumours. The National Cancer Institute (NCI) uses 
the term “head and neck” cancer, including tumours in the oral cavity, phar-
ynx, larynx the salivary gland as well as the paranasal sinuses and the nasal 
cavity [77]. Statistics Austria uses the term “head and neck” cancers as well, 
covering tumours of the pharynx, the lips and the oral cavity [78].  
For tumour staging of head and neck tumours, the TNM classification, de-
veloped by the American Joint Committee on Cancer (AJCC) as well as the 
Union for International Cancer Control (UICC), is used: T indicates more de-
tails about a tumour (i.e., the extent of a primary tumour). N (nodes) indi-
cates the node, and M (metastasis) whether distant metastasis occurred [79]. 
Tumours in the ENT region can be localised, regional, distant and unstaged 
(unknown): localised cancer refers to the stage when the cancer is only found 
in the part of the body in which cancer started. Cancer is regional if cancer 
already spread to (an)other part(s) of the body and distant if cancer has me-
tastasised as well [66].  
According to Statistics Austria, the age-adjusted incidence of all head and 
neck tumours was 15 per 100,000 persons in Austria in 2015. In the same year, 
those head and neck cancers accounted for approximately 3% of all new can-
cers, with 1,283 Austrians developing cancers in this region in this year. 
Overall, 5,489 male and 2,341 female Austrians had a diagnosis of malignant 
head and neck tumours at the end of 2015 [80, 81]. 
Current treatment regimens and prognosis 
The treatment of head and neck tumours may include surgical resection and 
chemotherapy and/or (chemo)radiation therapy differing according to the 
extent and histology of a specific tumour [79, 82, 83]. A combination of chem-
otherapy and RT represents the most common radio-oncological treatment. 
Background information on treatment modalities for specific indications can 
be found in the sections for the specific indications. Data from Statistics 
Austria shows a 5- and 10-year relative survival for all head and neck tumour 
patients of 47.6% and 35.6% respectively [84]. The patients included in the 
analysis were diagnosed with head and neck tumours within the time frame 
between 2003 and 2007. 
Included studies 
For tumours in the ENT region, 5 studies were included in this assessment: 
4 case series [31, 33, 85, 86] and 1 case-control study [87] from 3 cancer ther-
apy centres in Germany and Japan. That is to say, 2 studies [33, 86] were con-
ducted at the Heavy Ion Medical Accelerator in Chiba (HIMAC), 1 study [31] 
was conducted at the Gunma University Heavy Ion Medical Centre (GHMC) 
and 2 studies [85, 87] were conducted at the Heidelberg Ion Beam Therapy 
Centre (HIT) in Germany.  
In total, 415 patients were enrolled in the included studies. Of those, 381 re-
ceived CIRT at a total dose ranging from 18 GyE-72 GyE. 54 of the included 
patients received CIRT in a raster scanned carbon ion boost method, and co-
interventions included intensity-modulated RT in 54 patients and photon ir-
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radiation in 29 patients receiving CIRT. Moreover, photon radiotherapy, sur-
gery (prior and after CIRT), salvage therapy (re-irradiation), and post-chem-
otherapy were reported as further co-interventions by some of the included 
studies. 
1 study [86] included 27 patients, with unresectable bone and soft tissue sar-
comas in the head and neck. Of those, 11 were to be found in the nasal cavity 
and paranasal sinus. In addition, 2 other studies [85, 87] included 83 patients 
receiving CIRT and suffering from salivary gland tumours; of those, 54 were 
malignant [85], and 29 [87] were locally advanced tumours. Lastly, 2 further 
case series studies [31, 33] included 271 enrolled patients suffering from car-
cinomas of the head and neck in different regions. Of those, 134 patients 
(49.5%) were located in the nasal cavity and paranasal sinus.  
Several of those patients had cancer in the maxillary sinus, naso-/orophar-
ynx, adenoid cystic salivary gland carcinomas, and orbital tumours, with 11 
patients (4.1%), 27 patients (9.9%), 21 patients (7.7%) and 20 patients (7.4%) 
suffering from tumours in those regions respectively. The evidence regard-
ing those indications could not be synthesised. 
The reader is referred to the evidence synthesis for the specific indication 
and the data extraction table in the Appendix (see Table A-4) for more in-
formation on the included studies. 
Conclusion: Efficacy and safety 
Due to the heterogeneity of the different tumours (e.g., different prognosis) 
captured with the term “tumours in the ENT region”, the evidence synthesis 
for specific indications can be found in the following sections. 
For tumours in the ENT region, 5 studies were included in this assessment: 
the studies were not controlled, comparing CIRT to standard irradiation. 11 
oncologic13 indications were assessed regarding superiority/inferiority of 
CIRT on the basis of the selected endpoints regarding efficacy (OS, CSS, 
DFS, RFS, PFS, LCR, HRQoL) or safety (acute radiation morbidity, late 
radiation morbidity): no scientific evidence was found for 8 indications, and 
insufficient scientific evidence for superiority/inferiority of CIRT was found 
for 3 indications (sarcomas in the head and neck, tumours in the nasal cavity 
and paranasal sinus and adenoid cystic salivary gland carcinomas). Indirect 
comparisons were conducted in 1 study [87] for 2 indications: for adenoid 
cystic carcinoma of the salivary gland, 1 study found no statistically signifi-
cant difference of OS, DFS and LRC between 29 patients receiving CIRT in 
combination with photon radiotherapy when compared to 34 patients receiv-
ing photon radiotherapy alone. 
Neither superiority nor inferiority on the basis of the selected endpoints re-
garding efficacy (OS, CSS, DFS, RFS, PFS, LCR, HRQoL) or safety (acute 
radiation morbidity, late radiation morbidity) can be concluded from the ev-
idence. That is to say, (randomised) controlled studies are needed to clarify 
whether CIRT is more effective than or as effective as, or safer than or as 
safe as standard irradiation in patients with tumours in the ENT-region. 
In the following section results from specific ENT tumours are presented.  
                                                             
13 The indications “tonsil carcinomas” and “tongue base carcinoma” were summarized 
in oropharyngeal carcinomas and the oncologic indications “pleomorphic and ad-
enoid cystic carcinomas” can be found in the section salivary gland carcinoma. 
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5.3.4.1 Orbital tumours  
Definition and epidemiology 
Tumours in the orbit are rare and occur either in the tissue of the orbit or 
form of a metastasised/secondary tumour from tumours in neighbouring or-
gans. Tumours to be found in the orbit cover many different forms of cancer: 
tumours can be benign, e.g., chondroma, osteoma, or malignant, e.g., rhab-
domyosarcoma, osteosarcoma, rhabdomyosarcoma [41] [59]. Epidemiologic 
data on the incidence and prevalence of tumours specifically for orbital tu-
mours was not found. 
Current treatment regimens and prognosis 
The treatment of orbital tumours is dependent on the type of a tumour. No 
data on the prognosis specifically for orbital tumours were found. 
Included studies, efficacy and safety 
No study was included for the qualitative synthesis of orbital tumours. Thus, 
no evidence was found to answer the research question.  
Conclusion 
At present, there is no scientific evidence that CIRT is superior/inferior when 
compared to standard irradiation. 
 
5.3.4.2 Tumour of the nasal cavity and paranasal sinus 
Definition and epidemiology 
Tumours of the nasal cavity and paranasal sinus are rarely occurring tumours 
and include a great variety of different histologies (e.g., squamous cell carci-
noma, but also adenocarcinomas, adenoid cystic carcinomas, etc.) [82]. In 
paranasal sinus cancers, frequently occurring tumours are adenocarcinomas 
and squamous cell carcinoma, e.g., of the maxillary sinus [83]. Epidemiolog-
ic data on the incidence and prevalence of tumours specifically for the nasal 
cavity and paranasal sinus in Austria was not found. Data from the Surveil-
lance, Epidemiology, and End Results (SEER) Program of the National Can-
cer Institute (NCI) shows that 11.3 per 100,000 persons developed, oral cavity 
and pharynx in 2014 in the United States (age-adjusted incidence rate) [88]. 
Current treatment regimens and prognosis 
The treatment of tumours in the nasal cavity and paranasal sinus may include 
surgical resection and chemotherapy and/or (chemo)radiation therapy differ-
ing according to the extent and histology of a specific tumour [89]. A combi-
nation of chemotherapy and RT represents the most common radio-oncolog-
ical treatment. No data was found for the prognosis specifically for tumours 
in the nasal cavity and paranasal sinus. 
Included studies 
For tumours in the nasal cavity and paranasal sinus, 3 case series studies 
from 2 cancer therapy centres in Japan were eligible to be included in this 
assessment: 2 case series studies [33, 86] were conducted at the Heavy Ion 
Medical Accelerator in Chiba (HIMAC), and 1 case series study [31] was con-
ducted at the Gunma Heavy Ion Medical Centre (GHMC).  
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In total, 298 patients with head and neck tumours were enrolled in the in-
cluded studies. Of those, 145 patients suffered from tumours in the nasal 
cavity and paranasal sinus. The tumours were diverse and included a variety 
of different carcinomas and sarcomas. All patients received CIRT at a total 
dose ranging from 57.6 GyE to 70.4 GYE in 16 fractions in the included 
studies. Only 1 study [33] reported on co-interventions, including operation 
and/or chemoradiotherapy. 2 studies [31, 33] reported on tumour stage using 
the TNM classification: the tumour stage of the patients ranged between T2/ 
N0 to T4 N0. 1 study [86] used the histopathological grading according to 
the Union Internationale Contre le Cancer (UICC, 2002), with a histopatho-
logical tumour grade ranging from grade 1 to grade 4. 
Age ranges were reported either as mean (with a mean age of 46.2 years) or 
as median (ranging from 56.5 to 59 years) with 1 study [86] and 2 studies [31, 
33] using those measures respectively. All patients were aged between 16 and 
80 years. The loss to follow-up was not reported by the included studies. Study 
characteristics, i.e., information on patient population, intervention, and study 
design of the included study, can be found in the Appendix (Table A-4). 
 
Efficacy 
Overall survival (OS) 
The included studies measured overall survival (OS) at 3 and 5 years. No 
comparison between the OS of CIRT patients in comparison to the OS of pa-
tients undergoing conventional radiotherapy was undertaken. 
1-year OS was not reported in the included studies. 
2-year OS was not reported in the included studies. 
3-year OS was reported by 2 studies [31, 86], with all of the enrolled patients 
receiving CIRT: 1 case series study [86] with 27 patients with unresectable 
bone and soft tissue sarcomas in the head and neck14 observed a 3-year OS of 
74.1% (95% CI: 57.5–90.6%). Another study [31] observed an OS of 88% 
(95% CI: 77–99%) for 35 non-squamous cell carcinomas of the head and 
neck15 at 3 years. In the same study, the overall survival specifically for pa-
tients with tumours in the nasal cavity and paranasal sinus was calculated: 
patients with tumours in the maxillary sinus/nasal cavity (n=18) had a 3-
year OS of 88% (95% CI: NR). 
4-year OS was not reported in the included studies. 
5-year OS was reported by 2 studies [33, 86]: the case series [33] (n=236)16 
reported an OS of 47.6% (95% CI: NR, SE: 3.2%) for patients with head and 
neck tumours16 at 5 years. Another study [86] observed an OS of 57.6% at 5 
years for 27 patients with unresectable bone and soft tissue sarcomas in the 
head and neck14. 
10-year OS was not reported in the included studies. 
                                                             
14 Of those 27 patients, 11 patients were diagnosed with tumours in the nasal cavity 
and paranasal sinus [86]. 
15 Of those 35 enrolled patients, 18 were diagnosed with tumours in the nasal cavity 
and paranasal sinus [31]. 
16 Of those 236 patients, 116 patients were diagnosed with tumours in the nasal cavity 
and paranasal sinus [33]. 
OS in 2 Studien: 
 
3 Jahre: 74,1 %-88 % 
5 Jahre: 47,6 %-57,6 % 
Carbon ion beam radiotherapy (CIRT) for cancer treatment 
72 LBI-HTA | 2018 
Cause-specific survival (CSS)/Disease-specific survival (DSS) 
The endpoint cause-specific survival (CSS)/disease-specific survival (DSS) 
was not measured by the included study. 
Disease-free survival (DFS) 
The endpoint disease-free survival (DFS) was not measured  
by the included studies. 
Recurrence-free survival (RFS) 
The endpoint recurrence-free survival (RFS) was not measured  
by the included studies. 
Progression-free survival (PFS) 
One out of 3 included studies [31] measured the endpoint progression-free 
survival (PFS) at 3 years after CIRT. No comparison between the PFS of 
CIRT patients in comparison to the PFS of patients undergoing convention-
al radiotherapy was undertaken. 
1-year PFS was not reported in the included studies. 
2-year PFS was not reported in the included studies. 
3-year PFS was reported in 1 included case series study [31]: The 3-year PFS 
was 71% (95% CI: 56–86%) at 3 years for 35 non-squamous cell carcinomas 
of the head and neck. Of those, 18 patients (51.5%) suffered from tumours in 
the nasal cavity and paranasal sinuses. The same study did not report on the 
3-year PFS specifically for patients with tumours of the nasal cavity and pa-
ranasal sinus. 
4-year PFS was not reported in the included studies. 
5-year PFS was reported in the included studies. 
10-year PFS was not reported in the included studies. 
Local control rate (LCR) 
All of the included studies measured the local control rate (LCR) of head and 
neck tumour patients, undergoing CIRT at different time points. No compar-
ison between the LCR of CIRT patients and the LCR of patients undergoing 
conventional radiotherapy was undertaken. 
1-year LCR was not reported in the included studies. 
2-year LCR was not reported in the included studies. 
3-year LCR was reported in 2 included studies [31, 86] treating all of the 
enrolled patients with CIRT: 1 case series study [86] with 27 patients with 
unresectable bone and soft tissue sarcomas in the head and neck17 observed 
a LCR of 91.8% (95% CI: 81.0–100%) at 3 years. Another study [31] ob-
served a LCR of 93% (95% CI: 84–100%) at 3 years. In the same study, the 
3-year LCR specifically for patients with tumours in the nasal cavity and pa-
ranasal sinus was calculated: patients with tumours in the maxillary sinus/ 
nasal cavity (n=18) had a 3-year LCR of 93% (95% CI: NR). 
                                                             
17 Of those 27 patients, 11 patients (40.7%) were diagnosed with tumours in the nasal 
cavity and paranasal sinus [86]. 
keine Daten: 
CSS/DSS 
DFS 
RFS 
PFS in 1 Studie, 35 Pts  
3 Jahre: 71 % 
LCR in 2 Studien 
3 Jahre: 91,8 %-93 % 
 
LCR in 1 Studie: 
5 Jahre: 68 % 
Efficacy and safety of carbon ion radiotherapy (CIRT) for 54 indications 
LBI-HTA | 2018 73 
4-year LCR was not reported in the included studies. 
5-year LCR was reported in 1 included study [33]: the case series study re-
ported a LCR of 68% (95% CI: NR, SE: 3.5%) at 5 years. 
10-year LCR was not reported in the included studies. 
Health-Related Quality of Life (HRQoL) 
The endpoint Health-Related Quality of Life (HRQoL) was measured by 1 
out of 3 included studies [31]. HRQoL was measured for 35 patients, under-
going CIRT and suffering from non-squamous cell carcinomas of the head 
and neck15. The study used the Short-Form Health Survey (SF-8) question-
naire: physical component score (PCS) and mental component score (MCS) 
mean scores were measured before, at 1 month, at 3 months, at 6 months, 12 
months and 24 months, and compared to baseline scores respectively. The 
study found a gradual mid-term and longer-term improvement of the MCS 
mean score after treatment, with statistically significantly higher mean scores 
at 6 months (MCS: 45.9±1.7), at 12 months (MCS: 47.3±1.4) and 24 months 
(MCS: 48.4 ±1.6) when compared to the baseline score (MCS: 40.8 ±1.8)18 
[31]. No statistically significantly short-term (< 6 weeks), mid-term (> 6 weeks 
≤ 6 months) or longer-term (> 6 months) differences regarding the PCS mean 
scores were found. 
Safety 
Acute radiation morbidity 
Acute radiation morbidity was measured by all of the 3 included studies us-
ing the RTOG [33] or CTCAE v4.0 [31] and NCI-CTC v2.0 [86] criteria: 
acute radiation morbidities occurred as mucositis, dermatitis, conjunctivitis 
and dysgeusia. 
Grade 1 acute radiation morbidities were measured by 2 of the included stud-
ies [33, 86]: 1 study [33] (n=236)16 observed 91 (41%)19 and 115 (49%) acute 
radiation morbidities occurring in the mucosa and the skin respectively. An-
other study [86] observed 8 (29.6%) and 19 (70.4%) out of 27 patients with 
head and neck tumours17, developing grade 1 acute radiation morbidities in 
the mucosa and skin respectively. 
Grade 2 acute radiation morbidities were measured by all 3 included studies 
[31, 33, 86]: In the mucosa, grade 2 radiation morbidities ranged from 81 out 
of 223 patients16 [33] (36%) to 17 out of 27 patients14 [86] (63%). In the skin 
region, grade 2 acute radiation morbidities ranged from 6 out of 27 patients14 
[86] (22.2%) to 90 out of 236 patients16 [33] (38%). Furthermore, 1 study [31] 
reported 5 (14%) and 1 (3%) out of 35 patients15 developing grade 2 acute 
radiation morbidities such as conjunctivitis and dysgeusia respectively. 
                                                             
18 The author interpreted this difference by stating that the patients possibly had fear 
and anxiety due to the treatment before the therapy being improved after the ther-
apy. No analysis including fear or anxiety as variables in their analysis was under-
taken [31]. 
19 The total number of patients analysed for acute and late radiation morbidities for 
mucosas was 223, since normal mucosa of “(…) 13 cases was out of irradiation field” 
[33]. In addition, 116 out of 236 enrolled patients were diagnosed with tumours in 
the nasal cavity and paranasal sinus [33]. 
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Grade 3 acute radiation morbidities were measured by all 3 included studies 
[31, 33, 86]: in the mucosa, grade 3 acute radiation morbidities ranged from 
1 out of 27 patients14 [86] (3.7%) to 8 out of 35 patients15 [31] (23%). In the 
skin region, 2 studies observed no grade 3 acute radiation morbidities [31, 
86] and 1 study [33] observed 15 out of 236 patients (6%) developing grade 3 
skin acute radiation morbidities. No other grade 3 acute radiation morbidi-
ties were observed. 
Grade 4 acute radiation morbidities were measured by all 3 included studies 
[31, 33, 86]: no grade 4 acute radiation was observed by the included studies. 
Late radiation morbidity 
Late radiation morbidities were measured by all of the included studies us-
ing the RTOG/EORTC [33, 86] or CTCAE [31] criteria. 
Grade 1 late radiation morbidities were measured by 2 out of 3 included stud-
ies [33, 86]: 1 study [33] (n=236)16 observed 43 (19%)19 and 101 (43%) grade 
1 late radiation morbidities occurring in the mucosa and the skin respective-
ly. Another study [86] observed 9 cases (34.6%) and 6 cases (23%) in 26 pa-
tients14 acute grade 1 late radiation morbidities the mucosa and skin respec-
tively. In the same study, 5 (19.2%) and 1 (3.8%) out of 26 patients had grade 
1 late radiation morbidities in the brain and bone respectively. 
Grade 2 late radiation morbidities were measured by all 3 included studies 
[31, 33, 86]: In the mucosa, 1 study [86] did not observe any grade 2 late ra-
diation morbidities and the other 2 studies observed grade 2 mucositis in 4 
out of 223 patients [33] (2%) and 11 out of 35 patients [31] (31%) respectively. 
In the skin area, 1 study [33] observed grade 2 late radiation morbidities, 
with 7 cases (3%) occurring in this area. Moreover, 1 study [86] observed late 
radiation morbidities (grade 2) in the brain, eye, and bone, with 1 case (3.8%), 
1 case (3.8%) and 1 case (3.8%) in these regions respectively. In another study 
[31] (n=35), further grade 2 late radiation morbidities were observed: 1 pa-
tient (3%), 2 (6%) patients and 2 (6%) patients developed grade 2 conjuncti-
vitis, dysgeusia and brain necrosis respectively. In the same study, grade 2 
visual impairment, trismus, otitis media and olfactory nerve disorder oc-
curred, with 2 (6%), 3 (9%), 5 (14%) and 4 (11%) patients suffering from those 
radiation morbidities respectively. 
Grade 3 late radiation morbidities were measured by the all of the 3 includ-
ed studies [31, 33, 86]: In the mucosa, 1 out of 3 studies [31] observed 1 grade 
3 late mucositis (3%). In the skin region, no grade 3 late radiation morbidi-
ties were observed in any of the included studies. Also, 4 grade 3 bone late 
acute radiation morbidities (15.4%) were observed in 1 study [86]. In another 
study [31], 1 case of visual impairment (3%) and 2 cases of grade 3 cataract 
(6%) occurred. 
Grade 4 late radiation morbidities were measured by all of the included stud-
ies: in the mucosa and skin area, no grade 4 late radiation morbidities oc-
curred. 2 studies [31, 86] observed grade 4 late radiation morbidities in the 
eye, with 1 out of 26 patients (3.8%) [86] and 2 out of 35 patients (6%) [31] 
respectively. 
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Conclusion 
For tumours in the nasal cavity and paranasal sinus, 3 studies were eligible 
to be included in the assessment: none of the studies were controlled, com-
paring CIRT to standard irradiation. Thus, neither inferiority nor superiority 
of CIRT on the basis of the selected endpoints regarding efficacy (OS, CSS, 
DFS, RFS, PFS, LCR, HRQoL) or safety (acute radiation morbidity, late ra-
diation morbidity) can be concluded from the evidence. That is to say, (ran-
domised) controlled studies are needed to clarify whether CIRT is more ef-
fective than or as effective as, or safer than or as safe as standard irradiation 
in patients with tumours of the nasal cavity and paranasal sinus. 
 
5.3.4.3 Maxillary sinus carcinoma 
The maxillary sinus carcinoma is a type of paranasal sinus cancer [89]. The 
reader is referred to section tumours of the nasal cavity and paranasal sinus 
for information on the epidemiology, prognosis and treatment approaches of 
this cancer. 
Included studies, efficacy and safety 
For maxillary sinus carcinoma, no study was eligible to be included in this 
assessment. Thus, no evidence was found to answer the research question. 
Conclusion 
At present, there is no scientific evidence indicating superiority or inferiority 
regarding the use of carbon ion radiotherapy (CIRT) for maxillary sinus car-
cinoma. 
 
5.3.4.4 Nasopharyngeal carcinoma 
Definition and epidemiology 
Nasopharyngeal carcinomas are carcinomas to be found in the nasopharynx 
originating behind the nasal cavity [90]. Epidemiologic data on the inci-
dence and prevalence of tumours specifically for nasopharyngeal carcinomas 
in Austria was not found. Data from the Surveillance, Epidemiology, and 
End Results (SEER) Program of the National Cancer Institute (NCI) shows 
that 11.3 per 100,000 persons developed cancer in the oral cavity and phar-
ynx in 2014 in the United States (age-adjusted incidence rate) [88]. 
Current treatment regimens and prognosis 
The treatment of nasopharyngeal carcinomas may include (chemo)radiation 
therapy (R[C]T), e.g., intensity-modulated radiotherapy (IMRT), chemother-
apy. A combination of chemotherapy and RT represents the most common 
radio-oncological treatment. Surgery may not be used as a first-line treatment 
due to the nasopharynx being closely located to the neurovascular structure 
[91]. Treatments of all head and neck tumours differ according to the extent 
and histology of a specific tumour [79, 82, 83]. 
No data was found for the prognosis specifically for nasopharyngeal carci-
nomas. Statistics Austria shows a 5- and 10-year relative survival for all head 
and neck tumour patients of 47.6% and 35.6% respectively [84]. The patients 
included in the analysis were diagnosed with head and neck tumours within 
the time frame between 2003 and 2007. 
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Included studies, efficacy and safety 
For nasopharyngeal carcinomas, no study was included for the qualitative 
synthesis of the evidence regarding efficacy or safety of the use of CIRT. Thus, 
no evidence was found to answer the research question. 
Conclusion 
At present, there is no scientific evidence indicating superiority or inferiori-
ty regarding the use of carbon ion radiotherapy (CIRT) for nasopharyngeal 
carcinoma. 
 
5.3.4.5 Oropharyngeal carcinoma 
Definition and epidemiology 
Oropharyngeal carcinoma can be found in the following parts of the orophar-
ynx: the bottom of the tongue, the vallecula, the tonsillar region, the soft pal-
ate and the pharyngeal walls (posterior and lateral) [92]. Epidemiologic data 
on the incidence and prevalence of tumours specifically for oropharyngeal 
carcinomas in Austria was not found. Data from the Surveillance, Epidemi-
ology, and End Results (SEER) Program of the National Cancer Institute 
(NCI) shows that 11.3 per 100,000 persons in 2014 developed, oral cavity and 
pharynx cancer in the United States (age-adjusted incidence rate) [88]. 
Current treatment regimens and prognosis 
Treatment of oropharyngeal carcinomas may include one, or more of the fol-
lowing modalities: surgery, (chemo)radiation therapy, chemotherapy (con-
current or neoadjuvant) [92]. A combination of chemotherapy and RT repre-
sents the most common radio-oncological treatment. No data was found for 
the prognosis specifically for oropharyngeal carcinomas. Data from Statis-
tics Austria shows a 5- and 10-year relative survival for all head and neck 
tumour patients of 47.6% and 35.6% respectively [84]. The patients included 
in the analysis were diagnosed with head and neck tumours within the time 
frame between 2003 and 2007. 
Included studies 
For oropharyngeal carcinoma, no study was eligible to be included in the qual-
itative synthesis of the evidence regarding efficacy or safety of the use of CIRT 
to treat cancer in the oropharyngeal region. Thus, no evidence was found to 
answer the research question. 
Conclusion 
At present, there is no scientific evidence indicating superiority or inferiority 
regarding the use of carbon ion radiotherapy (CIRT) for oropharyngeal car-
cinoma.  
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5.3.4.6 Salivary gland carcinoma  
Definition and epidemiology 
Salivary gland tumours are rarely occurring heterogeneous group of histolo-
gies. Tumours in this region can be benign or malignant: Pleomorphic adeno-
mas are the most common type of benign salivary gland tumours. The most 
common type of malignant salivary gland tumours is, inter alia, adenoid cystic 
carcinomas [93]. Epidemiologic data regarding the incidence and prevalence 
specifically of salivary gland tumours in Austria was not found.  
Data of the Surveillance, Epidemiology, and End Results (SEER) Program of 
the National Cancer Institute (NCI) shows an age-adjusted incidence rate for 
salivary gland tumours of 1.2 cases per 100,000 persons in 2014 in the United 
States [88]. 
Current treatment regimens and prognosis 
Treatment of salivary gland tumours differs according to the stage and his-
tology of cancer: benign, low-grade salivary gland tumours may be treated 
with surgery alone. On the contrary, a combined treatment of surgery and 
postoperative radiotherapy may be indicated for patients with high-grade 
salivary gland carcinomas [79]. 
The Surveillance, Epidemiology, and End Results (SEER) Program of the Na-
tional Cancer Institute (NCI) estimates the 5-year relative survival (RS) to be 
75.1% based on calculations of patients having been diagnosed with salivary 
gland carcinomas in 2009 in the United States [66]. 
Included studies 
For pleomorphic salivary gland tumours, no study was identified. 
For adenoid cystic salivary gland tumours 2 clinical studies, conducted at the 
Heidelberg Ion Beam Therapy Centre (HIT) in Germany, were eligible to be 
included in the assessment: 1 case-control study [87] and 1 phase 2, dose-es-
calation, case series study [85]. 
In total, 117 patients were enrolled in the clinical studies, with 83 and 34 pa-
tients receiving, inter alia, carbon ion radiotherapy (CIRT)20 and photon ra-
diotherapy alone respectively. The irradiation dose of photon radiotherapy in 
combination with CIRT was a median dose of 72 GyE (54 Gy with photons 
and 18 GyE with C-ions) in 9 fractions for 29 patients. Another 54 patients 
received a carbon ion boost (CIB) at a dose of 24 GyE in 5-6 fractions followed 
by intensity-modulated radiotherapy (IMRT) at a total dose of 50 Gy in 5 
fractions. The median irradiation dose of photon therapy for the 34 patients 
receiving photon RT in the case-control study [87] was 66 Gy (range: 54.0-
70.4 Gy). Co-interventions included prior surgery and re-irradiation as a sal-
vage treatment for some patients. 
All 117 patients were diagnosed with malignant salivary gland tumours, of 
which 110 (94%) were adenoid cystic carcinomas. Tumour stages ranged from 
T1-T4, 13 patients had a positive lymph node status, and 12 patients had 
metastases. The age of the patients (median) ranged from 56 to 58 years. All 
patients were aged between 25 and 76 years. The median follow-up time of 
the included studies ranged from 16 to 42 months, and loss to follow-up was 
                                                             
20 CIRT alone or as a carbon ion boost (CIB) in a raster scanned technique. 
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not reported. Study characteristics, i.e., information on patient population, 
intervention, control and study design of the included studies, can be found 
in the data extraction table in the Appendix (Table A-4). 
Efficacy 
Overall survival (OS) 
Both 2 included studies [85, 87] measured overall survival (OS) at different 
time points. 
1-year OS was not reported in any of the included studies. 
2-year OS was reported in 1 study [87]: the case-control study included 63 
patients with locally advanced adenoid cystic carcinomas of the salivary gland. 
The study observed an OS of 86.6% at 2 years for 29 patients receiving a 
combination of photon therapy and CIRT and an OS of 77.9% at 2 years for 
34 patients receiving photon therapy alone. The difference in survival be-
tween the treatment groups was not statistically significant. 
3-year OS was reported in 1 study [85]: the dose-escalation study included 54 
patients with malignant salivary gland tumours receiving a CIB before in-
tensity-modulated RT and observed an OS of 78.4% (95% CI: NR) at 3 years.  
4-year OS was reported in 1 study [87]: the case-control study included 63 
patients with locally advanced adenoid cystic carcinomas of the salivary 
gland. The study observed an OS of 75.8% at 4 years for 29 patients receiving 
a combination of photon therapy and CIRT and an OS of 77.9% at 4 years for 
34 patients receiving photon therapy alone. The difference in OS between 
the treatment groups was not statistically significant. 
5-year OS was not reported in any of the included studies. 
10-year OS was not reported in any of the included studies. 
Cause-specific survival (CSS)/Disease-specific survival (DSS) 
The endpoint cause-specific survival (CSS)/disease-specific survival (DSS) 
was not measured by the included studies. 
Disease-free survival (DFS) 
The endpoint disease-free survival (DFS) was measured by 1 included study 
[87]. 
1-year DFS was not reported in any of the included studies. 
2-year DFS was reported in 1 study [87]: the case-control study included 63 
patients with locally advanced adenoid cystic carcinomas of the salivary gland. 
The study observed a DFS of 71.5% at 2 years for 29 patients receiving a 
combination of photon therapy and CIRT and a DFS of 69.2% at 2 years for 
34 patients receiving photon therapy. The difference in DFS between the 
treatment groups was not statistically significant. 
3-year DFS was not reported in any of the included studies. 
patients with locally advanced adenoid cystic carcinomas of the salivary 
gland. The study observed a DFS of 53% at 4 years for 29 patients receiving 
a combination of photon therapy and CIRT and a DFS of 23.6% at 4 years 
for 34 patients receiving photon therapy alone. The difference in DFS be-
tween the treatment groups was not statistically significant. 
5-year DFS was not reported in any of the included studies. 
10-year DFS was not reported in any of the included studies. 
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Recurrence-free survival (RFS)  
The endpoint recurrence-free survival (RFS) was not measured  
by the included studies. 
Progression-free survival (PFS) 
The endpoint progression-free survival (PFS) was measured  
by 1 included study [85] at 3 years. 
1-year PFS was not reported in any of the included studies. 
2-year PFS was not reported in any of the included studies. 
3-year PFS was reported in 1 study [85]: the dose-escalation study included 
54 patients with malignant salivary gland tumours receiving CIB in a raster 
scanned technique before intensity-modulated RT and observed and observed 
a PFS of 57.9% (95% CI: NR) at 3 years. 
4-year PFS was not reported in any of the included studies. 
5-year PFS was not reported in any of the included studies. 
10-year PFS was not reported in any of the included studies. 
Local control rate (LCR) 
1-year LCR was not reported in any of the included studies. 
2-year LCR was reported in 2 studies [85, 87]: the case-control study [87] in-
cluded 63 patients with locally advanced adenoid cystic carcinomas of the 
salivary gland and observed an loco-regional control (LRC) of 77.5% at 2 years 
for 29 patients receiving a combination of photon therapy and CIRT and an 
LRC of 72.2% at 2 years for 34 patients receiving photon therapy alone. The 
difference in LRC between the treatment groups was not statistically signifi-
cant. Another study [85] included 54 patients with malignant salivary gland 
tumours, receiving CIB in a raster scanned technique before intensity-mod-
ulated RT, and observed an LCR of 84.3% (95% CI: NR) at 2 years. 
3-year LCR was reported in 1 study [85]: the dose-escalation study included 
54 patients with malignant salivary gland tumours receiving CIB in a raster 
scanned technique before intensity-modulated RT and observed an LCR of 
81.9% (95% CI: NR) at 3 years. 
4-year LCR was reported in 1 study [87]: the case-control study included 63 
patients with locally advanced adenoid cystic carcinomas of the salivary gland 
and observed an LRC of 77.5% at 4 years for 29 patients receiving a combi-
nation of photon therapy and CIRT and an LRC of 24.6% at 4 years for 34 
patients receiving photon therapy. The difference in LRC between the treat-
ment groups was not statistically significant. 
5-year LCR was not reported in any of the included studies. 
10-year LCR was not reported in any of the included studies. 
Health-Related Quality of Life (HRQoL) 
The endpoint Health-Related Quality of Life (HRQoL) was not measured by 
the included studies. 
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Safety 
Acute radiation morbidity 
Acute radiation morbidities were measured in both 2 included studies [85, 
87] using the CTCAE version 3 respectively. 
Grade 1 acute radiation morbidities were reported in 1 study [85]: 15 cases 
(28%) of grade 1 mucositis, 40 cases (75%) of grade 1 dermatitis, 18 cases 
(34%) of grade 1 dysphagia and 28 cases (53%) of grade 1 xerostomia were 
observed in 1 dose escalation study at completion of CIRT with 53 patients21 
with malignant salivary gland tumours receiving CIB in a raster scanned 
technique before intensity-modulated RT. In addition, the study reported on 
several other morbidities without mentioning the respective grades; further 
toxicities occurred 6-8 weeks after CIRT and can be found in the data ex-
traction table (Table A-4). 
Grade 2 acute radiation morbidities were reported in 1 study [85]: 21 cases 
(40%) of grade 2 mucositis, 8 cases (15%) of grade 2 dermatitis, 10 cases (19%) 
of grade 2 dysphagia and 6 cases (11%) of grade 2 xerostomia were observed 
at completion of CIRT in 1 dose escalation study with 53 patients with ma-
lignant salivary gland tumours, receiving CIB in a raster scanned technique 
before intensity-modulated RT. In addition, further toxicities occurred 6-8 
weeks after CIRT and can be found in the data extraction table (Table A-4). 
Grade 3 acute radiation morbidities were reported in both included studies 
[85, 87]: 1 dose-escalation study [85] with 53 patients with malignant Sali-
vary gland tumours, receiving CIB in a raster scanned technique before in-
tensity-modulated RT, observed 14 cases (26%) of grade 3 mucositis and 3 
cases (6%) of grade 3 dermatitis after completion of CIRT. In the same study, 
further toxicities occurred 6-8 weeks after CIRT and can be found in the da-
ta extraction table (Table A-4). Another study [87] reported on differences of 
grade 3 radiation morbidities in the mucosa between 1 group (n=29), receiv-
ing combined therapy (photon and CIRT) and another group (n=34), receiv-
ing photon therapy alone, with 2 out of 29 patients (6.5%) and 11 out of 34 
patients (32.3%) developing grade 3 mucositis in those groups respectively. 
Grade 4 acute radiation morbidities were not reported in any of the included 
studies. 
However, the frequencies of acute radiation morbidities must be seen with 
caution, since both studies [85, 87] reported on several other acute radiation 
morbidities without mentioning the grade of those radiation morbidities. The 
reader is referred to the data extraction table to see those further radiation mor-
bidities with unreported respective grades (see Table A-4 in the Appendix). 
Late radiation morbidity 
Late radiation morbidities were measured by both included studies using 
the CTCAE v.3.0 criteria, but a stringently applied standardised reporting of 
those toxicities was absent in both studies22. 
                                                             
21 54 patients were initially enrolled in the study and 1 person refused a follow-up. 
The calculations of acute and late radiation morbidities are based on the 53 patients 
included in the analysis. 
22 That is, 1 study [85] reported on numerous late radiation morbidities without in-
cluding the grade of many of those, and another study [87] only reported on grade 
3 late radiation morbidities. 
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Grade 1 late radiation morbidities were reported in 1 dose-escalation, case 
series study [85]: the dose escalation study with 53 patients with malignant 
salivary gland tumours, receiving CIB in a raster scanned technique before 
intensity-modulated RT, observed 26 cases (49%) of grade 1 xerostomia and 
another 3 cases (6%) of grade 1 blood-brain barrier changes (CNS necrosis). 
Grade 2 late radiation morbidities were reported in 1 study [85]: the dose es-
calation study with 53 patients with malignant salivary gland tumours, re-
ceiving CIB in a raster scanned technique before intensity-modulated RT, 
observed 3 cases (6%) of grade 2 dysphagia and 1 case (2%) of grade 2 xero-
stomia. 
Grade 3 late radiation morbidities were reported in 1 case-control study [87]: 
1 patient developed grade 3 late radiation morbidities (not specified). It was 
not stated whether the grade 3 late radiation morbidity occurred in patients 
receiving a combined radiation treatment using photons and C-ions (n=29), 
or if it occurred in patients receiving photon radiotherapy alone (n=34). 
Grade 4 late radiation morbidities were reported in 1 study [85]: 1 dose esca-
lation study with 53 patients21 with malignant salivary gland tumours re-
ceiving CIB in a raster scanned technique before intensity-modulated RT 
observed 1 case of grade 4 haemorrhage (2%). 
However, the frequencies of late radiation morbidities must be seen with cau-
tion, since 1 study [87] selectively reported on late radiation morbidities (on-
ly severe grade 3 late radiation morbidities were reported) and another study 
[85] did not report on the grades for numerous observed late radiation mor-
bidities. The reader is referred to the data extraction table to see those fur-
ther radiation morbidities with respective unreported grades (Table A-4 in 
the Appendix). 
Conclusion 
For pleomorphic salivary gland tumours, no study was included. That is to 
say, at present, there is no scientific evidence supporting or refuting the use 
of CIRT for pleomorphic salivary gland tumours. 
For adenoid cystic salivary gland tumours, 2 studies were eligible to be in-
cluded in this assessment [85, 87]: none of the studies were controlled, com-
paring CIRT to standard irradiation. Indirect comparisons were undertaken 
in 1 study [87] and showed no statistically significant 3-year OS, DFS and 
LRC when comparing combined treatment (photon and CIRT) to photon 
radiotherapy alone. Thus, neither inferiority nor superiority of CIRT on the 
basis of the selected endpoints regarding efficacy (OS, CSS, DFS, RFS, PFS, 
LCR, HRQoL) or safety (acute radiation morbidity, late radiation morbidity) 
can be concluded from the evidence. That is to say, (randomised) controlled 
studies are needed to clarify whether CIRT is more effective than or as ef-
fective as, or safer than or as safe as, standard irradiation in patients with 
salivary gland tumours. 
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5.3.4.7 Sarcoma in the ENT area including Ewing's sarcoma 
Definition and epidemiology 
Sarcomas in the head and neck region are rare tumours and include, inter alia, 
osteosarcomas, rhabdomyosarcomas, chondrosarcomas, and soft tissue sarco-
mas. Within sarcomas in the head and neck region, Ewing’s sarcomas are less 
commonly occurring [60]. Epidemiologic data regarding the incidence and prev-
alence specifically of sarcomas in the ENT area in Austria was not found. 
Current treatment regimens and prognosis 
Treatment modalities may depend on the histologic subtype of a tumour and 
include one, or a combination of the following treatments: surgery, adjuvant 
radiotherapy or adjuvant chemotherapy [60]. Epidemiologic data regarding 
the prognosis of sarcomas in the ENT area in Austria was not found. Data 
from Statistics Austria shows a 5- and 10-year relative survival for all head 
and neck tumour patients of 47.6% and 35.6% respectively [84]. The patients 
included in the analysis were diagnosed with head and neck tumours within 
the time frame between 2003 and 2007. 
Included studies 
For sarcoma in the ENT area (including Ewing’s sarcoma), 1 study was in-
cluded in this assessment: 1 prospective case series study [86] conducted at 
the Heavy Ion Medical Accelerator in Chiba (HIMAC). In total, 27 patients 
with unresectable soft tissue sarcoma of the head and neck were enrolled in 
the included study. The enrolled patients received carbon ion radiotherapy 
(CIRT) at a total dose of 70.4 GyE in 16 fractions. Of the 27 patients, 16 were 
classified as low grade (grade 1-2), and 10 were classified as high-grade (grade 
3-4) using the histopathological grading system of the Union Internationale 
Contre le Cancer (UICC-2002). Moreover, 1 patient’s histopathological grade 
was unknown. The median age was 46.2 years, and all patients were aged be-
tween 17 and 78 years at the enrolment in the clinical trial. The median fol-
low up was 37 months (range: 4.1-73.0), and loss to follow-up was not re-
ported. Study characteristics, i.e., information on patient population, inter-
vention, control and study design of the included studies, can be found in 
Table A-4 in the Appendix. 
Efficacy 
Overall survival (OS) 
Overall survival (OS) of patients undergoing carbon ion radiotherapy (CIRT) 
was measured by the included study [86] at different time points.  
1-year OS was not reported in the included study. 
2-year OS was not reported in the included study. 
3-year OS was reported in the included study [86]: the case series study, with 
27 patients with bone and soft tissue sarcoma of the head and neck receiving 
CIRT, observed an OS of 74.1% (95% CI: 57.5–90.6) at 3 years. 
4-year OS was not reported in the included study. 
5-year OS was reported in the included study [86]: the case series study, with 
27 patients with bone and soft tissue sarcoma of the head and neck receiving 
CIRT, observed an OS of 57.6% (95% CI: 33.7–81.4) at 5 years. 
10-year OS was not reported in the included study. 
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Cause-specific survival (CSS)/Disease-specific survival (DSS) 
The endpoint cause-specific survival (CSS)/disease-specific survival (DSS) 
was not measured by the included study. 
Disease-free survival (DFS) 
The endpoint disease-free durvival (DFS) was not measured  
by the included study. 
Recurrence-free survival (RFS) 
The endpoint recurrence-free survival (RFS) was not measured  
by the included study. 
Progression-free survival (PFS) 
The endpoint progression-fyree survival (PFS) was not measured  
by the included study. 
Local control rate (LCR) 
The local control rate was measured by the included study [86] at 3 and 5 
years after CIRT. 
1-year LCR was not reported in the included study. 
2-year LCR was not reported in the included study. 
3-year LCR was reported in the included study: the case series study [86], with 
27 patients with bone and soft tissue sarcoma of the head and neck, receiv-
ing CIRT at a total dose of 70.4 GyE, observed an LCR of 91.8% (95% CI = 
81.0–100%) at 3 years. 
4-year LCR was not reported in the included study. 
5-year LCR was reported in the included study [86]: the case series study 
with 27 patients with bone and soft tissue sarcoma of the head and neck re-
ceiving CIRT observed an LCR of 80.4% (95% CI = 57.3–100%) at 5 years. 
10-year LCR was not reported in the included study. 
Health-Related Quality of Life (HRQoL) 
The endpoint Health-Related Quality of Life (HRQoL) was not measured by 
the included study. 
Safety 
Acute radiation morbidity 
Acute radiation morbidities were measured by the included study [86] using 
the National Cancer Institute Common Toxicity Criteria (NCI-CTC) v.2.0. 
The study reported on all grade 1-4 acute radiation morbidities for 27 pa-
tients with bone and soft tissue sarcoma of the head and neck receiving CIRT. 
Grade 1 acute radiation morbidities were observed by the included study [86], 
with 8 out of 27 patients (29.6%) and 19 out of 27 patients (70.4%), develop-
ing grade 1 acute radiation morbidities in the mucosa and skin respectively. 
Grade 2 acute radiation morbidities were observed by the included study [86], 
with 17 out of 27 patients (63%) and 6 out of 27 patients (22.2%) developing 
grade 2 acute radiation morbidities in the mucosa and skin respectively. 
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Grade 3 acute radiation morbidities were observed by the included study [86], 
with 1 out of 27 patients (3.7%) developing grade 3 acute radiation morbidity 
in the mucosa. 
Grade 4 acute radiation morbidities were not observed by the included study. 
Late radiation morbidity 
Late radiation morbidities were measured by the included study [86] using 
the RTOG/EORTC criteria. The study reported on all grade 1-4 late radiation 
morbidities for 27 patients with bone and soft tissue sarcoma of the head and 
neck receiving CIRT. 
Grade 1 late radiation morbidities were observed by the included study [86]: 
9 patients (34.6%), 6 patients (23%), and 5 patients (19.2%) developed grade 
1 radiation morbidities in the mucous membrane, skin and brain respective-
ly. Also, 1 patient (3.8%) developed grade 1 late bone radiation morbidity. 
Grade 2 late radiation morbidities were observed by the included study [86], 
with 1 patient (3.8%) developing grade 2 radiation morbidities in the brain, 
eye and bone respectively. 
Grade 3 late radiation morbidities were observed by the included study [86], 
with 4 patients (15.4%) developing grade 3 late radiation morbidities in the 
bone region. 
Grade 4 late radiation morbidities were observed in 1 patient (3.8%) in the 
eye region. 
Conclusion 
For sarcomas in the ENT area, 1 study was included in this assessment: the 
study was not controlled, comparing CIRT to standard irradiation. No indi-
rect statistical comparison between CIRT and standard radiotherapy was un-
dertaken. Neither inferiority nor superiority of CIRT on the basis of the se-
lected endpoints regarding efficacy (OS, CSS, DFS, RFS, PFS, LCR, HRQoL) 
or safety (acute radiation morbidity, late radiation morbidity) can be con-
cluded from the evidence. That is to say, (randomised) controlled studies are 
needed to clarify whether CIRT is more effective than or as effective as, or 
safer than or as safe as standard irradiation in patients with sarcomas in the 
ENT area. 
 
5.3.4.8 Rhabdomyosarcoma 
Definition and epidemiology 
Rhabdomyosarcomas are rare, malignant, and considered to be paediatric 
tumours [61]. Approximately 25% of all rhabdomyosarcomas occur in the 
head and neck region [62]. Epidemiologic data regarding the incidence and 
prevalence specifically for rhabdomyosarcomas in the head and neck area in 
Austria was not found. 
Current treatment regimens and prognosis 
Treatment modalities may include one, or a combination of the following: 
surgery, radiation therapy, chemotherapy [62]. Epidemiologic data regard-
ing the survival specifically for rhabdomyosarcomas in the skull base area in 
Austria was not found. 
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Included studies, efficacy and safety 
For rhabdomyosarcomas in the ENT area, no studies were included in this 
assessment. Thus, no evidence was found to answer the research question. 
Conclusion 
At present, there is no scientific evidence indicating superiority or inferiority 
regarding the use of carbon ion radiotherapy (CIRT) for rhabdomyosarcoma 
in the ENT area. 
 
5.3.5 Lung cancer 
5.3.5.1 Non-small cell lung carcinomas 
Definition and epidemiology 
The non-small cell lung carcinoma (NSCLC) is the most frequent form of 
lung cancer and includes adenocarcinomas, squamous cell carcinomas and 
large cell carcinomas. The size of the cells in a tumour to be found under a 
microscope is decisive whether a lung tumour is classified as a non-small or 
small cell lung cancer [35, 94].  
In 2014, 2,894 men and 1,822 women developed lung cancer in Austria. As 
such, lung cancer is one of the most frequently occurring malignant tumours, 
being the second and third most frequent cancer disease among men and 
women respectively. In 2015, the age-adjusted incidence rate of lung and 
bronchus cancer was 57.9 per 100,000 persons [95]. In 2016, deaths caused 
by NSCLC and small-cell, tracheal and bronchus cancer accounted for 4.72% 
(95% CI: 4.44-5.02) of all deaths in Austria [96]. 
Lung and bronchus cancer can be localised, regional, distant and unstaged (un-
known): localised lung and bronchus cancer refers to the stage when the cancer 
is only found in the part of the body in which cancer started. Lung and bron-
chus cancer is regional if cancer already spread to another part (s) of the body 
and distant if cancer has metastasised as well [66]. 
Current treatment regimens and prognosis 
The treatment of patients suffering from NSCLC differs according to the pa-
tient’s tumour stage, overall medical condition and the molecular character-
istics of a tumour. For NSCLC patients within stages I-III, curative treat-
ments are typically used: surgeries, chemotherapy, radiation therapy (RT) – 
or a combination of those therapies – are current treatment modalities. In case 
NSCLC is advanced (i.e., if metastatic), systemic therapy is indicated [94]. 
According to the Statistics from the Surveillance, Epidemiology, and End 
Results (SEER), the 5-year survival of all lung and bronchus cancer patients 
was 18.1% (2007–2013) in the United States (US). However, variations among 
the stages of cancer can be seen: patients with localised or regional lung and 
bronchus cancer have a higher chance of surviving 5 years after the diagnosis 
in comparison to patients suffering from distant lung and bronchus cancer, 
or patients with an unknown lung and bronchus stage, with a 5-year survival 
of 55.6%, 28.9%, 4.5% and 7.5% respectively [66]. 
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Included studies 
For non-small cell lung carcinomas (NSCLC), 6 clinical studies [97-102] from 
2 cancer therapy centres in Japan were included in this assessment. 4 studies 
conducted at the Heavy Ion Medical Accelerator in Chiba (HIMAC) and 2 
studies conducted at the Hyogo Ion Beam Medical Center (HIBMC): 2 case-
control studies [99, 100], 2 dose-escalation/non-randomised, open-label, sin-
gle-centre, case series studies [97, 98] and 2 case series focusing on toxicity 
and local control [101, 102].  
In total, 559 patients were enrolled in the included studies, with 459 and 100 
patients receiving carbon ion radiotherapy (CIRT) and proton radiotherapy 
(PRT) respectively. The irradiation dose for CIRT and PRT patients between 
all included studies ranged from 52.8 to 76 GyE in 1-20 fractions and 60-80 
GyE in 10-26 fractions respectively. In addition, 7 patients received co-inter-
ventions: 5 and 2 patients were treated with neoadjuvant therapy and salvage 
chemotherapy respectively. Of the 559 patients, the majority had stage IA and 
stage IB NSCLC, with 236 (42%) and 238 (43%) patients respectively. The rest 
of the patients suffered from Stage IIA, Stage IIB and Stage IIIA NSCLC, with 
40 (7%), 22 (4%), and 23 (4%) patients in those tumour groups respectively. 
Age ranges were reported either as mean (ranging from 74.1 to 74.8 years) or 
median (ranging from 75 to 76 years), with 2 [101, 102] and 4 [97-100] stud-
ies using those measures respectively. All patients were aged between 46 and 
92 years at the start of the enrolment in the clinical trials. The loss to follow-
up was not adequately reported in any of the included studies. 2 of the in-
cluded studies may have overlapping patient populations: it is assumed, but 
not clearly stated, that the sample in Takahashi et al. 2015 [98] (n=62) is al-
so included in Yamamoto et al. 2017 [97] (n=218). Study characteristics, i.e., 
information on patient population, intervention, control and study design of 
the included studies, can be found in Table A-6. 
Efficacy 
Overall survival (OS) 
All 6 included studies measured overall survival (OS) of carbon ion radiother-
apy (CIRT) patients at different time points [97-102]. 2 included studies com-
pared the OS to the OS of patients undergoing proton radiotherapy (PRT) 
and found no statistically significant differences between the survival rates 
of those therapy groups. 
1-year OS was reported in 1 study [98] with 62 stage II NSCLC patients un-
dergoing CIRT (17 Stage IIA, 22 Stage IIB, 23 Stage IIIA) with a 1-year OS 
of 77.2% (95% CI: 66.7%-87.7%).  
2-year OS was reported in the same study [98] with an OS of 51.9% (95% CI: 
39.2%-64.5%) at 2 years. 
3-year OS was reported in 2 studies: 1 study ([100], 80 patients: 23 and 57 
undergoing CIRT and PRT respectively) reported on a 3-year OS of 75% 
(95% CI: 64%-86%; IA: 74%, IB: 76%). In the same study, OS of the therapy 
groups was reported: the OS for 23 patients undergoing CIRT was 86.6% 
(95% CI: NR). The OS for 20 and 37 patients undergoing PRT at different 
doses was 90% (95% CI: NR) and 61% (95% CI: NR) at 3 years respectively. 
There were no statistically significant differences between the results of the 
3 treatment protocols [100]. The other identified study [97] reported on a 3-
year OS of 68.3% (95% CI: NR) for 218 NSCLC (123 stage IA, 95 stage IB) 
patients, undergoing CIRT [97]. 
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4-year OS was reported in 1 study [99] with 70 patients undergoing CIRT or 
PRT with a survival of 58% (95% CI: 46%–70%; IB: 53%; IIA: 67%) at 4 years. 
In the same study, it was stated that there were no statistically significant dif-
ferences between the respective rates of PRT and CIRT patients. However, 
no survival rates of the therapy groups were reported. 
5-year OS was reported in 3 studies [97, 101, 102]: 2 studies with 79 NSCLC 
patients [102] (42 IA and 37 IB NSCLC patients) and 50 NSCLC patients 
[101] (29 IA and 21 IB NSCLC patients) observed OS rates of 45% (95% CI: 
NR; T1 IA: 62%, T2 IB: 25%) and 50.0% (95% CI: NR; IA 55.2, IB: 42.9) re-
spectively. The patients involved in those studies received CIRT. Another 
study reported on a 5-year OS of 49.4% (95% CI: NR) of 218 NSCLC pa-
tients (123 stage IA, 95 stage IB) undergoing CIRT [97]. 
10-year OS was not reported in the included studies. 
Cause-specific survival (CSS) 
Overall, 4 out of 6 included studies measured cause-specific survival (CSS) 
of CIRT patients at different time points [98, 100-102]. None of the included 
studies compared the CSS to the CSS of patients undergoing conventional 
radiotherapy 
1-year CSS was not reported in any of the included studies. 
2-year CSS was reported in 1 study [98] with 62 stage II NSCLC patients (17 
Stage IIA, 22 Stage IIB and 23 Stage IIIA) undergoing CIRT and was 71.7% 
(95% CI: NR). 
3-year CSS was reported in 1 study [100] with 80 NSCLC patients undergo-
ing CIRT (n=23) or PRT (n=57) with a CSS of 86% (95% CI: 77%-95%; IA: 
84%; IB: 88%) at 3 years. CSS of the specific therapy groups was not reported 
in the study. 
4-year CSS was not reported in any of the included studies. 
5-year CSS was reported in 2 studies [101, 102]: 1 study reported on a CSS of 
68% (95% CI: NR) for 79 NSCLC patients [102] (42 IA and 37 IB NSCLC 
pts). In the same study, CSS according to tumour stage was 87% (95% CI: 
NR) for IA patients and 42% (95% CI: NR) for IB patients at 5 years. Anoth-
er study [101] reported on the 5-year CSS of 50 NSCLC patients (29IA and 
21 IB NSCLC patients receiving CIRT: The 5-year CSS for all patients was 
75.7% (95 CI: NR) at 5 years. The CSS according to tumour stage was 89.4 
(95% CI: NR) for IA patients and 55.1 (95% CI: NR) for IB patients at 5 years. 
10-year CSS was not reported in the included studies. 
Disease-free survival (DFS) 
The endpoint disease-free survival (DFS) was measured by 2 [98, 100] out of 
6 included studies. 
1-year DFS was not reported in any of the included studies. 
2-year DFS was reported in 1 study [98] with 62 stage II NSCLC patients 
(17 Stage IIA, 22 Stage IIB and 23 Stage IIIA) undergoing CIRT and was 
35.7% (95% CI: NR). 
3-year DFS was reported in 1 study [100] with 80 NSCLC patients undergo-
ing CIRT (n=23) or PRT (n=57): The study observed a DFS of 54% (95% 
CI: 43%-68%; IA: 67%; IB: 46%) at 3 years. 
4-year DFS was not reported in any of the included studies. 
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5-year DFS was not reported in any of the included studies. 
10-year DFS was not reported in the included studies. 
Recurrence-free survival (RFS) 
The endpoint recurrence-free survival (RFS) was not measured by any of the 
included studies. 
Progression-free survival (PFS) 
1 out of 6 included studies measured progression-free survival (PFS) of CIRT 
patients [99]: the progression-free survival of CIRT and PRT patients (n=70) 
was 46% (95% CI: 33%–59%; IB: 43%; IIA: 52%) at 4 years. The authors of 
this study stated that there were no statistically significant differences be-
tween the respective rates of PRT and CIRT patients. However, the PFS ac-
cording to the groups was not reported in the study [99]. 
Local control rate (LCR) 
All 6 included studies measured the local control rate (LCR) of CIRT patients 
at different time points [97-102]: 1 study compared the LCR of CIRT patients 
to the LCR of patients undergoing PRT and found no statistically significant 
differences regarding local control rates between therapy groups. 
1-year LCR was reported in 1 study [98] with 62 stage II NSCLC patients 
undergoing CIRT (17 Stage IIA, 22 Stage IIB, 23 Stage IIIA) with a 1-year 
LCR of 96.0% (95% CI: 90.5%-100.0). 
2-year LCR was reported in the same study [98] with an LCR of 93.1% (95% 
CI: 85.4%-100.0) at 2 years. 
3-year LCR was reported in 2 studies: 1 study [100] (80 patients, stage IA-IB: 
23 and 57 undergoing CIRT and PRT respectively) reported on a 3-year LCR 
of 82% (95% CI: 72%-92%). In the same study, the LCR for each therapy group 
was reported: the LCR for 23 patients undergoing CIRT was 86% (95% CI: 
NR). The LCR for 20 and 37 patients undergoing PRT at different doses was 
83% (95% CI: NR) and 81% (95% CI: NR) at 3 years respectively. There were 
no statistically significant differences between the results of the 3 treatment 
protocols [100]. The other identified study [97] reported on a 3-year LCR of 
77.9% (95% CI: NR) for 218 NSCLC (123 stage IA, 95 stage IB) patients. 
Diff. zwischen PRT und CIRT hinsichtlich 3 und 4 Jahre LCR n. s. 
4-year LCR was reported in 1 study [99] with 70 NSCLC patients (47 stage IB 
patients, 23 stage IIA patients) undergoing CIRT or PRT with a local control 
rate of 75% (95% CI: 63%–86%; IB: 70%; IIA: 84%) at 4 years. In the same 
study, it was stated that there were no statistically significant differences be-
tween the respective rates of PRT and CIRT patients. However, no LCR of 
the specific therapy groups were reported [99]. 
5-year LCR was reported in 3 studies [97, 101, 102]: 2 studies with 79 NSCLC 
patients [102] (42 IA and 37 IB NSCLC pts) and 50 NSCLC patients [101] 
(29 IA and 21 IB NSCLC pts) observed LCR rates of 90% (95% CI: NR; T1 
IA: 97%, T2 IB: 80%) and 94.7% (95% CI: NR)23 respectively. Another study 
reported on a 5-year LCR of 72.7% (95% CI: NR) of 218 NSCLC patients (123 
stage IA, 95 stage IB) [97]. 
10-year LCR was not reported in the included studies. 
                                                             
23 The tumour-stage specific LCR was not reported. 
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Health-Related Quality of Life (HRQoL) 
The endpoint Health-Related Quality of Life (HRQoL) was not measured by 
any of the included studies. 
Safety 
All of the included studies measured radiation morbidities: common toxici-
ties within CIRT were in the lung (i.e., radiation pneumonitis) and skin (i.e., 
dermatitis). 4 studies [97, 98, 101, 102] distinguished acute and late radia-
tion morbidities, while 2 studies [99, 100] did not clearly report when the 
observed radiation morbidities occurred. 
Acute radiation morbidity 
Overall, 4 out of 6 studies elaborated on acute radiation morbidities using the 
CTCAE [98], NCI-CTC [97] or the RTOG [101, 102] criteria: no grade 4, 
and 1 grade 3 acute radiation morbidity in the lung region were observed in 
1 study [98]. Several grade 1-2 acute radiation morbidities were observed in 
the lung and skin region [97, 98, 101, 102]. 
Grade 1 acute radiation morbidity (lung and skin) was reported in 3 studies 
[97, 101, 102]: in the lung area, 2 studies reported on none (0%) and 1 (1.9%) 
case of grade 1 acute radiation morbidity in 79 NSCLC patients with 80 pri-
mary lesions [102] and 50 NSCLC patients with 51 primary lesions [101] re-
spectively. In the skin area, radiation morbidities were observed in 2 studies, 
with grade 1 radiation morbidities occurring in 75 out of 80 primary NSCLC 
lesions (93.8%) [102] and 50 out of 51 primary NSCLC lesions (98%) [101] 
respectively. 1 study did not specify the regions in detail and reported on 212 
out of 218 NSCLC patients (97.2%) developing grade 1 acute radiation mor-
bidities [97]. 
Grade 2 acute radiation morbidity (lung and skin) was reported in 4 studies: 
in the lung area, acute radiation morbidities ranged from 1 in 79 lesions 
(1.3%) [102] to 1 in 51 primary lesions (1.9%) [101]. In the skin area, acute 
radiation morbidities ranged from 1 in 51 primary lesions (1.9%) [101] to 5 
in 62 NSCLC patients (8%) [98]. 1 study did not specify the regions in detail 
and reported on 3 out of 218 NSCLC patients (1.3%) developing grade 2 acute 
radiation morbidities [97] 
Grade 3 acute radiation morbidities were reported in 4 studies: 1 study [98] 
observed 1 in 62 patients (1.6%) developing grade 3 radiation pneumonitis 
(lung region). The other studies did not observe grade 3 acute radiation mor-
bidities in their samples [97, 101, 102]. 
Grade 4 acute radiation morbidities were reported in all 4 studies [97, 98, 101, 
102]: none of those studies observed any grade 4 acute radiation morbidities. 
Late radiation morbidity 
Overall, 4 out of 6 studies reported on late radiation morbidities using the 
RTOG/EORTC [97, 98, 101, 102] criteria. In addition, 2 studies did not re-
port on whether the radiation morbidities occurred in the acute or late peri-
od and used the CTCAE criteria to assess radiation morbidities: 2 grade 3 
radiation morbidities and several grade 2 radiation morbidities were observed 
in those studies [99, 100]. 
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Grade 1 (late) radiation morbidity (lung and skin) was reported in 3 studies 
[97, 101, 102]: in the lung area, 2 studies observed radiation morbidities in 69 
out of 76 primary lesions (90.8%) [102] and in 48 out of 51 primary NSCLC 
lesions (94%) [101] respectively. In the skin area, radiation morbidities were 
observed in 2 studies, with grade 1 radiation morbidities occurring in 76 out 
of 77 NSCLC primary lesions (98.7%) [102] and 49 out of 51 NSCLC prima-
ry lesions (96%) [101] respectively. 1 study did not specify the regions in de-
tail and observed 207 out of 212 NSCLC patients (97.6%) developing grade 1 
late radiation morbidities [97]. 
Grade 2 late radiation morbidity (lung and skin) was reported in 4 studies: in 
the lung area, late radiation morbidities ranged from 1 in 76 primary lesions 
(1.3%) [102] to 3 in 62 NSCLC patients (4.8%) [98]. In the skin area, late ra-
diation morbidities ranged from 1 out of 77 primary lesions (1.3%) [102] to 1 
out of 51 primary lesions (1.9%) [101]. 1 study did not specify the regions in 
detail and reported on 1 out of 212 NSCLC patients (0.5%) developing grade 
2 late radiation morbidities [97]. 
In addition, grade 2 radiation morbidity (lung and skin) was reported in 2 
further studies that did not specify whether the morbidities occurred in the 
acute or late period: 1 study [100] observed 2 out of 23 CIRT patients (8.7%) 
and 7 out of 57 PRT patients (12.3%) developing grade 2 radiation pneu-
monitis. In the same study, 2 in 23 CIRT patients (8.7%) and 8 in 57 PRT 
patients (14%) suffered from grade 2 dermatitis. No statistical comparison 
regarding the difference was conducted. In the same study, 23% and 5% of 
all patients had a grade 2 rib fracture and grade 2 soft tissue radiation mor-
bidities respectively. In another study [99], 10 out of 70 patients (14.3%) re-
ceiving CIRT (n=27) or PRT (n=43) developed grade 2 radiation pneumon-
itis and dermatitis respectively24. 
Grade 3 late radiation morbidities were reported in all 4 studies: 1 study 
(n=50) observed 1 grade 3 radiation morbidity in 51 lesions in the skin region 
(1.9) [101] and 1 other study observed 1 out of 62 NSCLC patients (1.6%) de-
veloping a grade 3 radiation morbidity in the oesophagus [98]. 
Additionally, grade 3 radiation morbidity (lung and skin) was reported in both 
2 studies not specifying whether the morbidities occurred in the acute or late 
period: 1 study [100] observed no radiation pneumonitis or dermatitis (0%) 
in the CIRT sample (n=23). In the same study, grade 3 radiation pneumon-
itis and dermatitis were observed in PRT patients (n=57), with 1 (1.8%) and 
3 (5.3%) patients with those radiation morbidities respectively. No statistical 
comparison regarding the difference was conducted. In another study [99], 2 
(2.9%) and 4 (5.7%) grade 3 late radiation morbidities occurred in the lung 
and skin respectively. 
Grade 4 late radiation morbidities were reported in all 4 studies: no grade 4 
late radiation morbidities were observed in any of the included studies. 
In addition, grade 4 radiation morbidity (lung and skin) was reported in both 
2 studies not specifying whether the morbidities occurred in the acute or late 
period: 1 study [100] observed no grade 4 radiation morbidity and another 
                                                             
24 Radiation morbidities of the therapy groups were not reported in this study [99]. 
However, tumour stage specific radiation morbidities were reported and can be 
found in the data extraction-table in the Appendix (see Table A-6). 
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study [99] observed 1 grade 4 dermatitis in 70 patients (1.4%) having been 
irradiated with CIRT (n=27) or PRT (n=43)25. 
Conclusion 
For non-small cell lung cancer (NSCLC), 6 studies were identified: none of 
the eligible studies were controlled, comparing CIRT to standard irradiation. 
Indirect comparisons of overall survival (OS) and local control rate (LCR) and 
progression-free survival (PFS) show equal results when comparing CIRT to 
PRT (no statistically significant differences) [99, 100]. Neither inferiority nor 
superiority of CIRT on the basis of the selected endpoints regarding efficacy 
(OS, CSS, DFS, RFS, PFS, LCR, HRQoL) or safety (acute radiation morbid-
ity, late radiation morbidity) can be concluded from the evidence. That is to 
say, (randomised) controlled studies are needed to clarify whether CIRT is 
more effective than or as effective as and safer than or as safe as standard ir-
radiation in NSCLC patients. 
 
5.3.5.2 Mediastinal tumours (including thymoma) 
Definition and epidemiology 
Mediastinal tumours are rare tumours that develop from structures within, 
or while passing through the mediastinum and are a set of various different 
tumours being benign or malignant [103, 104]. 
Current treatment regimens and prognosis 
The current treatment of mediastinal tumours is dependent on the size and 
type of a tumour: therapy options may include a surgical approach, chemo-
therapy or radiation therapy [104]. 
Included studies, efficacy and safety 
For mediastinal tumours, no studies were included in this assessment. Thus, 
no evidence was found to answer the research question. 
Conclusion 
At present, there is no scientific evidence indicating superiority or inferiority 
regarding the use of carbon ion radiotherapy (CIRT) in comparison to stand-
ard irradiation for mediastinal tumours (including thymoma). 
 
5.3.5.3 Pleural mesothelioma 
Definition and epidemiology 
Mesothelioma is a rare cancer arising from mesothelial surfaces to be found, 
inter alia, in the pleural cavity [105].  
Current treatment regimens and prognosis 
The treatment approach of pleural mesotheliomas depends on the extent of 
the tumour as well as on the patient’s condition and may include, among oth-
ers, one, or a combination of the following: chemotherapy (standard approach 
                                                             
25 It is not clearly stated whether the grade 4 dermatitis occurred in the CIRT or PRT 
sample. 
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for malignant pleural mesotheliomas), resection, and radiation therapy (RT). 
However, malignant pleural mesotheliomas have a poor diagnosis, without 
further improvements through new therapeutic interventions. The benefits of 
surgery and RT are currently not derived from randomised trials, but rather 
from observational studies [105]. 
Included studies, efficacy and safety 
No studies for pleural mesotheliomas were included in this assessment. Thus, 
no evidence was found to answer the research question. 
Conclusion 
At present, there is no scientific evidence indicating superiority or inferiority 
regarding the use of carbon ion radiotherapy (CIRT) in comparison to stand-
ard irradiation for pleural mesotheliomas. 
 
5.3.6 Gastrointestinal tumours 
In this section, the body of evidence of the included studies focusing on effi-
cacy and/or safety of carbon ion radiotherapy (CIRT) for tumours in the gas-
trointestinal (GI) region will be assessed. That is, the evidence of CIRT for 
the following 6 indications will be assessed. 
Included studies 
Overall, 2 studies [106, 107] with 215 patients enrolled patients were includ-
ed in this assessment: 184 and 31 patients suffered from rectal cancer and 
esophageal cancer respectively. 
Conclusion: Efficacy and safety 
Due to the heterogeneity of the different tumours (e.g., different prognosis) 
captured with the term gastrointestinal tumours, the reader is referred to the 
results from specific gastrointestinal tumours. For gastrointestinal tumours, 
there is insufficient scientific evidence indicating superiority/inferiority of 
CIRT regarding efficacy or safety for thoracic oesophageal squamous cell car-
cinoma and rectal cancer without distant metastases when compared to con-
ventional radiotherapy (evidence base: 1 prospective case series respectively). 
No scientific evidence indicating superiority/inferiority of CIRT regarding 
efficacy or safety when compared to standard irradiation was found for pan-
creatic cancer, liver carcinoma, schwannomas/malignant schwannomas, and 
Ewing’s sarcomas. 
In the following section results from specific gastrointestinal tumours are 
presented. 
In the following section results from specific gastrointestinal tumours are 
presented. 
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5.3.6.1 Oesophageal carcinoma 
Definition and epidemiology 
Most of the oesophagal cancers are either squamous cell carcinomas (SCC) or 
adenocarcinomas, accounting for approximately 95% of all malignant tumours 
occurring in the oesophagal area [108]. The tumor, node, metastasis (TNM) 
classification, developed by the American Joint Committee on Cancer (AJCC) 
as well as the Union Internationale Contre le Cancer (UICC), is used for oe-
sophagal carcinomas. However, oesophagal SCC and adenocarcinomas starts 
to be differentiated when it comes to stage grouping, due to growing evidence 
suggesting that those oesophagal cancer types may be 2 different diseases 
due to heterogeneous features of those tumour types, i.e., regarding patho-
genesis, epidemiology and tumour biology [108]. 
In Austria, the occurrence of oesophagal cancer was rare in 2015, with 418 
new cases, accounting for 1% of all newly diagnosed cancer cases, in the same 
year. The age-adjusted incidence rate was 5 cases per 100,000 persons in the 
same year. In 2015, oesophagal cancer was prevalent in 920 and 271 men and 
women respectively [109].  
Current treatment regimens and prognosis 
The treatment of oesophagal cancer differs according to the tumour stage 
and may include 1 or more of the following therapies: surgery, preoperative 
chemoradiation therapy, preoperative chemotherapy, definitive chemoradia-
tion, postoperative radiation therapy [110]. 
Data from Statistics Austria based on 1,744 patients diagnosed with oesoph-
agal carcinomas within the time period of 2003 and 2007 shows a relative 
survival of 46% and 23.7% at 1 and 3 years respectively. The relative 5- and 
10 year survival was 18.4% and 14.3% respectively [111]. 
Included studies 
For oesophagal carcinomas, 1 dose-escalation, case series study from the 
Heavy Ion Medical Accelerator in Chiba (HIMAC) [106] was eligible to be 
included in the assessment. In total, 31 patients were enrolled in the includ-
ed studies and underwent neoadjuvant carbon ion radiotherapy (CIRT) at a 
dose ranging from 28.8 GyE to 36.8 GyE in 8 fractions over 2 weeks. All pa-
tients received surgery after CIRT. 
All of the 31 patients were diagnosed with thoracic oesophagal squamous cell 
carcinoma (ESCC). Of those, the tumour stage ranged from 1-3 (T1: 12 pa-
tients, T2: 8 patients, T3: 11 patients). In 9 patients, the tumour spread to 
nearby lymph nodes (N1: 8, N2: 1). The study reported that 10, 14 and 7 pa-
tients were stage 1, stage 2, and stage 3 patients respectively. The mean age of 
the included patients was 65.4 (SD: 7.1). The range of the patients was further 
reported. The loss to follow-up was not reported in the included study. 
Study characteristics, i.e., information on patient population, intervention, 
control and study design of the included studies, can be found in the Appen-
dix (Table A-5).  
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Efficacy 
Overall survival (OS) 
The included dose-escalation study [106] measured overall survival (OS) at 
different time points. 
1-year OS was reported in the included study [106]: The OS was 91% (95% 
CI: NR), 100% (95% CI: NR) and 71% (95% CI: NR) for stage 1 patients 
(n=10), stage 2 patients (n=14) and stage 3 patients (n=7) at 1 year after 
surgery respectively. Overall survival of all patients was not reported. 
2-year OS was not reported in the included study. 
3-year OS was reported in the included study [106]: The OS was 81% (95% 
CI: NR), 85% (95% CI: NR) and 43% (95% CI: NR) for stage 1 patients 
(n=10), stage 2 patients (n=14) and stage 3 patients (n=7) at 1 year after 
surgery respectively. Overall survival of all patients was not reported. 
4-year OS was not reported in the included study. 
5-year OS was reported in the included study [106]: The OS was 61% (95% 
CI: NR), 77% (95% CI: NR) and 29% (95% CI: NR) for stage 1 patients 
(n=10), stage 2 patients (n=14) and stage 3 patients (n=7) at 1 year after 
surgery respectively. Overall survival of all patients was not reported. 
10-year OS was not reported in the included study. 
Cause-specific survival (CSS)/Disease-specific survival (DSS) 
The endpoint cause-specific survival (CSS)/disease-specific survival (DSS) 
was measured at different time points by the included study [106]. 
1-year CSS was reported in the included study and observed a CSS of 97% 
(95% CI: NR) at 1 year (stage 1: 100%; stage 2: 100%; stage 3: 83%) for 31 
ESCC patients. 
2-year CSS was not reported in the included study. 
3-year CSS was reported in the included study and observed a CSS of 79% 
(95% CI: NR) at 3 years (stage 1: 90%; stage 2: 85%; stage 3: 50%) for 31 
ESCC patients. 
4-year CSS was not reported in the included study. 
5-year CSS was reported in the included study and observed a CSS of 71% 
(95% CI: NR) at 5 years (stage 1: 90%; stage 2: 77%; stage 3: 33%) for 31 
ESCC patients. 
10-year CSS was not reported in the included study. 
Disease-free survival (DFS) 
The endpoint disease-free survival (DFS) was not measured by the included 
study. 
Recurrence-free survival (RFS) 
The endpoint recurrence-free survival (RFS) was measured at different time 
points by the included study [106].  
1-year RFS was reported in the included study and observed an RFS of 87% 
(95% CI: NR) at 1 year after surgery (stage 1: 100%; stage 2: 92%; stage 3: 
51%) for 31 ESCC patients. 
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2-year RFS was not reported in the included study. 
3-year RFS was reported in the included study and observed an RFS of 62% 
(95% CI: NR) at 3 years after surgery (stage 1: 80%; stage 2: 69%; stage 3: 
17%) for 31 ESCC patients. 
4-year RFS was not reported in the included study. 
5-year RFS was reported in the included study and observed an RFS of 62% 
(95% CI: NR) at 5 years after surgery (stage 1: 80%; stage 2: 69%; stage 3: 
17%) for 31 ESCC patients. 
10-year RFS was not reported in the included study. 
Progression-free survival (PFS) 
The endpoint progression-free survival (PFS) was not measured  
by the included study [106]. 
Local control rate (LCR) 
The endpoint local control rate (LCR) was not measured  
by the included study [106]. 
Health-Related Quality of Life (HRQoL) 
The endpoint Health-Related Quality of Life (HRQoL) was not measured  
by the included study [106]. 
Safety 
Acute radiation morbidity 
Acute radiation morbidity was measured by the included study [106] using 
the CTCAE v.3.0 criteria. Acute radiation morbidities were observed in the 
oesophagus, skin, respiratory organs and blood. 
Grade 1 acute radiation morbidities were reported in the included study [106] 
(with 31 ESCC patients) and were observed in the following regions: 19 in 
the oesophagus (61.3%), 27 cases in the skin (87.1%), 4 cases in the blood 
(12.9%). No grade 1 acute radiation morbidity was observed in respiratory 
organs. 
Grade 2 acute radiation morbidities were reported in the included study [106]: 
the study observed 12 cases (38.7%) and 2 cases (6.4%) of grade 2 acute radi-
ation morbidity in the esophagus and blood respectively. No grade 2 acute 
radiation morbidity was observed in respiratory organs or skin. 
Grade 3 acute radiation morbidities were reported in the included study [106]: 
the study observed 1 case (3.2%) of grade 3 acute radiation morbidity in res-
piratory organs. 
Grade 4 acute radiation morbidities were reported in the included study [106]: 
no grade 4 acute radiation morbidities occurred in any region. 
Late radiation morbidity 
Late radiation morbidities were measured by the included study [106] using 
the CTCAE v.3.0, but not reported in the included study26. 
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Conclusion 
For oesophagal cancer, 1 case series study [106] was eligible to be included in 
the assessment: the study was not controlled, comparing CIRT to standard 
irradiation. Thus, neither inferiority nor superiority of CIRT on the basis of 
the selected endpoints regarding efficacy (OS, CSS, DFS, RFS, PFS, LCR, 
HRQoL) or safety (acute radiation morbidity, late radiation morbidity) can 
be concluded from the evidence. That is to say, (randomised) controlled stud-
ies are needed to clarify whether CIRT is more effective than or as effective 
as, or safer than or as safe as standard irradiation in patients with oesoph-
agal cancer. 
 
5.3.6.2 Pancreatic cancer 
Definition and epidemiology 
Pancreatic cancer is the third most frequent gastrointestinal tumour, occur-
ring more likely in older people [112]. In 2015, 1,757 persons developed pan-
creatic cancers in Austria; leading to an age-adjusted incidence of 21 cases 
per 100,000 persons. At the end of the same year, 1,178 men and 1,240 wom-
en were alive and diagnosed with pancreas carcinomas [113]. 
Current treatment regimens and prognosis 
The treatment of pancreatic cancer depends on the stage and localisation of 
a tumour and may include surgery, systemic chemotherapy, and adjuvant ra-
dio-chemotherapy [112]. Data from Statistics Austria based on 5,888 patients 
diagnosed with pancreas carcinomas within the time period of 2003 and 2007 
shows a relative survival of 28% and 10.2% at 1 and 3 years respectively. The 
relative 5- and 10-year survival was 7% and 5.5% respectively [114]. 
Included studies 
No studies for pancreatic cancer were included in this assessment. Thus, no 
evidence was found to answer the research question. 
Conclusion 
At present, there is no scientific evidence indicating superiority or inferiority 
regarding the use of carbon ion radiotherapy (CIRT) in comparison to stand-
ard irradiation for pancreatic cancer. 
 
5.3.6.3 Liver carcinoma 
Definition and epidemiology 
Liver carcinomas (hepatocellular carcinoma) are aggressive tumours, fre-
quently occurring when chronic liver diseases are existent [115]. In Austria, 
941 malignant liver cancers were diagnosed in 2015, accounting for 2% of the 
annual cancer diseases in this year. The age-adjusted incidence rate is 11.2 
cases per 100,000 men and women developing liver cancer in 2015 respec-
tively. At the end of the same year, liver cancer was prevalent in 1,227 and 
483 men and women respectively [116].  
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Current treatment regimens and prognosis 
Surgical resection may be described as the mainstay of current treatment mo-
dalities. However, patients are frequently not eligible for surgical resection 
due to the extent of the tumour. Alternatively, other treatment modalities in-
clude, among others, tumour ablation using nonsurgical methods (radiofre-
quency ablation, transarterial chemoembolisation, radiation therapy, percu-
taneous ethanol injection) and systemic therapy [115]. Data from Statistics 
Austria based on 3,843 patients diagnosed with liver cancer within the time 
period of 2003, and 2007 shows a relative survival of 33.2% and 17.0% at 1 
and 3 years respectively. The relative 5- and 10-year survival was 12.2% and 
7.5% for the same population [117]. 
Included studies, efficacy and safety 
For liver carcinoma, none of the identified studies met the inclusion criteria 
for the qualitative synthesis. Thus, no evidence was found to answer the re-
search question. 
Conclusion 
None of studies for liver carcinoma were eligible to be included in the as-
sessment. Thus, no evidence was found indicating superiority or inferiority 
of CIRT for liver carcinomas. 
 
5.3.6.4 Rectal carcinoma 
Definition and epidemiology 
Rectal carcinoma is a type of cancer in the lower gastrointestinal tract (rec-
tum). Rectal cancer may not be easily distinguishable from colon cancer when 
epidemiological data is concerned. That is, most epidemiological studies do 
not separate those 2 diseases and use the term colorectal cancer for their 
analysis [118]. Epidemiologic data on the incidence and prevalence of colorec-
tal cancer in Austria shows an age-adjusted incidence rate of 51.9 cases per 
100,000 people in Austria. In the same year, colorectal cancer was diagnosed 
more often in men than in women, with 68 and 39.9 new cases per 100,000 
people respectively [119]. 
The tumor, node, metastasis (TNM) classification, developed by the Ameri-
can Joint Committee on Cancer (AJCC) as well as the Union Internationale 
Contre le Cancer (UICC), is usually used to stage rectal carcinomas [118]. 
Colorectal cancer can be localised, regional, distant and unstaged (unknown): 
localised colorectal cancer refers to the stage when the cancer is only found 
in the part of the body in which cancer started. Colorectal cancer is regional 
if cancer already spread to another part of the body and distant if cancer has 
metastasised as well. In the United States, 39.2% of colorectal cancer patients 
are diagnosed when a tumour is in the local stage [66].  
Current treatment regimens and prognosis 
The standard treatment modalities of rectal cancer depend on the stage of a 
tumour and may include one, or more of the following: polypectomy or sur-
gery, pre- or postoperative chemoradiation therapy [118]. Data from Statis-
tics Austria based on 24,205 patients diagnosed with colorectal cancer within 
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the time period of 2003 and 2007 shows a relative survival of 79.8 and 67.2 at 
1 and 3 years respectively. The relative 5- and 10-year relative survival was 
61% and 55.6% for the same population [120]. 
According to the Statistics from the Surveillance, Epidemiology and End Re-
sults (SEER), the 5-year survival of all colorectal cancer patients was 64.9% 
(2007–2013) in the United States. However, variations among the stages of 
cancer can be seen: patients with localised or regional colorectal cancer have 
higher relative survival after the diagnosis in comparison to patients suffer-
ing from distant or unstaged colorectal cancer, with a 5-year relative survival 
of 89.9%, 71.3%, 13.9% and 35.4% respectively [66]. 
Included studies 
For rectal cancer, 1 study [107] was identified and eligible for the qualitative 
synthesis: the study consisted of 1 dose-escalation (phase 1/2) and 1 non-ran-
domised, single-arm study part (phase 2). In total, 184 patients with locally 
recurrent rectal cancer were included in the study and were treated with 
carbon ion radiotherapy (CIRT) at a dose ranging from 67.2 to 73.6 GyE in 
the dose escalation part (phase 1/2) of the study (n=38) and 70.4 to 73.6 GyE 
for the patients in the phase 2 part of the study (n=146). 
Of the 184 patients, all patients had locally recurrent rectal cancer. Tumour 
stage using the TNM classification was not reported in the study. However, 
the average tumour size of the patients was 3.4 cm (SD: 1.4) and ranged from 
1.0 to 14.0 cm. The median age of the patients enrolled in the included study 
was 61.3, and all patients were aged between 37 and 79 years. The median 
follow-up time was 42 months (range: 7-131). 4 patients were excluded from 
the analysis and the loss to follow-up was not further reported in the includ-
ed study.  
Study characteristics, i.e., information on patient population, intervention, 
control and study design of the included study, can be found in the Appen-
dix (Table A-5). 
Efficacy 
Overall survival (OS) 
The endpoint overall survival (OS) was measured by the included study [107] 
at 3 and 5 years after carbon ion radiotherapy. 
1-year OS was not reported in the included study. 
2-year OS was not reported for all patients in the included study. However, 
the 2-year OS in phase 2 [107] for 139 patients was 91% (95 %CI: NR). 
3-year OS was reported in the included study [107] with 184 enrolled  
patients: the study observed a 3-year OS of 72% (95 %CI: 66%-79%). 
4-year OS was not reported in the included study. 
5-year OS was reported in the included study [107] with 184 enrolled  
patients: the study observed a 5-year OS of 53% (95% CI: 45%-62%). 
10-year OS was not reported in the included study. 
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Cause-specific survival (CSS)/Disease-specific survival (DSS) 
The endpoint cause-specific survival (CSS)/disease-specific survival (DSS) 
was not measured by the included study.  
Disease-free survival (DFS) 
The endpoint disease-free survival (DFS) was not measured  
by the included study. 
Recurrence-free survival (RFS) 
The endpoint recurrence-free survival (RFS) was not measured  
by the included study. 
Progression-free survival (PFS) 
The endpoint progression-free survival (PFS) was not measured  
by the included study. 
Local control rate (LCR) 
The endpoint local control rate (LCR) was measured at 5 years for different 
dose groups by the included study. 
1-year LCR was not reported in the included study. 
2-year LCR was not reported in the included study. 
3-year LCR was not reported in the included study. 
4-year LCR was not reported in the included study. 
5-year LCR was reported in the included study [107]: the study observed a 
dose-dependent 5-year LCR ranging from 35% (95% CI: 2-76) to 88% (95% 
CI: 80-93). 
10-year LCR was not reported in the included study. 
Health-Related Quality of Life (HRQoL) 
The endpoint Health-Related Quality of Life (HRQoL) was not measured by 
the included study.  
Safety 
Acute radiation morbidity 
Acute radiation morbidities were measured by the included study using the 
NCI-CTC criteria. 
Grade 1 acute radiation morbidities were reported in the included study [107]: 
In the phase 2 part of the study (n=143), 112 (78.3%) skin radiation morbid-
ities occurred. Within the dose-escalation part of the study (n=37), 20 cases 
(54%) of grade 1 acute skin radiation morbidities occurred. No grade 1 GI or 
urinary radiation morbidities occurred. 
Grade 2 acute radiation morbidities were reported in the included study [107]: 
In the phase 2 part of the study (n=143), 5 (3.5%) and 3 (2.1%) grade 2 acute 
radiation morbidities occurred in the skin and gastrointestinal (GI) region 
respectively. Within the dose-escalation part of the study (n=37), 2 (5.4%) 
and 1 (2.7%) grade 2 acute radiation morbidities occurred in the skin and GI 
tract respectively. No urinary grade 2 acute radiation morbidities occurred. 
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Grade 3 acute radiation morbidities were reported in the included study [107]: 
no grade 3 acute radiation morbidities were observed in 180 patients. 
Grade 4 acute radiation morbidities were reported in the included study [107]: 
no grade 4 acute radiation morbidities were observed in 180 patients. 
Late radiation morbidity 
Late radiation morbidities were measured by the included study using the 
RTOG/EORTC criteria. 
Grade 1 late radiation morbidities were reported in the included study [107]: 
In the phase 2 part of the study (n=143), 64 (44.8%), 1 (0.6%) and 1 (0.6%) 
case of grade 1 late radiation morbidities were observed in the skin, GI tract 
and urinary system respectively. Within the dose-escalation part of the study 
(n=37), 14 (37.8%) grade 1 late radiation morbidities were observed in the 
skin region and no GI or urinary grade 1 radiation morbidities occurred. 
Grade 2 late radiation morbidities were reported in the included study [107]: 
In the phase 2 part of the study (n=143), 1 (0.6%) and 1 (0.6%) case of grade 
2 late radiation morbidity occurred in the GI and urinary system respectively 
and no grade 2 radiation morbidity occurred in the skin. Within the dose-
escalation part of the study (n=37), 1 (2.7%) and 1 (2.7%) case of grade 2 
late radiation morbidity were observed in the skin and GI tract respectively. 
Grade 3 late radiation morbidities were reported in the included study [107]: 
In the phase 2 part of the study (n=143), 2 (1.4%) cases and 1 (0.6%) case of 
grade 3 late radiation morbidities were observed in the skin and GI tract re-
spectively. Within the dose-escalation part of the study (n=37), no grade 3 
late radiation morbidity was observed. 
Grade 4 late radiation morbidities were reported in the included study [107]: 
No grade 4 late radiation morbidities were observed in the included study. 
Conclusion 
For rectal carcinoma, 1 study [107] was included in the assessment: a dose-
escalation, phase 2 case series study. The study was not controlled and did 
not compare CIRT to standard irradiation. Thus, neither inferiority nor su-
periority of CIRT on the basis of the selected endpoints regarding efficacy 
(OS, CSS, DFS, RFS, PFS, LCR, HRQoL) or safety (acute radiation morbid-
ity, late radiation morbidity) can be concluded from the evidence. That is to 
say, (randomised) controlled studies are needed to clarify whether CIRT is 
more effective than or as effective as, or safer than or as safe as standard ir-
radiation in patients with rectal carcinomas. 
 
5.3.6.5 Gastrointestinal schwannomas/malignant schwannomas 
Definition and epidemiology 
A gastrointestinal schwannoma is an utterly rare, mesenchymal tumour [121]. 
Epidemiologic data regarding the incidence and prevalence for gastrointes-
tinal schwannomas was not found. 
Current treatment regimens and prognosis 
No information was found to answer current treatment and prognosis specif-
ically for gastrointestinal schwannomas. 
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Included studies, efficacy and safety 
For gastrointestinal schwannomas, no studies were included in this assess-
ment. Thus, no evidence was found to answer the research question. 
Conclusion 
At present, there is no scientific evidence indicating superiority or inferiority 
regarding the use of carbon ion radiotherapy (CIRT) in comparison to stand-
ard irradiation for gastrointestinal schwannomas. 
 
5.3.6.6 Gastrointestinal Ewing’s sarcoma 
Definition and epidemiology 
Ewing’s sarcomas are rare cancers to be found in bones (e.g., legs, arms, feet, 
pelvis, skull) or soft tissues (e.g., abdominal cavity, arms, head and neck) 
[122]. No epidemiological data regarding the incidence and prevalence of 
gastrointestinal Ewing’s sarcomas in Austria was found. 
Current treatment regimens and prognosis 
According to the National Cancer Institute (NCI) of the United States, there 
are 5 types of standard treatments currently used for Ewing’s sarcomas: chem-
otherapy, radiation therapy (RT), surgery, targeted therapy and high-dose 
chemotherapy in combination with stem cell rescue [122]. No epidemiologi-
cal data regarding survival rates of gastrointestinal Ewing’s sarcomas in Aus-
tria was found. 
Included studies, efficacy and safety 
For gastrointestinal Ewing’s sarcomas, no studies were included in this as-
sessment. Thus, no evidence was found to answer the research question. 
Conclusion 
At present, there is no scientific evidence indicating superiority or inferiority 
regarding the use of carbon ion radiotherapy (CIRT) for gastrointestinal 
Ewing’s sarcomas. 
 
5.3.7 Bone and soft tissue tumours 
Definition and epidemiology 
In this section, the body of the evidence of the included studies focusing on 
efficacy and/or safety of carbon ion radiotherapy (CIRT) for bone and soft 
tissue sarcomas will be assessed. An evidence synthesis will be conducted for 
5 specific indications. Available evidence for bone and soft tissue tumours in 
the skull base can be found in a previous section (Skull base tumours). The 
Surveillance, Epidemiology, and End Results Program (SEER) calculated the 
age-adjusted incidence of bone and joint cancers to be 0.9 cases per 100,000 
persons per year (based on data in the time period of 2010 and 2014) [66]. 
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Current treatment regimens and prognosis 
Treatment modalities differ according to the tumour type. The specific treat-
ment modalities for bone and soft tissue tumours can be found in the follow-
ing sections. The Surveillance, Epidemiology, and End Results Program 
(SEER) calculated the 5-year survival of patients with bone and joint cancer 
to be 67.7% based on data from the SEER in the time period of 2007 and 2014 
in the United States [66]. 
Included studies 
Overall, 1 study was included for bone and soft tissue tumours including 17 
patients with localised primary sarcoma of the extremities (medically inop-
erable or declined surgery). 
Conclusion: Efficacy and safety 
For bone and soft tissue tumours, insufficient scientific evidence indicating 
superiority/inferiority of CIRT regarding efficacy or safety was found for soft 
tissue sarcoma (localised primary sarcoma of the extremities) when compared 
to conventional radiotherapy (evidence base: 1 prospective case series study). 
No scientific evidence indicating superiority/inferiority of CIRT regarding 
efficacy or safety when compared to standard irradiation was found for oste-
osarcoma, sacral chordoma, sacral chondrosarcoma and spinal meningioma. 
In the following section results from specific bone and soft tissue tumours 
are presented. 
 
5.3.7.1 Osteosarcoma 
Definition and epidemiology 
Osteosarcomas are uncommonly occurring malignant tumours in the bone 
[123]. Epidemiologic data regarding the incidence and prevalence of osteo-
sarcomas in Austria was not found. However, the Surveillance, Epidemiolo-
gy, and End Results Program (SEER) calculated the age-adjusted incidence 
of bone and joint cancers to be 0.9 cases per 100,000 persons per year (based 
on data in the time period of 2010 and 2014) [66]. 
Current treatment regimens and prognosis 
According to the National Cancer Institute (NCI) of the United States, there 
are 5 types of standard treatments for osteosarcomas: surgery, chemotherapy, 
radiation therapy and targeted therapy [123]. Epidemiologic data regarding 
survival rates of osteosarcomas in Austria was not found. However, the Sur-
veillance, Epidemiology, and End Results Program (SEER) calculated the 5-
year survival of patients with bone and joint cancer to be 67.7% based on data 
from the SEER in the time period of 2007 and 2014 in the United States [66]. 
Included studies, efficacy and safety 
For osteosarcoma, no study was included. Thus, no evidence was found to 
answer the research question. 
Conclusion 
At present, there is no scientific evidence indicating superiority or inferiority 
regarding efficacy or safety of the use of carbon ion radiotherapy (CIRT) for 
osteosarcoma. 
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5.3.7.2 Soft tissue sarcoma 
Definition and epidemiology 
Soft tissue sarcoma is a rare cancer and forms a heterogeneous group of tu-
mours. That is, there are more than 100 distinct histopathologic subtypes of 
this cancer [124]. Soft tissue sarcomas could potentially occur anywhere in 
soft tissues of the body, but there are common regions for the occurrence of 
soft tissue sarcomas (e.g., head and neck, arms, and legs) [125]. Epidemio-
logic data regarding the incidence and prevalence of soft tissue sarcoma in 
Austria was not found. 
For tumour staging of nasopharyngeal carcinoma, the TNM classification, 
developed by the American Joint Committee on Cancer (AJCC) as well as 
the Union Internationale Contre le Cancer (UICC), is often used. However, 
different tier systems were developed to increase the prognostic value. A three-
tiered system is also incorporated in the AJCC’s TNM classification of soft 
tissue sarcomas and includes the following: well differentiated (grade 1), mod-
erately differentiated (grade 2) or poorly differentiated (grade 3) [124]. 
Current treatment regimens and prognosis 
According to the National Cancer Institute (NCI) of the United States, the 
standard treatment of soft tissue sarcoma may include one, or a combination 
of the following: surgery, radiation therapy and chemotherapy [125]. Epi-
demiologic data regarding survival rates in Austria was not found. 
Included studies 
For soft tissue sarcoma, 1 case series study [126] from the Heavy Ion Medi-
cal Accelerator in Chiba (HIMAC) was eligible to be included in the qualita-
tive synthesis. In total, 17 patients with localised primary sarcomas of the 
extremities, being either medically inoperable or surgery declined, were en-
rolled in the clinical study. Of those, the majority of the patients had soft tis-
sue sarcomas, with 13 out of 17 (76.5%) suffering from this disease. The other 
patients had either osteosarcomas (n=3) or chondrosarcomas (n=1).  
Patients were irradiated with CIRT at a total dose, ranging from 52.8-70.4 
GyE. The median age of the patients in the included study was 53, and all 
patients were aged between 14 and 87 years. The median follow-up time was 
37 months (range: 11-97) and loss to follow-up was not reported by the includ-
ed study.  
Study characteristics, i.e., information on patient population, intervention, 
control and study design of the included study, can be found in Table A-2. 
Efficacy 
Overall survival (OS) 
The included study measured the endpoint overall survival at 3 and 5 years. 
1-year OS was not reported by the included study [126]. 
2-year OS was not reported by the included study [126]. 
3-year OS was reported by the included study [126] and observed a 3-year OS 
of 68% (95% CI: 42-86). 
4-year OS was not reported by the included study [126]. 
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5-year OS was reported by the included study [126] and observed a 5-year OS 
of 56% (95% CI: 29-80%). 
10-year OS was not reported by the included study [126]. 
Cause-specific survival (CSS)/Disease-specific survival (DSS) 
The endpoint cause-specific survival (CSS)/disease-specific survival (DSS) 
was not measured by the included study. 
Disease-free survival (DFS) 
The endpoint disease-free survival (DFS) was not measured  
by the included study. 
Recurrence-free survival (RFS) 
The endpoint recurrence-free survival (RFS) was not measured  
by the included study [126]. 
Progression-free survival (PFS) 
The endpoint progression-free survival (PFS) was not measured  
by the included study [126]. 
Local control rate (LCR) 
Local control rate (LCR) was measured at 3 and 5 years by the included study 
[126]. 
1-year LCR was not reported by the included study [126]. 
2-year LCR was not reported by the included study [126]. 
3-year LCR was reported by the included study [126] and observed  
a 3-year LCR of 76% (95% CI: 51-93). 
4-year LCR was not reported by the included study [126]. 
5-year LCR was reported by the included study [126] and observed  
a 3-year LCR of 76% (95% CI: 51-93). 
10-year LCR was not reported by the included study [126]. 
Health-Related Quality of Life (HRQoL) 
The endpoint Health-Related Quality of Life (HRQoL) was not measured by 
the included study [126]. 
Safety 
Acute radiation morbidity 
The included study measured acute radiation morbidity with the CTCAE 
v.3.0 criteria. 
Grade 1 acute radiation morbidities were measured by the included study 
[126]: 16 out of 17 (94.1%) developed grade 1 acute radiation morbidities. 
Grade 2 acute radiation morbidities were measured by the included study 
[126]: no grade 2 acute radiation morbidities were observed. 
Grade 3 acute radiation morbidities were measured by the included study 
[126]: no grade 3 acute radiation morbidities were observed. 
Grade 4 acute radiation morbidities were measured by the included study 
[126]: no grade 3 acute radiation morbidities were observed. 
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 Late radiation morbidity 
The included study [126] measured late radiation morbidities using the 
CTCAE v.3.0 criteria.  
Grade 1 late radiation morbidities were not reported in the included study. 
Grade 2 late radiation morbidities were reported by the included study [126]: 
1 out of 17 patients (5.9%) developed grade 2 skin toxicities, and 4 patients 
(23.5%) developed grade 2 neurological toxicities. 
Grade 3 late radiation morbidities were reported by the included study [126]: 
1 out of 17 patients (5.9%) developed a grade 3 femoral fracture. 
Grade 4 late radiation morbidities were not reported by the included study. 
In addition, the same study [126] reported on 3 and 1 patient, developing a 
lower limb tumour and an upper limb tumour respectively. 
Conclusion 
For soft tissue sarcomas, 1 study was eligible to be included in the assessment: 
the study was not controlled, comparing CIRT to standard irradiation. Thus, 
neither inferiority nor superiority of CIRT on the basis of the selected end-
points regarding efficacy (OS, CSS, DFS, RFS, PFS, LCR, HRQoL) or safety 
(acute radiation morbidity, late radiation morbidity) can be concluded from 
the evidence. That is to say, (randomised) controlled trials are needed to clar-
ify whether CIRT is more effective than or as effective as, or safer than or as 
safe as standard irradiation in patients with soft tissue sarcomas. 
 
5.3.7.3 Sacral chordoma  
Definition and epidemiology 
Chordomas are rare types of bone tumours to be found in the skull base or in 
the lower spine [127, 128]. Epidemiologic data on the incidence and preva-
lence of sacral chordomas in Austria was not found. However, the Surveil-
lance, Epidemiology, and End Results Program (SEER) calculated the age-
adjusted incidence of bone and joint cancers to be 0.9 cases per 100,000 per-
sons per year (based on data in the time period of 2010 and 2014) [66] 
Current treatment regimens and prognosis 
For chordomas in the spinal cord, surgery and postoperative radiation ther-
apy (RT) may be used [129]. Epidemiologic data on the survival of sacral 
chordomas in Austria was not found. However, the Surveillance, Epidemiol-
ogy, and End Results Program (SEER) calculated the 5-year survival of pa-
tients with bone and joint cancer to be 67.7% based on data from the SEER 
in the time period of 2007 and 2014 in the United States [66]. 
Included studies, efficacy and safety 
For sacral chordomas, none of the identified studies met the inclusion criteria 
for the qualitative synthesis. 
Conclusion 
At present, there is no scientific evidence indicating superiority or inferiority 
regarding the use of carbon ion radiotherapy (CIRT) for sacral chordomas. 
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5.3.7.4 Sacral chondrosarcoma  
Definition and epidemiology 
Chondrosarcomas are malignant tumours of the cartilage. Most of the chon-
drosarcomas occur in the pelvis and relatively infrequent in the sacrum, with 
approximately 5% of chondrosarcomas occurring in the spine [127, 129]. Ep-
idemiologic data on the incidence and prevalence of sacral chondrosarcomas 
was not found. However, the Surveillance, Epidemiology, and End Results 
Program (SEER) calculated the age-adjusted incidence of bone and joint can-
cers to be 0.9 cases per 100,000 persons per year (based on data in the time 
period of 2010 and 2014) [66]. 
Current treatment regimens and prognosis 
Treatment of chondrosarcomas depends on the stage of the disease and con-
sists of surgery. In addition, radiation therapy is only indicated in some cir-
cumstances (i.e., after incomplete resection) since chondrosarcomas are rela-
tively radioresistant. Chemotherapy is not used for the treatment of chondro-
sarcomas [130]. Epidemiologic data on the survival of sacral chondrosarcoma 
in Austria was not found. However, the Surveillance, Epidemiology, and End 
Results Program (SEER) calculated the 5-year survival of patients with bone 
and joint cancer to be 67.7% based on data from the SEER in the time period 
of 2007 and 2014 in the United States [66]. 
Included studies, efficacy and safety 
For chondrosarcomas, none of the identified studies were eligible to be in-
cluded in the qualitative synthesis: No evidence was found to answer the re-
search question. 
Conclusion 
At present, there is no scientific evidence indicating superiority or inferiority 
regarding the use of carbon ion radiotherapy (CIRT) for the treatment of sa-
cral chondrosarcoma.  
 
5.3.7.5 Spinal meningiomas 
Definition and epidemiology 
Spinal meningiomas are invasive lesions commonly occurring in the thoracic 
spine. [129]. No epidemiologic data regarding the incidence and prevalence 
of spinal meningiomas in Austria was found. However, data from Statistics 
Austria including all tumours in the brain and central nervous system in Aus-
tria shows an age-adjusted incidence rate of 9.0 per 100,000 persons in 2015. 
In addition, those tumours were prevalent in 1,948 men and 2,043 women in 
the same year [67]. 
Current treatment regimens and prognosis 
The current treatment modality of spinal meningiomas is typically complete 
resection. Symptomatic recurrence may be treated by using surgery, radiation 
therapy (RT) or radiosurgery [129]. No epidemiological data regarding the 
prognosis of spinal meningiomas in Austria was found. However, epidemio-
logic data regarding relative survival (RS) of all tumours in the brain and nerv-
ous system between 2003 and 2007 shows a 1-, 3-, 5-and 10-year RS of 59.8%, 
39.1%, 33.9% and 28.7% in Austria respectively [67]. 
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Included studies, efficacy and safety 
For spinal meningioma, no studies were included in this assessment. Thus, 
no evidence was found to answer the research question. 
Conclusion 
At present, there is no scientific evidence indicating superiority or inferiority 
regarding the use of carbon ion radiotherapy (CIRT) for spinal meningioma. 
 
5.3.8 Prostate cancer 
Definition and epidemiology 
Prostate cancer occurs in a gland in tissues of the male reproductive system 
to be found between the rectum and bladder [66]. In Austria, prostate cancer 
is the most frequent cancer occurring in men: 4,532 men developed, and 1,116 
died due to, prostate cancer in 2012. After age-standardisation, the incidence 
of prostate cancer was 64 in 100,000 men developing prostate cancer in 2012, 
and the respective mortality rate was 14 in 100,000 men in the same year [95].  
Prostate cancer can be localised, regional, distant and unstaged (unknown): lo-
calised prostate cancer refers to the stage when the cancer is only found in the 
part of the body in which cancer started. Prostate cancer is regional if the 
prostate cancer already spread to another part(s) of the body and distant if 
cancer has metastasised as well. The majority of prostate cancer patients 
(79.2%) are diagnosed when the cancer is still localised [66].  
In addition, prostate cancer may be defined according to tumour stages: stage 
1 refers to the localised prostate cancer, and stage 2-4 differs according to the 
prostate-specific antigen (PSA) level and the Gleason score, as well as to the 
extent of a tumour spreading out to other body parts (for a more precise de-
scription, see [131]). 
Current treatment regimens and prognosis 
According to the National Cancer Institute (NCI) of the US, treatment regi-
mens differ depending on the stage of a tumour: For stage 1 and stage 2 pros-
tate cancer watchful waiting/active surveillance (monitoring), radical prostat-
ectomy, external beam radiation therapy (EBRT) and interstitial implanta-
tion of radioisotopes may be used as treatment modalities. For prostate can-
cers higher or equal to grade 2, EBRT may or may not be combined with hor-
monal therapy [131]. 
In addition, hormonal manipulations with or without radiation therapy, rad-
ical prostatectomy with or without EBRT, watchful waiting under certain cir-
cumstances can be described as treatment modalities for stage 3 prostate can-
cer. For stage 4 prostate cancer, hormonal manipulations, bisphosphonates, 
palliative radiation therapy, palliative surgery with transurethral resection 
of the prostate (TURP) and watchful waiting/active surveillance (monitoring) 
may be used as treatment modalities [131]. 
According to statistics from the Surveillance, Epidemiology, and End Re-
sults (SEER), the 5-year survival of all prostate cancer patients was 98.6% 
(2007–2013) in the United States (USA). However, variations among the 
stages of cancer can be seen: patients with localised or regional prostate cancer 
have a relatively high chance of surviving 5 years after the diagnosis in com-
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parison to patients suffering from distant prostate cancer or patients with an 
unknown prostate stage, with a 5-year survival of 100%, 100%, 29.8% and 
81.2% respectively [66]. 
Included studies 
For prostate cancer, 8 studies were included in this assessment: 1 randomised, 
paralelly assigned, open-label, pilot study focusing on toxicity [132], 3 before-
after studies measuring primarily Health-Related Quality of Life (HRQoL) 
[133-135], and 4 case series (1 interim report of acute side effects [136], 1 dose-
escalation study [137], 1 multi-institutional study [138], 1 phase 2 case series 
focusing on efficacy and feasibility of CIRT [139]). 
Overall, the sum of the samples in the included studies resulted in approxi-
mately 2,715 prostate-enrolled patients27. Of those, 2,668 received CIRT. The 
tumour stage ranged from T1a-T3b. The patients were irradiated with CIRT 
at a total dose ranging from 51.6-72.0 GyE and fractions ranging from 12-20. 
However, 14 patients, enrolled in 1 study [136] received intensity-modulated 
radiotherapy (IMRT) and carbon ion boost (CIB), using 60 Gy in 5 fractions 
and 18 GyE in 6 fractions respectively. Co-interventions included hormonal 
therapy and neoadjuvant hormonal depending on the risk group of prostate 
cancer patients. 
Most of the studies defined risk groups and measured differences between 
those risk groups according to tumour stage, prostate-specific antigen (PSA) 
level and Gleason score (GS). The definitions of the risk groups were not 
standardised and, therefore, differed between each respective study primari-
ly according to PSA level and GS. All of the patients were between 45 and 92 
years old at the start of enrolment in the clinical trials. 
The median follow-up time ranged from 28-60 months. 2 studies did not re-
port on the follow-up time [135, 137], and no included study explicitly report-
ed on loss to follow-up. 5 of the included studies may have an overlapping 
patient population: it is assumed that some patients included in the Ishika-
wa et al. 2006 (n=175) [139] and the Wakatsuki et al. 2008 (n=194) [135] 
studies are included in the case series study of Tsuji et al. 2005 (n=201) using 
3 prospective protocols [137]. In addition, it may be assumed that some pa-
tients of Maruyama et al. 2017 (n=417) [134] and Ishikawa et al. 2015 (n=76) 
[133] are included in the multi-institutional case series study of Nomiya et 
al. 2016 (n=2,157) [138]. None of the studies were excluded from this analysis 
since they provided data on different endpoints: Wakatsuki et al. 2008 [135] 
conducted a health-related quality of life (HRQoL) assessment and Ishikawa 
et al. 2006 [139] provided more nuanced data regarding risk group-specific 
survival rates. Additionally, Maruyama et al. 2017 (n=417) [134] and Ishika-
wa et al. 2015 (n=76) [133] reported on HRQoL, while the multi-institutional 
observational study of Nomiya et al. 2016 (n=2,157) [138] did not use this 
endpoint in their analysis.  
Study characteristics, i.e., precise information on patient population, inter-
vention, control and study design of the included studies, can be found in 
the Appendix (Table A-7). 
                                                             
27 2 included studies [134, 135] assessed the quality of life for 611 patients already 
included in other studies. Thus, those patients were not included in the calculation. 
There may be significant overlapping samples in further studies. The reader is re-
ferred to the data extraction table (Table A-7) for more information. 
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Efficacy 
Overall survival (OS) 
Overall, 5 out of the 8 included studies measured overall survival (OS) of 
CIRT patients at different time points [133, 136-139]. None of the included 
studies compared the OS with the OS of patients undergoing conventional 
radiotherapy. 
1-year OS was not reported in any of the included studies. 
2-year OS was not reported in any of the included studies. 
3-year OS was not reported in any of the included studies. However, 1 study 
calculated an actuarial 3-year OS of 100% (95% CI: NR) for intermediate-
risk prostate cancer patients [136]. 
4-year OS was reported in 2 studies [133, 139]: 1 study (n=76)[133] observed 
a 4-year OS of 97.4% (95% CI: 93.8-100.0%) for low-, intermediate-, and high-
risk prostate cancer patients, with 3, 29 and 40 prostate cancer patients28 in 
those groups respectively. Another study (n=175) [139] observed a 4-year OS 
of 91% (95% CI: 87–96%), with a 4-year OS of 94% (95% CI: 90–98%) and 
91% (95% CI: 85–96%) for the low and high-risk group respectively (with 33 
and 142 low-risk and high-risk prostate cancer patients respectively). 
5-year OS was reported in 2 studies [137, 138]: 1 multi-institutional study 
(n=2.157) reported on the 5-year OS for low-, intermediate-, and high-risk 
prostate cancer patients, with an OS of 100% (95% CI: NR), 99% (95% CI: 
NR) and 96% (95% CI: NR) at 5 years respectively. Another study [137] ob-
served a 5-year OS of 89.2% (95% CI: NR) for 201 prostate cancer patients.  
10-year OS was reported in 1 study [138]: The multi-institutional study (n= 
2,157) reported a 10-year OS for low-, intermediate-, and high-risk prostate 
cancer patients, with an OS of 96% (95% CI: NR), 78% (95% CI: NR) and 
88% (95% CI: NR) in those risk groups respectively. The number of patients 
in each risk group were 263 (12%), 679 (31%) and 1,215 (56%) in the low-, 
intermediate-, and high-risk group respectively. 
Cause-specific survival (CSS)/Disease-specific survival (DSS) 
Overall, 3 out of the 8 included studies measured cause-specific survival (CSS) 
of CIRT patients at different time points [137-139]. None of the included 
studies compared the CSS to the CSS of patients undergoing conventional 
radiotherapy. 
1-year CSS was not reported in any of the included studies. 
2-year CSS was not reported in any of the included studies. 
3-year CSS was not reported in any of the included studies. 
4-year CSS was reported in 1 study [139]: the study (n=175) observed a cause-
specific survival (CSS) of 97% (95% CI: 95–100%) at 4 years. The CSS with-
in the risk groups at 4 years was 100% (95% CI: NR) and 97% (95% CI: 95–
98%) in the low- and high-risk group respectively (with 33 and 142 low-risk 
and high-risk prostate cancer patients respectively). 
                                                             
28 The sample included 4 castration resistant patients who were not included in any 
of those risk groups. 
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5-year CSS was reported in 2 studies [137, 138]: 1 multi-institutional study 
(n=2,157)[138] reported on the 5-year CSS for low-, intermediate-, and high-
risk prostate cancer patients, with a CSS of 100% (95% CI: NR), 100% (95% 
CI: NR) and 99% (95% CI: NR) at 5 years in those risk groups respectively. 
Another study [137] reported on the 5-year disease-specific survival (DSS) of 
201 t1-t2a, t2b and t3 prostate cancer patients with 81, 39 and 81 in those 
groups respectively. The 5-year DSS was 92.2% (95% CI: NR) for the includ-
ed patients. 
10-year CSS was reported in 1 study [138]: the multi-institutional study (n= 
2,157) reported a 10-year CSS for low-, intermediate-, and high-risk prostate 
cancer patients, with a CSS of 100% (95% CI: NR), 88% (95% CI: NR), and 
98% (95% CI: NR) in those risk groups respectively. The number of patients 
in each risk group were 263 (12%), 679 (31%) and 1,215 (56%) in the low-, 
intermediate-, and high-risk group respectively [138]. 
Disease-free survival (DFS) 
The endpoint disease-free survival (DFS) was not measured by the included 
study. 
Recurrence-free survival (RFS) 
Overall, 5 out of 8 included studies measured recurrence-free survival (RFS) 
of CIRT patients at different time points [133, 136-139]. None of the includ-
ed studies compared the observed RFS to the RFS of patients undergoing 
conventional radiotherapy. 
1-year RFS was not reported in any of the included studies.  
2-year RFS was not reported in any of the included studies. 
3-year RFS was not reported in any of the included studies. 1 study [136] 
(n=14) including prostate patients at an intermediate risk reported on an 
actuarial 3-year biochemical relapse-free survival of 86% (95% CI: NR). 
4-year RFS was reported in 2 studies [133, 139]: 1 study [133] observed a 4-
year biochemical recurrence-free (BRF) rate of 94.6% (95% CI: 89.4-99.8%) 
for low-, intermediate-, and high-risk prostate cancer patients, with 3, 29 and 
40 prostate cancer patients28 in those groups respectively. Another study [139] 
observed a 4-year biochemical relapse-free survival (bNED) of 88% (95% CI: 
83–93%). The bNED for each risk group at 4 years was 87% (95% CI: 77–
98%) and 88% (95% CI: 82–94%) for the low-, and high-risk group respec-
tively. 
5-year RFS was reported in 2 studies [137, 138]: 1 multi-institutional study 
(n=2,157) [138] reported on the 5-year BRFS for low-, intermediate-, and 
high-risk prostate cancer patients, with a BRFS of 92% (95% CI: NR), 89% 
(95% CI: NR) and 92% (95% CI: NR) at 5 years in those risk groups re-
spectively. Another study [137] observed a 5-year bNED of 83.2% (95% CI: 
NR). Data of the risk groups29 showed a bNED of 100% (95% CI: NR) and 
80.5% (95% CI: NR) for patients in the low- and high-risk groups respectively. 
 
                                                             
29 bNED was the only outcome for which risk-group related data was reported. The 
bNED rates refer to 37 and 164 prostate cancer patients in the low-risk and high-
risk group respectively. 
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10-year RFS was reported in 1 study [138]: 1 multi-institutional study (n= 
2,157) [138] reported on the 10-year BRFS for low-, intermediate-, and high-
risk prostate cancer patients, with a BRFS of 77% (95% CI: NR), 70% (95% 
CI: NR) and 79% (95% CI: NR) in those risk groups respectively. The num-
ber of patients in each risk group were 263 (12%), 679 (31%) and 1,215 (56%) 
in the low-, intermediate-, and high-risk group respectively. 
Progression-free survival (PFS) 
The endpoint progression-free survival (PFS) was not measured by any of 
the included studies. 
Health-Related Quality of Life (HRQoL) 
Overall, 5 out of 8 included studies used health-related quality of life (HRQoL) 
as an endpoint at different time points. No study compared HRQoL in CIRT 
patients to HRQoL of patients undergoing conventional therapy. 
1 study [132] measured HRQoL, using the QLQC30 and PR25 questionnaire, 
in CIRT (n=45) and PRT (n=46) patients before, at the end of, 6 weeks, and 
6 months after CIRT/PRT. For both groups, a significant worsening of qual-
ity of life was seen during RT, and several improvements in QLQC30 and 
the QLQPR25 scores during follow-up were observed. It is stated that uri-
nary symptoms, as well as pain and fatigue, were reduced both during and 6 
weeks after CIRT. Differences in HRQoL between treatment arms were only 
found in some subscales: it was stated that urinary and bowel symptoms 
scores were statistically significantly lower for CIRT patients when compared 
to PRT patients at different time points after treatment. However, it was not 
stated in their analysis for which time point the reported significant p-values 
for the differences between treatment groups apply. In addition, it was not 
stated whether the difference refers to the time point or changes over time of 
the 2 groups under comparison. Scores of urinary and bowel symptoms and 
precise changes of all of the subscales of those tools can be found in Table A-7. 
The study concluded that CIRT and PRT patients have comparable HRQoL 
parameters. 
The other 4 studies [133-135, 139] did not compare HRQoL of CIRT patients 
with HRQoL of patients undergoing other forms of radiotherapy and meas-
ured and compared HRQoL before and up to 1 year after CIRT: in 1 study 
[133], no short-term or mid-term statistical differences and a slight and sta-
tistically significant longer-term decrease of the physical component sum-
mary (PCS) score [baseline vs. 12 months: 51.14 (±1.85) vs. 47.71 (±1.84)] of 
CIRT, using the Japanese version of the SF-8 (p<0.05), were found. There 
were no statistically significant short-term, mid-term or longer-term changes 
in the mental component summary (MCS) score before and after 12 months 
of CIRT in this study. 
In 1 study [134], the FACT-G, FACT-P and TOI mean scores before CIRT 
were 84.2 (±12.6), 119.5 (±16.9) and 81.8 (±12.0) respectively. The study 
found statistically significant short-term changes (at 1 month) in FACT-P 
and TOI (with 116.2 and 77.8 respectively) and no short-term statistical differ-
ence in FACT-G score (83.7). In addition, longer-term differences in HRQoL 
were found: FACT-G and FACT-P long-term differences were statistically 
significantly lower, and no statistical difference in TOI scores was observed. 
The study found, for instance, statistically significantly lower FACT-G and 
FACT-P, and no statistically significant changes in TOI mean scores at 60 
months after CIRT when compared to the corresponding scores before CIRT 
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was initiated, with mean scores of 82.7 (±15.0), 117.6 (±20.2), 81.4 (±14.6) 
respectively. The reader is referred to the data extraction table for more in-
formation on the detailed changes at the respective long-term time points 
(Table A-7). 
Another study [135] measured the HRQoL of CIRT alone (n=25) and CIRT 
in combination with adjuvant therapy (n=125) before, post-interventional and 
longer-term (at 12 months): in the 25 patients receiving CIRT alone, there 
were no significant differences between the mean scores before, just after, 
and 12 months after CIRT alone, using the FACT-G and FACT-P question-
naire, with a mean score of 88.4 (±13.2) and 122.6 (±19.8) before and 89.1 
(±13.6) and 123.8 (±20.3) at 12 months after CIRT respectively. On the con-
trary, there were significant mean score differences in the CIRT+ADT group, 
with statistically significantly lower mean scores at 12 months after CIRT in 
comparison to the respective baseline scores. That is, the FACT-G and FACT-
P scores in this group were 86.1 (±19.4) and 120.0 (±26.1) before CIRT and 
83.9 (±21.7) and 116.7 (±29.1) at 12 months after CIRT (s. s. to baseline 
score). 
Another study [139], including 175 prostate cancer patients, found no longer-
term statistically significant changes in health-related quality of life (HRQoL) 
when comparing the mean FACT-G and FACT-P scores before and 1 year 
after CIRT, with a difference of 1.8±1.1 (89.1 vs. 87.3; p=0.1) and 2.6±1.4 
(123.1 vs. 120.4; p=0.07) using those tools respectively. 
Safety 
Acute radiation morbidity 
From the included studies, 5 out of 8 studies measured acute radiation mor-
bidities using the CTCAE [132, 133, 136, 138] or the RTOG [139] criteria: 
none of the studies observed severe radiation morbidities (Grade ≥3), except 
for 1 study [138], in which 1 out of 2,157 patients developed grade 3 genitou-
rinary (GU) toxicities. Several grade 1-2 acute radiation morbidities were ob-
served in the genitourinary (GU) and gastrointestinal (GI) region. In addition, 
1 study compared toxicity profiles of CIRT patients and PRT patients.  
Grade 1 acute radiation morbidity (genitourinary and gastrointestinal) was 
reported in all 5 studies [132, 133, 136, 138, 139]: in the GU region, grade 1 
acute radiation morbidities ranged from 57 out of 175 (33%) [139] to 43 out 
of 76 (57%) [133] prostate cancer patients in 3 of the included studies [133, 
136, 139]. In the GI region, the incidence of grade 1 acute radiation morbidi-
ties ranged from 1 out of 76 patients (1%) [133] to 5 out of 14 patients (35%) 
[136] in 3 of the included studies [133, 136, 139]. In addition, 1 study [138] 
did not specify whether grade 1 or grade 0 acute radiation morbidities oc-
curred and observed 2,037 (94.4%) and 2,157 (100%) grade 0-1 acute radia-
tion morbidities in the GU and GI region respectively. Moreover, 1 study 
[132] reported on grade 1 radiation morbidities in 45 CIRT patients with lo-
calised prostate cancer: proctitis, diarrhoea and cystitis were observed with 5 
(11%), 25 (55.6%) and 13 (28.9%) patients suffering from those toxicities re-
spectively. In the PRT group in this study, those radiation morbidities oc-
curred in 6 patients (13%), 28 patients (60.9%) and 18 patients (39.1%) re-
spectively. 
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Grade 2 acute radiation morbidity (genitourinary and gastrointestinal) was 
reported in all 5 studies [132, 133, 136, 138, 139]: in the GU region, 3 studies 
[133, 136, 138] observed grade 2 acute radiation morbidities, ranging from 
119 out of 2,157 prostate cancer patients (5.5%) [138] to 5 out of 14 prostate 
cancer patients (35.7%) [136]. In the GI region, 4 studies [133, 136, 138, 139] 
did not observe any grade 2 radiation morbidities. In addition, 1 study ob-
served grade 2 proctitis, diarrhea and cystitis in 45 CIRT patients and 46 pa-
tients undergoing PRT: In the CIRT group, 1 patient (2.2%), no patients (0%) 
and 6 patients (13.3%) developed those diseases respectively. In the PRT 
treatment group, 4 patients (8.7%), 4 patients (8.7%) and 10 patients (21.7%) 
developed the aforementioned grade 2 morbidities respectively. 
Grade 3 acute radiation morbidity (genitourinary and gastrointestinal) was 
reported in all 5 studies [132, 133, 136, 138, 139]: in the GU region, 1 study 
observed 1 incidence of acute grade 3 radiation morbidities in 2,037 (0%) 
prostate cancer patients. In the GI region, 1 study [132] observed no grade 3 
acute radiation morbidities in the CIRT group of their study (n=45) and 2 
patients (4.3%) in the PRT group (n=46) developing grade 3 proctitis (rec-
tum fistula). No other grade 3 acute radiation morbidities occurred in the 
included studies. 
Grade 4 acute radiation morbidity (genitourinary and gastrointestinal) was 
reported in all 5 studies [132, 133, 136, 138, 139]: grade 4 acute radiation 
morbidities were neither observed in the GU nor in the GI region. 
One of the included studies [132] compared toxicity profiles of 45 CIRT pa-
tients to the toxicity profiles of 46 PRT profiles and found no statistically 
significant differences between those arms. 
Late radiation morbidity 
From the included studies, 5 out of 8 studies measured late radiation mor-
bidities using the CTCAE [133, 138] or the RTOG/EORTC [134, 137, 139] 
criteria: none of the studies reported on severe radiation morbidities (grade 
≥ 3), except for 2 studies, in which grade 3 genitourinary (GU) toxicities were 
observed, with 1 out of 1,92930 patients [138] and 1 out of 417 patients [134] 
developing grade 3 GU toxicities occured. Several grade 1-2 late radiation 
morbidities were observed in the genitourinary (GU) and gastrointestinal (GI) 
region. 
Grade 1 late radiation morbidity (genitourinary and gastrointestinal) was re-
ported in 5 studies [133, 134, 137-139]: in the GU region, several grade 1 late 
radiation occurred in 4 studies [133, 134, 137, 139], ranging from 66 out of 
394 (16.8%) [134] to 108 out of 175 (62%) [139] prostate cancer patients de-
veloping grade 1 late morbidities in this region. In the GI region, grade 1 
late radiation morbidities were observed less frequently in the same studies, 
ranging from 7 out of 201 prostate cancer patients (3.5%) [137] to 23 out of 
175 prostate cancer patients (13%) [139] developing grade 1 late morbidities 
in the rectum. Additionally, 1 study [138] did not specify whether grade 1 or 
grade 0 late radiation morbidities occurred and observed 1,840 (95.4%) and 
1,921 (99.6%) out of 1,929 prostate cancer patients (95.4%) with grade 0-1 
late radiation morbidities in the GU and GI region respectively.  
                                                             
30 The study stated that patients with a follow-up <6 months were excluded from the 
analysis. 
Grad 2: 
GU: 0-35,7 % in  
4 Studien 
GI: 0 % in 4 Studien 
 
1 Studie mit Vergleich: 
45 CIRT pts: proctitis: 
2,2 %; diarrhoea: 0 %; 
cystitis: 13,3 % 
46 PRT pts: proctitis: 
8,7 %; diarrhoea: 8,7 %; 
cystitis: 21,7 % 
 
Grad 3: 0 % in 4 Studien 
 
1 Studie mit Vergleich: 
45 CIRT pts: 0 % 
46 PRT pts: 4,3 % 
Grad 4: 0 % 
1 Studie: keine stat. 
signifikanten 
Unterschiede 
hinsichtlich 
Toxizitätsprofilen 
zwischen CIRT und PRT  
späte Strahlenbelastung 
in 5 Studien 
Grad 1:  
GU: 16,3 %-62 % in  
4 Studien 
GI: 3,5 %-13 % in  
4 Studien 
 
Grad 0-1 in 1 Studie: 
GU: 95,4 % 
GI: 99,6 % 
Carbon ion beam radiotherapy (CIRT) for cancer treatment 
114 LBI-HTA | 2018 
Grade 2 late radiation morbidity was reported in 5 studies [133, 134, 137-139]: 
in the GU region, late radiation morbidities were observed in all studies, rang-
ing from 10 out of 394 prostate cancer patients (2.5%) [134] to 5 out of 76 
prostate cancer patients (7%) [133], developing late radiation morbidities in 
the bladder/urethra. In the GI region, late radiation morbidities ranged from 
0.4-2%. 
Grade 3 late radiation morbidity was reported in 5 studies [133, 134, 137-139]: 
in the GU region, 2 studies observed grade 3 late radiation morbidities in the 
bladder/urethra, with 1 out of 1,921 (0%) [138] and 1 out of 394 (0.3%) [134] 
prostate cancer patients developing grade 3 GU late radiation morbidities in 
those studies respectively. In the GI region, none of the studies reported on 
CIRT patients with prostate cancer developing any grade 3 GI late radiation 
morbidities [133, 134, 137-139]. 
Grade 4 late radiation morbidity (genitourinary and gastrointestinal) was re-
ported in all 5 studies [133, 134, 137-139]: grade 4 late radiation morbidities 
were neither observed in the GU nor in the GI region. 
Conclusion 
For prostate cancer, 8 studies were identified: for efficacy-related endpoints, 
none of the eligible studies were controlled, comparing CIRT to standard ir-
radiation. 1 randomised, parallel assigned, open-label, pilot study was iden-
tified comparing toxicities between CIRT and PRT and found no statistically 
significantly different toxicity profiles between both experimental arms [132]. 
However, neither inferiority nor superiority of CIRT on the basis of the se-
lected endpoints regarding efficacy (OS, CSS, DFS, RFS, PFS, LCR, HRQoL) 
or safety (acute radiation morbidity, late radiation morbidity) can be conclud-
ed from the evidence. That is to say, further (randomised) controlled trials 
are needed to clarify whether CIRT is more effective than, or as effective as, 
or safer than, or as safe as conventional irradiation in prostate patients. 
 
5.3.9 Breast cancer  
Definition and epidemiology 
Breast cancer occurs in the tissues of the breast caused by malignant cancer-
ous cells [140]. Breast cancer is the most frequent cancer occurring in wom-
en, constituting 30% of all cancers in women in 2014. In 2015, the age-ad-
justed incidence rate for breast cancer was 116.7 cases per 100,000 women, 
and 2.4 cases per 100,000 men. At the end of the same year, 647 men and 
74,170 women were alive with a breast cancer diagnosis [141]. 
Current treatment regimens and prognosis 
There are 5 types of standard treatment currently used: surgery, radiation 
therapy (RT), chemotherapy, hormone therapy, and targeted therapy [140]. 
According to Statistics Austria, the relative survival of breast cancer patients 
was 94.6% and 88.9% at 1 and 3 years after their diagnosis respectively. The 
5-, and 10-year relative survival for the same population was 84.4% and 77.9% 
respectively. The analysis was based on 24,767 patients (267 men and 24,500 
women) diagnosed with breast cancer in the time period of 2003 and 2007 
[142]. 
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Included studies, efficacy and safety 
For breast cancer, no clinical study was identified in this assessment. Thus, 
no evidence was found to answer the research question. 
Conclusion 
At present, there is no evidence indicating superiority/inferiority of CIRT for 
breast cancer when compared to standard irradiation. 
 
5.3.10 Kidney 
For renal cancer, evidence was only assessed for 1 renal paediatric cancer 
(nephroblastoma). 
 
5.3.1.1  Nephroblastoma 
Definition and epidemiology 
Nephroblastoma (Wilms tumour) is a paediatric renal cancer accounting for 
approximately 7% of all paediatric cancers [143]. In Austria, the age-adjust-
ed incidence rate was 8.2 per 1,000,000 children (0-14 years old) diagnosed 
with nephroblastomata between 2002 and 2012 [57]. 
Current treatment regimens and prognosis 
The treatment approach is typically multimodal and usually all of the pa-
tients suffering from this tumour should be considered to be enrolled in clin-
ical trials, since Wilms tumours are rarel cancers. Current treatment of neph-
roblastomata depends on the stage of the disease and may consist of the fol-
lowing: surgery, chemotherapy, and radiation therapy (RT) in some circum-
stances [143]. Treatment approaches may differ according to the clinical 
groups. For instance, the National Wilms Tumor Study (NWTS) group es-
tablished standard treatment for this disease consisting of nephrectomy (if 
feasible) and postoperative chemotherapy and RT (in some circumstances), 
while trials from the European consortium typically provide chemotherapy 
before a surgical operation (definitive resection) [143]. 
According to Statistics Austria, the 5-year survival of patients suffering from 
nephroblastomata is measured to be 93.6% (95% CI: 85.3-97.3) based on anal-
ysis including 78 children (0-14 years old) diagnosed with this disease be-
tween 2002 and 2009 [58]. 
Included studies, efficacy and safety 
No studies elaborating on the efficacy or safety of carbon ion radiotherapy 
(CIRT) for patients with this specific indication were identified. Thus, no 
evidence was found to answer the research question. 
Conclusion 
At present, there is no scientific evidence indicating superiority or inferiority 
regarding the use of carbon ion radiotherapy (CIRT) for nephroblastomata 
when compared to standard irradiation. 
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5.3.11 Central nervous system (CNS) 
For tumours in the nervous system, evidence was assessed for neuroblastoma. 
 
5.3.11.1 Neuroblastoma 
Definition and epidemiology 
Neuroblastomas are paediatric, malignant and extracranial solid tumours 
[144]. In Austria, the age-adjusted incidence rate of neuroblastomas and other 
tumours occurring in other peripheral nerves was 11.9 cases per 1,000,000 
children (0-14 years old) in the time period of 2002 and 2012. [57]. 
Current treatment regimens and prognosis 
Treatment modalities are dependent on the risk group of neuroblastomas and 
may include one, or a combination of the following: observation, surgery, 
chemotherapy, radiation therapy, isotretinoin, immunotherapy, myeloablative 
therapy and stem cell transplantation [58]. According to Statistics Austria, 
the 5-year survival of patients suffering from neuroblastomas or other peri-
pheral nerve tumours is 79.8% (95% CI: 71-86.2) based on analysis including 
109 children (0-14 years old) diagnosed with this disease between 2002 and 
2009 [58]. 
Included studies, efficacy and safety 
No studies elaborating on the efficacy or safety of carbon ion radiotherapy 
(CIRT) for patients with this specific indication were identified. Thus, no 
evidence was found to answer the research question.  
Conclusion 
At present, there is no scientific evidence indicating superiority or inferiority 
regarding the use of carbon ion radiotherapy (CIRT) for neuroblastomas. 
 
5.3.12 Hematologic cancer 
For hematologic cancer types, evidence was assessed for Non-Hodgkin’s lym-
phoma and Hodgkin’s lymphoma. 
Included studies, efficacy and safety 
No study was included for hematologic cancer: no scientific evidence indi-
cating superiority/inferiority regarding efficacy or safety of CIRT when com-
pared to conventional radiotherapy for Non-Hodgkin’s lymphoma and Hodg-
kin’s lymphoma. 
Conclusion 
At present, there is no scientific evidence indicating superiority or inferiority 
regarding the use of carbon ion radiotherapy (CIRT). 
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5.3.12.1 Non-Hodgkin's lymphoma 
Definition and epidemiology  
Non-Hodgkin’s lymphomas are tumours originating in lymphoid tissues [145]. 
In Austria, the age-adjusted incidence of NHL was 15.5 cases per 100,000 
persons in 2015. At the end of the same year, 6,131 men and 5,668 women 
were diagnosed with non-Hodgkin’s lymphomas [146]. 
Current treatment regimens and prognosis 
Treatment options for NHL may include, inter alia, one, or a combination of 
the following: radiation therapy, chemotherapy, drug therapy (e.g., rituximab, 
lenalidomide) [145]. Statistics Austria data based on 5,519 patients diagnosed 
with non-Hodgkin’s lymphomas within the time period of 2003, and 2007 
shows a relative survival of 77.2% and 68% at 1 and 3 years respectively. The 
relative 5- and 10-year survival was 64.1 and 57.4% for the same population 
[147]. 
Included studies, efficacy and safety 
For non-Hodgkin’s lymphoma, no studies were included in this assessment. 
Thus, no evidence was found to answer the research question. 
Conclusion 
At present, there is no scientific evidence indicating superiority or inferiority 
regarding the use of carbon ion radiotherapy (CIRT) in comparison to stand-
ard irradiation for non-Hodgkin’s lymphoma. 
 
5.3.12.2 Hodgkin’s Lymphoma 
Definition and epidemiology  
Hodgkin’s lymphomas (Morbus Hodgkin) are malignant tumours of the lym-
phatic system. In Austria, the age-adjusted incidence of Hodgkin’s lympho-
mas was 1.7 cases per 100,000 persons in 2015. At the end of the same year, 
1,832 men and 1,723 women were diagnosed with Morbus Hodgkin [148]. 
Current treatment regimens and prognosis 
Treatment modalities of Hodgkin’s lymphomas may include, among others, 
one, or a combination of the following: radiation therapy, chemotherapy and 
drug therapy [145]. Data of Statistics Austria based on 908 patients diagnosed 
with Morbus Hodgkin within the time period of 2003, and 2007 shows a rela-
tive survival of 91.7% and 87.4% at 1 and 3 years respectively. The relative 
5- and 10-year relative survival was 84.1% and 80% for the same population 
[149]. 
Included studies 
For Hodgkin’s lymphomas, no studies were included in this assessment. Thus, 
no evidence was found to answer the research question. 
Conclusion: Efficacy and safety 
At present, there is no scientific evidence indicating superiority or inferiority 
regarding the use of carbon ion radiotherapy (CIRT) in comparison to stand-
ard irradiation for Hodgkin’s lymphomas. 
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5.3.13 Other oncologic indications 
In this section, one will find the assessed evidence for “other oncologic indi-
cations” according to the MedAustron list of potential CIRT indications. 
That is, solitary liver metastases in colorectal cancer, retroperitoneal metas-
tases in controlled primary tumours, as well as oligometastases in controlled 
primary tumours in selected indications. 
Included studies, efficacy and safety 
No study was included for any of those indications: no scientific evidence 
indicating superiority/inferiority regarding efficacy or safety of CIRT when 
compared to conventional radiotherapy for solitary liver metastases in colo-
rectal cancer, retroperitoneal metastases in controlled primary tumours, and 
oligo-metastasis in controlled primary tumours in selected indications. 
 
5.3.13.1 Solitary liver metastases in colorectal cancer 
Included studies, efficacy and safety 
No evidence was found to answer the research question. 
Conclusion 
At present, there is no scientific evidence indicating superiority or inferiority 
regarding the use of carbon ion radiotherapy (CIRT) in comparison to stand-
ard irradiation for solitary liver metastases in colorectal cancer. 
 
5.3.13.2 Retroperitoneal metastases in controlled primary 
tumours 
Included studies, efficacy and safety 
No evidence was found to answer the research question. 
Conclusion 
At present, there is no scientific evidence indicating superiority or inferiority 
regarding the use of carbon ion radiotherapy (CIRT) in comparison to stand-
ard irradiation for retroperitoneal metastases in controlled primary tumours. 
 
5.3.13.3 Oligometastases in controlled primary tumours  
in selected indications 
Included studies, efficacy and safety 
No study was included in the analysis. Thus, no evidence was found to an-
swer the research question. 
Conclusion 
At present, there is no scientific evidence indicating superiority or inferiority 
regarding the use of carbon ion radiotherapy (CIRT) in comparison to stand-
ard irradiation for oligometastases in controlled primary tumours in selected 
indications. 
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6 Discussion 
Until 2016, approximately 21,580 patients were recorded to have been treat-
ed with CIRT [2] internationally. In this assessment, 56 clinical studies were 
identified to assess for which cancer indications CIRT is currently used: the 
majority of the studies included cancer in the brain & skull base region, pros-
tate and lung, with 14, 11 and 9 identified studies respectively. In addition, 7 
clinical studies were identified for the tumours in the ENT region and 4 stud-
ies were identified for gastrointestinal tumours. Less frequently identified 
studies enrolled patients with bone and soft tissue and eye tumours, with 2 
and 1 identified study respectively. Furthermore, 2 tumour regions not on the 
MedAustron list were identified on the basis of the identified studies: 7 stud-
ies had gynecologic tumour patients in their sample and 1 further study had 
skin cancer patients included in the sample. The number of patients in those 
published clinical trials resulted in an estimated 6,052 patients (5,651 patients 
receiving CIRT). However, 1 multi-institutional study [138] was included with 
more than 2,000 included patients. Those patients are possibly also included 
in other studies (overlap in enrolment time), and thus the number of patients 
included in the identified studies may be significantly lower. 
The search for ongoing studies revealed that the great majority of currently 
undertaken studies are uncontrolled: 65 studies were identified of which 10 
are controlled, enrolling patients suffering from tumours in the following re-
gions: brain and skull base, bone and soft tissue, gastrointestinal, and ENT 
as well as lung. Interestingly, no randomised controlled trials were found in 
the prostate or lung region, and only 1 controlled trial enrolled lung cancer 
patients in their study. 
In addition, results from (randomised) controlled trials are expected to arise 
in the following years, since the primary completion date of 4 of the ongoing 
RCTs has already passed (region brain and skull base:studies include: 319 
patients with chordomas, 80 patients with meningioma, 150 patients with 
primary glioblastomas and 436 patients with recurrent gliomas in 1 study 
respectively, see: “List of ongoing randomised and non-randomised clinical 
trials“). The primary completion date of the other controlled and randomised 
controlled trials is in the next 4 years (bone & soft tissue: 2 studies, with 
100 patients respectively; chondrosarcoma: 1 phase 3 RCT, with 154 patients; 
adenoid cystic carcinoma and sarcoma: 1 RCT, with 250 patients; hepatocel-
lular cancer: 1 CT, with 48 patients; lung cancer: 1 CT, with 525 patients, 
see “List of ongoing randomised and non-randomised clinical trials“). 
Of those published 56 studies, 27 clinical studies were eligible for the quali-
tative synthesis of the efficacy and safety of CIRT when compared to stand-
ard irradiation: 1 randomised controlled trial focusing on toxicity and feasi-
bility of CIRT/PRT with a high risk of bias and 26 were either prospective 
case series or – less frequently – case-control studies or single-arm before-
after studies focusing on HRQoL. No other controlled study was found. When 
assessing the superiority/inferiority of CIRT in comparison to standard ir-
radiation regarding efficacy and safety on the basis of the selected oncologic 
endpoints, no scientific evidence was found for 41 indications, and insuffi-
cient scientific evidence was found for 13 indications in 7 regions (Skull base: 
chordomas, chondrosarcomas; brain: glioma grade II, glioma grade III; glio-
blastoma; ear-nose-throat: sarcomas in the head and neck, tumours in the 
nasal cavity and paranasal sinus, adenoid cystic salivary gland carcinoma; 
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bone and soft tissue: soft tissue sarcoma; lung: non-small cell lung carcino-
ma; prostate: prostate carcinoma; gastrointestinal: oesophageal carcinoma, 
rectum carcinoma) (see Table 6-1, Table 6-2, Table 6-3).  
Limitations of this systematic review are as follows: although the literature 
was selected independently by 2 researchers, as was the Risk of Bias Assess-
ment (RoB) done, the data was extracted by 1 researcher and controlled by 
the second, there is always the risk of error or of overseeing data, though this 
risk is small. The exclusion criteria also applied, i.e., to exclude studies with 
high RoB and retrospective case series may have led to not capturing the 
whole available body of evidence. That is, retrospective studies or low-quality 
studies (with a high risk of bias) were not included within this systematic re-
view. In case of lack of explicit description of the retrospective or prostpec-
tive study design and data collection, the authors tended to take a ‘liberal’ 
inclusion strategy and to include the respective study. 
The results found in this assessment are in accordance with existing knowl-
edge from other systematic reviews to some extent: 1 recent systematic review 
[15] on charged particle therapy for hepatocellular carcinoma identified 4 
CIRT studies, but did not compare any of the results to standard irradiation. 
Another systematic review [14] conducted in 2013 found no randomised con-
trolled trial and concluded that CIRT should be considered as an experi-
mental treatment, and comparisons (by using RCTs) of CIRT and photon as 
well as proton therapy are necessary. 
3 other less recent systematic reviews compared CIRT to conventional RT 
and other newer forms of RT on the basis of observational studies: 1 system-
atic review [13] conducted an evidence synthesis and meta-analysis of the re-
sults of 86 observational and comparative in-silico studies. The review iden-
tified 5 studies in which CIRT was used and found statistically significantly 
higher 5-year survival in mucosal malignant melanoma patients after CIRT 
in comparison to photon therapy (44% vs. 25%; p=0.007). While those re-
sults sound promising and may indicate that CIRT could potentially be su-
perior in this indication, it must be stated that a) the evidence base of the 
meta-analysis are observational studies and b) the percentage of patients hav-
ing undergone operation was not included in those observational studies and, 
thus, a potentially significant confounder was not statistically tested. 
Another meta-analysis [12] conducted in 2010 included 3 studies comparing 
the efficacy of different radiotherapy treatment modalities for non-small cell 
lung cancer and found statistically significantly higher survival rates of CIRT 
when compared to conventional photon radiotherapy and no statistically sig-
nificant survival rates when compared to stereotactic radiotherapy or proton 
radiotherapy. Another less recent systematic review on particle therapy from 
the same author group was identified with similar conclusions: “promising 
results” with a lack of evidence to suffice particle therapy replacing the stand-
ard treatment. In addition, a conflict of interest is existent in this study [11]. 
However, it must be stated that many of the identified systematic reviews 
and meta-analyses have been undertaken by researchers working for hadron 
therapy centres, and were sometimes even funded by manufacturers [11, 12]. 
Thus, a conflict of interest may exist. 
A previous report by the Belgian Health Care Knowledge Centre KCE [19] 
on the use of proton beam therapy PBT found that no randomised controlled 
trials were available for paediatric cancer indications and pointed out that 1 
factor may be that many clinicians are highly convinced that proton beam 
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therapy is superior to conventional radiotherapy, leading to a high degree of 
reluctance to randomise patients. For CIRT, a similar scenario may be true, 
potentially explaining the lack of controlled and randomised controlled tri-
als proving superiority or inferiority of CIRT. 
In the same report [19], it is argued that ethical reasons, legitimating not con-
ducting controlled or randomised controlled trials due to the better physical 
properties of hadron therapy, may not be convincing except for some indica-
tions in which physical or anatomical reasons against using photons are prev-
alent. 
However, and even if ethical reasons were evident hindering conducting ran-
domised controlled trials for proton therapy for some indications, the same 
logic may not necessarily apply to the difference of carbon ion radiotherapy 
when compared to other treatment modalities: the advantage of carbon ion 
radiotherapy is – to the knowledge of the authors – even theoretically speak-
ing not known extensively. The reviewed medical literature describes CIRT 
as a two-edged sword [24]: some of the radiobiological differences are ad-
vantages, and some may be disadvantageous [19, 150]. At the same time, many 
new and potentially promising techniques in radiation therapy, such as in-
tensity-modulated radiation therapy (IMRT), CyberKnife and PRT, coexist 
alongside with CIRT [151], leading to a necessity to conduct more compre-
hensive evaluations. 
Furthermore, there may be other significant boundaries and structural fac-
tors hindering the generation of sound scientific evidence: a lack of collabo-
ration between the cancer therapy centres [19] exists within the European 
Union (EU). The member states of the EU are asked to establish an envi-
ronment in which collaboration and evidence generation is promoted, and a 
“medical arms race” [152] between cancer therapy centres is hindered in or-
der to reach more patient-relevant outcomes (PRO) for cancer patients with-
in the EU.  
In this context, cooperation cannot be limited to generating clinical evidence 
solely: questions regarding the adequate allocation of resources [153] within 
the Austrian health care system, but also more broadly in the EU arise: more 
scientific health service research evaluations [154], and economic evaluations 
[155] – including societal parameters – may help to reach a scientific basis 
for decisions in the EU, leading to the greatest PROs for cancer patients. 
In conclusion, the evidence regarding superiority/inferiority of CIRT regard-
ing efficacy or safety can as of today only be called an experimental therapy: 
more research (prospective controlled and randomised studies) is necessary 
to reach a sophisticated evidence base for the evaluation of CIRT for cancer 
therapy. 
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Table 6-1: Summary of the included studies for the skull base and brain and ENT region 
Study Indication Method 
FU in months 
(unit of central 
tendency, range) 
Additional 
treatment Control 
Efficacy:  
reported crucial and  
relevant outcomes 
Safety: Radiation morbidities:  
Cases/n [Gr.1 (%)/Gr.2 (%)/ 
Gr.3 (%)/Gr.4 (%)] 
Conclusion 
Skull base (3 studies) 
Mizoe et al. 
2009 [44] 
Chordoma of 
the skull base 
and the 
paracervical 
spine 
Prospective; 
Pilot study, 
dose-escalation 
study, 
enrolment: 
1995-2007; 
n=33; age: 47 
(median, 
range: 16-76) 
53  
(median, range: 
8-29) 
Variable31 
(incl. 
surgery) 
- OS (5yr): 87.7%  
(95% CI: NR, SE: 7%) at 5 years  
OS (10yr): 67%  
(95% CI: NR, SE: 14%) at 10 years  
LCR (5yr): 85.1%  
(95% CI: NR, SE: 8%) at 5 years  
LCR (10yr): 63.8% (95% CI: NR, 
SE: 19%) at 10 years 
Acute: Mucosa: 12/34 [6 (17.6)/ 
6 (17.6)/0(0)/0(0)]; skin: 13/34  
[12 (35.3)/1 (2.9)/0 (0)/0 (0)] 
Late: Mucosa: 2/34 [2 (5.9)/0 (0)/ 
0 (0)/0 (0)]; skin: 2/34 [2 (5.9)/0 (0)/ 
0 (0)/0 (0)]; brain: 6/34  
[5 (14.7)/1 (2.9)/0 (0)/0 (0)] 
At present 
insufficient 
scientific 
evidence 
indicating 
superiority/ 
inferiority 
of CIRT for 
skull base 
tumours 
Schulz-Ertner 
et al. 2007 
[43] 
Low-grade and 
intermediate- 
grade chondro-
sarcomas of  
the skull base 
Prospective; 
case series; 
enrolment: 
1998-2005; 
n=54;  
age: 46 
(median, 
range: 6–74) 
33  
(median, range: 
3–84) 
Variable31 
(incl. 
surgery) 
- OS (3yr): 98.2%  
(95% CI: 94.6–100%) 
OS (4yr): 98.2%  
(95% CI: 94.6–100%) 
LCR (3yr): 96.2%  
(95% CI: 88.8–100%)  
LCR (4yr): 89.8%  
(95% CI, 75.6–100%) at 4 years 
Acute32: Mucositis: 3/54 (5%)  
[Grade 1: 2 (3.7)/Grade 2: NR/ 
Grade 3: 1 (1.9)/Grade 4: 0];  
Parotitis: 1 (1.9)  
Late32: Grade ≤ 2: 5 (9.3)/ 
Grade 3: 1 (1.9)/Grade 4: 0 (0) 
Uhl  
et al. 2014 
[42] 
Chordoma 
(n=20) & 
Chondrosar-
coma (n=5) 
Prospective; 
case series; 
enrolment: 
2010-2012; 
n=25;  
age: 50 
(median, 
range: 39–76) 
14  
(median, range: 
2–30) 
Variable31  
(incl. 
surgery, 
other 
radiation 
therapies 
such as 
photon or 
proton 
irradiation) 
- LPFS (2yr): 79.3%  
(95% CI: NR) 
Acute: Mucosa: 1/25 (NR/1* (4)/0/0); 
Hypacusis: 3/25 [NR/3 (12)/0 (0)/0 (0)]; 
Asymptomatic temporal lobe  
reaction*: 5/25  
[5 (20)/0(0)/0 (0)/0 (0)]: 
Osteoradionecrosis:  
1/25 (NR/NR/1 (4)/0(0)] 
Late: NR 
                                                             
31 Before, during or after radiation therapy. 
32 Standardised way of reporting not possible due to the lack of clarification in the study (Grade 0 Grade 1). 
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Study Indication Method 
FU in months 
(unit of central 
tendency, range) 
Additional 
treatment Control 
Efficacy:  
reported crucial and  
relevant outcomes 
Safety: Radiation morbidities:  
Cases/n [Gr.1 (%)/Gr.2 (%)/ 
Gr.3 (%)/Gr.4 (%)] 
Conclusion 
Brain (2 studies 
Mizoe et al. 
2007 [68] 
Anaplastic 
astrocytoma 
(AA; n=16), 
Glioblastoma 
multiforme 
(GBM; n=32) 
Prospective; 
case series; 
enrolment: 
1994-2002; 
n=48; age:  
53 (median, 
range: 18–78) 
NR Surgery +  
X-RAY  
radio-
therapy + 
Chemo-
therapy 
- NR33 Acute: Skin 36/48 [27 (56)/9 (19)/0 
(0)/0 (0)]; White Blood Cells: 37/48  
[6 (13)/11 (23)/17 (35)/3 (6)]; Phatelet: 
33/48 [7 (15)/17 (35)/6 (13)/3 (6)]; Brain: 
6/48 [6 (13)/0 (0)/0 (0)/0 (0)] 
Late: Skin 1/48 [1 (2)/0 (0)/0 (0)/0 (0)]; 
Brain RTOG/EORTC: 11/48  
[7 (15)/4 (8)/0 (0)/0 (0)];  
Brain (MR by LENT/SOMA): 14/48  
[10 (21)/4 (8)/0 (0)/0 (0)] 
At present 
insufficient 
scientific 
evidence 
indicating 
superiority/ 
inferiority  
of CIRT  
for brain 
tumours 
Hasegawa et 
al. 2012 [69] 
Diffuse 
astrocytoma 
Prospective; 
case series/ 
dose escalation 
study, 
enrolment: 
1994-2002; 
n=14; age: 32.5 
(median, 
range: 18-66) 
62  
(mean,  
range: 10-152) 
Variable31 
(incl. 
surgery, 
salvage 
treatment, 
i.e., chemo;  
RT; OP) 
- OS (5yr): 43%  
(95% CI: NR, SEM: 13%) 
OS (10yr): 36%  
(95% CI: NR, SEM: 13%) 
PFS (5yr): 36%  
(95% CI: NR; SE: 13%) 
Acute: Grade ≤1: 12 (86%);  
Grade 2: 2 (14%); Grade 3: 0; Grade 4: 0 
Late: skin: 1/12 [1 (8.3)/0 (0)/0 (0)/0 (0)]; 
brain: 10/12 [8 (66.7)/2 (16.7)/0 (0)/0 (0)] 
ENT-Tumours (5 studies) 
Jensen et al. 
2015 [85] 
Malignant 
Salivary Gland 
Tumours 
Prospective; 
case series/ 
dose 
escalation 
study34; 
enrolment: 
2010-2011; 
n=54;  
age: 58 
(median, 
range: 25-74) 
42.0  
(median, range:  
11.4-53.1) 
Intensity-
modulated 
radiation 
therapy 
(IMRT); 
variable 
(incl. 
surgery) 
- OS (3yr): 78.4% (95% CI: NR)  
PFS (3yr): 57.9% (95% CI: NR)  
LCR (2yr): 84.3% (95% CI: NR)  
LCR (3yr): 81.9% (95% CI: NR) 
Acute35: Mucosities: Grade 1: 15 (28%); 
Grade 2: 21 (40%); Grade 3: 14 (26%) 
Dermatities: Grade 1: 40 (75%);  
Grade 2: 2 (8%); Grade 3: 3 (6%). 
Dysphagia: 18 (34%) grade 1, 10 (19%) 
grade 2; xerostomia: 28 (53%) grade 1, 
6 (11%) grade 2 
Late35: e.g.: Dysphagia: 3 (6%) Grade 2; 
Xerostomia: 26 (49%) Grade 1, 1 (2%) 
Grade 2; Hemorrhage: 1 (2%) Grade 4; 
blood brain barrier changes  
(CNS necrosis): 3 (6%) grade 1 
 
At present 
insufficient 
scientific 
evidence 
indicating 
superiority/
inferiority 
of CIRT for 
tumours in 
the ENT 
region. 
                                                             
33 However, the median survival time (MST) was measured: MST (AA): 35 months; MST (GBM): 17 months.  
In addition, the median progression-free survival (m-PFS) was measured in months by 1 study [68]: m-PFS (AA): 18; m-PFS (GBM): 7 months. 
34 Patients received CIRT as a carbon ion boost. 
35 Numerous other toxicities occurred without grades reported: The study [85] did not report on the grades for numerous observed late radiation morbidities.  
The reader is referred to the data extraction table to see those further radiation morbidities with unreported respective grades (Table A-4 in the Appendix). 
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Study Indication Method 
FU in months 
(unit of central 
tendency, range) 
Additional 
treatment Control 
Efficacy:  
reported crucial and  
relevant outcomes 
Safety: Radiation morbidities:  
Cases/n [Gr.1 (%)/Gr.2 (%)/ 
Gr.3 (%)/Gr.4 (%)] 
Conclusion 
Jingu et al. 
2012 [86] 
Unresectable 
adult bone 
and soft-
tissue 
sarcoma of 
the head and 
neck 
Prospective; 
case series36; 
enrolment: 
2001-2008; 
n=27;  
age: 46.2 
(mean, range: 
17–78) 
37  
(median, range: 
4.1 73.0) 
NR - OS (3yr): 74.1%  
(95% CI: 57.5–90.6%)  
OS (5yr): 57.6%  
(95% CI: 33.7–81.4%) 
LCR (3yr): 91.8%  
(95% CI: 81.0–100%) 
LCR (5yr): 80.4%  
(95% CI: 57.3–100%) 
Acute: mucosa: 27/27 [8 (29.6)/17 (63)/ 
1 (3.7)/0 (0)]; skin: 25/27  
[19 (70.4)/6 (22.2)/0 (0)/0 (0)] 
Late: mucosa: 9/26 [9 (34.6%)/0 (0)/ 
0 (0)/0 (0)]; skin: 6/26 [6 (23%)/0 (0)/ 
0 (0)/0 (0)]; Brain: 5/26 [5 (19.2)/1 (3.8)/ 
0 (0)/0 (0)]; Eye: 2/26 [0 (0)/1 (3.8)/0/ 
1 (3.8)]; Bone: 6/26 [1 (3.8)/1 (3.8)/ 
4 (15.4)/0 (0)] 
continuation: 
Indirect 
comparisons 
show:  
No statistical 
significant 
difference  
on the basis 
of OS, DFS 
and LRC 
between 
CIRT+ 
Photon  
when 
compared  
to photons 
alone in 
locally 
advanced 
adenoid 
cystic 
carcinoma  
of the 
salivary 
gland [87]. 
Mizoe et al. 
2012 [33] 
Various Head 
and neck 
carcinoma 
Prospective; 
case series 
study, 
enrolment: 
1997-2006; 
n=236; age: 
56.5 (median, 
range: 16–80) 
54  
(mean,  
range: 3-162) 
Variable31 
(incl. 
operation; 
chemo) 
- OS (5yr)37: 47% (95% CI: NR, SE: 
3.2%) (68%  
LCR (5yr)38: 68% (95% CI: NR, SE: 
3.5%)  
Acute: mucosa: 196/223 [91 (41)/81 
(36)/24 (11)/0 (0)]; skin: 220/236  
[115 (49%)/90 (38%)/15 (6%)/0 (0)] 
Late: mucosa: 47/223 [43 (19)/4 (2)/0 
(0)/0 (0)]; skin: 108/236 [101 (43%)/7 
(3%)/0 (0)/0 (0%)] 
Shirai et al. 
2017 [31] 
Non-
squamous cell 
carcinoma of 
the head and 
neck 
Prospective; 
case series 
study, 
enrolment: 
2010-2014; 
n=35;  
age: 59 
(median, 
range: 31-77) 
39  
(median, range: 
6–70). 
none 
reported39 
- OS (3yr): 88% (95% CI: 77–99%) 
(T2: 100%; T3: 88%; T4: 85%) 
PFS (3yr): 71% (95% CI: 56–86%) 
at 3 years (T2:100%; T3: 63%;  
T4: 68%) 
LCR (3yr): 93% (95% CI: 84–100%) 
at 3 years ( T2: 100%;  
T3: 86%; T4: 94%) 
Change in HRQoL: MCS:  
n. s. short-term and at 3 months; s. 
s. mid-term and longer term 
improvements (baseline: MCS: 
40.8 ±1.8; 6 m: 45.9±1.7; at 12 m: 
47.3±1.4; at 24 months: 48.4 ±1.6): 
n.s. ; PCS: short-term, mid-term 
and longer term differences n. s. 
Acute: mucosa: 23/35 [NR/15 (43%)/8 
(23%)/0 (0%)]; skin: 11/35 [NR/11 
(31%)/0 (0%)/0 (0%)]; Conjunctivitis: 
5/35 [NR/5 (14)/0 (0)/0 (0)]; Dysgeusia: 
1/35 [NR/1 (3)/0 (0)/0 (0)] 
Late: mucosa: 12/35 [NR/11 (31%)/1 
(3%)/0 (0)]; dermatitis: 0/35 [NR/ 
0 (0)/0 (0)/0 (0)]; Conjunctivitis: 1/35 
[NR/1 (3%)/0 (0%)/0 (0)]; Dysgeusia: 
2/35 [NR/2 (6%)/0 (0)/0 (0)]; Brain 
necrosis: 2/35 [NR/2 (6%)/0 (0)/0 (0)]; 
Cataract: 2/35 [NR/0 (0)/2 (6)/0 (0)]: 
Visual imparment: 5/35 [NR/2 (6%)/1 
(3%)/2 (6%)]; Trismus: 3/35 [NR/3 
(9%)/0 (0%)/0 (0%)]; Otitis media: 5/35 
[NR/5 (14)/0 (0)/0 (0)]; Olfactory nerve 
disorder: 4/35 [NR/4 (11)/0 (0)/0 (0)] 
                                                             
36 The study included a statistical analysis using a historical control. However, the purpose may have primarily been to demonstrate which dose is superior/inferior,  
since the study used as a comparison included patients receiving CIRT as well. 
37 68% for adenoidcystic carcinoma, 56% for adenocarcinoma and 35% for malignant melanoma). 
38 75% for the 85 patients with malignant melanoma, 73% for the 69 patients with adenoid cystic carcinoma, 73% for the 27 patients with adenocarcinoma,  
61% for the 13 patients with papillary adenocarcinoma, 61% for the 12 patients with squamous cell carcinoma and 24% for the 14 patients with sarcomas. 
39 Reported are only “no other RT in the head and neck region” and no other chemotherapy 1 month before CIRT (history of chemotherapy: NR). 
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Study Indication Method 
FU in months 
(unit of central 
tendency, range) 
Additional 
treatment Control 
Efficacy:  
reported crucial and  
relevant outcomes 
Safety: Radiation morbidities:  
Cases/n [Gr.1 (%)/Gr.2 (%)/ 
Gr.3 (%)/Gr.4 (%)] 
Conclusion 
Schulz-Ertner 
et al. 2005 
[87] 
Locally 
Advanced 
Adenoid 
Cystic 
Carcinoma  
of Salivary 
Gland 
Case-control 
study, 
enrolment: 
1995-2003; 
n=63  
(29 photon + 
CIRT);  
age: 56 
(median, 
range: 25–76) 
16  
(median, range: 
2–60) 
Photons;  
Variable31 
[incl. 
Surgery, 
salvage 
therapy 
(reir-
radiation)] 
34 pts 
receiving 
photon 
RT 
OS (2yr): CIRT+photon: 86.6% 
(95% CI: NR); photon alone: 77.9% 
(95% CI: NR); diff. n. s.  
OS (4yr): CIRT+photon:75.8% 
(95% CI: NR); photon alone: 77.9% 
(95% CI: NR); diff. n. s.  
DFS (2yr): CIRT+photon: 71.5% 
(95% CI: NR); photon alone: 
69.2% (95% CI: NR); diff. n. s.  
DFS (4yr): CIRT+photon: 53% 
(95% CI: NR); photon alone: 23.6% 
(95% CI: NR); diff. n. s. 
LRC (2yr): CIRT+photon: 77.5% 
(95% CI: NR); photon alone: 72.2% 
(95% CI: NR); diff. n. s.  
LRC (4yr): CIRT+photon: 77.5% 
(95% CI: NR); photon alone: 
24.6% (95% CI: NR); diff. n. s. 
CIRT+photon40: mucosities: Grade 1: NR; 
Grade 2: NR; Grade 3: 2 (6.5%); local 
bacterial infection after RT: 2 (6.5%) 
Photon alone: mucositis: grade 1: NR; 
grade 2: NR; grade 3: 11 (32.3%) 
 
  
                                                             
40 The study may have selectively reported on the toxicities, since many grade 1 and grade 2 toxicities were not reported. 
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Table 6-2: Summary of the included studies for lung and bone & soft tissue cancer 
Study Indication Method 
FU in months 
(Unit of central 
tendency, range) 
Additional 
treatment Control group 
Efficacy: reported crucial  
and relevant outcomes 
Safety: Radiation morbidities: 
Cases/n [Gr.1 (%)/Gr.2 (%)/ 
Gr.3 (%)/Gr.4 (%)] Conclusion 
Lung (6 studies) 
Iwata et 
al. 2010 
[100] 
NSCLC: 
stage IA 
(n=42) + 
stage IB 
(n=38) 
Case-control 
study; 
enrolment: 
2003-2007; 
n=80  
(23 CIRT pts); 
age: 75 y. o. 
(54-89) 
30.541  
(median, range: 
4-66) 
None 
reported 
57 pts 
receiving 
OS (3yr):42 CIRT: 86% (95% CI: NR) 
vs. PRT1: 90% (95% CI: NR)  
vs. PRT2: 61% (95% CI: NR) 
LCR (3yr): 86% (95% CI: NR)  
vs. PRT1: 83% (95% CI: NR) vs.  
PRT2: 81% (95% CI: NR) 
CSS and DFS only reported for all  
80 pts: CSS (3yr): 86% (95% CI,  
77%-95%; IA: 84%; IB: 88%) at 3 years 
DFS (3yr): 54% (95% CI: 43%-68%; 
IA: 67%; IB: 46%) at 3 years 
Acute: NR 
Late: CIRT (n=23): lung: 2/23 
[NR/2 (8.7)/0 (0.0)/0 (0.0)]; skin: 
2/23 (NR/2 (8.7)/0 (0.0)/0 (0.0)); 
PRT (n=57): lung: 8/57 [NR/7 
(12.3)/1 (1.8)/0 (0.0)]; skin: 11/57 
(NR/8 (14.0)/3 (5.3%)/0 (0)) 
Footnote: 23% had a grade 2 rib 
fracture and Gr. 2 soft tissue AE 
occurred in 6% 138 
At present 
insufficient 
scientific 
evidence 
indicating 
superiority/ 
inferiority  
of CIRT for 
NSCLC when 
compared to 
conventional 
radiotherapy. 
Indirect 
comparisons 
show: 
no statistically 
significant 
difference on 
the basis of 
OS [99, 100], 
PFS [99] and 
LCR [99, 100] 
between  
CIRT when 
compared  
to PRT for 
stage IB/IIA 
NSCLC pts. 
Iwata et 
al. 2013 
[99] 
NSCLC: 
stage IB 
(n=47) + 
stage IIA 
(n=23) 
Case-control 
study; 
enrolment: 
2003-2009; 
n=70  
(27 CIRT pts); 
age: 75 y. o. 
[median, range: 
57-92, for all pts 
(incl. PRT pts)] 
44  
(median, range: 
4–103) 
None 
reported 
43 pts 
receiving PRT 
Outcomes only measured for all  
70 pts (CRT and PRT pts) 
OS (4yr): 58% (95% CI: 46%–70%; 
IB: 53%; IIA: 67%)  
PFS (4yr): 46% (95% CI: 33%–59%; 
IB: 43%; IIA: 52%), 52%) at 4 years 
LCR (4yr): 75% (95% CI: 63%–86%; 
IB: 70%; IIA: 84%) at 4 years 
There were no significant differences 
between PRT and CIRT (rates: NR). 
Acute: NR 
Late: lung: 12/70 [NR/10 (14.3)/2 
(8.7)/0 (0)]; skin: 15/70  
[NR/10 (14.3)/4 (5.7)/1 (1.4)] 
Miyamoto 
et al. 
2007a 
[102] 
NSCLC: 
stage IA 
(n=42) + 
stage IB 
(n=37) 
Prospective; 
case series 
study; 
enrolment: 
2000-2003; 
n=79;  
age: 74.8 y. o. 
(average, range: 
47–88) 
38.6  
(median, range: 
2.5-72.2) 
None 
reported 
- OS (5yr): 45% (95% CI: NR;  
IA: 62%, IB: 25%) 
CSS (5yr): 68% (95% CI: NR;  
IA: 87%, IB: 42%) 
LCR (5yr): 90% (95% CI: NR;  
IA 97%, IB 80%) 
Acute: lung: 1/79 [0 (0)/1 (1.3)/0 
(0)/0 (0)]; skin: 80/80 (75 
(93.8)/5 (6.3)/0 (0)/0) 
Late: lung: 70/76 [69 (90,8)/1 
(1.3)/0 (0)/0 (0)]; skin: 77/77  
[76 (98.7)/1 (1.3)/0 (0)/0 (0)] 
                                                             
41 FU includes intervention group and control group (if applicable). 
42 CIRT: 52.6 GyE; PRT1: 80 GyE/20 Fr; PRT2: 60 GyE/10 fr. 
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Study Indication Method 
FU in months 
(Unit of central 
tendency, range) 
Additional 
treatment Control group 
Efficacy: reported crucial  
and relevant outcomes 
Safety: Radiation morbidities: 
Cases/n [Gr.1 (%)/Gr.2 (%)/ 
Gr.3 (%)/Gr.4 (%)] Conclusion 
Miyamoto 
et al. 
2007b 
[101] 
NSCLC: 
stage IA 
(n=29) + 
stage IB 
(n=21) 
Prospective;  
case series study; 
enrolment:  
1999-2000; 
n=50; age:  
74.1 y. o. 
(average, range: 
61 -84) 
59.2  
(median, range: 
6.0–83.0) 
None 
reported 
- OS (5yr): 50.0% (95% CI: NR;  
IA 55.2, IB: 42.9)  
CSS (5yr): 75.7% (95% CI: NR;  
IA: 89.4, IB: 55.1 ) 
LCR (5yr): 94.7% (95% CI: NR;  
IA: NR, IB: NR) 
Acute: lung: 2/51 [1 (1.9)/1 (1.9)/0 
(0)/0 (0)]; skin: 51/51 [50 (98)/1 
(1.9)/0 (0)/0 (0)] 
Late: lung: 50/51 [48 (94.1)/2 
(3.9)/0 (0)/0 (0)]; skin: 51/51 [(49 
(96)/1 (1.9)/1 (1.9)/0 (0)] 
Takahashi 
et al. 2015 
[98] 
Locally 
Advanced 
NSCLC (IIA 
(n=17) + 
IIB (n=22) 
+ IIIA 
(n=23) 
Prospective; 
dose escalation 
study; case 
series study; 
enrolment: 
2000-2013; 
n=62; age: 76 y. 
o. (median, 
range: 46-88) 
25.2  
(1.6 - 157.2) 
Variable43 
(incl. Neo-
adjuvant 
therapy, 
salvage 
chemo) 
- OS (1yr): 77.2% (95% CI: 66.7%-87.7%)  
OS (2yr): 51.9% (95% CI: 39.2%-64.5%) 
DFS (2yr): 35.7% (95% CI: NR). 
CSS (2yr): 71.7% (95% CI: NR)  
LCR (1yr): 96.0% (95%  
CI: 90.5%-100.0)  
LCR (2yr): 93.1% (95%  
CI: 85.4%-100.0) 
Acute: lung: 2/62 [NR/1 (1.6)/1 
(1.6)/0 (0)]; skin: 5/62  
[NR/5 (8)/0 (0)/0 (0)]  
Late: lung: 3/62 [NR/3 (4.8)/0 
(0)/0 (0)]; skin: 1/62 [NR/1 (1.6)/0 
(0)/0 (0)]; Oesophagus: 1/62 (2) 
(NR/0/1/0) 
Yamamot
o et al. 
2017 [97] 
NSCLC: 
stage stage 
IA (n=123) 
+ stage IB 
(n=95) 
Prospective; 
dose escalation 
study; case 
series study; 
enrolment: 
2003-2012; 
n=218; age: 75 
(median, range: 
46-89) 
57.8  
(median, range: 
1.6-160.7) 
None 
reported 
- OS (3yr): 68.3% (95% CI: NR)  
OS (5yr): 49.4% (95% CI: NR)  
LCR (3yr): 77.9% (95% CI: NR)  
LCR (5yr): 72.7% (95% CI: NR) 
Acute: 
215/218 [212 (97.2)/3 (1.3)/0 
(0.0)/(0.0)]  
Late: 
208/212 [207 (97.6%)/1 (0.4)/0 
(0.0)/0 (0.0)] 
Bone & Soft tissue (1 study) 
Sugahara 
et al. 2012 
[126] 
Localised 
primary 
sarcoma  
of the 
extremities 
(medically 
inoperable 
or declined 
surgery) 
Prospective; 
case series; 
dose escalation 
study; 
enrolment: 
2000 -2010; 
n=17; age: 53 
(median; range: 
14–87 years) 
37  
(median; range: 
11–97 months) 
Variable43 
(incl. 
surgery, 
chemo) 
- OS (3yr): 68% (95% CI: 42–86%)  
OS (5yr): 56% (95% CI: 29–80%)  
LCR (3yr): 76% (95% CI: 51–93%) 
LCR (5yr): 76% (95% CI: 51–93%) 
Acute: Skin:  
16/17 [16 (94)/0 (0)/0 (0)/0 (0)] 
Late: 1 pt with grade 2 skin 
toxicities (5.9%); 4 pts had grade 
2 neurological toxicity (23.5%);  
3 pts had lower limb tumours;  
1 pt had an upper limb tumour;  
1 pt with a grade 3 femoral 
fracture (5,9%) 
At present 
insufficient 
scientific 
evidence 
indicating 
superiority/ 
inferiority  
of CIRT 
 
                                                             
43 Before, during or after radiation therapy. 
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Table 6-3: Summary of the included studies for prostate and gastrointestinal cancer 
Study Indication Method 
FU in months 
(unit of central 
tendency, range) 
Additional 
treatment Control 
Efficacy: reported crucial  
and relevant outcomes 
Safety: Radiation morbidities: 
Cases/n [Gr.1 (%)/Gr.2 (%)/ 
Gr.3 (%)/Gr.4 (%)] Conclusion 
Prostate (8 studies) 
Habl  
et al. 2016 
[132] 
Localised 
prostate 
cancer 
(Prostatic 
Neoplasms) 
randomised, 
controlled, 
parallely 
assigned, open-
label, toxicity 
study; enrolment: 
2012-2013; 
n=9244 (45 CIRT 
pts); age: 68 y. o. 
(median, range: 
50-80) 
22.3  
(median time, 
range: NR) 
Variable45 
(incl. ADT) 
46 pts 
receiving 
PRT 
Change in HRQoL: QLQ-C30 & PR25 
scores: Comparable between treatment 
arms: only some subscales were s s. 
different (urinary symptom and bowel 
symptom score46): 
Pre-interventional: urinary:  
CIRT: 20 (±14) vs PRT: 19 (±14);  
bowel: CIRT: 5 (±9) vs PRT: 2 (±4) 
Post-interventional: urinary: 47 (±23) 
vs. 37 (±17); bowel: 14 (±19) vs. 6 (±10) 
Mid-term (at 6 weeks): urinary: 34 (±26) 
vs. 25 (±13); bowel: 11 (±15) vs. 3 (±6); 
at 6 months: urinary: 28 (±24) vs.  
20 (±16); bowel: 8 (±15) vs. 4 (±8) 
Acute: 
Proctitis: CIRT: 6/45 [5 (11.1)/1 
(2.2)/0 (0)/0 (0)) vs. PRT: 12/46 [6 
(13.0)/4 (8.7)/2 (4.3)/0 (0)]; 
Diarrhoea: CIRT: 25/45 [25 
(55.6)/0 (0)/0 (0)/0 (0)] vs. PRT: 
32/46 [28 (60.9)/4 (8.7)/0 (0)]; 
Cystitis: CIRT: 19/45 [13 (28.9)/6 
(13.3)/0 (0)/0 (0)] vs. PRT: 28/46 
[18 (39.1)/10 (21.7)/0 (0)/0 (0)] 
Toxicity profiles between arms: n. s. 
Late: NR 
At present 
insufficient 
scientific 
evidence 
indicating 
superiority/ 
inferiority  
of CIRT for 
prostate 
cancer 
Direct 
comparisons 
show n. s. 
difference  
in acute 
radiation 
morbidity 
profiles 
between 
CIRT and 
PRT patients 
Comparable 
HRQoL when 
comparing 
CIRT to PRT 
(only some 
subscales 
were s. s. 
different in  
1 study: 
lower urinary 
and bowel 
symptoms). 
Ishikawa 
et al. 2015 
[133] 
Prostate: 
T1-T3b 
Prospective; 
before-after 
study; feasibility 
study; enrolment: 
2010-2011; n=76; 
age: 66 (median, 
range: 53-88) 
51  
(median time, 
range: 8-58) 
Variable45 
(incl. 
Adjuvant/ 
neoadjuvant 
ADT) 
- OS (4yr): 97.4% (95% CI: 93.8-100.0%) 
BRFS (4yr): 94.6% (95% CI: 89.4-99.8%) 
Change in HRQoL (SF-8): slight s. s.  
long-term (>6m) of PCS score: baseline:  
PCS: 51.14 (1.85); short-term (at 1 m):  
51.14 (1.85); mid-term (at 3 m): 50.76 (1.87)  
(diff. to baseline n. s.); long-term (at 12m):  
PCS: 47.71 (1.84)* diff. to baseline s. s.;  
n. s. diff in MCS: pre-interventional: MCS: 
49.18 (1.96); short-term (at 1m): 48.45 
(1.96); mid-term (at 3 m): MCS: 51.63 (1.98); 
long-term (at 12 m): MCS: 49.75 (1.95). 
Acute: 
GU: 50/76 [43 (57)/7 (9)/0 (0)/0 (0)] 
GI: 1/76 [1 (1)/(0)/0 (0)/0 (0)] 
Late: 
GU: 40/76 [35 (46)/5 (7)/0 (0)/0 (0)] 
GI: 7/76 [6 (8)/1 (1)/0 (0)/0 (0)] 
Ishikawa 
et al. 2006 
[139] 
Prostate: 
T1-T3 
Prospective; case 
series, feasibility 
study; enrolment: 
2000-2003; 
n=175; age: 70 y. o. 
(median, range: 
53–83) 
46  
(median time, 
range: NR) 
Variable45 
(incl. Neo-
adjuvant/ 
adjuvant 
hormonal 
therapy; 
surgical 
castration) 
- OS (4yr): 91% (95% CI: 87–96%)  
CSS (4yr): 97% (95% CI: 95–100%) at  
4 years 
bNED (4yr): 88% (95% CI: 83–93%) 
FACT-G (1yr): d=1.8 (± 1.1), n. s. (p=0.1)  
FACT-P (1yr): d: 2.6 (±1.4), n. s. (p=0.07) 
Acute:  
GU: 57/175 [57 (33)/0 (0)/0 (0)/0 (0)]; 
GI: 2/175 [2 (1)/0 (0)/0 (0)/0 (0)] 
Late:  
GU: 117/175  
[108 (62)/9 (5)/0 (0)/0 (0)];  
GI: 27/175 [23 (13)/4 (2)/0 (0)/0 (0)] 
                                                             
44 92 patients were enrolled in the clinical study; 1 pt dropped out and it was not clear whether this patient received CIRT or PRT (total sample size = 92). 
45 Before, during or after radiation therapy. 
46 Further changes over time for all enrolled pts can be found in the data extraction table. No other QLQ-C30 & PR25 scores subscales between treatment arms were statistically 
significantly different. The results must be interpreted with caution since the study failed to mention at which time point or time period those differences were statistically different. 
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Study Indication Method 
FU in months 
(unit of central 
tendency, range) 
Additional 
treatment Control 
Efficacy: reported crucial  
and relevant outcomes 
Safety: Radiation morbidities: 
Cases/n [Gr.1 (%)/Gr.2 (%)/ 
Gr.3 (%)/Gr.4 (%)] Conclusion 
Niko-
ghosyan 
et al. 2011 
[136] 
inter-
mediate 
risk 
prostate 
cancer pts 
Prospective;  
case series study; 
enrolment 1997-
2007; n=14;  
age: 68 (median, 
range 55 – 75) 
28  
(median, range: 
12-36) 
Variable45 
(incl. 
Adjuvant 
hormonal 
therapy) 
- OS (actuarial, 3yr): 100% (95% CI: NR)  
BRFS (3yr): 86% (95% CI: NR)  
Distant metastastes free survival (1yr): 
100% 
Acute:  
GU: 12/14 [7 (50)/5 (35,7)/ 
0 (0)/(0/0)];  
GI: 5/14 [5 (35)/0 (0)/0(0)/0(0)] 
Late: NR 
Maruyama 
et al. 2017 
[134] 
inter-
mediate 
and high 
risk 
prostate 
cancer pts 
Before-after  
study; enrolment: 
2000-2007;  
n=417; age: 69 y. o. 
(median, range: 
47–92) 
60  
(NR, range: NR) 
Variable45 
(incl. 
Adjuvant/ 
neoadjuvant 
ADT) 
- HRQoL: preinterventional: FACT-G:  
84.2 (12.6), FACT-P (baseline): 119.5 (16.9), 
TOI (baseline): 81.8 (12.0);  
Post-interventional: NR; short-term: 
FACT-G (1 m): 83.7 (12.9), n. s.; FACT-P (1m): 
116.2* (17.1), s. s.TOI (1m): 77.8* (12.1), s. s.; 
mid-term: NR; longer-term: FACT-G (12 m):  
82.6 (13.7), s. s. ; at 36m: 82.4* (14.3), s. s., 
at 60 m: 82.7*(15.0), s. s.; FACT-P: 12 m: 
116.9* (18.4) s. s., 36 months: 117.5 (19.3)  
s. s., 60 months: 117.6* (20.2) s. s.;  
TOI: 12 m: 80.3 (13.0) n. s., 36 m: 81.6  
(13.7) n. s., 60 m: 81.4 (14.6) n. s. 
Acute: NR 
Late: 
GU: 58/416 at 12 months  
[56 (13.5)/2 (0.5)/0 (0.0)/0 (0.0)]; 
114/402 at 36 months[108 (26.9)/ 
6 (1.5)/0 (0.0)/0 (0.0)]; 77/394 at 
60 months [66 (16.8)/10 (2.5)/ 
1 (0.3)/0 (0.0)] 
GI: 4/417 at 12 months [4 (1.0)/ 
0 (0.0)/0 (0.0)/0 (0.0)]; 32/402 at 
36 months [29 (7.2)/3 (0.7)/ 
0 (0)/0 (0)]; 18/394 at 60 months 
[16 (4.1)/2 (0.5)/0 (0.0)/0 (0)] 
Nomiya 
et al. 2016 
[138] 
 
 
 
 
 
 
 
 
 
 
 
 
 
Prostate: 
T1-T3b 
Prospective; 
multi-institutional 
observational 
case series study; 
enrolment:  
2003-2014; 
n=2,157;  
age: 67 y. o. 
(mean, range:  
45–92) 
29  
(NR, range: NR) 
Variable45 
(incl. 
Adjuvant 
hormonal 
therapy) 
- OS (5yr): low risk: 100% (95% CI: NR); 
Intermediate risk group: 99% (95% CI: 
NR) at 5 years; High-risk group:  
96% (95% CI: NR)  
OS (10yr): low risk: 96% (95% CI: NR); 
intermediate risk group: 78% (95% CI: 
NR) at 10years; high-risk group: 88% 
(95% CI: NR) at 10years 
CSS (5yr): low-risk: 100% (95% CI: NR); 
Intermediate risk: 100% (95% CI: NR); 
High-risk group: 99% (95% CI: NR) 
CSS (10yr): low-risk: 100% (95% CI: NR); 
intermediate risk: 88% (95% CI: NR); 
high-risk: 98% (95% CI: NR). 
BRFS (5yr): Low-risk group: 92% (95% CI: 
NR); Intermediate risk: 89% (95% CI: 
NR); high-risk: 92% (95% CI: NR). 
BRFS (10yr): low risk: 77% (95% CI: NR); 
intermediate risk: 70% (95% CI: NR); 
high-risk: 79% (95% CI: NR).  
LCR (5yr): Low-risk: 98% (95% CI: NR); 
Intermediate risk: 96% (95% CI: NR); 
High-risk: 99% (95% CI: NR).  
Acute47:  
GU: Grade 0–1: 2037 (94.4%); 
Grade 2: 119 (5.5%); Grade 3:  
1 (0.0%); Grade 4: 0 (0%) 
GI: Grade 0-1: 2157 (100%);  
Grade 2: 0 (0%); Grade 3: 0 (0%); 
Grade 4: 0 (0%) 
Late: 
GU: Grade 0-1: 1840 (95.4%); 
Grade 2: 88 (4.6%); Grade 3:  
1 (0.0%); Grade 4: 0 (0%) 
GI: Grade 0-1: 1921 (99.6%);  
Grade 2: 8 (0.4%); Grade 3:  
0 (0%); Grade 4: 0 (0%) 
                                                             
47 Standardised way of reporting not possible due to the lack of clarification in the study (grade 0; grade 1). 
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Study Indication Method 
FU in months 
(unit of central 
tendency, range) 
Additional 
treatment Control 
Efficacy: reported crucial  
and relevant outcomes 
Safety: Radiation morbidities: 
Cases/n [Gr.1 (%)/Gr.2 (%)/ 
Gr.3 (%)/Gr.4 (%)] Conclusion 
Nomiya 
et al. 2016 
(continuation) 
LCR (10yr): Low-risk: 98% (95% CI: NR); 
intermediate-risk: 95% (95% CI: NR); 
high-risk: 98% (95% CI: NR) 
Tsuji  
et al. 2005 
[137] 
T1 prostate 
cancer pts 
Prospective; 
dose-escalation, 
prospective case 
series study using 
3 study protocols; 
enrolment: 1995-
2004; n=201; 
age: NR 
NR Variable45 
(incl. Neo-
adjuvant/ 
adjuvant 
hormonal 
therapy; 
surgery; ) 
- OS (5yr): 89.2% (95% CI: NR)  
DSS (5yr): 92.2% (95% CI: NR)  
bNED (5yr): 83.2% (95% CI: NR) 
LCR (10yr): 100% (95% CI: NR) at 5 years 
Acute: NR 
Late:  
Bladder/urethra: 95/201  
[83 (41.3)/12 (6.0)/0 (0.0)/0 (0.0)]; 
Rectum: 
9/201 [7 (3.5)/2 (1.0)/0 (0.0)/0 (0.0)] 
Wakatsuki 
et al. 2008 
[135] 
T1-T3 
prostate 
cancer pts 
Prospective; 
before-after-study 
focusing on 
HRQoL; 
enrolment: 2000-
2004; n=194; 
age: 69 (median, 
range: 53–83) 
NR Variable45 
(incl. Neo-
adjuvant/ 
adjuvant 
hormonal 
therapy; 
surgery; ) 
- HRQoL48: patients receiving CIRT alone 
(n=25): no significant differences in FACT-G 
and FACT-P results when comparing 
baseline scores to the postinterventional 
and at 12 months after CIRT: baseline: 
FACT-G: 88.4 (13.2), FACT-P 122.6 (19.8); 
postinterventional: FACT-G: 89.2 (11.3),  
n. s., FACT-P: 122.4 (16.6) n. s.; short-term: 
NR; mid-term: NR; longer-term (at 12m): 
FACT-G: 89.1 (13.6), n.s., FACT-P: 123.8 (20.3). 
pts receiving CIRT+ADT (n=125): s. s. 
lower FACT-G and FACT-P scores at 12 
months when compared to baseline: 
baseline: FACT-G: 86.1 (19.4), FACT-P: 
120.0 (26.1); postinterventional: FACT-G: 
85.5 (21.2), FACT-P: 118.0 (28.4); short-
term: NR; mid-term: NR; longer-term 
(12m): FACT-G: 83.9 (21.7),s. s.,  
FACT-P: 116.7 (29.1) s. s. 
NR 
Gastrointestinal (2 studies) 
Akutsu  
et al. 2012 
[106] 
T1-T3 
thoracic 
esophageal 
squamous 
cell 
carcinoma  
 
Prospective; 
dose-escalation, 
case series study; 
enrolment: 2004-
2008; n=31; age: 
65.4 y. o. (mean; 
range: NR, SD: 7.1) 
NR Variable45 
(incl. 
Surgery) 
- OS (1yr): Stage 1: 91%(95% CI: NR); 
Stage 2: 100% (95% CI: NR);  
Stage 3: 71% (95% CI: NR) 
OS (3yr): stage 1: 81% (95% CI: NR); 
stage 2: 85% (95% CI: NR);  
stage 3: 43%(95% CI: NR)  
 
Acute: 
Oesophagus: 31/31 [19 (61.3)/12 
(38.7)/0 (0)/0 (0)]; Skin 27/31  
[27 (87.1)/0 (0)/0 (0)/0 (0)]; 
respiratory: 1/31 [0 (0)/0 (0)/1 
(3.2)/0 (0)]; blood: 6/31 [4 (12.9)/2 
(6.4)/0 (0)/0 (0)] 
 
                                                             
48 UCLA-PCI scores were measured for a fragment of patients: no significant difference between baseline, postinterventional and at 12 months scores.  
Also, the study reported on the specific FACT-G and FACT-P subscales, but those subscores were not extracted due to the scope of this report. 
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Study Indication Method 
FU in months 
(unit of central 
tendency, range) 
Additional 
treatment Control 
Efficacy: reported crucial  
and relevant outcomes 
Safety: Radiation morbidities: 
Cases/n [Gr.1 (%)/Gr.2 (%)/ 
Gr.3 (%)/Gr.4 (%)] Conclusion 
Akutsu  
et al. 2012 
[106] 
(continuation) 
(ESCC):  
T1 (n=12) + 
T2 (n=8) + 
T3 (n=11) 
    OS (5yr): stage 1: 61%(95% CI: NR); 
stage 2: 77%(95% CI: NR) at 5 years; 
stage 3: 29%(95% CI: NR)  
CSS (1yr): 97% (95% CI: NR); stage 1: 
100% (95% CI: NR); stage 2: 100% (95% 
CI: NR); stage 3: 83% (95% CI: NR)  
CSS (3yr): 79% (95% CI: NR); stage 1: 
90% (95% CI: NR); stage 2: 85% (95% 
CI: NR); stage 3: 50% (95% CI: NR)  
CSS (5yr): 71% (95% CI: NR); stage 1: 
90% (95% CI: NR); stage 2: 77% (95% 
CI: NR); stage 3: 33% (95% CI: NR)  
RFS (1yr): 87% (95% CI: NR); stage 1: 
100% (95% CI: NR); stage 2: 92% (95% 
CI: NR); stage 3: 51% (95% CI: NR)  
RFS (3yr): 62% (95% CI: NR); stage 1: 
80%(95% CI: NR) ; stage 2: 69% (95% 
CI: NR); stage 3: 17% (95% CI: NR)  
RFS (5yr): 62% (95% CI: NR); stage 1: 
80% (95% CI: NR); stage 2: 69% (95% 
CI: NR); stage 3: 17% (95% CI: NR) 
Late: “No Toxicities including 
operative complications were 
observed after the 91st day from 
the first treatment” (data not 
shown in the study). 
At present 
insufficient 
scientific 
evidence 
indicating 
superiority/ 
inferiority of 
CIRT for 
gastro-
intestinal 
tumours 
Yamada 
et al. 
2016 
[107] 
Rectal 
cancer 
without 
distant 
metastasis 
Prospective, dose 
escalation, case 
series study; 
enrolment: 2001-
2012; n=184; age: 
61.3 y. o. (median, 
range: 37-79) 
42  
(median; range: 
7-131) 
Variable45 
(incl. 
Primary 
tumour 
operation) 
- OS (3yr): 72% (95% CI: 66%-79)  
OS (5yr): 53% (95% CI: 45%-62%)  
LCR (5-yr): 35% (95% CI: 2%-76%)-88% 
(95% CI: 80%-93%) (dose dependent)  
Acute: 
dose-escalation (n=37): Skin: 22/37 
[20 (54)/2 (5.4)/0 (0)/0 (0)];  
GI tract: 1/37 [0 (0)/1 (2.7)/0 (0)/0 
(0)] ;Urinary: 1/37 [0 (0)/1 (2.7)/0 
(0)/0 (0)] 
Phase 2 (n=143): skin: 117/143 [112 
(78.3)/5 (3.5)/0 (0)/0 (0)];  
GI: 3/143 [0 (0)/3 (2.1)/0 (0)/0 (0)]; 
Urinary: 0/143 [0 (0)/0 (0)/0 
(0)/0 (0)] 
Late: 
dose-escalation (n=37): Skin: 15/37 
[14 (37.8)/1 (2.7)/0 (0)/0 (0)];  
GI tract: 1/37 [0 (0)/1 (2.7)/0 (0)/0 
(0)]; Urinary: 0/37 [ 0 (0)/0 (0)/0 
(0)/0 (0)] 
Phase 2 (n=143): skin: 66/143  
[64 (44.8)/0 (0)/2 (1.4)/0 (0)];  
GI tract: 3/143 [1 (0.6)/1 (0.6)/1 
(0.6)/0(0)]; urinary: 2/143  
[1 (0.6)/1 (0.6)/0 (0)/0 (0)] 
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Appendix 
Data extraction tables of individual studies included for clinical effectiveness and safety 
Table A-1: Carbon ion radiotherapy (CIRT): Results from randomised controlled trials 
First Author  Habl [132] 
Year  2016 
Country Germany 
Cancer Therapy Centre (s) Heidelberg Ion Beam Therapy 
Centre (HIT) 
Sponsor Heidelberg University 
Sample Size 9249 
CIRT Sample 45 
Time Frame of Patient Enrolment May 2012 and December 2013 
Study Type Interventional 
Study Design Randomised, parallel assigned, open-label, pilot study 
The Phase of Clinical Trial Phase 2 
Intervention Hypofractionated irradiation in a raster scan technique with protons and C-ions. 
PRT (n=46): 20 x 3.3 GyE C-ions (arm A)  
CIRT (n=45): 20 x 3.3 GyE protons (arm B) 
Co-intervention: Androgen deprivation therapy (ADT): 21 patients received neoadjuvant/adjuvant ADT. 
Control (C) Historical control , PRT 
Age in years (Unit of Central Tendency, Range) 68 (median, range: 50-80) 
Sex, Female (%) vs. Male (%) 0 (0) vs. 92 (100) 
Population Indication Localised prostate cancer (Prostatic Neoplasms) 
   Protons (arm A) C-ions (arm B) 
Initial PSA (ng/mL) <10 
10-20 
>20 
32 
12 
2 
33 
13 
0 
                                                             
49 1 patient dropped out due to a small intestine loop directly next to the prostate. 
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First Author  Habl [132] 
 Gleason Score 5  
6  
7 (3 + 4)  
7 (4 + 3)  
8  
9 
0 
17  
15  
11  
3  
0 
2 
16 
13 
11 
3 
1 
Tumour Stage/TNM 
Classification 
T1a 
T1b  
T1c  
T2a  
T2b  
T2c 
T3a 
T3b 
0  
0  
37  
6  
0  
3  
0  
0 
1 
1 
31 
8 
1 
1 
2 
1 
Follow-Up in Months  
(Unit of Central Tendency; Range) 
22.3 (median time, range: NR) 
The Loss to Follow-Up n (%) NR 
Methods and Statistical Analysis “The study was designed to answer 2 questions: (1) is the toxicity of carbon ion irradiation (arm B) noninferior compared to that  
of standard radiation? and (2) is the toxicity of the proton irradiation (arm A) noninferior compared to that of standard radiation? 
Therefore, the null hypothesis H0: SFR<87.5% versus H1: SFR≥97.5% was tested for each arm with a type I error of aZ10% and a 
power of at least 90%,calculated using PASS software (Number Cruncher Statistical Systems, Kaysville, UT) and the procedure of 
Blackwelder for noninferiority trials; the study needed to recruit n=41 patients per arm. To account for dropout, a total of  
n=92 patients (n=46 per arm) were enrolled”. 
Statistical Analysis: 
1-sample binomial testing (for SFR hypothesis testing)50 
Descriptive, “exploratory” data analysis (for the analysis of HRQoL) with a statistical significance at p<0.05 
                                                             
50 The pilot study [132] tested whether CIRT (and PRT) was non-inferior when compared to standard irradiation (using a threshold created from data of historical controls). There-
fore, the secure feasibility rate (SFR) was calculated (no grade ≥3 AE, or minor AE leading to the drop-out of CIRT, within 6 weeks after CIRT) and compared to a threshold of 
97.5% using a 1-sample binomial test (H0: SFR<87.5% versus H1: SFR ≥97.5%). However, the test was limited to the secure feasibility and was, therefore, not extracted and de-
scribed in the qualitative synthesis. It was tested whether the SFR for both arms was higher than or equal to 97.5%. The authors found out that – within the CIRT sample – 0 out of 
45 patients (95% CI: 0.0%-7.87%) had any ≥grade 3 toxicity or terminated prematurely. The authors concluded that the therapy is feasible. 
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First Author  Habl [132] 
Outcomes 
Efficacy 
Overall Survival (OS) in % (95% CI) - 
Cause-Specific Survival (CSS) in % (95% CI) - 
Disease-Free Survival (DFS) in % (95% CI) - 
Recurrence-Free survival(RFS) in %(95% CI) - 
Progression-Free Survival (PFS)in % (95% CI) - 
Local Control Rate (LCR) in % (95% CI) - 
Health-Related 
Quality of Life 
(HRQOL) 
Results “Reduced QoL was evident mainly in fatigue, pain, and urinary symptoms during therapy and 6 weeks thereafter.  
All European Organization for Research and Treatment of Cancer QLQC30 and -PR25 scores improved during follow-up.” 
Comparable HRQoL. 
Statistically significant differences were only found in urinary and bowel symptoms between PRT vs. CIRT. Higher urinary and bowel 
symptoms scores within the PRT group when compared to the score of the CIRT group at different time points were observed51. 
No other subscores were statistically significantly different between treatment arms. 
Before (t0) 
Urinary symptom score (PR25): 20 (±14) vs 19 (±14) 
Bowel symptom score (PR25): 5 (±9) vs 2 (±4) 
At the end of CRT/PRT (t1) 
Urinary symptom score (PR25): 47 (±23) vs 37 (±17) 
Bowel symptom score (PR25): 14 (±19) vs 6 (±10) 
At 6 weeks after therapy (t2) 
Urinary symptom score (PR25): 34 (±26) vs 25 (±13) 
Bowel symptom score (PR25): 11 (±15) vs 3 (±6) 
At 6 months after therapy (t3) 
Urinary symptom score (PR25): 28 (±24) vs 20 (±16) 
Bowel symptom score (PR25): 8 (±15) vs 4 (±8) 
  Change in HRQOL (s. s. with p<0.05) 
  Dt1-t0* Dt2-t0* Dt3-t0* 
                                                             
51 The authors stated that the differences between treatment groups were statistically significant for urinary symptoms (p=0.026) and bowel symptoms (p=0.046). However, it was 
not stated in the study on which time point or time period this difference between treatment arms was statistically significant. No other subscales of the QLQC30 and -PR25. The 
authors wrote that they found “(…) significant differences between proton and carbon ion therapy in urinary and bowel symptoms (urinary P=.026; bowel P=.046). Bowel symp-
tom increases were statistically significant at the end of therapy (t1) compared to initial values but were improved in the sixth week follow-up (t2) (P=.046), indicating a slightly 
better tolerance for carbon ions” [132]. It remains unclear to the authors, whether this difference is the difference between the scores at different time points (depicted above), or 
differences of treatment arms of the changes over time (depicted in Change in HRQoL). 
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First Author  Habl [132] 
  t0: Before 
t1: At the end of PRT/CIRT 
t2: At 6 weeks after therapy 
t3: At 6 months after therapy 
QLQ-C30 tool    
Global health status -8 (p<.001) 1 (p=.6) 2 (p=.3) 
Functional scales    
Physical functioning -3 (p=.008) -2 (p=.030) -2 (p=.2) 
Role functioning -12 (p=.095) -9 (p <.001) -6 (p=.010) 
Emotional functioning -1 (p=.4) 4 (p=.027) 4 (p=.013) 
Cognitive functioning -1 (p=.4) -2 (p=.2) -2 (p=.034) 
Social functioning -8 (p<.001) -3 (p=.3) -2 (p=.3) 
Symptom scales  
Fatigue 15 (p<.001) 7 (p<.001) 6 (p<.001) 
Nausea and vomiting 1 (p=.08) 0 (p=1) 1 (p=.1) 
Pain 13 (p<.001) 5 (p=.023) 5 (p=.061) 
Dyspnea -1 (p=.7) 3 (p=.058) 2 (p=.1) 
Insomnia 3 (p=.5) 2 (p=1) 3 (p=.7) 
Appetite loss 7 (p<.001) 2 (p=.047) 2 (p=.025) 
Constipation 6 (p=.023) 2 (p=.3) -1 (p=.6) 
Diarrhoea 11 (p<.001) 3 (p=.094) 3 (p=.2) 
Financial difficulties 3 (p=.3) 1 (p=.6) -2 (p=.3) 
PR25 tool    
Symptom scales    
Urinary 23 (p<.001) 10 (p<.001) 5 (p=.071) 
Bowel 6 (p<.001) 3 (p=.007) 2 (p=.045) 
Treatment-related 2 (p=.027) 3 (p=.005) 4 (p=.001) 
Functional scales    
Sexual activity -11 (p<.001) -1 (p=.6) -1 (p=.7) 
Sexual functioning -6 (p=.067) -4 (p=.060) -3 (p=.3) 
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First Author  Habl [132] 
Safety 
Toxicity No statistically significant differences in toxicity profiles between arms were found. 
The incidence of acute 
adverse events (≤6 
months) 
  CTCAE Version 4.02 Protons (n=46) C-ions (n=45) 
Proctitis Grade 1  
Grade 2 
Grade 3 
Grade 4 
6 (13.0%)  
4 (8.7%)  
2 (4.3%)52  
0 (0%) 
5 (11.1%)  
1 (2.2%)  
0 (0%)  
0 (0%) 
Diarrhoea Grade 1  
Grade 2 
Grade 3 
Grade 4 
28 (60.9%)  
4 (8.7%)  
0 (0%) 
0 (0%) 
25 (55.6%)  
0 (0%)  
0 (0%) 
0 (0%) 
Cystitis Grade 1  
Grade 2 
Grade 3 
Grade 4 
18 (39.1%)  
10 (21.7%)  
0 (0%) 
0 (0%) 
13 (28.9%)  
6 (13.3%)  
0 (0%) 
0 (0%) 
Others  No other toxicities occurred/were reported No other toxicities occurred/were reported 
Late radiation morbidity  NR 
Abbreviations: ADT – Androgen Deprivation Therapy; CIRT – carbon ion radiotherapy; HRQoL – Health-Related Quality of Life; PRT – proton radiotherapy; SFR – Secure Feasibility Rate 
 
 
                                                             
52 The grade 3 toxicities were rectum fistula. 
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Table A-2: Carbon ion radiotherapy (CIRT) for cancers in the bone and soft tissue region:  
Results from observational studies 
First Author Sugahara [126] 
Year 2012 
Country Japan 
Cancer Therapy Center  Heavy Ion Medical Accelerator in Chiba (HIMAC) 
Sponsor Research Project with Heavy Ions at National Institute of Radiological Sciences 
(NIRS) – Heavy Ion Medical Accelerator in Chiba (HIMAC) 
Sample Size 17 
CIRT Sample 17 
Time Frame of Patient 
Enrolment  
April 2000 – May 2010 
Study Type Observational 
Study Design Prospective case series, dose escalation study 
The Phase of Clinical Trial Phase 1/2 
Intervention CIRT: 16 fixed fractions over 4 weeks at a mean dose of 67.9GyE: 
52.8 GyE (3.3 GyE/fr.) in 1 pt 
64.0 GyE (4.0 GyE/fr.) in 3 pts 
70.4 GyE (4.4 GyE/fr.) in 13 pts 
Previous treatment: 
Patients with recurrent resection (n=8): surgical resection alone in three 
patients and surgical resection followed by chemotherapy in five pts. 
Chemotherapy for 10 pts with grade ≥2 tumours more than 4 weeks prior to 
radiation therapy. 
Control - 
Age in Years (Unit of Central 
Tendency, Range) 
53 (median; range: 14–87 years) 
Sex, Female (%) vs. Male (%) 5 (29) vs. 12 (71) 
P
at
ie
n
t 
P
o
p
u
la
ti
o
n
 
Indication Localised primary sarcoma of the extremities (medically inoperable or declined 
surgery) 
Histology Bone tumour (n = 4) 
Osteosarcoma: 3 pts 
Chondrosarcoma: 1 pt 
Soft tissue tumour (n = 13) 
Synovial sarcoma: 2 pts 
Rhabdomyosarcoma: 2 pts 
Liposarcoma: 2 pts 
Pleomorphic sarcoma: 2 pts 
Myxofibrosarcoma: 1 pt 
Fibrosarcoma: 1 pt  
Spindle cell sarcoma: 1 pt 
Leiomyosarcoma: 1 pt 
ASPS: 1 pt 
Tumour Site Upper limbs: 4 pts 
Lower limbs: 13 pts 
Tumour Stage/TNM 
Classification 
Histological grade: 
Bone tumours (n=4): 
Grade 1: 2 pts 
Grade 2: 0 pt 
Grade 3: 2 pts 
Soft tissue tumour (n = 13) 
Grade 1: 0 pt 
Grade 2: 5 pts 
Grade 3: 8 pts 
Tumour Status  Primary tumours: 9 pts 
Recurrent tumours: 8 pts 
Follow-Up in Months (Unit of 
Central Tendency; Range) 
37 (median; range: 11–97 months) 
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First Author Sugahara [126] 
The Loss to Follow Up NR 
Methods & Statistical Analysis  “Survival time and local control time were defined as the interval between the 
initiation of CIRT and the date of death or the date of diagnosis of local failure, 
respectively. The cut-off date for the analysis was April 30, 2011. The survival and 
local control curves were generated by the Kaplan–Meier method using SPSS 
software 
(SPSS Inc., Chicago, IL, USA)”. 
Outcomes 
Efficacy 
Overall Survival (OS)  
in % (95% CI) 
68% (95% CI: 42–86%) at 3 years 
56% (95% CI: 29–80%) at 5 years 
Cause-Specific Survival (CSS)  
in % (95% CI) 
- 
Disease-Free Survival (DFS)  
in % (95% CI) 
- 
Recurrence-Free Survival (RFS) 
in % (95% CI) 
- 
 
Progression-Free Survival (PFS) 
in % (95% CI) 
- 
Local Control Rate (LCR)  
in % (95% CI) 
76% (95% CI: 51–93%) at 3 years 
76% (95% CI:51–93%) at 5 years 
Health-Related Quality of Life 
(HRQOL) 
- 
Safety 
A
cu
te
 
R
ad
ia
ti
o
n
 
M
o
rb
id
it
y Criteria 
Classification 
CTCAE v3.0 
Cases/n (Gr.1 (%)/Gr.2 (%)/Gr.3 (%)/Gr.4 (%)) 
 Skin: 16/17 [16 (94)/0 (0)/0 (0)/0 (0)] 
The authors stated that there were no other acute reactions 
 Criteria  
Classification 
CTCAE v3.0 
La
te
 R
ad
ia
ti
o
n
 
M
o
rb
id
it
y 
Criteria  CTCAE v3.0 
1 pt with Skin toxicities (Grade 2) 
4 pts had neurological toxicity (Grade 2) 
3 pts had lower limb tumours 
1 pt had an upper limb tumour 
1 pt with a femoral fracture (Grade 3) 
The authors stated that there were no other observed severe reactions (grade ≥3). 
Abbreviations: CIRT – carbon ion radiotherapy; CTCAE – Common Terminology Criteria for Adverse Events; fr. – fraction; 
Gr. – Grade; GyE – Gray Equivalent; pt – patient; pts – patients. 
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Table A-3: Carbon ion radiotherapy (CIRT) for cancers in the brain region: Results from observational studies 
First Author Mizoe [68] Hasegawa [69] 
Year 2007 2012 
Country Japan Japan 
Cancer Therapy Centre  Heavy Ion Medical Accelerator in Chiba (HIMAC) Heavy Ion Medical Accelerator in Chiba (HIMAC) 
Sponsor National Institute of Radiologic Sciences-Heavy 
Ion Medical Accelerator in Chiba (NIRS-HIMAC). 
NR 
Sample Size 48 14 
CIRT Sample 48 14 
Time Frame of Patient Enrolment Between October 1994 and February 2002 Between October 1994 and February 2002 
Study Type Observational Observational 
Study Design Prospective case series53 Dose-escalation, prospective 53case series study 
The Phase of Clinical Trial Phase 1/2 Phase 1/2 
Intervention X-RAY radiotherapy + Chemotherapy + CIRT: 
X-Ray: 50 GyE/25 fractions/5 weeks 
CIRT: 16.8-24.8GyE/8 fractions/2 weeks 
Chemotherapy: ACNU 
Co-interventions: 
All patients underwent surgical intervention prior 
to treatment54 
CIRT: total dose ranging from 46.2-55.2 GyE (24 fractions over 6 weeks) 
low-dose group (n=9):46.2 GyE for 2 pts and 50.4 GyE for 7 pts 
high-dose group (n=5): 55.2 GyE 
Surgical intervention prior to CIRT: 
gross total resection for 1 pt;  
partial resection for 6 pts 
biopsy for 5 pts 
Salvage treatment: Chemotherapy in 2 pts; operation in 6 pts; RT in 1 pt. 
Control - - 
Age in Years (Unit of Central Tendency, Range) 53 (median, range: 18–78) 32.5 (median, range: 18-66) 
Sex, Female (%) vs. Male (%) 19 (40) vs. 29 (60) 5 (36) vs. 9 (64) 
                                                             
53 Enrolment was judged to be prospective. 
54 Extent of surgical resection: Gross total in 8 patients (17%), subtotal in 8 patients (17%), partial in 27 patients (56%), and biopsy in 5 patients (10%). 
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First Author Mizoe [68] Hasegawa [69] 
P
o
p
u
la
ti
o
n
 
Indication Anaplastic astrocytoma, Glioblastoma multiforme Diffuse astrocytoma 
Histology Anaplastic astrocytoma (AA): 16 (33%) 
Glioblastoma multiforme (GBM): 32 (67%) 
Diffuse astrocytoma 
Tumour site Tumour location  
Frontal: 22 pts (46%) 
Temporal: 10 pts (21%) 
Parietal: 5 pts (10%) 
Occipital: 6 pts (13%) 
Others: 5 pts (10%)55 
Tumour location: 
Frontal: 4 pts 
Frontal/temporal: 3 pts 
Temporal: 1 pt 
Occipital/parietal: 2 pts 
Others: 4 pts 
Tumour stage (WHO classification) WHO grade III (anaplastic astrocytoma) + WHO 
grade IV tumours (glioblastoma multiforme) 
Grade II (WHO) 
Follow-Up in Months (Unit of Central Tendency; Range) NR 62 (mean, range: 10-152) 
Loss to Follow-Up n (%) NR NR 
Methods & Statistical Analysis The Kaplan-Meier Method was used for survival 
rates and local control.56 
The Kaplan-Meier Method was used for survival  
rates and local control.56 
Outcomes 
Efficacy 
Overall Survival (OS) in % (95% CI) NR57 43% (95% CI: NR, SEM: 13%) at 5 years 
36% (95% CI: NR, SEM: 13%) at 10 years 
Cause-Specific Survival (CSS) in % (95% CI) - - 
Disease-Free Survival in % (95% CI) - - 
Recurrence-free Survival(RFS) in %(95% CI) - - 
Progression-Free Survival (PFS)in % (95% CI) NR58 36% (95% CI: NR; SE: 13%) at 5 years 
low dose: 11% (95% CI: NR; SEM: 11%) 
high dose: 80% (95% CI: NR; SEM: 18%) at 5 years 
Local Control Rate (LCR)in % (95% CI) - - 
Health-Related Quality of Life (HRQOL) - - 
                                                             
55 Others = thalamus (2 patients), putamen (1 patient), corpus callosum (1 patient), and cerebellum (1 patient). 
56 Further analysis was undertaken in both studies including univariate and multivariate analysis [68]. Predictor variables were, inter alia, age and sex in both studies. However,  
no comparison to conventional radiotherapy was undertaken. A log-rank test was used to elaborate the differences between survival probabilities [68]/prognostic factors [69]. 
57 However, the median survival time (MST) was measured: MST (AA): 35 months; MST (GBM): 17 months. 
58 The progression free survival (PFS) in % was not reported in this study, but the median progression free survival time was measured: AA: 18 months; GBM: 7 months. 
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First Author Mizoe [68] Hasegawa [69] 
Safety 
A
cu
te
 R
ad
ia
ti
o
n
 M
o
rb
id
it
y 
Criteria RTOG RTOG 
Cases/n [(Gr.1 (%)/Gr.2 (%)/Gr.3 (%)/Gr.4 (%)] 59 
Region Unspecified - Grade ≤1: 12 (86%) 
Grade 2: 2 (14%) 
Grade 3: 0 
Grade 4: 0 
Skin 36/48 [27 (56)/9 (19)/0 (0)/0 (0)] - 
White Blood Cells 37/48 [6 (13)/11 (23)/17 (35)/3 (6)] - 
Phatelet 33/48 [7 (15)/17 (35)/6 (13)/3 (6)] - 
Brain 6/48 [6 (13)/0 (0)/0 (0)/0 (0)] - 
Others No other toxicities occurred/were reported. No other toxicities occurred/were reported. 
La
te
 R
ad
ia
ti
o
n
  
M
o
rb
id
it
y 
Criteria RTOG/EORTC (+LEnT-SOMA) RTOG/EORTC 
Cases/n [(Gr.1 (%)/Gr.2 (%)/Gr.3 (%)/Gr.4 (%)] Cases/n [(Gr.1 (%)/Gr.2 (%)/Gr.3 (%)/Gr.4 (%)] 
Skin 1/48 [1 (2)/0 (0)/0 (0)/0 (0)] 1/12 [1 (7)/0 (0)/0 (0)/0 (0)] 
Brain RTOG/EORTC 
11/48 [7 (15)/4 (8)/0 (0)/0 (0)] 
Brain (MR by LENT/SOMA)  
14/48 [ 10 (21)/4 (8)/0 (0)/0 (0)] 
10/1260 [8 (66.7)/2 (16.7)/0 (0)/0 (0)] 
Others No other toxicities occurred/were reported. No other toxicities occurred/were reported. 
Abbreviations: AA – anaplastic astrocytoma; CIRT – carbon ion radiotherapy; EORTC – European Organisation for Research and Treatment of Cancer; fr. – fraction; 
 GBM – glioblastoma multiforme; Gr. – Grade; GyE – Gray Equivalent; LENT-SOMA – Late Effects Normal Tissue Task Force Subjective, Management Analytic, Objective;  
pt – patient; pts – patients; RTOG – Radiation Therapy Oncology Group; WHO – World Health Organisation 
 
 
                                                             
59 The format of reporting on acute radiation morbidities Cases/n [(Gr.1 (%)/Gr.2 (%)/Gr.3 (%)/Gr.4 (%)] was not used for this study since the study did not separate  
grade 0 and grade 1 acute radiation morbidities. 
60 2 patients dropped out because of local recurrence within 3 months after carbon ion radiotherapy. 
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Table A-4: Carbon ion radiotherapy (CIRT) for cancers in the Ear-Nose-Throat (ENT) region: Results from observational studies 
First Author Jensen [85] Jingu [86] Mizoe [33] Shirai [31] Schulz-Ertner [87] 
Year 2015 2012 2012 2017 2005 
Country Germany Japan Japan Japan Germany 
Cancer Therapy Centre (s) Heidelberg Ion Beam 
Therapy Centre (HIT) 
Heavy Ion Medical 
Accelerator in Chiba (HIMAC) 
Heavy Ion Medical Accelerator  
in Chiba (HIMAC) 
Gunma University Heavy 
Ion Medical Center (GHMC) 
Heidelberg Ion Beam 
Therapy Centre 
Sponsor NR NR NR NR Tumor Center 
Heidelberg/ 
Mannheim 
Sample Size 5461 27 236 35 63 
CIRT Sample 54 27 236 35 29 
Time Frame of Patient 
Enrolment 
Between July 2010 and 
August 2011 
Between April 2001 and 
February 2008 
Between April 1997 and 
February 2006 
Between June 2010 and 
November 2014 
Between June 1995 and 
December 2003 
Study Type Observational Observational Observational Observational Observational 
Study Design Dose-escalation study, 
prospective case series study 
Prospective case series 
(including a comparative 
historical control62) 
Prospective Case series Prospective Case series Case-control study 
The Phase of Clinical Trial Phase 2 NR Phase 2 NR NR 
Intervention (I) Raster Scanned carbon ion 
boost (CIB) immediately 
followed by Intensity-
modulated Radiation Therapy 
(IMRT) over 7 weeks: 
CIB (5-6 fractions/week):  
24 Gy(RBE) in 3 Gy (RBE)  
per fraction 
IMRT(5 fractions/week):  
50Gy IMRT in 2 GyE per 
fraction 
Co-intervention: 
Prior Surgery in 37 pts 
CIRT at a total dose of  
70.4 GyE/16 fractions (fr)  
in 4.4 GyE per fraction. 
Co-interventions: NR 
CIRT: 64.0 GyE/16 fractions/ 
4 weeks  
(57.6 GyE/16 fractions/ 
4 weeks in case a wide range  
of skin was included in the 
target volume) 
Co-intervention: 
Post operation (PO) in 52 pts 
Post chemotherapy (PC)  
in 27 pts 
PC+PO in 8 pts 
CIRT: 64.0 Gy (RBE)/16 
fractions for 32 pts (91%) 
and 57.6 Gy (RBE)/16 
fractions for 3 pts (9%) 
Co-interventions: no other 
RT of head and neck;  
no chemotherapy at least  
1 month before CIRT (history 
of chemotherapy: NR) 
Photons + CIRT:  
A median tumour dose  
of 72 GyE  
(54 Gy with photons and  
18 GyE with C-ions) for  
29 patients. 
Co-intervention: surgery 
prior to CIRT63;  
salvage therapy in 2 pts  
(re-irradiation) 
                                                             
61 1 person was, but not considered to be, lost to follow-up.  
62 The study included a statistical analysis using a historical control. However, the purpose may have primarily been to demonstrate which dose is superior/inferior,  
since the study used as a comparison included patients receiving CIRT as well. 
63 Partial resection in 20 patients; biopsy in 7 patients; recurrence in 2 patients: perineural tumour spread in 8 patients. 
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First Author Jensen [85] Jingu [86] Mizoe [33] Shirai [31] Schulz-Ertner [87] 
Control (C) - - - - Photon RT: FSRT (n=13)  
or IMRT (n=21) with a 
median tumour dose of 66 
Gy (range: 54.0 –70.4 Gy) 
for 34 patients 
Co-intervention: 
surgery64 
Age in Years (Unit of Central 
Tendency, Range) 
58 (median, range: 25-74) 46.2 (mean, range: 17–78) 56.5 (median, range: 16–80) 59 (median, range: 31-77) I: 56 (median, range:  
25–76); C: 56 (median, 
range: 22–78) 
Sex, Female (%) vs. Male (%) NR 14 (52) vs. 13(48) 111 (47) vs. 125 (53) 20 (57) vs. 15 (43) 33 (52) vs. 30 (48); 
P
at
ie
n
t 
P
o
p
u
la
ti
o
n
 
Indication Malignant Salivary Gland 
Tumours 
Resectiom status: 
R1: microscopically in-
complete resections (n=20) 
R2: gross residual disease 
(n=17) 
inoperable disease (n=16) 
Unresectable adult bone and 
soft-tissue sarcoma of the 
head and neck 
Head and neck carcinoma Non-squamous cell 
carcinoma of the head  
and neck 
Locally Advanced 
Adenoid 
Cystic Carcinoma of 
Salivary Gland65 
Histology Adenoid cystic carcinoma: 
47 pts (89%) 
Mucoepidermoid: 3 pts (6%) 
Adeno: 1 pt (2%) 
Squamous cell carcinoma:  
1 pt (2%) 
Not otherwise specified:  
1 pt (2%) 
Osteosarcoma: 9 pts 
Malignant Fibrous 
Histiocytoma: 5 pts 
Hemangioperisarcoma:3 pts 
Myxoid fibrous sarcoma: 2 pts 
Leiomyosarcoma: 2 pts 
Chondrosarcoma: 2 pts 
PNET: 1 pt 
Fibrosarcoma: 1 pt 
Small round cell sarcoma: 1 pt 
Spindle cell sarcoma: 1 pt 
Mucosal malignant melanoma: 
85 pts 
Adenoid cystic carcinoma: 69 pts 
Adenocarcinoma:27 pts 
Sarcomas: 14 pts 
Papillary adenocarcinoma: 13 pts 
Squamous cell carcinoma: 12 pts 
Mucoepidermoid carcinoma: 7 pts 
Myoepithelial carcinoma 3 pts 
Odontogenic clear cell 
carcinoma: 1 pt 
Malignant pleomorphic 
adenoma: 1 pt 
Cylindrocelluar carcinoma:1 pt 
Undifferentiated carcinoma: 1 pt 
Sebaceous carcinoma: 1 pt 
Acinic cell carcinoma: 1 pt 
Adenoid cystic carcinoma:  
21 pts (60%) 
Olfactory neuroblastoma:  
5 pts (14%) 
Mucoepidermoid carcinoma: 
4 pts (11%) 
Adenocarcinoma: 2 pts (6%) 
Others: 3 pts (9%) 
12 pts diagnosed with the 
cribriform subtype,  
1 pt was diagnosed with a 
tubular tumour,  
7 pts had solid tumours,  
12 pts presented with 
tumours of mixed 
histology, and  
31 pts with no histologic 
subclassification 
performed 
                                                             
64 Resection status: Partial resection in 17 patients; biopsy in 16 patients; recurrence in 1 patient; perineural tumour spread in 6 patients. 
65 Only patients were considered with “macroscopic tumour residual after resection, inoperable tumors, or recurrent tumors” [87]. 
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First Author Jensen [85] Jingu [86] Mizoe [33] Shirai [31] Schulz-Ertner [87] 
Tumour Site The base of skull 2 pts (4%)  
External auditory canal  
1 pt (2%)  
Lacrimal gland/lacrimal duct  
3 pts (6%) 
Maxilla 1 pt (2%)  
Nasopharynx 5 pts (9%)  
Palate 7 pts (13%)  
Paranasal sinus 18 pts (34%) 
Parotid 7 pts (13%)  
Petrous bone 1 pt (2%)  
Submandibular gland  
8 pts (15%) 
Nasal and paranasal: 11 pts 
Maxillary bone: 8 pts 
Mandibular bone: 2 pts 
Skull base: 2 pts 
Parapharyngeal space: 1 pt 
Temporal: 1 pt 
Frontal bone: 1 pt 
Parotid gland: 1 pt 
Paranasal sinus: 60 pts 
Nasal cavity: 56 pts 
Salivary gland: 30 pts 
Oral cavity: 26 pts 
Pharynx: 23 pts 
Orbita: 20 pts 
Thyroid: 11 pts 
Ears: 5 pts 
Temporal bone: 2 pts  
Maxillar bone: 2 pts  
Mandibular bone: 1 pt 
 
Maxillary sinus: 9 pts (26%) 
Nasal cavity: 9 pts (26%) 
Parotid gland: 6 pts (17%) 
Oral cavity: 5 pts (14%) 
Pharynx: 4 pts (11%) 
External auditory canal:  
2 pts (6%) 
- 
Tumour Stage Tumour stage 
T1: 1 pt (2%) 
T2: 7 pts (13%) 
T3: 12 pts (23%) 
T4a: 12 pts (23%) 
T4b: 17 pts (32%) 
T4c: 1 pt (2%) 
T4 unspecified: 1 pt (2%) 
Unknown: 1 pt (2%) 
No TNM: 1 pt (2%) 
N+: 6 pts (11%) 
M1: 7 pts (13%) 
Histopathological grade 
(UICC-2002) 
Grade 1–2 (low): 16 pts 
Grade 3–4 (high): 10 pts 
Unknown: 1 pt 
Tumour stage for 149 (63%)*  
T1/N0: 3 pts 
T2/N0: 22 pts 
T3/N0: 25 pts; T3/N1: 2 pts; 
T3/N2: 2 pts;  
T4/N0: 79 pts; T4/N1: 12 pts; 
T4/N2: 4 pts 
Tumour stage 
T2/N0: 5 pts (14%) 
T3/N0: 8 pts (23%) 
T4/N0: 22 pts (63%) 
T (tumour) 
All but 3 patients had 
tumours infiltrating the 
skull base (T4), and the 
remaining 3 patients had 
T3 tumours infiltrating  
the orbits. 
N (node status): 
Positive lymph node status:  
I: 2/29 
C: 5/34 
M1: 
I: 2/29  
C: 3/34 
Follow-Up in Months (Unit 
of Central Tendency; Range) 
42.0 (median, range:  
11.4-53.1) 
37.0 (median, range: 
4.1-73.0) 
54 (mean, range: 3-162) 39 (median, range: 6–70). I: 16 (median, range:  
2–60), C: 24  
(median, range: 2–92) 
The Loss to Follow-Up n (%) NR NR NR NR NR 
Methods The Kaplan-Meier Method 
was used for survival rates 
and local control. 
“Log-rank test; Chi-square 
and Kruskal-Wallis tests 
were used to compare 
groups for nominal and 
ordinal variables. All tests 
were 2-tailed (level of 
significance: <0.05)” 
The Kaplan-Meier Method 
was used for survival rates 
and local control. 
Log-rank test for differences 
between survival rates (level 
of significance: <0.05) 
The Kaplan-Meier Method  
was used for survival rates  
and local control. 
Log-rank test for differences 
between survival rates (level  
of significance: <0.05) 
The Kaplan-Meier Method 
was used for survival rates 
and local control. 
Log-rank test for differences 
between survival rates (level 
of significance: <0.05) 
HRQoL: SF-8 
The Kaplan-Meier 
product-limit Method 
was used for survival 
rates and local control. 
Log-rank test for 
differences between 
survival rates (level of 
significance: <0.05) 
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First Author Jensen [85] Jingu [86] Mizoe [33] Shirai [31] Schulz-Ertner [87] 
Outcomes 
Efficacy 
Overall Survival (OS) in % 
(95% CI) 
78.4% (95% CI: NR) at 3 years 
R1: 79.2% (95% CI: NR)  
at 3 years  
R2: 87.5% (95% CI: NR)  
at 3 years  
inoperable: 74.5%  
(95% CI: NR) at 3 years 
Difference: n. s. 
74.1% (95% CI: 57.5–90.6%) 
at 3 years 
57.6% (95% CI: 33.7–81.4%) 
at 5 years 
47% (95% CI: NR, SE: 3.2%) at 
5 years (68% for adenoid 
cystic carcinoma, 56% for 
adenocarcinoma and 35% for 
malignant melanoma) 
88% (95% CI: 77–99%) at  
3 years (T2: 100%; T3: 88%; 
T4: 85%) 
Maxillary sinus/nasal cavity 
(n=18): 88%  
Oral cavity/pharynx (n=9): 
100% 
Parotid gland (n=6): 100% 
External auditory canal 
(n=2): 0% 
I: 86.6% at 2 years and 
75.8% at 4 years 
C: 77.9% at 2 years and 
77.9% at 4 years 
Diff.: n. s. (p=0.64;  
log-rank test) 
Cause-Specific Survival (CSS) - - - - - 
Disease-Free Survival in % 
(95% CI) 
- - - - I: 71.5% at 2 years and 
53% at 4 years 
C: 69.2% at 2 years and 
23.6% at 4 years 
Diff.: n. s. (p= 0.19;  
log-rank test) 
Recurrence-Free 
Survival(RFS) in %(95% CI) 
- - - - - 
Progression-Free Survival 
(PFS) 
57.9% (95% CI: NR) at 3 years 
(median time: 42.3 months) 
R1: 64.6% (95% CI: NR) at  
3 years  
R2: 58.8% (95% CI: NR) at  
3 years  
inoperable: 49.2%  
(95% CI: NR) at 3 years  
Difference: n. s. 
- - 71% (95% CI: 56–86%) at  
3 years (T2:100%; T3: 63%; 
T4: 68%) 
- 
Local Control Rate (LCR) 84.3% (95% CI: NR) at 2 years 
81.9% (95% CI: NR) at 3 years 
R1:89.7% (95% CI: NR) at  
3 years  
R2: 86.9% (95% CI: NR) at  
3 years  
inoperable: 75.0%  
(95% CI: NR) at 3 years  
Difference: n. s. 
91.8% (95% CI: 81.0–100%) 
at 3 years 
80.4% (95% CI: 57.3–100%) 
at 5 years 
68% (95% CI: NR, SE: 3.5%)  
at 5 years 
75% for the 85 pts with 
malignant melanoma,  
73% for the 69 pts with 
adenoid cystic carcinoma,  
73% for the 27 pts with 
adenocarcinoma,  
61% for the 13 pts with 
papillary adenocarcinoma,61% 
for the 12 pts with squamous 
cell carcinoma and 24% for the 
14 pts with sarcomas. 
93% (95% CI: 84–100%) at 
3 years (T2: 100%; T3: 86%; 
T4: 94%) 
Maxillary sinus/nasal cavity 
(n=18): 93% 
Oral cavity/pharynx  
(n=9): 100%  
Parotid gland (n=6): 83% 
External auditory canal 
(n=2): – 
Locoregional control 
(LRC): 
I: 77.5% at 2 years and 
77.5% at 4 years 
C: 72.2% at 2 years and 
24.6% at 4 years 
Diff.: n. s.  
(p=0.08; log-rank test) 
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First Author Jensen [85] Jingu [86] Mizoe [33] Shirai [31] Schulz-Ertner [87] 
H
ea
lt
h-
R
el
at
ed
 Q
ua
lit
y 
of
 L
if
e 
(H
R
Q
O
L)
 
Pre-Interventional - - - SF-8 
Before CIRT:  
PCS: 46.9 (1.7) 
MCS: 40.8 (1.8)  
- 
Postinterventional - - - NR - 
Short-Term(<6 weeks) - - - 1 month:  
PCS: 42.3 (1.6) (n. s.) 
MCS: 41.1 (1.6) (n. s.) 
- 
Mid-Term  
(>6weeks- ≤ 6 months) 
- - - 3 months: 
PCS: 46.1 (1.3) (n. s.) 
MCS: 45.0 (1.6) (n. s.) 
6 months:  
PCS: 46.0 (1.2) (n. s.) 
MCS: 45.9 (1.7) (s. s.)66 
 
Longer Term  
(>6 months):  
Mean Score  
(Standard Deviation) 
   12 months:  
PCS: 46.9 (1.3) 
MCS: 47.3 (1.4) (s. s.). 
24 months:  
PCS: 48.4 (1.2)  
MCS: 48.4 (1.6) (s. s.) 
- 
Safety 
A
cu
te
 R
ad
ia
ti
o
n
 M
o
rb
id
it
y 
Criteria CTCAE version 3 National Cancer Institute-
Common Toxicity Criteria, 
version 2.0 
RTOG CTCAE version 4.0 CTCAE version 3 
 Cases/n [Gr.1 (%)/Gr.2 (%)/ 
Gr.3 (%)/Gr.4 (%)] 
Cases/n [Gr.1 (%)/Gr.2 (%)/ 
Gr.3 (%)/Gr.4 (%)] 
Cases/n [(Gr.1 (%)/Gr.2 
(%)/Gr.3 (%)/Gr.4 (%)] 
 
Mucosa At completion: 
Mucosities67:  
Grade 1: 15 (28%)  
Grade 2: 21 (40%)  
Grade 3: 14 (26%) 
Mucous membrane: 
27/27 [8 (29.6)/17 (63)/1 (3.7)/ 
0 (0)] 
 
196/223 [91 (41)/81 (36)/24 (11)/ 
0 (0)] 
Mucositis:  
23/35 [NR/15 (43%)/8 (23%)/ 
0 (0%)] 
I: Mucosities  
Grade 1: NR  
Grade 2: NR  
Grade 3: 2 (6.5%)  
local bacterial infection 
after RT: 2 (6.5%) 
                                                             
66 Score is statistically significantly different to baseline score, with p<0.05. The author's interpretation of this difference was by stating that the patients possibly had fear and  
anxiety due to the treatment before the therapy being improved after the therapy. No analysis including fear or anxiety as variables in their analysis was undertaken [31]. 
67 The study [85] also measured on acute radiation morbidities after 6-8 weeks with selectively reporting on the grade of the morbidities: Mucositis (grade 1):4 (8%);  
hyperpigmentation (grade 1): 9 (17%); dysphagia (grade 1): 6 (11%) weight loss: 8 (15%); xerostomia (grade 1): 37 (70%); xerostomia (grade 2): 6 (11%); Impairment of taste 47 (89%); 
middle ear effusion: 12 (23%); otitis: 2 (4%);hearing impairment: 3 (6%); trismus: 9 (17%); facial nerve paralysis: 1 (2%); xerophthalmia: 5 (9%); epiphora: 3 (6%); keratitis: 1 (2%); 
conjunctivitis: 2 (4%); lymphedema: 10 (19%); tissue defect (Tx response): 1 (2%). 
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First Author Jensen [85] Jingu [86] Mizoe [33] Shirai [31] Schulz-Ertner [87] 
Mucosa 
(continuation) 
    C: Mucosities  
Grade 0: NR  
Grade 1: NR  
Grade 2: NR 
Grade 3: 11 (32.3%) 
Skin Dermatities  
Grade 1: 40 (75%)  
Grade 2: 8(15%)  
Grade 3: 3 (6%) 
 
25/27 [19 (70.4)/6 (22.2)/0 (0)/ 
0 (0)] 
 
220/236 [115 (49%)/90 (38%)/ 
15 (6%)/0 (0)] 
 
11/35 [NR/11 (31%)/0 (0%)/ 
0 (0%)] 
NR 
Others  At the completion of CIRT67: 
Epitheliolysis: 11 (21%);  
Dysphagia: 18 (34%)  
Grade 1, 10 (19%) Grade 2;  
Dysphagia preexistent/ 
postoperatively: 4 (8%); 
Weight loss: 41 (77%); 
feeding tube (PEG): 4 (8%); 
Xerostomia: 28 (53%)  
Grade 1 and 6 (11%) Grade 2; 
Loss of taste: 47 (89%); 
Middle ear effusion: 16 (30%); 
Otitis: 1 (2%); 
Hearing impairment: 3 (6%); 
Trismus: 13 (25%); 
Trismus postoperatively/ 
due to tumour: 10 (19%); 
Facial nerve paralysis: 1 (2%); 
Facial nerve paralysis 
postoperatively: 1 (2%); 
Xerophthalmia: 5 (9%); 
Conjunctivitis 2: (4%); 
Paresthesia: 3 (6%); 
Paresthesia postoperatively:  
1 (2%) 
Lymphedema: 2 (4%) 
Rhinitis: 1 (2%) 
- - Conjunctivitis 
5/35 [NR/5 (14)/0 (0)/0 (0)] 
Dysgeusia  
1/35 [NR/1 (3)/0 (0)/0 (0)] 
NR 
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First Author Jensen [85] Jingu [86] Mizoe [33] Shirai [31] Schulz-Ertner [87] 
La
te
 R
ad
ia
ti
o
n
 M
o
rb
id
it
y 
Criteria CTCAE version 368 RTOG/EORTC or LENT-SOMA RTOG/EORTC CTCAE version 4.0 CTCAE version 3 
 Cases/n (Gr.1 (%)/Gr.2 
(%)/Gr.3 (%)/Gr.4 (%)) 
Cases/n (Gr.1 (%)/Gr.2 
(%)/Gr.3 (%)/Gr.4 (%)) 
Cases/n (Gr.1 (%)/Gr.2 
(%)/Gr.3 (%)/Gr.4 (%)) 
Cases/n (Gr.1 (%)/Gr.2 
(%)/ Gr.3 (%)/Gr.4 (%)) 
Mucosa - Mucous membrane 
9/26 [9 (34.6%)/0 (0)/ 
0 (0)/0 (0)] 
47/223 [43 (19)/4 (2)/0 (0)/ 
0 (0)] 
Mucositis  
12/35 [NR/11 (31%)/1 (3%)/ 
0 (0)] 
NR 
Skin - 6/26 [6 (23%)/0 (0)/0 (0)/ 
0 (0)] 
108/236 [101 (43%)/7 (3%)/ 
0 (0)/0 (0%)] 
Dermatitis  
0/35 [NR/0 (0)/0 (0)/0 (0)] 
NR 
Others  Dysphagia: 3 (6%) Grade 2;  
Odynophagia: 3 (6%);  
Xerostomia: 26 (49%) Grade 
1, 1 (2%) Grade 2; 
Impairment of taste: 5 (9%);  
Middle ear effusion: 6 (11%);  
Hearing impairment: 13 (25%);  
Hearing loss: 1 (2%); 
Vestibular problems: 2 (4%);  
Trismus: 8 (15%);  
Facial nerve paralysis: 1 (2%); 
Anosmia: 1 (2%); 
Xerophthalmia: 2 (4%); 
Epiphora: 4 (8%);  
Lacrimal duct stenosis: 3 (6%); 
Enophthalmos: 1 (2%); 
Paresthesia: 1 (2%);  
Fatigue: 2 (4%);  
Blood brain barrier changes 
(CNS necrosis) 3 (6%) Grade 1; 
Meningitis: 1 (2%);  
Loss of teeth: 1 (2%); 
Osteoradionecrosis: 2 (4%);  
Lymphedema: 5 (9%); 
Tissue defect: 2 (4); 
Tissue necrosis: 1 (2%) ; 
Impaired healing: 2 (4%);  
Hemorrhage: 1 (2%) Grade 4; 
Rhinitis sicca: 2 (4%);  
Pain: 3 (6%) 
Brain 
5/26 [5 (19.2)/1 (3.8)/0 (0)/ 
0 (0)] 
Eye 
2/26 [0 (0)/1 (3.8)/0/1 (3.8)] 
Bone 
6/26 [1 (3.8)/1 (3.8)/ 
4 (15.4)/0 (0)] 
No other toxicities 
occurred/were reported 
No other toxicities 
occurred/were reported 
Conjunctivitis  
1/35 [NR/1 (3%)/0 (0%)/0 (0)] 
Dysgeusia  
2/35 [NR/2 (6%)/0 (0)/0 (0)] 
Brain necrosis  
2/35 [NR/2 (6%)/0 (0)/0 (0)] 
Cataract  
2/35 [NR/0 (0)/2 (6)/0 (0)] 
Visual impairment  
5/35 [NR/2 (6%)/1 (3%)/2 
(6%)] 
Trismus  
3/35 [NR/3 (9%)/0 (0%)/ 
0 (0%)]  
Otitis media  
5/35 [NR/5 (14)/0 (0)/0 (0)] 
Olfactory nerve disorder  
4/35 [NR/4 (11)/0 (0)/0 (0)] 
No other toxicities 
occurred/were reported 
I: 1/NR 
(NR/NR/NR/1/NR) 
No other toxicities  
were reported 
Abbreviations: CIB – Carbon Ion Boost; CIRT – Carbon Ion Radiotherapy; CTCAE – Common Terminology Criteria for Adverse Events; EORTC – European Organisation for Research and 
Treatment of Cancer; fr. – fraction; Gr. – Grade; GyE – Gray Equivalent; LENT-SOMA – Late Effects Normal Tissue Task Force Subjective, Objective, Management Analytic;  
n.s. – not statistically significant; pt – patient; pts – patients; RTOG – Radiation Therapy Oncology Group; s. s. – statistically significant; v. – version. 
                                                             
68 The authors did not stringently report on the grade of the morbidities. The reader is referred to the “others” section of this table below. 
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Table A-5: Carbon ion radiotherapy (CIRT) for cancers in the gastrointestinal (GI) region: Results from observational studies 
First Author Akutsu [106] Yamada [107] 
Year 2012 2016 
Country Japan Japan 
Cancer Therapy Centre  Heavy Ion Medical Accelerator in Chiba (HIMAC) Heavy Ion Medical Accelerator in Chiba (HIMAC) 
Sponsor Research Project with Heavy Ions at NIRS-HIMAC and 
21st Century COE Project of Japanese Ministry of Education, 
Culture Sports, Science and Technology for Chiba University 
Research Project with Heavy Ions of the 
National Institute of Radiological Sciences in Japan. 
Sample Size 31 18469 
CIRT Sample 31 184 
Time Frame of Patient Enrolment Between July 2004 and June 2008 From April 2001 to August 2012 
Study Type Observational Observational 
Study Design Prospective, dose escalation, case series study Prospective, dose escalation, case series & nonrandomised,  
open-label, single-centre, case series study 
The Phase of Clinical Trial Phase 1/2 Phase 1 & Phase 2 
Intervention Neoadjuvant CIRT: 8 fractions over 2 weeks 
Dose escalation: from 28.8 GyE in 5% increments up to 36.8 GyE 
when no severe adverse events (CTCAE grade3 and more) were 
observed. 
Co-intervention: surgery 
CIRT: 16 fractions in 4 weeks  
Dose escalation (n=37): 67.2 to 73.6 Gy (RBE); RBE-weighted 
absorbed dose: 4.2 to 4.6 Gy (RBE)/fraction 
Phase 2 (n=143) trial: 70.4 GyE and 73.6 GyE for 4 and  
139 patients respectively 
Co-intervention: primary tumour operation before CIRT70 
Control (C) - - 
Age in Years (Unit of Central Tendency, Range) 65.4 (mean; range: NR, SD: 7.1) 61.3 (median, range: 37-79) 
Sex, Female (%) vs. Male (%) 6 (19) vs. 25 (81) 127 (71) vs. 53 (29) 
P
o
p
u
la
ti
o
n
 
Indication Thoracic esophageal squamous cell carcinoma (ESCC) Locally recurrent rectal cancer 
Histology Well-differentiated SCC: 3 
Moderately differentiated SCC: 22 
Poorly differentiated SCC: 4 
Unclear: 2 
Well-differentiated adenocarcinoma: 58 (32%) 
Moderate: 111 (62%) 
Poor: 4 (2%); Mucinous: 6 (3%) 
Adenosquamous: 1 (1%) 
Tumour Site Upper thoracic: 3 
Middle thoracic: 18 
Lower thoracic: 10 
Presacral: 70 (39%) 
Sidewall: 77 (43%) 
Perineal: 28 (16%) 
Perianastomosis: 5 (3%) 
                                                             
69 184 pts with 190 lesions and the study excluded 4 patients due to pretreatmeant subarachnoid or distant metastasis.. 
70 According to the patient characteristics table provided, some information on previous treatments could have been retrieved: abdominoperineal excision in 92 pts (51%) pts;  
low anterior resection in 83 pts (46%); Hartmann’s resection in 3 pts (2%); “other” in 3 pts (2%). 
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First Author Akutsu [106] Yamada [107] 
Tumour Stage/TNM Classification T category 
T1: 12 
T2: 8 
T3: 11 
N category 
N0: 22 
N1: 8 
N2: 1 
N3: 0 
Stage grouping 
Stage I: 10 
Stage II: 14 
Stage III: 7 
Tumour stage/TNM classification: NR 
Tumour size (in cm): 
Range: 1.0-14.0 
Average: 3.4 (SD: 1.4) 
Follow-Up in Months (Unit of Central 
Tendency; Range) 
NR 42 (median; range: 7-131) 
The Loss to Follow-Up n (%) NR NR 
Outcomes 
Efficacy 
Overall Survival (OS) in % (95% CI) All patients: NR 
Stage 1 cases: 
91%(95% CI: NR) at 1 year 
81% (95% CI: NR) at 3 years 
61%(95% CI: NR) at 5 years 
Stage 2 cases: 
100%(95% CI: NR)at 1 year 
85% (95% CI: NR) at 3 years 
77%(95% CI: NR) at 5 years 
Stage 3 cases: 
71% (95% CI: NR)at 1 year 
43%(95% CI: NR) at 3 years 
29%(95% CI: NR) at 5 years 
All patients: 
72% (95% CI: 66%-79%) at 3 years 
53% (95% CI: 45%-62%) at 5 years 
Within the phase 2 study at 73.6 GyE (n=139): 
91% (95% CI: NR) at 2 years 
59% (95% CI: 50%-68%) at 5 years 
Within the dose-escalation part of the study (n=37):  
20%-78% (depending on the dose of CIRT) 
Cause-Specific Survival (CSS) in % (95% CI) All patients: 
97% (95% CI: NR) at 1 year 
79% (95% CI: NR) at 3 years 
71% (95% CI: NR) at 5 years 
Stage 1 cases: 
100% (95% CI: NR) at 1 year 
90% (95% CI: NR) at 3 years 
90% (95% CI: NR) at 5 years 
Stage 2 cases: 
100% (95% CI: NR) at 1 year 
85% (95% CI: NR) at 3 years 
77% (95% CI: NR) at 5 years 
- 
  
C
arb
o
n
 io
n
 b
eam
 rad
io
th
erap
y (C
IR
T
) fo
r can
cer treatm
en
t 
16
8
 
LB
I-H
T
A
 | 20
18
 
First Author Akutsu [106] Yamada [107] 
Cause-Specific Survival (CSS) in % (95% CI) 
(continuation) 
Stage 3 cases: 
83% (95% CI: NR) at 1 year 
50% (95% CI: NR) at 3 years 
33% (95% CI: NR) at 5 years 
 
Disease-Free Survival (DFS) in % (95% CI) - - 
Recurrence-Free Survival (RFS)/ 
Recurrence-Free Survival (RFS) in % 
(95% CI) 
All patients: 
87% (95% CI: NR) at 1 year 
62% (95% CI: NR) at 3 years 
62% (95% CI: NR) at 5 years 
Stage 1 cases: 
100% (95% CI: NR) at 1 year 
80%(95% CI: NR) at 3 years 
80% (95% CI: NR) at 5 years 
Stage 2 cases:  
92% (95% CI: NR) at 1 year 
69% (95% CI: NR) at 3 years 
69% (95% CI: NR) at 5 years 
Stage 3 cases: 
51% (95% CI: NR) at 1 year 
17% (95% CI: NR) at 3 years 
17% (95% CI: NR) at 5 years 
- 
Progression-Free Survival (PFS)in % (95% CI) - - 
Local Control Rate (LCR)in % (95% CI) - Overall 5-year LCR: 
35% for 10 pts at 67.2 Gy (RBE) (95% CI: 2%-76%),  
77% for 19 pts at 70.4 Gy (RBE) (95% CI: 49%-91%)  
88% for 151 pts at 73.6 Gy (RBE) (95% CI: 80%-93%) 
Health-Related Quality of Life (HRQOL) - - 
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First Author Akutsu [106] Yamada [107] 
Safety 
A
cu
te
 R
ad
ia
ti
o
n
 M
o
rb
id
it
y Criteria CTCAE v. 3.0 CTCAE v. 3.0 
  Cases/n [Gr.1 (%)/Gr.2 (%)/Gr.3 (%)/Gr.4 (%)] Cases/n [Gr.1 (%)/Gr.2 (%)/Gr.3 (%)/Gr.4 (%)] 
  Toxicities71 including operative complications were observed 
within 90 days after the onset of the first treatment 
Oesophagus 31/31 [19 (61.3)/12 (38.7)/0 (0)/0 (0)] 
Skin 27/31 [27 (87.1)/0 (0)/0 (0)/0 (0)] 
Respiratory 1/31 [0 (0)/0 (0)/1 (3.2)/0 (0)] 
Blood 6/31 [4 (12.9)/2 (6.4)/0 (0)/0 (0)] 
Within the Phase 2 Study (n=143) using the NCI-CTC ≤ 3 months 
Skin: 117/143 [112 (78.3)/5 (3.5)/0 (0)/0 (0)]  
GI: 3/143 [0 (0)/3 (2.1)/0 (0)/0 (0)] 
Urinary: 0/143 [0 (0)/0 (0)/0 (0)/0 (0)] 
Within the Phase 1/2 (n=37) part of the study 
Skin: 22/37 [20 (54)/2 (5.4)/0 (0)/0 (0)]  
GI tract: 1/37 [0 (0)/1 (2.7)/0 (0)/0 (0)]  
Urinary: 0/37 [0 (0)/0 (0)/0 (0)/0 (0)] 
La
te
 R
ad
ia
ti
o
n
 M
o
rb
id
it
y Criteria CTCAE v. 3.0 RTOG/EORTC 
Cases/n [Gr.1 (%)/Gr.2 (%)/Gr.3 (%)/Gr.4 (%)] Cases/n [Gr.1 (%)/Gr.2 (%)/Gr.3 (%)/Gr.4 (%)] 
  No Toxicities including operative 
complications were observed after the 91st day from 
the first treatment (data not shown in the study). 
Within the Phase 2 Study (n=143) 
Skin: 66/143 [64 (44.8)/0 (0)/2 (1.4)/0 (0)] 
GI tract: 3/143 [1 (0.6)/1 (0.6)/1 (0.6)/0(0)] 
Urinary: 2/143 [1 (0.6)/1 (0.6)/0 (0)/0 (0)] 
Phase 1/2 (n=37) 
Skin: 15/37 [14 (37.8)/1 (2.7)/0 (0)/0 (0)] 
GI tract: 1/37 [0 (0)/1 (2.7)/0 (0)/0 (0)] 
Urinary: 0/37 [ 0 (0)/0 (0)/0 (0)/0 (0)] 
Abbreviations: CIRT – Carbon Ion Radiotherapy; CTCAE – Common Terminology Criteria for Adverse Events; fr. – fraction; GI – gastrointestinal; Gr. – Grade; GyE – Gray Equivalent;  
LCR – Local Control Rate; n.s. – not statistically significant; pt – patient pts – patients; RBE – relative biological effectiveness; RTOG – Radiation Therapy Oncology Group;  
s. s. – statistically significant; TNM – Tumour Node Metastases; v. – version. 
 
                                                             
71 The authors did not explicitly report on grade 4 radiation morbidities. It was assumed that no grade 4 radiation morbidities occurred since the authors wrote that only 1 radiation 
morbidity “exceeded” grade 3. It was assumed that the respiratory grade 3 radiation morbiditiy was hereby meant by the authors. 
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Table A-6: Carbon ion radiotherapy (CIRT) for cancers in the lung region: Results from observational studies 
First Author Iwata[100] Iwata[99] Miyamoto[102] Miyamoto[101] Takahashi [98] Yamamoto[97] 
Year 2010 2013 2007a 2007b 2015 2017 
Country Japan Japan Japan Japan Japan Japan 
Cancer Therapy Center Hyogo Ion 
Beam Medical Center 
(HIBMC) 
Hyogo Ion 
Beam Medical Center 
(HIBMC) 
Heavy Ion Medical 
Accelerator in Chiba 
(HIMAC) 
Heavy Ion Medical 
Accelerator in Chiba 
(HIMAC) 
Heavy Ion Medical 
Accelerator in Chiba 
(HIMAC) 
Heavy Ion Medical 
Accelerator in Chiba 
(HIMAC) 
Sponsor Japanese Ministry of 
Education, Culture, 
Sports, Science, and 
Technology 
NR National Institute of 
Radiological Sciences 
(NIRS) under its research 
project on heavy ions at 
NIRS-HIMAC 
National Institute of 
Radiological Sciences 
(NIRS) under its research 
project on heavy ions at 
NIRS-HIMAC 
NR NIRS 
Sample Size 80 70 7972 5073 62 218 
CIRT Sample 23 27 79 50 62 218 
Time Frame of  
Patient Enrolment 
April 2003 to  
April 2007 
April 2003 to  
December 2009 
From December 2000 
to November 2003 
April 1999 and 
December 2000 
May 2000 to  
February 2013 
Between April 2003 and 
February 2012 
Study Type Observational Observational Observational Observational Observational Observational 
Study Design Case-control study Case-control study Prospective case series74 Prospective Case series74 Dose-escalation and pro-
spective case series study 
Dose-escalation pro-
spective case series study 
Phase of Clinical Trial NR NR Phase 2 Phase 1/2 Phase 1/2 Phase 1/2 
Intervention (I) CIRT: 52.8 GyE/4 Fr.  
for 23 pts 
Co-intervention:  
none reported 
CIRT:  
52.8 GyE/4 fr. for 16 pts; 
66 GyE/10 fr. for 8 pts; 
68.4 GyE/9 fr. for 3 pts 
Co-intervention:  
none reported 
CIRT in four fractions 
during 1 week: 
52.8 GyE/4fr for  
stage IA NSCLC  
60.0 GyE/4fr for stage 
IB NSCLC 
Co-intervention:  
none reported 
CIRT: A fixed total dose 
of 72 GyE/9fr at a 
fraction dose of 8GyE 
over 3 weeks 
Co-intervention:  
none reported 
CIRT:  
Phase 1 (dose escalation, 
n=36): 68 to 72 GyE and 
then to 76 GyE, using 16 
fractions over 4 weeks  
Phase 2 (n=26): 72 GyE 
using 16 fractions over  
4 weeks 
Co-intervention: 
Neoadjuvant therapy (not 
within 1 month of CIRT) 
and salvage chemotherapy 
after recurrence/ 
metastases, with 5 and 3 
patients undergoing those 
therapies respectively. 
CIRT (single-fraction): 
28-50GyE 
Co-intervention:  
none reported 
                                                             
72 79 patients with 80 primary lesions. 
73 1 patient died before the start of CIRT. 50 patients with 51 lesions. 
74 Enrolment judged to be prospective. 
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First Author Iwata[100] Iwata[99] Miyamoto[102] Miyamoto[101] Takahashi [98] Yamamoto[97] 
Control (C) PRT: 80 GyE/20 Fr. for 
20 pts and 60 GyE/10 Fr. 
for 37 pts 
Co-intervention:  
none reported 
PRT: 
70.2GyE/26 fr. for 1 pts; 
66 GyE/10 fr. for 8 pts; 
60 GyE/10 fr. for 20 pts; 
80 GyE/20 fr. for 14 pts 
Co-intervention:  
none reported 
- - - - 
Age in Years  
(Unit of Central 
Tendency, Range) 
All: 76 (median, range: 
48-89)75 
CIRT-sample: 75 (54-89) 
75 (median, range:  
57-92)76 
74.8 (average, range: 
47–88) 
74.1 (average, range:  
61 -84) 
76 (median, range:  
46-88) 
75 (median, range:  
46-89) 
Sex, Female (%)  
vs. Male (%) 
23 (28.8) vs. 57 (71.2) 19 (27.1) vs. 51 (72.9) 25 (31.6) vs. 54 (68.4) 12 (24) vs. 38 (76) 14 (23) vs. 48 (77) 61 (28) vs. 157 (72) 
P
at
ie
n
t 
P
o
p
u
la
ti
o
n
 
Indication Non-Small-Cell Lung 
Cancer (NSCLC) 
Non-Small-Cell Lung 
Cancer (NSCLC) 
Non-Small-Cell Lung 
Cancer (NSCLC) 
Non-Small-Cell Lung 
Cancer (NSCLC) 
Locally Advanced 
Non-Small Cell Lung 
Cancer (NSCLC) 
Non-Small-Cell Lung 
Cancer (NSCLC) 
Histology Squamous cell 
carcinoma: 27 pts 
Adenocarinoma: 47 pts 
Others: 6 pts 
Squamous cell 
carcinoma: 21 pts 
Adenocarinoma: 39 pts 
Others: 10 pts 
Adenocarinoma: 53 pts 
Squamous cell 
carcinoma: 24pts 
Large-cell carcinoma: 2pt 
adenosquamous 
carcinoma: 1pt 
Adenocarinoma: 32 pts 
Squamous cell 
carcinoma: 19 pts 
Squamous cell  
carcinoma 33 (53%) 
Adenocarinoma 25 (40%) 
Large-cell carcinoma 3 (5%) 
Non–small cell lung cancer, 
not otherwise specified 1 
(2%) 
Squamous cell  
carcinoma: 68 pts 
Adenocarinoma: 146 pts 
Large-cell carcinoma: 3 pts  
Mucoepidermoid 
carcinoma: 1 pt 
Tumour Site - - - - - - 
Tumour 
Stage/TNM 
Classification 
UICC 6th Edition (2002)77 UICC 7th Edition77 UICC (Edition: NR)77 UICC (Edition: NR)77 UICC 7th edition77 UICC 6th edition77 
42 (52.5%) stage IA pts 
(T1N0M0) 
38 (47.5%) stage IB pts 
(T2N0M0) 
CIRT (52.8 GyE/4 fr.): 
15 stage IA pts (T1N0M0) 
8 stage IB pts (T2N0M0) 
PRT (80 GyE/20 fr.): 
6 stage IA pts 
14 stage IB (T2N0M0) 
PRT (60 GyE/10 fr.): 
21 stage IA pts (T1N0M0) 
16 stage IB (T2N0M0) 
47 (67%) stage IB pts 
(T2aN0M0) pts  
23 (33%) stage IIA 
(T2bN0M0) pts 
42 (53%) stage IA pts 
37 (47%) stage IB pts 
29 (58%) stage IA pts 
(with 30 lesions) 
21 (42%) stage IB pts 
17 (27%) stage IIA pts 
22 (35%) stage IIB pts 
23 (37%) stage IIIA pts 
Tumour stage: 
123 (56%) stage IA pts 
(45 T1a , 78 T1b ) 
95 (44%) stage IB pts 
(87 T2a, 8 T2b ) 
                                                             
75 23 CIRT pts (52.8 GyE): 75 (54-89); 20 PRT pts (receiving 80 GyE): 75 (48-87); 37 PRT pts (receiving 60 GyE): 78 (57-87). 
76 47 T2aN0M0 pts: 75 (57–87); 23 T2bN0M0 pts: 76 (60–92). 
77 For more information on the UICC criteria, see https://www.uicc.org/resources/tnm (download on 10.12.2017). 
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First Author Iwata[100] Iwata[99] Miyamoto[102] Miyamoto[101] Takahashi [98] Yamamoto[97] 
Follow-Up in Months 
(Unit of Central 
Tendency; Range) 
30.5 (median, range:  
4-66) 
44 (median, range:  
4–103) 
38.6 (median, range: 
2.5-72.2) 
59.2 (median, range: 
6.0–83.0) 
25.2 (1.6 - 157.2) 57.8 (median, range:  
1.6-160.7) 
Loss to Follow-Up n (%) NR NR NR NR NR NR 
Methods The Kaplan-Meier 
Method was used for 
survival rates and local 
control. 
Log-rank test for 
differences between 
survival rates (level of 
significance: <0.05) 
The Kaplan-Meier 
Method was used for 
survival rates and local 
control. 
Log-rank test for 
differences between 
survival rates (level of 
significance: <0.05) 
The Kaplan-Meier 
Method was used for 
survival rates and local 
control. 
Log-rank test for 
differences between 
survival rates (level of 
significance: <0.05)78 
The Kaplan-Meier 
Method was used for 
survival rates and local 
control. 
Log-rank test for 
differences between 
survival rates (level of 
significance: <0.05)78 
The Kaplan-Meier 
Method was used for 
survival rates and local 
control. 
Wilcoxon test for 
differences between 
survival rates of different 
tumour stage (N-stage) 
groups78 (level of 
significance: <0.05) 
The Kaplan-Meier 
Method was used for 
survival rates and local 
control. 
Log-rank test for 
differences between 
survival rates (level of 
significance: <0.05)78. 
Outcomes 
Efficacy 
Overall Survival (OS) 
in % (95% CI) 
75% (95% CI: 64%-86%; 
stage IA: 74%;  
IB: 76%) at 3 years 
There were no 
significant differences  
in the treatment results 
among the 3 protocols 
CIRT (52.8 GyE/4 Fr): 86% 
(95% CI: NR) at 3 years 
PRT (80 GyE/20 Fr): 90% 
(95% CI: NR) at 3 years 
PRT (60 GyE/10): 61% 
(95% CI: NR) at 3 years 
58% (95% CI: 46%-70%; 
IB: 53%; IIA: 67%)  
at 4 years 
There were no 
significant differences  
in OS between PRT and 
CIRT patients79 
45% (95% CI: NR)  
at 5 years 
IA: 62% (95% CI: NR)  
at 5 years 
IB: 25% (95% CI: NR)  
at 5 years 
50.0% (95% CI: NR)  
at 5 years 
IA 55.2 (95% CI: NR)  
at 5 years 
IB: 42.9 (95% CI: NR)  
at 5 years 
77.2% (95% CI:  
66.7%-87.7%) at 1 year 
51.9% (95% CI:  
39.2%-64.5%) at 2 years 
68.3% (95% CI: NR)  
at 3 years 
49.4% (95% CI: NR)  
at 5 years 
Cause-Specific Survival 
(CSS) in % (95% CI) 
86% (95% CI, 77%-95%; 
IA: 84%; IB: 88%)  
at 3 years80 
- 68% (95% CI: NR)  
at 5 years 
IA: 87% (95% CI: NR)  
at 5 years 
IB: 42% (95% CI: NR) 
at 5 years 
75.7% (95% CI: NR)  
at 5 years 
IA: 89.4 (95% CI: NR)  
at 5 years 
IB: 55.1 (95% CI: NR)  
at 5 years 
71.7% (95% CI: NR)  
at 2 years 
- 
                                                             
78 The results regarding statistical significance of those potential differences was not extracted since it was only tested whether patients with different characteristics or tumour 
stage had statistically significant differences in survival, i.e. overall survival (OS), or local tumour control (LCR) and no comparison between OS or LCR of CIRT patients and 
OS or LCR of patients undergoing another therapy was compared statistically. 
79 Survival and local control rates of the patients undergoing CIRT or PRT were not reported. 
80 Results/differences between different therapy groups were not reported. 
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First Author Iwata[100] Iwata[99] Miyamoto[102] Miyamoto[101] Takahashi [98] Yamamoto[97] 
Clinical Recurrence-Free 
Survival (CRFS) in % 
(95% CI) Biochemical 
Recurrence-Free Survival 
(BRFS)in % (95% CI) 
- - - - - - 
Disease-Free Survival 
(DFS) in % (95% CI) 
54% (95% CI: 43%-68%; 
IA: 67%; IB: 46%)  
at 3 years 
- - - 35.7% (95% CI: NR)  
at 2 years 
 
Recurrence-Free Survival 
(RFS) in % (95% CI) 
      
Progression-Free 
Survival (PFS)in % 
(95% CI) 
- 46% (95% CI: 33%-59%; 
IB: 43%; IIA: 52%), 
52%) at 4 years 
There were no significant 
differences in PFS be-
tween PRT and CIRT pts79 
- - - NR81 
Local Control Rate 
(LCR) in % (95% CI) 
82% (95% CI,72%-92%: 
IA: 87%; IB: 77%)  
at 3 years 
Differences between 
treatment results among 
the 3 protocols n. s.: 
CIRT (52.8 GyE/4 Fr): 
86% (95% CI: NR)  
at 3 years 
PRT (80 GyE/20 Fr): 
83% (95% CI: NR)  
at 3 years 
PRT (60 GyE/10): 81% 
(95% CI: NR) at 3 years 
75% (95% CI: 63%-86%; 
IB: 70%; IIA: 84%)  
at 4 years 
There were no significant 
differences between 
PRT and CIRT79 
90% (95% CI: NR)  
at 5 years 
IA 97% (95% CI: NR)  
at 5 years 
IB 80% (95% CI: NR)  
at 5 years 
94.7% (95% CI: NR)  
at 5 years 
IA: NR 
IB: NR 
96.0% (95% CI:  
90.5%-100.0) at 1 year 
93.1% (95% CI:  
85.4%-100.0) at 2 years 
77.9% (95% CI: NR)  
at 3 years 
72.7% (95% CI: NR)  
at 5 years 
Health-Related Quality 
of Life (HRQOL) 
- - - - - - 
                                                             
81 Data on the progression free survival (PFS) in % was not found in the included study. However, the authors stated that PFS was measured in the study [97]. 
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First Author Iwata[100] Iwata[99] Miyamoto[102] Miyamoto[101] Takahashi [98] Yamamoto[97] 
Safety 
A
cu
te
 R
ad
ia
ti
o
n
 M
o
rb
id
it
y 
Criteria CTCAE v.4.0 CTCAE v.4.1 RTOG RTOG CTCAE v.3.0 NCI-CTC 
Cases/n (Gr.1 (%)/Gr.2 
(%)/Gr.3 (%)/Gr.4 (%)) 
Cases/n (Gr.1 (%)/Gr.2 
(%)/Gr.3 (%)/Gr.4 (%)) 
Cases/n (Gr.1 (%)/Gr.2 
(%)/Gr.3 (%)/Gr.4 (%)) 
Cases/n 
(Gr.1/Gr.2/Gr.3/Gr.4) 
Cases/n (Gr.1 (%)/Gr.2 
(%)/Gr.3 (%)/Gr.4 (%)) 
Cases/n (Gr.1 (%)/Gr.2 
(%)/Gr.3 (%)/Gr.4 (%)) 
Lung NR83 NR83 Overall82: 
1/79 [0 (0)/1 (1.3)/ 
0 (0)/0 (0)] 
T1 IA: 0/41 (0 (0)/0 (0)/ 
0 (0)/0) 
T2 IB: 1/38 [0 (0)/1 (2.6)/ 
0 (0)/0 (0)] 
2/51 [1 (1.9)/1 (1.9)/0 
(0)/0 (0)]82  
T1 IA: NR  
T2 IB: NR 
Radiation pneumonitis:  
2/62 [NR/1 (1.6)/1 (1.6)/0] 
See below 
Skin NR83 NR83 Overall82: 
80/80 (75 (93.8)/ 
5 (6.3)/0 (0)/0) 
T1 IA: 42/42 [40 (95.2)/ 
2 (4.8)/0 (0)/0 (0)] 
T2 IB: 38/38 [35 (92.1)/ 
3 (7.9)/0 (0)/0 (0)] 
51/51 [50 (98)/1 (1.9)/ 
0 (0)/0 (0)]82 
T1 IA: NR 
T2 IB: NR 
Radiation dermatitis:  
5/62 [NR/5 (8)/0 (0)/ 
0 (0)] 
See below 
Others NR83 NR83 No other toxicities 
occurred/were reported 
No other toxicities 
occurred/were reported 
No other toxicities 
occurred/were reported 
Not specified:  
215/218 [212 (97.2)/3 
(1.3)/0 (0.0)/(0.0)] 
La
te
 R
ad
ia
ti
o
n
 M
o
rb
id
it
y 
Criteria CTCAE v.4.0 CTCAE v.4.1 RTOG/EORTC RTOG/EORTC RTOG/EORTC RTOG/EORTC 
  Cases/N [Gr.1 (%)/Gr.2 
(%)/Gr.3 (%)/Gr.4 (%)] 
Cases/N [Gr.1 (%)/Gr.2 
(%)/Gr.3 (%)/Gr.4 (%)] 
Cases/N [Gr.1 (%)/Gr.2 
(%)/Gr.3 (%)/Gr.4 (%)] 
Cases/N [Gr.1 (%)/Gr.2 
(%)/Gr.3 (%)/Gr.4 (%)] 
Cases/N [Gr.1 (%)/Gr.2 
(%)/Gr.3 (%)/Gr.4 (%)] 
Cases/N [Gr.1 (%)/Gr.2 
(%)/Gr.3 (%)/Gr.4 (%)] 
Lung Radiation 
pneumonitis83 
CIRT (n=23) 
2/23 [NR/2 (8.7)/ 
0 (0.0)/0 (0.0)] 
PRT (n=57) 
8/57 [NR/7 (12.3)/ 
1 (1.8)/0 (0.0)] 
Radiation 
pneumonitis83 
12/70 [NR/10 (14.3)/ 
2 (2.9)/0 (0)]84 
IB NSCLC pts (n=47) 
7/47 [NR/7 (14.9%)/ 
0 (0.0%)/0 (0.0%)] 84 
IIA NSCLC pts (n=23) 
5/23 [NR/3 (13%)/ 
2 (8.7%)/0 (0.0%)) 
Overall8285 
70/76 [69 (90,8)/1 
(1.3)/0 (0)/0 (0)] 
IA: 36/40 [35 (90)/ 
1 (2.5)/0 (0)/0 (0)] 
IB: 34/36 [34 (94.4)/ 
0 (0)/0 (0)/0 (0)] 
50/51 [48 (94.1)/2 
(3.9)/0 (0)/0 (0)]82 
IA: NR 
IB: NR 
3/62 [NR/3 (4.8)/0 (0)/0 
(0)] 
See below 
                                                             
82 The denominator refers to the number of lesions of the included patients. 
83 The authors stated that most of the toxicities occurred in the late phase. However, the time frame was unclear and it remained unclear whether those radiation morbidities  
occurred in the acute or late phase. 
84 Toxicities of the patients undergoing CIRT or PRT were not reported. 
85 A clinical assessment of lung and skin reaction was conducted in 76 and 77 patients respectively. 3 patients were lost to observation. 
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First Author Iwata[100] Iwata[99] Miyamoto[102] Miyamoto[101] Takahashi [98] Yamamoto[97] 
Skin 83 
CIRT pts (n=23) 
2/23 (NR/2 (8.7)/0 
(0.0)/0 (0.0)) 
PRT pts (n=57) 
11/57 (NR/8 (14.0)/3 
(5.3%)/0 (0)) 
15/70 [NR/10 (14.3)/ 
4 (5.7)/1 (1.4)] 84 
IB NSCLC (n=47) 
10/47 [NR/7 (14.9%)/ 
3 (6.4%)/0 (0)] 
IIA NSCLC pts (n=23) 
5/23 [NR/3 (13%)/ 
1 (4.4%)/1 (4.4%)] 
Overall 82 85 
77/77 [76 (98.7)/1 (1.3)/ 
0 (0)/0 (0)] 
IA: 40 [40 (100)/0 (0)/ 
0 (0)/0 (0)]  
IB: 37 [36 (97.3)/ 
1 (2.7)/0 (0)/0 (0)] 
 
51/51 [(49 (96)/1 (1.9)/1 
(1.9)/0 (0)]82 
IA: NR 
IB: NR 
 
1/62 [NR/1 (1.6)/0 (0)/0 
(0)] 
See below 
Others 23% had a grade 2 rib 
fracture and Gr. 2 soft tis-
sue AE occurred in 6%83 
No other toxicities 
occurred/were reported 
No other toxicities 
occurred/were reported 
No other toxicities 
occurred/were reported 
No other toxicities 
occurred/were reported 
Oesophagus: 1/62 (2) 
(NR/0/1/0) 
No other toxicities 
occurred/were reported 
208/212[207 (97.6%)/ 
1 (0.4)/0 (0.0)/0 (0.0)] 
No other toxicities 
occurred/were reported 
Abbreviations: CIRT – Carbon Ion Radiotherapy; CTCAE – Common Terminology Criteria for Adverse Events; EORTC – European Organisation for Research and Treatment of Cancer; fr. – 
fraction; Gr. – Grade; GyE – Gray Equivalent; n.s. – not statistically significant; NCI-CTC – National Cancer Institute-Common Toxicity Criteria; NR – not reported; OS – overall survival; 
PFS – Progression-Free Survival; pt – patient; pts – patients; RTOG – Radiation Therapy Oncology Group; s. s. – statistically significant; TNM – Tumour Node Metastases; UICC – Union 
Internationale Contre le Cancer; v. – version 
 
Table A-7: Carbon ion radiotherapy (CIRT) for cancers in the prostate region: Results from observational studies (part 1) 
First Author  Ishikawa [133] Ishikawa [139] Nikoghosyan [136] Maruyama [134] 
Year  2015 2006 2011 2017 
Country Japan Japan Germany Japan 
Cancer Therapy Centre (s) Gunma University Heavy Ion 
Medical Center (GHMC) 
Heavy Ion Medical Accelerator 
in Chiba (HIMAC) 
Gesellschaft für Schwerionen-
forschung (GSI) in Darmstadt 
Heavy Ion Medical Accelerator 
in Chiba (HIMAC) 
Sponsor Ministry of Education,  
Culture, Sports, Science, and 
Technology of Japan. 
Scientific Research from  
the Ministry of Education, 
Culture, Sports, Science and 
Technology of Japan 
European Network for  
light ion hadrontherapy 
(ENLIGHT) with EU support 
Japan Society for the Promotion 
of Science (JSPS) 
Sample Size 76 175 14 417 
Time Frame of Patient Enrolment Between March 2010 and 
February 2011 
Between April 2000 and 
November 2003, 
Between 1997 and 2007 Between April 2000 and  
January 2007 
Study Design Before-after study;  
feasibility study 
Case series, feasibility study Prospective case series: Interim 
report of acute side effects of 
intermediate-risk PC 
Before-after study 
The Phase of Clinical Trial Phase 2 Phase 2 Phase 1/2 N.A. 
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First Author  Ishikawa [133] Ishikawa [139] Nikoghosyan [136] Maruyama [134] 
Intervention CIRT: 57.6 GyE/16 fractions over 
4 weeks (with a fractional dose of 
3.6 GyE for 4 fractions per week) 
Co-Intervention: Androgen 
deprivation therapy (ADT) 
Intermediate- and high-risk groups 
received neoadjuvant ADT for  
6 months before the start of  
C-ion RT. Adjuvant ADT without 
antiandrogens was continued 
only for high-risk patients, in 
whom ADT was administered for 
24 months. If patients with T1c-
T2b disease had a GS of 7 (3+4) 
and iPSA value <10 ng/mL, they 
were considered to have 
intermediate-risk cancer but 
received C-ion RT without ADT. 
CIRT: 66.0 GyE/20 fractions over 
5 weeks (fraction dose: 3.3 GyE) 
Co-intervention: 
androgen deprivation therapy 
(ADT) for high-risk patients 
(n=142), consisting of medical or 
surgical castration with or without 
anti-androgen. Length of neo-
adjuvant ADT: 2-6 months before 
CIRT; length of adjuvant ADT: 
≥12months (median time: 
22months [range: 1-57 months]. 
IMRT+CIRT: photon IMRT 
with a total target dose of 60 Gy 
prescribed to the median dose of 
the planning target volume (PTV, 
weekly fractionation 5 x 2.0 Gy) 
and a carbon ion boost with a 
total boost dose of 18 GyE 
(weekly fractionation 6 x 3 GyE) 
to the prostate (gross target 
volume = GTV). 
Co-intervention: Adjuvant 
hormonal therapy (6-42 months) 
CIRT: Total dose of 63–66 Gray-
equivalents (GyE) in 20 
fractions over 5 weeks 
Co-intervention: Androgen 
deprivation therapy (ADT) 
Intermediate-risk group: 6 
months of ADT + 2-6 months of 
neoadjuvant therapy. 
High-risk group: 24 months of 
ADT + 2-6 months of 
neoadjuvant therapy. 
Control (C) - - - - 
Age in Years  
(Unit of Central Tendency, Range) 
66 (median, range: 53-88) 70 (median, range: 53–83) 68 (median, range 55 – 75) 69 years (median, range: 47–92) 
Sex, Female (%) vs. Male (%) Male Male Male  Male 
P
at
ie
n
t 
P
o
p
u
la
ti
o
n
 
Indication/Risk Group Patients were stratified into  
three (3) risk groups: 
low-risk: T1–T2a, initial prostate-
specific antigen (iPSA) < 10 ng/mL, 
and Gleason sum (GS) ≤6  
(n=3 [4%]) 
intermediate-risk: not low-risk 
and not highrisk (n=29 [38%]) 
high-risk: T2c–T3b or iPSA  
≥20 ng/mL or GS≥8 (n=40 [53%]) 
Castration resistant (n=4) 
Patients were stratified into  
two (2) groups: 
low risk: T1/T2aN0M0 with an 
iPSA < 20 ng/mL and a  
GS <7 (n=33) 
high risk: T2b/T3 or  
iPSAP ≥20 ng/mL or  
GS ≥7 (n=142) 
Intermediate-risk prostate 
cancer: (PSA between 10.1 ng/mL 
and 20 ng/mL or at least T2b 
tumour or a Gleason Score of at 
least 7), no distant metastases 
intermediate and 
high-risk prostate cancer 
Initial PSA (ng/mL) <10.00: 41 (54%)  
10.00-19.99: 16 (21%) 
≥20.00: 19 (25%) 
-19.9: 100 (57%)  
20.0–49.9: 46 (26%)  
50.0+: 29 (21%) 29 (17%) 
<10.00: 0 (0%)  
10.00-19.99: 14 (100%)  
≥20.00: 0 (0%) 
Median PSA:  
14.0 ng/mL  
(range: 2.1–260) 
Gleason Score <6: 4 (5%)  
7 (3+4): 23 (30%) 
7 (4+3): 19 (25%) 
≥8: 30 (40%) 
Gleason sum: 4–5: 19 (11%)  
6: 35 (20%)  
7: 80 (46%)  
8–9: 41 (23%) 
<6: 0 (0%)  
7: 9 (64%)  
8: 4 (29%)  
9: 1 (7%) 
≤6: 119 (28.5)  
7: 183 (43.9)  
≥8: 115 (27.6) 
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First Author  Ishikawa [133] Ishikawa [139] Nikoghosyan [136] Maruyama [134] 
Tumour Stage/TNM Classification 23 (30%)T1c pts 
16 (21%)T2a-b pts 
10 (13%)T2c pts 
24 (32%)T3a pts 
2 (3%)T3b pts 
1 (1%)T4 pts 
56 (32%) T1 pts with 22 (67%) 
and 34 (24%) in the low and 
high risk group respectively. 
24 (14%) T2a pts with 11 (33%) 
and 13 (9%) in the low and high 
risk group respectively 
29 (16%) T2b pts with 0 (0%) 
and 29 (20%) in the low and 
high risk group respectively 
66 (38%) T3 with 0 (0%) and 66 
(47%) in the low and high risk 
group respectively 
4 T1c pts 
4 T2a pts 
3 T2b pts 
2 T2c pts 
1 T3 pt 
109 (26.1%) ≤T1c pts 
87 (20.9%) T2a pts 
81 (19.4%) T2b pts 
140 (33.6%) T3a–b pts 
Follow-Up in Months  
(Unit of Central Tendency; Range) 
51 (median time, range: 8-58) 46 (median time, range: NR) 28 (median, range: 12 – 36) 60 (NR, range: NR) 
The Loss to Follow-Up n (%) NR NR NR NR 
Methods Survival rates: NR 
Change in QoL: Physical 
Component Summary (PCS) and 
Mental Component Summary 
(MCS) using the Japanese version 
of SF-8 questionnaire before, 
immediately after completion, at 
3 and 12 months after CIRT 
Statistical analysis: Linear 
mixed models for comparison 
of the scores at different time 
points (not further specified) 
Survival rates: Kaplan–Meier 
method (comparison:  
log-rank tes; s. s. with p<0.05) 
QoL: FACT-G and FACT-P 
before, immediately after and  
1 year after CIRT  
(further statistical analysis: NR) 
 HRQOL: Japanese Version of the 
Functional Assessment of Cancer 
Therapy-General (FACT-G) and for 
prostate Cancer Patients (FACT-P) 
questionnaire (measured 
immediately before (t1), after 
(t2) and after 12 (t3), 36 (t4) and 
60 (t5) months after CIRT. 
Statistical analysis: Paired t-test. 
Statistical significance was set  
at p < 0.05 
Outcomes 
Efficacy 
Overall Survival (OS) in % (95% CI) 97.4% (95% CI: 93.8-100.0%)  
at 4 years 
91% (95% CI: 87-96%) at 4 years 
low-risk group:  
94% (95% CI: 90–98%)  
high-risk group:  
91% (95% CI: 85–96%) 
Actuarial: 100%(95% CI: NR)  
at 3 years 
- 
Cause-Specific Survival (CSS) in % (95% CI) NR 97% (95% CI: 95–100%) at 4 years 
low-risk group:  
100% (95% CI: NR)  
High-risk group:  
97% (95% CI: 95–98%) 
- - 
Disease-Free Survival in % (95% CI) - - - - 
Recurrence-Free survival (RFS) in % (95% CI) NR - - - 
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First Author  Ishikawa [133] Ishikawa [139] Nikoghosyan [136] Maruyama [134] 
Biochemical Recurrence-Free Survival 
(BRFS) in % (95% CI) 
4-year BRF rate:  
94.6% (95% CI: 89.4-99.8%) 
4-year rate bNED:  
88% (95% CI: 83-93%) 
low-risk group: 
87% (95% CI: 77-98%) 
high-risk group: 
88% (95% CI: 82-94%) 
Actuarial three year 
biochemical relapse-free 
survival: 86% 
- 
Progression-Free Survival (PFS) in % (95% CI) - - - - 
Local Control Rate (LCR) in % (95% CI) NR - - - 
H
ea
lt
h
-R
el
at
ed
 Q
u
al
it
y 
o
f 
Li
fe
 (
H
R
Q
O
L)
 
Instruments 
Results 
Japanese Version of the SF-8 
slight and statistically significant 
(p<0.05) decrease of PCS score 
FACT-G & FACT-P 
No statistically significant 
changes in FACT-G or FACT-P 
scores. 
- FACT-G, FACT-P & TOI 
Short-term: s. s. reduction in 
FACT-P and TOI; no statistical 
difference in FACT-G score 
Long-term: s. s. reduced FACT-P 
& Fact-G score, no statistical 
difference in TOI score  
s. s.= diff to baseline,  
with p<0.05 
Pre-Interventional:  
Mean (Standard Deviation) 
SF-8 
Before CIRT:  
PCS: 51.14 (1.85) 
MCS:49.18 (1.96) 
FACT-G:  
Before CIRT: 89.1 (13.3) 
FACT-P: Before CIRT: 123.1 ± 18.5 
- FACT-G: Before: 84.2 (12.6) 
FACT-P: Before: 119.5 (16.9) 
TOI: Before: 81.8 (12.0) 
Post-Interventional: 
Mean Score (Standard Deviation) 
NR NR - NR 
Short-Term (<6 weeks) 
Mean Score (Standard Deviation)  
SF-8 
After 1 month:  
PCS: 51.14 (1.85) 
MCS: 48.45 (1.96) 
NR - FACT-G: At 1 month: 83.7 (12.9), 
n. s. 
FACT-P: 1 month: 116.2* (17.1), s. s. 
TOI: 1 month: 77.8* (12.1), s. s. 
Mid-Term (>6 weeks – ≤6 months) 
Mean Score (Standard Deviation) 
SF-8 
After 3 months: 
PCS: 50.76 (1.87) 
MCS: 51.63 (1.98) 
NR -  
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First Author  Ishikawa [133] Ishikawa [139] Nikoghosyan [136] Maruyama [134] 
Longer Term (>6 months):  
Mean Score (Standard Deviation) 
SF-8 
After 12 months: 
PCS: 47.71 (1.84)* diff: s. s. 
MCS: 49.75 (1.95) 
FACT-G  
At 1 year after CIRT: 87.3 (15.5)  
Difference to baseline d:  
1.8 (1.1), p=0.1 (n. s.) 
FACT-P 
At 1 year after CIRT: 120.4 ± 21.1 
Difference d:  
2.6 ± 1.4, p = 0.07 (n. s.) 
 FACT-G 
At 12 months: 82.6*86 (13.7), s. s. 
At 36 months: 82.4 (14.3), s. s. 
At 60 months: 82.7* (15.0), s. s. 
FACT-P 
12 months: 116.9* (18.4) s. s.  
36 months: 117.5* (19.3) s. s.  
60 months: 117.6* (20.2) s. s. 
TOI: 
12 months: 80.3 (13.0), n. s. 
36 months: 81.6 (13.7), n. s.  
60 months: 81.4 (14.6), n. s. 
Safety 
A
cu
te
 R
ad
ia
ti
o
n
 
M
o
rb
id
it
y 
Criteria CTCAE Version 4.03 
Cases/Total [Gr.1 (%)/Gr.2 (%)/ 
Gr.3 (%)/Gr.4 (%)] 
RTOG 
Cases/Total [Gr.1 (%)/Gr.2 (%)/ 
Gr.3 (%)/Gr.4 (%)] 
CTCAE Version 3.0 
Cases/Total [Gr.1 (%)/Gr.2 (%)/ 
Gr.3 (%)/Gr.4 (%)] 
- 
Genitourinary (GU) 50/76 [43 (57)/7 (9)/0 (0)/0 (0)] Bladder/urethra:  
57/175 [57 (33)/0 (0)/0 (0)/0 (0)] 
12/14 [7 (50)/5 (35.7)/0 (0)/ 
(0/0)] 
NR 
Gastrointestinal (GI) 1/76 [1 (1)/(0)/0 (0)/0 (0)] Rectum: 
 2/175 [2 (1)/0 (0)/0 (0)/0 (0)] 
5/14 [5 (35)/0 (0)/0(0)/0(0)] NR 
La
te
 R
ad
ia
ti
o
n
 M
o
rb
id
it
y 
Criteria CTCAE Version v. 4.03 
Cases/Total [Gr.1 (%)/Gr.2 (%)/ 
Gr.3 (%)/Gr.4 (%)] 
RTOG/EORTC 
Cases/Total [Gr.1 (%)/Gr.2 (%)/ 
Gr.3 (%)/Gr.4 (%)] 
- RTOG/EORTC 
Cases/Total [Gr.1 (%)/Gr.2 (%)/ 
Gr.3 (%)/Gr.4 (%)] 
Genitourinary (GU) 40/76 [35 (46)/5 (7)/0 (0)/0 (0)] Bladder/urethra:  
117/175 [108 (62)/9 (5)/ 
0 (0)/0 (0)] 
- Bladder/Urethra 
At 12 months: 
58/416 [56 (13.5)/2 (0.5)/0 (0.0)/ 
0 (0.0)] 
At 36 months: 114/402[108 
(26.9)/6 (1.5)/0 (0.0)/0 (0.0)] 
At 60 months: 77/394[66 
(16.8)/10 (2.5)/1 (0.3)/0 (0.0)] 
Gastrointestinal (GI) 7/76 [6 (8)/1 (1)/0 (0)/0 (0)] Rectum: 
27/175 [23 (13)/4 (2)/0 (0)/0 (0)] 
- Rectum 
At 12 months:  
4/417 [4 (1.0)/0 (0.0)/0 (0.0)/ 
0 (0.0)] 
At 36 months: 32/402 [29 (7.2)/ 
3 (0.7)/0 (0)/0 (0)] 
At 60 months: 18/394 [16 (4.1)/ 
2 (0.5)/0 (0.0)/0 (0)] 
                                                             
86 * Statistically significantly different to the baseline score, with p<0.05. 
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Table A-7: Carbon ion radiotherapy (CIRT) for cancers in the prostate region: Results from observational studies (part 2) 
First Author  Nomiya [138] Tsuji 2005 [137] Wakatsuki [135] 
Year  2016 2005 2008 
Country Japan Japan Japan 
Cancer Therapy Centre (s) Heavy Ion Medical Accelerator 
in Chiba (HIMAC)  
Gunma University Heavy Ion 
Medical Center (GHMC) 
Heavy Ion Medical Accelerator 
in Tosu (HIMAT) in Saga 
Heavy Ion Medical Accelerator 
in Chiba (HIMAC) 
Heavy Ion Medical Accelerator in Chiba (HIMAC) 
Sponsor Japan Society for the Promotion 
of Science (JSPS) 
NR NR 
Sample Size 215787 20188 194 
Time Frame of Patient Enrolment Between December 2003 and 
December 2014 
between June 1995 and  
February 2004 
between April 2000 and February 2004 
Study Design Multi-institutional analysis of 
prospective case series studies 
Dose-escalation, prospective 
case series study using 3 protocols 
Before-after study 
The Phase of Clinical Trial Phase 1 & 2 Phase 1 & 2 N.A. 
Intervention CIRT: once daily/6-8 times  
per two weeks 
Dosage/fractions:  
People treated (%) 
66 Gy(RBE)/20 fr.: 78 (3.6%) 
63 Gy(RBE)/20 fr.: 213 (9.9%) 
57.6 Gy(RBE)/16 fr.: 1296 (60.1%) 
51.6 Gy(RBE)/12 fr.: 570 (26.4%) 
Co-intervention: androgen 
deprivation therapy (ADT) 
HIMAC:  
low risk: none 
intermediate:  
NAADT 4–6 months 
high: NAADT + adjv. ADT totalP 
24 months 
GHMC: 
low risk: none 
Hypofractionated CIRT  
(20 fractions): 
Dose-escalation:  
54.0–72.0 GyE for stage B2–C 
patients in the time period of 
06/95–12/97 (+hormone therapy) 
Protocol 9402 (n=35) 
60.0–66.0 GyE for stage A2–B1 
patients in the time period of 
01/98–02/00 (no hormone 
therapy). Protocol 9703 (n=20) 
Fixed-dose: 
66.0 GyE for patients with cancer 
in the B2–C tumour stage in the 
time period of 01/98–02/00 
(+hormone therapy).  
Protocol 9703 (n=42). 
CIRT: once daily, four days/week at 66.0 Gy equivalents  
(GyE)/20 fractions (with a fraction dose of 3.3 GyE). 
Co-intervention: 
Hormonal treatment for patients in the high-risk group (n=125), 
i.e., neoadjuvant therapy, such as medical or surgical castration 
with or without an antiandrogen, for 2-6 months before CIRT with 
continued adjuvant therapy for at least 1 year after CIRT. 
                                                             
87 It is assumed that the sample of Maruyama et al. 2017 [134] is also included in Nomiya et al. 2016 [138].  
However, none of the studies was excluded due to overlapping sample since both studies included different crucial endpoints in their analysis. 
88 It is assumed that the sample of Wakatsuki et al. 2008 is also included in Tsuji et al. 2005.  
However [135] was not excluded due to overlapping sample due to the fact that the crucial endpoint was reported in this study, while not being reported in [137]. 
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First Author  Nomiya [138] Tsuji 2005 [137] Wakatsuki [135] 
Intervention 
(continuation) 
intermediate:  
NAADT 6-8 months 
high:NAADT + adjv. ADT total 
24 months 
HIMAT: 
low risk: none 
intermediate:  
NAADT 4-8 months 
high: NAADT + adjv. ADT total 
24-36 months 
66.0 GyE for patients with 
prostate cancer in the A2–C 
tumour stage in the time period 
of 04/00–02/04 (hormone 
therapy stratified by risk 
factors). Protocol 9904 (n=176) 
Co-intervention: 
neoadjuvant hormonal therapy 
(i.e., medical/surgical castration 
with or without antiandrogen) 
before CIRT for the high-risk 
group (time period: 2-6 months). 
Continuation of adjuvant 
hormonal therapy for at least  
1 year. 
 
Control (C) - - - 
Age in Years  
(Unit of Central Tendency, Range) 
67 (mean, range: 45–92) NR 69 (median, range: 53–83) 
Sex, Female (%) vs. Male (%) Male Male Male 
P
at
ie
n
t 
P
o
p
u
la
ti
o
n
 
Indication/Risk Group Patients were stratified into 
three (3) risk groups: 
low-risk: T1–T2a, initial prostate-
specific antigen (iPSA) < 10 ng/mL, 
and Gleason sum (GS) ≤6  
(n=263 [12%]) 
intermediate-risk: not low-risk 
and not high risk (n=679 [31%]) 
high-risk: T2c–T3b or iPSA >20 ng/ 
mL or GS≥7 (n=1215 [56%]) 
Prostate cancer Patients were stratified into two groups: 
low risk: Patients with T1/T2aN0M0 with an 
iPSA level <20 ng/mL, and a Gleason score (GS) <7 
high risk: T2b/T3 or iPSA level ≥20 ng/mL or GS ≥7 
Initial PSA (ng/mL) ≤10: 1268 (58.8%)  
10 < and ≤20: 523 (24.2%)  
>20: 366: (17.0%) 
<20: 107 (53%)  
≥20: 94 (47%) 
16.6 ng/mL (median, range: 3.4–260.0 ng/mL). 
Gleason Score 5: 7 pts (0.3%)  
6: 407 pts (18.9%)  
7: 1074 pts (49.8%)  
8: 279 pts (12.9%)  
9: 381 pts (17.7%)  
10: 9 pts (0.4%) 
≤ 6: 63 (31%)  
7: 79 (39%)  
≥ 8: 52 (26%)  
Not evaluated (N.E.): 7 (4%) 
NR 
Tumour Stage/TNM Classification 1 ( 0.0%)T1b pt 
682 (31.6%) 1c pts  
527 (24.4%) 2a pts  
73 (3.4%) 2b pts  
388 (18.0%) 2c pts  
397 (18.4%) 3a pts  
89 (4.1%) 3b pts 
T1–T2a: 81 (PSA score:  
63pts <20, 18pts ≥20) 
T2b: 39(PSA score:  
19pts <20, 20pts ≥20) 
T3: 81≥(PSA score:  
25pts <20, 56pts ≥20) 
46 T1c pts 
25 T2a pts 
20 T2b pts 
59 T3 pts 
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First Author  Nomiya [138] Tsuji 2005 [137] Wakatsuki [135] 
Follow-Up in Months  
(Unit of Central Tendency; Range) 
29 (NR, range: NR)89 NR NR 
The Loss to Follow-Up n (%) NR NR NR 
Methods Survival rates: Kaplan-Meier 
Method(comparison: log-rank 
test; significance level: NR) 
Survival rates: Kaplan–Meier 
method (comparison: log-rank 
test; s. s. with p<0.05) 
HRQOL: self-administered questionnaires before, just after,  
at 12 months after CIRT using the following questionnaires: 
FACT-P; FACT-G and UCLA-PCI questionnaires 
Statistical analysis: Paired t-test. Statistical significance  
was set at p < 0.05 
Outcomes 
Efficacy 
Overall Survival (OS) in % (95% CI) Low-risk group: 100%  
(95% CI: NR) at 5 years;  
96% (95% CI: NR) at 10 years 
Intermediate risk group: 99% 
(95% CI: NR) at 5 years;  
78% (95% CI: NR) at 10years 
High-risk group:96%  
(95% CI: NR) at 5 years; 88% 
(95% CI: NR) at 10years 
89.2% (95% CI: NR) at 5 years - 
Cause-Specific Survival (CSS) in % (95% CI) Low-risk group: 100%  
(95% CI: NR) at 5 years;  
100% (95% CI: NR) at 10 years 
Intermediate risk group: 100% 
(95% CI: NR) at 5 years; 88% 
(95% CI: NR) at 10years 
High-risk group: 99%  
(95% CI: NR) at 5 years;  
98% (95% CI: NR) at 10years 
Disease-specific 
survival: 92.2%  
(95% CI: NR) at 5 years 
- 
Disease-Free Survival in % (95% CI) - - - 
Recurrence-Free survival (RFS) in % (95% CI) - - - 
Biochemical Recurrence-Free Survival 
(BRFS) in % (95% CI) 
Low-risk group: 92%  
(95% CI: NR) at 5 years; 77% 
(95% CI: NR) at 10 years 
Intermediate risk group: 89% 
(95% CI: NR) at 5 years; 70% 
(95% CI: NR) at 10years 
High-risk group: 92%  
(95% CI: NR) at 5 years; 79% 
(95% CI: NR) at 10 years 
5-year bNED: 83.2% (95% CI: 
NR) 
low-risk group:  
100% (95% CI: NR)  
high-risk group: 
80.5% (95% CI: NR) 
- 
Progression-Free Survival (PFS) in % (95% CI) - - - 
                                                             
89 The median follow-up periods of surviving patients in NIRS, GHMC, and HIMAT were 43, 23, and 7 months, respectively [138]. 
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First Author  Nomiya [138] Tsuji 2005 [137] Wakatsuki [135] 
Local Control Rate (LCR) in % (95% CI) Low-risk group: 98%  
(95% CI: NR) at 5 years;  
98% (95% CI: NR) at 10 years 
Intermediate risk group: 96% 
(95% CI: NR) at 5 years; 95% 
(95% CI: NR) at 10years 
High-risk group: 99%  
(95% CI: NR) at 5 years; 98% 
(95% CI: NR) at 10years 
100% (95% CI: NR) at 5 years - 
H
ea
lt
h
-R
el
at
ed
 Q
u
al
it
y 
o
f 
Li
fe
 (
H
R
Q
O
L)
 
Instruments  
Results 
- - CIRT alone (n=25)90 CIRT+ADT (n=125)90 
Patients showed no significant 
change compared to those 
before C-ion RT when using 
results from the FACT-G or 
FACT-P questionnaire 
No significant change in the 
average of the UCLA-PCI 
scores91 in the low-risk patients 
was seen at 12 months. 
FACT-G (100): 
Score at 12 months stat. 
significantly lower than at 
baseline with p<0.01 
FACT-P (148): 
Score at 12 months stat. 
significantly lower than at 
baseline with p<0.05 
No significant change in the 
average of the UCLA-PCI 
scores91 in the low-risk patients 
was seen at 12 months. 
Pre-Interventional:  
Mean (Standard Deviation) 
- - FACT-G: 88.4 (13.2  
FACT-P 122.6 (19.8) 
FACT-G: Before CIRT: 86.1 (19.4) 
FACT-P: Before CIRT: 120.0 (26.1) 
Post-Interventional: 
Mean Score (Standard Deviation) 
- - FACT-G: 89.2 (11.3), n. s., 
FACT-P: 122.4 (16.6) n. s. 
FACT-G: Just after: 85.5 (21.2) 
FACT-P: Just after: 118.0 (28.4) 
Short-Term (<6 weeks) 
Mean Score (Standard Deviation)  
- - NR NR 
Mid-Term (>6 weeks – ≤6 months) 
Mean Score (Standard Deviation) 
- - NR NR 
Longer Term (>6 months):  
Mean Score (Standard Deviation) 
- - FACT-G: 89.1 (13.6), n.s., 
FACT-P: 123.8 (20.3), n.s.. 
FACT-G 
At 12 months: 83.9 (21.7)  
(s. s. with p<0.01) 
FACT-P 
At 12 months: 116.7 (29.1)*  
(s. s. with p<0.05) 
                                                             
90 Response rate: 77.3% (FACT-P) and 78.1% (UCLA-PCI). 
91 The UCLA-PCI questionnaire was only used for the low-risk group and not extracted. 
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First Author  Nomiya [138] Tsuji 2005 [137] Wakatsuki [135] 
Safety 
A
cu
te
 R
ad
ia
ti
o
n
 
M
o
rb
id
it
y 
Criteria CTCAE Version 4  - 
Genitourinary (GU) Grade 0–1: 2037 (94.4%)  
Grade 2: 119 (5.5%) 
Grade 3: 1 (0.0%)  
Grade 4: 0 (0%) 
NR - 
Gastrointestinal (GI) Grade 0-1: 2157 (100%) 
Grade 2: 0 (0%)  
Grade 3: 0 (0%) 
Grade 4: 0 (0%) 
NR - 
La
te
 R
ad
ia
ti
o
n
 M
o
rb
id
it
y 
Criteria CTCAE v. 4 RTOG/EORTC + LENT SOMA 
Cases/Total [Gr.1 (%)/Gr.2 
(%)/Gr.3 (%)/Gr.4 (%)] 
 
Genitourinary (GU) n= 1929 (excluded patients with 
a follow-up <6months from the 
analysis of late morbidities) 
Genitourinary (GU) 
Grade 0-1: 1840 (95.4%)  
Grade 2: 88 (4.6%)  
Grade 3: 1 (0.0%) 
Grade 4: 0 (0%) 
Bladder/urethra: 
95/201 [83 (41.3)/12 (6.0)/0 
(0.0)/0 (0.0)] 
- 
Gastrointestinal (GI) Grade 0-1: 1921 (99.6%)  
Grade 2: 8 (0.4%)  
Grade 3: 0 (0%)  
Grade 4: 0 (0%) 
Rectum:  
9/201 [7 (3.5)/2 (1.0)/ 
0 (0.0)/0 (0.0)] 
- 
Abbreviations: ADT – Androgen Deprivation Therapy; bNED or BRF – biochemical relapse-free rate; CIRT – Carbon Ion Radiotherapy; CTCAE – Common Terminology Criteria for Adverse 
Events; EORTC – European Organisation for Research and Treatment of Cancer; FACT-G – Functional Assessment of Cancer Therapy-General; FACT-P – Functional Assessment of Cancer 
Therapy-Prostate; fr. – fraction; GHMC – Gunma University Heavy Ion Medical Center; Gr. – Grade; GS – Gleason Score; GyE – Gray Equivalent; HIMAC – Heavy Ion Medical Accelerator 
in Chiba; HIMAT – Heavy Ion Medical Accelerator in Tosu; iPSA – initial prostate-specific antigen; LENT-SOMA – Late Effects Normal Tissue Task Force Subjective, Objective, Management, 
Analytic ml. – millilitre; N.A. – not applicable; n.s. – not statistically significant; NAADT – Neoadjuvant ADT; ng. – nanogram; pt – patient; pts – patients; RTOG – Radiation Therapy 
Oncology Group; TNM – Tumour Node Metastases; TOI – Trial Outcome Index; v. – version 
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Table A-8: Carbon ion radiotherapy (CIRT) for cancers in the skull base region: Results from observational studies 
First Author  Mizoe [44] Schulz-Ertner [43] Uhl [42] 
Year  2009 2007 2014 
Country Japan Germany Germany 
Cancer Therapy Centre Heavy Ion Medical Accelerator in Chiba 
(HIMAC) 
Heidelberg Ion Beam Therapy Centre (HIT) Heidelberg Ion Beam Therapy Centre (HIT) 
Sponsor NR NR NR 
Sample Size 3392 54 25 
CIRT Sample 33 54 25 
Time Frame of Patient Enrolment Between June 1995 and June 2007 Between November 1998 and September 
2005 
Between January 2010 and October 2012 
Study Type Observational Observational Observational 
Study Design Prospective; Pilot study;  
dose-escalation study 93 
Prospective case series 93 Prospective case series 93 
The Phase of Clinical Trial Phase 1/2 & Phase 2 Phase 1/2 NR 
Intervention CIRT (16 fr./4 weeks) : 
Pilot study: total dose of 48.0 GyE/16 fr.  
(4 cases) 
Dose-escalation: 48.0, 
52.8, 57.6, and 60.8 GyE/16 fr. (16 cases) 
Phase 2 study: 60.8 GyE/16 fr. (14 cases) 
Previous treatment: Surgery?94 
CIRT (raster scan technique):  
a median total dose of 60 CGE  
(weekly fractionation 7 x 3.0 CGE) 
Previous treatment: 
At least 1 surgery in all patients 
CIRT Reirradiation (active raster scanning 
technique) using a median total dose of  
51 GyE (range: 45–60 GyE) in five to six 
fractions of 3 GyE per week95 
Previous treatment: 
Photon (n=2;hypofractionated) 3 × 7 Gy 
(80% isodose) 5 × 5 Gy (80% isodose) 
Photon (n=9; normofractionated) 
66 Gy (38-72.5 Gy) 
Proton (n=2; normofractionated): 
68.4 GyE; 72 GyE 
Carbon ion (n=12; hypofractionated):  
60 GyE (42-60 GyE) 
Surgery for 24 pts 
Control - - - 
                                                             
92 34 cases in 33 patients. 
93 Enrolment judged to be prospective. 
94 In the study, it was stated that “(…) each patient had recovered from the effects of surgery before entry into the study” (see [44]). 
95 23 pts were previously treated with irradiation (once), and 2 pts twice. Of all 25 pts, 14 were previously treated with particle therapy. 
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First Author  Mizoe [44] Schulz-Ertner [43] Uhl [42] 
Age in Years (Unit of Central Tendency, 
Range) 
47 (median, range: 16-76) 46 (median, range: 6-74) 50 (median, range: 39-76) 
Sex, Female (%) vs. Male (%) 19 (58) vs. 14 (42) 27 (50) vs. 27 (50) 8 (32) vs. 17 (68) 
P
at
ie
n
t 
P
o
p
u
la
ti
o
n
 
Indication Chordoma of the skull base and the 
paracervical spine 
Low-grade and intermediate-grade 
chondrosarcomas of the skull base 
Recurrence of skull base chondrosarcoma 
(n=5) or skull base chordoma (n=20) 
Histology Not further specified Not further specified Chordoma: 20 
Chondrosarcoma: 5 
Tumour Site Of 34 cases, 7 (21%) involved  
the paracervical spine. 
Ethmoidal/paranasal sinus 8 (14.8%) 
Parasellar 18 (33.3%) 
Sphenopetrosal 20 (37.0%) 
Temporooccipital 5 (9.3%) 
Clivus 3 (5.6%) 
Skull base: Not further specified 
Tumour Stage - Grade 1: 37 (68.5%) 
Grade 2: 12 (22.2%) 
Grade 1 with focal Grade 2 areas: 5 (9.3%) 
- 
Follow-Up in Months  
(Unit of Central Tendency; Range) 
53 (median, range: 8-29) 33 (median, range: 3-84) 14 (median, range: 2-30) 
The Loss to Follow-Up n (%) NR NR NR 
Outcomes 
Efficacy 
Overall Survival (OS) in % (95% CI) 87.7% (95% CI: NR, SE: 7%) at 5 years  
67% (95% CI: NR, SE: 14%) at 10 years 
98.2% (95% CI: 94.6-100%)  
at 3 and 4 years96 
NR 
Cause-Specific Survival (CSS) in (95% CI) NR NR NR 
Disease-Free Survival (DFS) in % (95% CI) NR NR NR 
Recurrence-Free Survival (RFS) in % (95% CI) NR NR NR 
Progression-Free survival (PFS) in % (95% CI) NR NR 2-year-local progression-free survival (LPFS): 
79.3% (95% CI: NR) 
Local Control Rate (LCR)in % (95% CI) 85.1% (95% CI: NR, SE: 8%) at 5 years  
63.8% (95% CI: NR, SE: 19%) at 10 years 
Cumulative local control rates: 
96.2% (95% CI: 88.8–100%) at 3 years  
89.8% (95% CI, 75.6–100%) at 4 years 
NR 
Health-Related Quality of Life (HRQOL) - - - 
                                                             
96 The included study stated in the abstract that the 5-year OS for 54 patients with chondrosarcomas was 98.2%. In the results section, this rate is referred to be for 3 and 4 years  
respectively. Moreover, it is stated that only 9 patients survived 5 years possibly without having calculated the respective 5-year OS. 
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First Author  Mizoe [44] Schulz-Ertner [43] Uhl [42] 
Safety 
A
cu
te
 R
ad
ia
ti
o
n
 M
o
rb
id
it
y 
Criteria RTOG CTCAE v.3.0 CTCAE v.4.03 
Cases/n (Gr.1 (%)/Gr.2 (%)/Gr.3 (%)/Gr.4 (%)) Cases/n (%) Cases/n (Gr.1 (%)/Gr.2 (%)/Gr.3 (%)/Gr.4 (%)) 
Mucosa 12/34 [6 (17.6)/6 (17.6)/0(0)/0(0)] Mucositis: 3/54 (5)* 
Grade 1: 2 (3.7) 
Grade 2: NR 
Grade 3: 1 (1.9) 
Grade 4: 0 (0) 
1/25 (NR/1* (4)/0/0) 
Skin 13/34 [12 (35.3)/1 (2.9)/0 (0)/0 (0)] - - 
Others - Parotitis: 1 (1.9) 97 Hypacusis:  
3/25 [NR/3 (12)/0 (0)/0 (0)] 
Asymptomatic temporal lobe reaction*:  
5/25 [5 (20)/0(0)/0 (0)/0 (0)] 
Osteoradionecrosis:  
1/25 (NR/NR/1 (4)/0(0)] 
La
te
 R
ad
ia
ti
o
n
 
M
o
rb
id
it
y 
Criteria RTOG/EORTC RTOG/EORTC NR 
Cases/n (Gr.1 (%)/Gr.2 (%)/Gr.3 (%)/Gr.4 (%)) Cases/n (%) Cases/n (Gr.1 (%)/Gr.2 (%)/Gr.3 (%)/Gr.4 (%)) 
Mucosa 2/34 [2 (5.9)/0 (0)/0 (0)/0 (0)] see below NR 
Skin 2/34 [2 (5.9)/0 (0)/0 (0)/0 (0)] see below NR 
Others Brain: 6/34 [5 (14.7)/1 (2.9)/0 (0)/0 (0)] Grade ≤ 2: 5 (9.3)98 
Grade 3: 1 (1.9) 
Grade 4: 0 (0) 
NR 
Abbreviations: CGE – Cobalt Gray Equivalent; CIB – carbon ion boost; CIRT – carbon ion radiotherapy; CTC – Common Toxicity Criteria; CTCAE – Common Terminology Criteria for 
Adverse Events; fr. – fraction; FSRT – fractionated stereotactic radiation therapy; Gy – gray; GyE – gray equivalent; IMRT – intensity-modulated radiation therapy; NR – not reported;  
PFS – progression-free survival; RT – radiation therapy; RTOG – Radiation Therapy Oncology Group; v. – version; WHO – World Health Organisation. 
 
                                                             
97 Other toxicities were also reported without a nuanced description of the frequency and severity using a standardised tool: “Minor acute toxicity included focal hair loss in 6 patients 
with superficial tumor location. Temporary middle ear effusion, sinusitis, and mastoiditis were frequent findings in patients at risk for this toxicity because of their tumor location”. 
98 Not further specified. 
Carbon ion beam radiotherapy (CIRT) for cancer treatment 
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IHE checklist used for the risk of bias assessment 
Table A-9: IHE-18 Quality appraisal checklist for case series and instructions for use (adapted to the assessment) [156] 
Study objective 
1. Is the hypothesis/aim/objective of the study stated clearly in the abstract, introduction, or methods section? 
Yes: The hypothesis/aim/objective of the study was clearly reported (includes patients, intervention and outcome). 
Partial: Only one or two components (patients, intervention, or outcome) were included.  
No: The hypothesis/aim/objective was not reported. 
Study design 
2. Are the characteristics of the participants included in the study described? 
Yes: All of the most relevant characteristics of the patients were reported: 
 Number,  
 Age,  
 Gender,  
 Severity of disease/condition,  
 Comorbidity, or  
 Etiology 
Partial: Some (at least 2) of the most relevant characteristics were reported. 
No: Less than 2 of the described characteristics of patients were reported.  
3. Were the cases collected in more than one centre? 
Yes: Cases were collected in more than one centre (multicentre study). 
Unclear: It was unclear whether patients from one or more cancer-therapy centre were included in the study.  
No: Cases were collected from one centre.  
4. 4. Are the eligibility criteria (inclusion and exclusion criteria) for entry into the study explicit and appropriate? 
Yes: Both inclusion and exclusion criteria were reported.  
Partial: Either the inclusion or exclusion criteria were reported. 
No: Neither inclusion nor exclusion criteria was reported. 
Study population 
5. Were participants recruited consecutively? 
Yes: All of the most relevant characteristics of the patients were reported (for example, number, age, gender, 
ethnicity, the severity of disease/condition, comorbidity, or etiology).  
Partial: Some, but not all, of the most relevant characteristics, were reported. 
No: Only the number of patients was reported.  
6. Did participants enter the study at a similar point in the disease? 
Yes: The baseline data presented in the study (tables of patients’ characterises) suggests that the majority  
(at least 80%) of patients entered the study at similar point of disease (i.e., regarding severity of the disease 
and the presence of complications: histological TU type, clinical stage based on TNM/WHO classification were 
used to make a judgement regarding similarity of the patient’s diseases). 
Unclear: There was no/not enough baseline information on clinical and histological stage/type to make a 
judgment (e.g., only data on tumour dimensions, histological type or information on primary tumour for 
metastases and locally advanced TU)  
No: The baseline data presented in the study (tables of patients’ characterises) suggests that the majority  
(at least 80%) of patients did not enter the study at similar point of disease (i.e., regarding severity of the 
disease and the presence of complications: histological TU type, clinical stage based on TNM/WHO classification 
were used to make a judgement regarding similarity of the patient’s diseases). 
7. Was the intervention of interest clearly described? 
Yes: All of the most relevant characteristics of the intervention were reported: 
Dosage 
Frequency or duration of intervention,  
Administration methods 
Characteristics of CIRT 
Partial: Some (>1), but not all, of the most relevant characteristics were reported.  
No: Only the name (or ≤1 of the characteristics described above) of the intervention was reported.  
Appendix 
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Intervention and co-intervention 
8. Were additional interventions (co-interventions) clearly described? 
Yes: All of the most relevant characteristics of the co-intervention(s) were reported (for example, different 
type, dosage, the frequency of administration, or duration); or the study clearly stated that a co-intervention 
was not administered for clinical reasons.  
Partial: Some, but not all, of the most relevant characteristics of the co-intervention, were reported. Authors 
report on other prior or concurrent interventions, i.e. photon therapy, but other possible co-interventions 
were not mentioned. 
No: No information regarding co-intervention(s) was provided; or only the name(s) of the co-intervention(s) 
were mentioned.  
9. Were relevant outcome measures clearly stated and defined in introduction or methods section? 
Yes: All relevant outcome measures were stated and defined in the introduction or methods section.  
Partial: Some, but not all, of the relevant outcome measures, were stated and defined in the introduction  
or method section, or all outcomes were stated but not defined. 
No: None of the relevant outcome measures was stated in the introduction or method section. 
Outcome measures 
10. Were the relevant outcomes measured using appropriate objective/subjective methods? 
Yes: All relevant outcomes were measured with appropriate methods. These measures can be objective  
(for example, gold standard tests or standardised clinical tests), subjective (for example, self-administered 
questionnaires, standardised forms, or patient symptoms interview forms), or both. 
Partial: Some, but not all, relevant outcomes were measured with appropriate methods.  
No: The methods used to measure the relevant outcomes were inappropriate.  
11. Were the relevant outcome measures made before and after the intervention? 
Yes: The relevant outcome measures were made pre- and post-intervention;  
or baseline measurements were not possible (for example, death). 
Unclear: The study did not report when the outcome measures were made. 
No: The outcome(s) were only measured post-interventional. 
12. Were the statistical tests used to assess the relevant outcomes appropriate? 
Yes: The statistical tests were used appropriately (for example, parametric test for normally distributed 
population vs nonparametric test for non-Gaussian population). Answer yes if no statistical analysis was 
performed and reasons for this were stated. 
Unclear: The statistical tests were not (rigorously) described in the methods section of the study, or it was  
not clearly stated for which purpose a certain test was used. 
No: The statistical tests used were inappropriate. 
13. Was follow-up long enough for important events and outcomes to occur?  
Yes: It was clear from the information provided that the follow-up period was long enough for the majority  
(at least 80%) of patients, to allow for important events and outcomes (for example, changes in clinical status, 
adverse events) to occur.  
Partial: Some indicators for the length of follow up are reported, but not all (i.e., median follow-up time but no range) 
Unclear: The length of follow-up was not clearly reported 
No: It is clear from the information provided that the follow-up period was not long enough to allow  
for important events and outcomes to occur.  
Note: Assessor(s) should define the appropriate duration of follow-up for each outcome of interest  
(for example, short-term and long-term adverse events 
Statistical analysis 
14. Were losses to follow-up reported? 
Yes: The number or proportion of patients lost to follow-up was clearly reported; the authors reported 
outcome results on all patients initially included, or the number lost to follow-up can be clearly subtracted 
from the number of patients enrolled, and the number of patients included in the final analysis. 
Partial: If Author did not clearly report on loss to follow-up (i.e., the reader may be able to draw conclusions 
on the loss to follow up without eradicating uncertainties regarding the true number or proportion having 
been lost to follow-up). 
Unclear: There was a discrepancy between the number or proportion of patients reported in tables,  
figures, and text. 
No: The number or proportion of patients lost to follow-up was not reported. 
Carbon ion beam radiotherapy (CIRT) for cancer treatment 
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Results and conclusions 
15. Did the study provide estimates of random variability in the data analysis of relevant outcomes? 
Yes: The estimates of the random variability (for example, standard error, standard deviation, the confidence 
interval for normally distributed data or range and interquartile range for non-normally distributed data) were 
reported for all of the relevant outcomes or could be calculated from the raw data presented in the study.  
Partial: The estimates of the random variability were reported for some, but not all of the relevant outcomes. 
No: The estimates of the random variability were not reported for any of the relevant outcomes. 
16. Were the adverse events reported? 
Yes: The undesirable or unwanted events during the study period or within a pre-specified time period were 
reported, or the absence of adverse event(s) was mentioned in the study.  
Partial: Some, but not all, important adverse events were reported.  
No: There was no statement about the presence or absence of adverse events. 
17. Were the conclusions of the study supported by the results? 
Yes: The conclusions of the study were supported by the evidence presented in the results and discussion sections. 
Unclear: Unclear conclusion statement that makes it difficult to link the presented evidence to conclusions.  
Partial: Some, but not all, conclusions are supported by the evidence presented in the results and discussion sections. 
No: The conclusions were not supported by the evidence presented in the results and discussion sections. 
18. Were both competing interests and sources of support for the study reported? 
Yes: Both competing interests and sources of support (financial or other) received for the study were reported, 
or the absence of any competing interest and source of support was acknowledged. 
Partial: Either the competing interest or source of support was reported. 
No: Neither competing interests nor sources of support were reported. 
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Risk of bias tables 
Internal validity of the included studies was judged by 2 independent researchers (GG, MM). In case of disagreement, a third researcher was involved to solve the 
differences. A more detailed description of the criteria used to assess the internal validity of the individual study designs can be found in the Internal Manual of 
the LBI-HTA [2] and in the Guidelines of EUnetHTA [16, 17]. 
Table A-10: Risk of bias – study level (randomised studies), Cochrane Risk of Bias Tool see [16] 
Trial 
Adequate generation  
of randomisation sequence 
Adequate allocation 
concealment 
Blinding Selective outcome 
reporting unlikely 
No other aspects which 
increase the risk of bias 
Risk of bias – 
study level Patient Treating Physician 
Habl, 2016 [132] Yes99 Unclear100 No No Yes No101 high 
 
 
 
                                                             
  99 Block randomization was used in the study: “randomization is performed in blocks of lenths [sic!] 4 stratified by one dichotomized factor  
(presence/absence of anti-hormonal therapy during radiation). GS and PSA values will be used for defining post-randomization strata” [157]. 
100 The authors do not provide a clear description of how/if the allocation was concealed. That is to say; the researchers involved in randomly assigning  
the patients may have had foreknowledge regarding forthcoming allocations. 
101 Block randomization in combination with a lack of blinding increases the probability of compromising, and thus leading to a threat to, the random assignment process  
(see for a description of critical combinations between certain elements of selected allocation and blinding strategies [158]). 
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Table A-11: Risk of bias for prostate cancer studies – study level (case series) see [156] 
Study  
reference/ID A
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 1. Is the hypothesis/aim/objective of the study stated clearly  
in the abstract, introduction, or methods section? 
Yes Yes Yes Yes Yes Yes Yes Partial102 Yes Yes 
 2. Are the characteristics of the participants included in the study 
described? 
Partial Partial Partial Partial Partial Partial Partial Partial Partial Partial 
 3. Were the cases collected in more than one centre? No No No No No Yes No No No No 
 4. Are the eligibility criteria (inclusion and exclusion criteria)  
for entry into the study explicit and appropriate? 
Yes Yes Yes Yes Partial Yes No No Yes Yes 
 5. Were participants recruited consecutively? Unclear Unclear Unclear Unclear Unclear Unclear Unclear Unclear Unclear Unclear 
 6. Did participants enter the study at a similar point in the disease? No No No No Yes No No No No No 
 7. Was the intervention clearly described in the study? Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
 8. Were additional interventions (co-interventions) clearly reported 
in the study? 
Partial Partial Partial Partial Yes Partial Partial Yes Partial Partial 
 9. Are the outcome measures clearly defined in the introduction  
or methods section? 
No Yes Yes Yes Yes Yes Yes No Yes Yes 
10. Were relevant outcomes appropriately measured with objective 
and/or subjective methods? 
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
 11. Were outcomes measured before and after intervention? Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
 12. Were the statistical tests used to assess the relevant outcomes 
appropriate? 
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
 13. Was the length of follow-up reported? Yes Yes Yes Yes Yes Yes Yes No Yes Yes 
 14. Was the loss to follow-up reported? No No No No No No No No No No 
 15. Does the study provide estimates of the random variability  
in the data analysis of relevant outcomes? 
No Yes Yes Yes No No Yes Yes Yes Yes 
16. Are adverse events reported? Yes Yes Yes Yes Yes Yes No Yes Yes No 
17. Are the conclusions of the study supported by results? Yes Yes No Yes Yes No No Partial Yes Yes 
 18. Are both competing interest and source of support for the study 
reported? 
No Yes Partial Yes Yes Partial Partial Partial No Partial 
Total points 10,5 13,5 12 13,5 13,5 12 10 9,5 12,5 12 
Risk of Bias  High moderate moderate moderate moderate moderate High High moderate moderate 
 
                                                             
102 Outcome measures were not reported in the introduction or methods section. 
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Table A-12: Risk of bias for brain, ENT, eye, and skull base tumour studies – study level (case series) see [156] (part 1) 
Study  
reference/ID C
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 1. Is the hypothesis/aim/objective of the study stated 
clearly in the abstract, introduction, or methods section? 
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
 2. Are the characteristics of the participants included  
in the study described? 
Partial No Partial Partial Partial Partial Partial Partial Partial Partial Partial 
 3. Were the cases collected in more than one centre? No No No No No No No No No No No 
 4. Are the eligibility criteria (inclusion and exclusion 
criteria) for entry into the study explicit and appropriate? 
No No No No Partial Partial Partial Partial Partial Partial Partial 
 5. Were participants recruited consecutively? Unclear Unclear Unclear Unclear Unclear Unclear Unclear Unclear Unclear Unclear Unclear 
 6. Did participants enter the study at a similar point  
in the disease? 
No No No No Unclear No Unclear No No No Unclear 
 7. Was the intervention clearly described in the study? Yes Partial Yes Yes Yes Yes Yes Yes Yes Yes Yes 
 8. Were additional interventions (co-interventions) 
clearly reported in the study? 
No No Partial Yes Partial Partial No No Yes Yes No 
 9. Are the outcome measures clearly defined in the 
introduction or methods section? 
Yes Yes Partial No Yes Yes Yes Yes Yes Yes No 
10. Were relevant outcomes appropriately measured with 
objective and/or subjective methods? 
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
 11. Were outcomes measured before and after intervention? Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
 12. Were the statistical tests used to assess the relevant 
outcomes appropriate? 
Unclear Unclear Unclear Unclear Yes Yes Yes Yes Yes Yes Yes 
 13. Was the length of follow-up reported? Yes Yes Yes Partial Yes Partial Yes Yes Yes No Yes 
 14. Was the loss to follow-up reported? No No No No No No No No No103 No103 No 
 15. Does the study provide estimates of the random 
variability in the data analysis of relevant outcomes? 
No No No No Yes No Yes No Partial Yes Yes 
 16. Are adverse events reported? Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
 17. Are the conclusions of the study supported by results? Yes Yes Unclear No Yes Yes Yes No No Yes Yes 
 18. Are both competing interest and source of support  
for the study reported? 
Unclear104 Yes Partial Partial No Partial Partial Partial Partial Yes No 
Total points 10 9,5 9,5 8,5 12,5 11 12,5 10 11,5 12,5 11 
Risk of Bias High High High High moderate moderate moderate High moderate moderate moderate 
 
                                                             
103 The authors reported that no patient was “lost to follow up“. However and critically speaking, people who died were not considered as “loss to follow up”. 
104 The authors wrote that they “made no disclosure” regarding the conflict of interest [162]. 
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Table A-12: Risk of bias for brain, ENT, eye, and skull base tumour studies – study level (case series) see [156] (part 2) 
Study  
reference/ID M
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 1. Is the hypothesis/aim/objective of the study stated 
clearly in the abstract, introduction, or methods section? 
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
 2. Are the characteristics of the participants included  
in the study described? 
No Partial Partial Partial Partial Partial Partial Partial Partial Partial Partial 
 3. Were the cases collected in more than one centre? No No No No No No No No No No No 
 4. Are the eligibility criteria (inclusion and exclusion 
criteria) for entry into the study explicit and appropriate? 
Partial No No No No No Yes No Partial No No 
 5. Were participants recruited consecutively? Unclear Unclear Unclear Unclear Unclear Unclear Unclear Unclear Unclear Unclear Unclear 
 6. Did participants enter the study at a similar point  
in the disease? 
Unclear No No No Yes No No Unclear No Unclear Unclear 
 7. Was the intervention clearly described in the study? Yes Yes Yes Yes Yes Yes Yes Yes No Yes Yes 
 8. Were additional interventions (co-interventions) 
clearly reported in the study? 
No Yes No No No Yes No Yes No Yes No 
 9. Are the outcome measures clearly defined in the 
introduction or methods section? 
Yes Partial Yes Yes Yes Yes Yes Partial Yes Yes Yes 
10. Were relevant outcomes appropriately measured with 
objective and/or subjective methods? 
Yes Yes Yes Yes Yes Yes Yes Partial Yes Yes Yes 
 11. Were outcomes measured before and after intervention? Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
 12. Were the statistical tests used to assess the relevant 
outcomes appropriate? 
Yes Unclear Yes Yes Yes Yes Unclear Unclear Yes Yes Yes 
 13. Was the length of follow-up reported? Yes Partial Yes Yes Yes Yes Yes Yes Yes Yes Yes 
 14. Was the loss to follow-up reported? No No No No No No No Partial No No No 
 15. Does the study provide estimates of the random 
variability in the data analysis of relevant outcomes? 
No No No No No Yes Yes Yes No No No 
 16. Are adverse events reported? Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
 17. Are the conclusions of the study supported by results? Yes Unclear No No Yes No Yes No105 No No No 
 18. Are both competing interest and source of support  
for the study reported? 
No106 Partial No Partial Partial Partial Partial No No Partial Partial 
Total points 10,5 9,5 9 9,5 11,5 11,5 12 10,5 8,5 11 10 
Risk of Bias High High High High moderate moderate moderate High High moderate High 
                                                             
105 The study concluded, inter alia, that the Quality of Life (QoL) for patients with skull base chordomas will be improved by a combination of surgical removal and CIRT  
without having measured quality of life within the study. 
106 The authors report on both competing interest and source of support. However, source of support is vaguely formulated: “(…) there has been no significant financial support  
for this work that could have influenced its outcome” [166]. 
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Table A-13: Risk of bias for GI tumour studies – study level (case series) see [156] 
Study  
reference/ID 
Akutsu,  
2012 [106] 
Kasuya,  
2017 [173] 
Kato,  
2004 [174] 
Yamada,  
2016 [107] 
 1. Is the hypothesis/aim/objective of the study stated clearly in the abstract, introduction, or methods section? Yes Yes Yes Yes 
 2. Are the characteristics of the participants included in the study described? Partial Partial Partial Partial 
 3. Were the cases collected in more than one centre? Yes No No No 
 4. Are the eligibility criteria (inclusion and exclusion criteria) for entry into the study explicit and appropriate? Yes Yes Partial Yes 
 5. Were participants recruited consecutively? Unclear Unclear Unclear Unclear 
 6. Did participants enter the study at a similar point in the disease? No No No No 
 7. Was the intervention clearly described in the study? Yes Partial Yes No 
 8. Were additional interventions (co-interventions) clearly reported in the study? Yes No Yes No 
 9. Are the outcome measures clearly defined in the introduction or methods section? Yes Yes Yes Yes 
10. Were relevant outcomes appropriately measured with objective and/or subjective methods? Yes Yes Yes Yes 
 11. Were outcomes measured before and after intervention? Yes Yes Yes Yes 
 12. Were the statistical tests used to assess the relevant outcomes appropriate? Unclear Yes Yes Unclear 
 13. Was the length of follow-up reported? Partial Yes Yes Yes 
 14. Was the loss to follow-up reported? No No No No 
 15. Does the study provide estimates of the random variability in the data analysis of relevant outcomes? No Yes Yes Yes 
 16. Are adverse events reported? Yes Yes Yes Yes 
 17. Are the conclusions of the study supported by results? No No107 No Yes 
 18. Are both competing interest and source of support for the study reported? Partial No Partial Yes 
Total Points 11,5 10,5 12 11,5 
Risk of Bias (RoB) moderate High moderate moderate 
 
 
                                                             
107 The study [173] draws conclusions on the effectiveness of CIRT in the selected patient group on the basis of the underlying results. However, the study was neither a randomised 
controlled study nor a controlled study. In addition, no indirect comparison of the observed survival rates with the survival of conventional therapies (or other types of radio-
therapy) was conducted leading to an inability to draw such conclusions – even more so when considering that they stated that the intervention was effective while having found 
no favourable results when using patient relevant outcomes (i.e., survival rates). 
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Table A-14: Risk of bias for NSCLC studies – study level (case series) see [156] 
Study  
reference/ID Iw
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 1. Is the hypothesis/aim/objective of the study stated clearly in the abstract, 
introduction, or methods section? 
Yes Yes Yes Yes Yes Yes Yes Yes Yes 
 2. Are the characteristics of the participants included in the study described? Partial Partial No Partial Partial Partial Partial No Partial 
 3. Were the cases collected in more than one centre? No No No No No No No No No 
 4. Are the eligibility criteria (inclusion and exclusion criteria) for entry  
into the study explicit and appropriate? 
Partial Partial No No Partial Partial Yes Partial Yes 
 5. Were participants recruited consecutively? Unclear Unclear Unclear Unclear Unclear Unclear Unclear Unclear Unclear 
 6. Did participants enter the study at a similar point in the disease? Yes Yes Yes No Yes No No No Yes 
 7. Was the intervention clearly described in the study? Yes Yes Yes Yes Yes Yes Yes Yes Yes 
 8. Were additional interventions (co-interventions) clearly reported in the study? Partial Yes No No No No No No No 
 9. Are the outcome measures clearly defined in the introduction or  
methods section? 
Yes Yes Partial Yes Yes Yes Yes Yes Yes 
10. Were relevant outcomes appropriately measured with objective and/or 
subjective methods? 
Yes Yes Unclear109 Yes Yes Partial Yes Unclear110 Yes 
 11. Were outcomes measured before and after intervention? Yes Yes Yes Yes Yes Yes Yes Yes Yes 
 12. Were the statistical tests used to assess the relevant outcomes appropriate? Yes Yes Unclear109 Yes Yes Yes Yes Unclear110 Yes 
 13. Was the length of follow-up reported? Yes Yes Yes Partial111 Yes Yes Yes Yes Yes 
 14. Was the loss to follow-up reported? No No No No Partial112 Partial112 No No No 
 15. Does the study provide estimates of the random variability in the  
data analysis of relevant outcomes? 
Yes Yes No No Yes Yes Yes No Yes 
 16. Are adverse events reported? Yes Yes No Yes Yes Yes Yes Yes Yes 
 17. Are the conclusions of the study supported by results? No No Yes Yes No No113 Yes No Yes 
 18. Are both competing interest and source of support for the study reported? Partial Partial No Partial Yes Yes Yes No Yes 
Total points 12.5 13 8 10 13 11.5 13 8 14 
Risk of Bias (RoB) Moderate Moderate High High Moderate Moderate Moderate High Moderate 
                                                             
108 2 Studies [29, 30] used the same sample in their analysis. None of the studies were excluded prior to the risk of bias assessment since the studies reported on different endpoints. 
109 The authors did not sufficiently report on the methods and statistical analysis used in the study. 
110 A clear description of the subjective/objective methods as well as the statistical analysis used in this study was absent. 
111 The median follow-up time was reported without including the range. 
112 The authors stated that no patients were lost to follow-up. However, people dying were not considered as a loss to follow up. 
113 The study draws conclusions on improved quality of life (QoL) for patients, without having measured QoL. 
Appendix 
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Table A-15: Risk of bias for bone and soft tissue tumour studies – study level (case series) see [156] 
Study  
reference/ID 
Kamada, 
2002 [176] 
Sugahara, 
2012[126] 
 1. Is the hypothesis/aim/objective of the study stated clearly in the abstract, 
introduction, or methods section? 
Yes Yes 
 2. Are the characteristics of the participants included in the study described? Partial Partial 
 3. Were the cases collected in more than one centre? No No 
 4. Are the eligibility criteria (inclusion and exclusion criteria) for entry into the study 
explicit and appropriate? 
Yes Partial 
 5. Were participants recruited consecutively? Unclear Unclear 
 6. Did participants enter the study at a similar point in the disease? No No 
 7. Was the intervention clearly described in the study? Yes Yes 
 8. Were additional interventions (co-interventions) clearly reported in the study? No No 
 9. Are the outcome measures clearly defined in the introduction or methods section? Yes Yes 
10. Were relevant outcomes appropriately measured with objective and/or  
subjective methods? 
Yes Yes 
 11. Were outcomes measured before and after intervention? Yes Yes 
 12. Were the statistical tests used to assess the relevant outcomes appropriate? Yes Yes 
 13. Was the length of follow-up reported? Yes Yes 
 14. Was the loss to follow-up reported? No No 
 15. Does the study provide estimates of the random variability in the data analysis  
of relevant outcomes? 
Yes Yes 
 16. Are adverse events reported? Yes Yes 
 17. Are the conclusions of the study supported by results? No Partial 
 18. Are both competing interest and source of support for the study reported? Partial Yes 
Total Points 11.5 12 
Risk of Bias (RoB) Moderate Moderate 
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Applicability table 
Table A-16: Summary table characterising the applicability of a body of studies 
Domain Description of applicability of evidence 
Population In total, the sum of all of all samples of the included studies lead to approximately 4,095 patients 
enrolled patients114 in 27 included clinical studies and 3,914 received carbon ion radiotherapy (CIRT). 
Most patients suffered from prostate, lung or ENT tumours, with 2,715115, 559 and 415 enrolled 
patients with cancer in those areas respectively. In addition, 215 and 112 patients suffered from 
different gastrointestinal tumours and skull base tumours respectively. Brain and bone & soft tissue 
sarcomas were less frequently prevalent in the patient population of the included studies, with  
62 and 17 enrolled patients respectively. 
The majority of the patients were adults, with a median age of all included patients above 18 years 
and the gender was predominantly male due to the large proportion of prostate cancer patients 
enrolled in the included studies. 
Within all enrolled patients,the stage and histology of the tumours were heterogenous of the 
included studies due to the scope of this assessment. 
Intervention Carbon ion radiotherapy was used as the intervention in all of the included studies at different 
dosages. However, varieties of co-interventions (e.g., prior chemotherapy, surgery, photon RT, 
androgen deprivation therapy, etc.) were indicated for the enrolled patients, depending on the 
histology and grade of a tumour.In addition, 1 study described the use of raster scanned carbon ion 
as a boost (CIB) in combination with other forms of RT (e.g., intensity-modulated RT). 
Comparators Only 1 of the included studies, focusing on the safety of CIRT solely, included a comparison group. 
Indirect comparisons were undertaken by some of the included studies. Thus, efficacy and safety 
could insufficiently be assessed due to the lack of controlled studies. 
Outcomes Most of the included studies reported on mortality related endpoints that is; overall survival (OS) 
was most frequently reported but also other survival related crucial endpoints were reported by 
some of the included studies, such as progression-free survival (PFS) or disease-free survival (DFS). 
Most of the statistical tests for those outcomes were not performed to compare those outcomes 
with patients undergoing other types of radiotherapy. As such, only 5 studies ( 1 case series and  
1 case-control study in the ENT area and 2 case-control studies in the lung area) statistically compared 
the efficacy and/or safety related outcomes with patients undergoing other forms of radiotherapy. 
Some studies used a historical control group, and others used a case-control study design. As such, 
most of the studies used statistical tests to either elaborate predictor variables for certain outcomes, 
and/or to elaborate the ideal dose for CIRT (i.e., the studies with a dose-escalation study design). 
Other crucial patient-reported outcomes (PRO) such as Health-related Quality of Life were only 
reported in some of the included studies. 
For safety parameters, a variety of different acute and late radiation morbidities were observed,  
and only 1 study compared those with a historical control of conventional radiotherapy. 
Setting One of the included studies was a multi-centre study. The rest of the studies were single centre 
studies. All of the included studies were based in Japan or Germany, with 21 and 6 included studies 
from those countries respectively. Many ongoing studies are currently undertaken in the same 
geographical regions, but ongoing controlled studies were also found in countries such as Italy, 
France and China. 
All included studies were published between 2005 and 2017. Applicability issues regarding the 
different geographical settings are not expected. 
 
 
                                                             
114 Patients may have enrolled in multiple studies. In case it was clearly stated or obvious (i.e., quality of life assess-
ments of patients being enrolled in other included studies), patients were only calculated once for the applicability 
table. 
115 2 included studies [134, 135], assessed the quality of life for 611 patients being already included in other included 
studies. The reader is referred to the data extraction table (Table A-7) for more information. 
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List of ongoing randomised and non-randomised clinical trials 
Table A-17: Ongoing controlled studies elaborating on the efficacy and/or safety of carbon ion radiotherapy (CIRT) 
Source & 
Identifier/ 
Trial Name Conditions Phase 
Target 
Group 
Study 
Types 
Study  
Designs Intervention Comparison 
Enrolled 
Patients 
Primary 
Outcome 
Primary 
Completion 
Date Sponsor 
Bone and Soft Tissue Sarcoma 
ClinicalTrials.gov 
NCT01811394 
Sacral 
Chordoma 
Ph. 2 Adults Interven
tional 
Allocation: 
Randomised/Interven
tion Model: Parallel 
Assignment/Masking: 
None (Open-Label)/ 
Primary Purpose: 
Treatment 
PRT: Treatment  
is performed using  
16 x 4 GyE protons 
CIRT: Treatment  
is performed using  
16 x 4 GyE C-ions 
100 Safety and 
feasibility 
(incidence 
of Grade  
3-5 toxicity) 
June  
2020 
Heidelberg 
University 
ClinicalTrials.gov 
NCT02986516 
Sacral 
Chordoma 
NR Adults Interven
tional 
Allocation: 
Randomised/Interven
tion Model: Parallel 
Assignment/Masking: 
None (Open-Label)/ 
Primary Purpose: 
Treatment 
Randomised Cohort: 
Surgical treatment with 
a different approach, 
based on the charac-
teristics of the tumour 
or definitive high dose 
radiotherapy (carbon 
ion radiotherapy, 
proton-therapy,  
mixed photons-proton 
therapy) will be 
assigned by 
randomization 
Prospective cohort: 
Surgical treatment or 
definitive high dose 
radiotherapy will be 
selected by the 
patients and will  
be prospectively 
evaluated 
100 Relapse-
Free 
Survival 
(RFS) 
September 
2021 
Italian 
Sarcoma 
Group 
Brain & skull base Cancer 
ClinicalTrials.gov 
NCT01182779 
Chordoma Ph. 3 Adults Interven
tional 
Allocation: 
Randomised 
Intervention Model: 
Parallel Assignment 
Masking: None  
(Open Label) 
Primary Purpose: 
Treatment 
CIRT: Total dose to 
the PTV2 - 45 Gy E in 
3 Gy E/d, 4-6 days a 
week, 15 fractions 
Total dose to the  
PTV1 - 63 Gy E ± 5%, 
further 5-7 fractions  
a 3 Gy E 
PRT: Total dose to the 
PTV2 - 50 to 56 Gy E in 
2 Gy E/d, 4-6 days a 
week, 28 fractions 
Total dose to the  
PTV1 - 72 Gy E ± 5%, 
further 6-9 fractions  
a 2 Gy E 
319 Local-
progression-
free  
survival 
(LPFS) 
August 
2015116 
Heidelberg 
University 
                                                             
116 The completion date is unknown: no study publishing results of this study was identified through the systematic search.  
The last update of the study in clinicaltrials.gov was in August 2010 (see https://clinicaltrials.gov/ct2/show/NCT01182779, download on 10/10/2018). 
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Source & 
Identifier/ 
Trial Name Conditions Phase 
Target 
Group 
Study 
Types 
Study  
Designs Intervention Comparison 
Enrolled 
Patients 
Primary 
Outcome 
Primary 
Completion 
Date Sponsor 
ClinicalTrials.gov 
NCT01795300 
Meningioma Ph. 1/ 
Ph. 2 
Adults Interven
tional 
Allocation: 
Randomised 
Intervention Model: 
Parallel Assignment 
Masking: None  
(Open Label) 
Primary Purpose: 
Treatment 
CIRT: Total Dose  
45 Gy E, 15 fractions,  
3 Gy E single dose; PRT: 
45 Gy E, 15 fractions,  
3 Gy E single dose; 
Hypofractionated 
Photon Therapy: 3 Gy E 
Total Dose 45 Gy E,  
15 fractions, 3 Gy E 
single dose; 
Conventional Photon 
Radiotherapy: 1.8 Gy E 
Total Dose 57.6 Gy E, 
32 fractions, 1.8 Gy E 
single dose 
80 Toxicity 
graded 
according 
to CTCAE 
Version 4.1 
after 1 year 
February 
2015117 
University 
Hospital 
Heidelberg 
ClinicalTrials.gov 
NCT01182753 
Chondro-
sarcoma 
Ph. 3 Adults Interven
tional 
Allocation: 
Randomised 
Intervention Model: 
Parallel Assignment 
Masking: None  
(Open Label) 
Primary Purpose: 
Treatment 
CIRT: Total dose to 
the PTV2 - 45 Gy E in 
3 Gy E/d, 4 - 6 days a 
week, 15 fractions 
Total dose to the  
PTV1 - 60 Gy E ± 5%, 
further 4 - 6 fractions 
a 3 Gy E 
PRT: Total dose to the 
PTV2 - 50 to 56 Gy E 
in 2 Gy E/d, 4 - 6 days 
a week, 25 - 28 
fractions Total dose 
to the PTV1 - 70 Gy E 
± 5%, further 6 - 10 
fractions a 2 Gy E 
154 Local-
Progression 
Free 
Survival 
(LPFS) 
[Time 
Frame:  
5 years] 
August 
2022 
Heidelberg 
University 
ClinicalTrials.gov 
NCT01165671 
Primary 
Glioblastoma 
Ph. 2 Adults Interven
tional 
Allocation: 
Randomised/Interven
tion Model: Parallel 
Assignment/Masking: 
None (Open-Label)/ 
Primary Purpose: 
Treatment 
CIRT: up to 18 Gy E in 
3 Gy E fractions to the 
macroscopic tumour 
Proton Radiotherapy: 
up to 10 Gy E in 2 Gy E 
fractions to the 
macroscopic tumour 
150 Overall 
Survival/ 
Progression-
free 
Survival/ 
Toxicity 
June 
2014118 
University 
Hospital of 
Heidelberg 
(Germany) 
ClinicalTrials.gov 
NCT01166308 
Recurrent 
Gliomas 
Ph. 1/ 
Ph. 2 
Adults Interven
tional 
Allocation: 
Randomised/Interven
tion Model: Parallel 
Assignment/Masking: 
None (Open-Label)/ 
Primary Purpose: 
Treatment 
CIRT: 10 x 3Gy E to  
16 x 3 Gy E 
Fractionated Stereo-
tactic Radiotherapy 
(FSRT): Standard 
Treatment as Re-
Irradiation performed 
as Fractionated Stereo-
tactic Radiotherapy 
(FSRT)up to 36 Gy in 
single doses of 2 Gy 
436 Overall 
Survival/ 
Progression-
free  
Survival 
July 
2014119 
University 
Hospital of 
Heidelberg 
(Germany) 
                                                             
117 The completion date is unknown: No study publishing results of this study was identified through the systematic search.  
The last update of the study in clinicaltrials.gov was in February 2013 (see https://clinicaltrials.gov/ct2/show/NCT01795300, download on 10/10/2018).  
118 1 publication [177] was identified within the systematic literature review: no results were included in this publication. Information regarding this study  
on the website on clinicaltrials.gov was last updated on 20/02/2013 (see https://clinicaltrials.gov/ct2/show/NCT01165671, download on 01/02/2018). 
119 1 publication [178] (study protocol) was identified within the systematic literature review: no results were included in this publication. Information regarding  
this study on the website on clinicaltrials.gov was last updated on 20/02/2013 (see https://clinicaltrials.gov/ct2/show/NCT01166308, download on 02/02/2018). 
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Source & 
Identifier/ 
Trial Name Conditions Phase 
Target 
Group 
Study 
Types 
Study  
Designs Intervention Comparison 
Enrolled 
Patients 
Primary 
Outcome 
Primary 
Completion 
Date Sponsor 
Cancer in the Ear-Nose-Throat Region 
ClinicalTrials.gov 
NCT02838602 
Adenoid 
Cystic 
Carcinoma 
and Sarcoma 
NR Adults Interven
tional 
Randomised, parallelly 
assigned, open-label, 
controlled study 
Radiation:  
C-ions therapy 
Radiation: Advanced 
external radiotherapy 
by X-rays or protons 
250 Progression-
free  
survival 
(PFS) 
May  
2024 
Hospices 
Civils de 
Lyon 
Gastrointestinal (GI) Carcinoma 
ClinicalTrials.gov 
NCT02802124 
Hepato-
cellular 
Carcinoma 
Ph. 1 Adults Interven
tional 
Allocation: Non-
Randomised/Interven
tion Model: Parallel 
Assignment/Masking: 
None (Open 
Label)/Primary 
Purpose: Treatment 
CIRT: Four dose levels 
[55 Gray equivalent 
(GyE)/10 fractions 
(Fx), 60GyE/10Fx, 
65GyE/10Fx, 
70GyE/10Fx] 
PRT + CIRT: Four dose 
levels (proton 50GyE/ 
25Fx+ carbon 15GyE/ 
5Fx, proton 34GyE/ 
17Fx+ carbon 30GyE/ 
10Fx, proton 18GyE/ 
9Fx+ carbon 45GyE/ 
15Fx, carbon 60GyE/ 
20Fx) 
48 Number of 
participants 
with treat-
ment-related 
adverse 
events as 
assessed by 
CTCAE v4.0 
June  
2019 
Shanghai 
Proton and 
Heavy Ion 
Center 
Lung Cancer 
Particle Therapy 
Co-Operative 
Group 
UMIN000023183 
Small-sized 
peripheral 
non-small 
cell lung 
cancer with 
clinical 
stage IA 
Ph. 2 Adults Interven
tional 
Parallel, non-
randomised, open-
label, controlled study 
CIRT: not specified Surgical removal 525 Five-year 
overall 
survival 
(OS) 
NR120 Kanagawa 
Cancer 
Center, 
Kanagawa 
Prefectural 
Hospital 
Organization 
Abbreviations: CIRT – carbon ion radiotherapy; CTCAE – Common Terminology Criteria for Adverse Events; Fx. – fraction; Gy – gray; GyE – gray equivalent; Ph. – Phase. 
 
                                                             
120 The anticipated start of the trial was in August 2016. No information regarding the estimated completion date is provided  
(see https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000026513, download on 10.10.2017).  
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Potential indications for the use of carbon ion 
radiotherapy (CIRT) according to clinical studies  
Table A-18: Potential indications for CIRT according to the MedAustron list  
(frequencies of identified clinical studies with patients with specific indications) 
 
Indication 
The frequency of clinical studies 
including pts with indication 
Skull Base Tumours Skull base tumours  
 Chordoma 6 
 Chondrosarcoma 6 
 Meningioma grade II/grade III 4 
 Meningioma grade I (complex) 2 
 Craniopharyngioma 1 
 Pituitary adenoma (not suitable for stereotaxy) 1 
 Acoustic neuroma 0 
 Other neurinomas 0 
 Glomus tumour 0 
 Retinoblastoma 0 
 Lacrimal gland tumours 1 
 Sarcomas incl. Ewing's sarcoma 0 
 Rhabdomyosarcomas of the skull base and orbit 0 
Eye Choroid Melanoma 1 
Brain Brain  
 Glioma grade II 3 
 Glioma grade III 3 
 Glioblastoma 3 
 Ependymoma 0 
 Medulloblastoma 0 
 Other childhood brain tumours 0 
 Orbital tumours121 1 
ENT-Tumours ENT-Tumours  
 Tumour of the nasal cavity and paranasal sinus 5 
 Maxillary sinus carcinoma 3 
 Nasopharyngeal carcinoma122 3 
 Oropharyngeal carcinoma122 3 
 Tonsil carcinoma 0 
 Tongue base carcinoma 0 
 Salivary gland carcinoma (pleomorphic) 0 
 Salivary gland carcinoma (adenoid cystic) 5 
 Sarcoma in the ENT area including Ewing's sarcoma 1 
 Rhabdomyosarcoma 0 
                                                             
121 The classification of orbita tumours may be confused here. In this assessment, information on orbita tumours can 
be found in the ear-nose-throat region. 
122 Region not specified in the identified studies: may include naso- or oropharynxcarcinoma. 
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Indication 
The frequency of clinical studies 
including pts with indication 
Lung Non-small cell lung carcinomas (NSCLC)123 8 
 Mediastinal tumours (including thymoma) 0 
 Pleural mesothelioma 0 
Gastrointestinal Tumours Gastrointestinal tumours  
 Esophageal carcinoma 1 
 Pancreatic cancer 0 
 Liver carcinoma 2 
 Rectal carcinoma recurrence presacral 1 
 Schwannomas/malignant schwannomas 0 
 Ewing's sarcoma 0 
Bone and Soft Tissue Bone and soft tissue  
 Osteosarcoma 2 
 Soft tissue sarcoma 2 
 Sacral chordoma 1 
 Sacral chondrosarcoma 2 
 Spinal meningiomas 0 
Prostate Cancer Prostate cancer 11 
Breast Cancer Breast cancer (left, young, patient) 0 
Kidney Nephroblastoma 0 
Nervous System Neuroblastoma124 0 
“Hematologic Cancer” Non-Hodgkin's lymphoma (in exceptional cases) 0 
 Hodgkin's lymphoma 0 
Other  Solitary liver metastases in colorectal cancer 0 
 Retroperitoneal metastases in controlled  
primary tumours 
0 
 Oligometastases in controlled primary tumours  
in selected indications125 
1 
Abbreviations: ENT – Ear-Nose-Throat; pts – patients;  
 
 
                                                             
123 8 studies with NSCLC patients and 1 further study [175] enrolled patients with oligo-recurrence in the lung in the 
sample. Therefore, 9 studies were identified for lung cancer in total. 
124 Only 1 study (n=35) [31] included 5 patients with olfactory neuroblastomas in their sample. For more information 
on this study, see the data extraction table for cancer in the ENT region (Table A-4). 
125 The identified study [175] enrolled patients with oligo-recurrence in the lung in the sample. 
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Table A-19: Skull base tumours – identified studies according to study design,  
sample size and specific indications according to the list of potential indications for carbon ion radiotherapy (CIRT 126) 
Name of first author,  
year of publication 
Study  
Design 
Chordoma/ 
Chondro-
sarcoma127 
Meningioma Grade II/ 
Grad III or Grade I 
(complex) 
Cranio-
pharyngioma 
Pituitary 
adenoma 
Lacrimal  
gland tumours 
Number of patients 
enrolled in the clinical 
studies receiving CIRT 
Number of patients 
enrolled in the  
clinical studies 
Combs, 2009 [162] Case series 17     17 17 
Combs, 2013 [163] Case series  107 5 14  84 260 
Combs, 2013 [164] Case series  70    26 70 
Debus, 2000 [165] Case series 27 6    45 45 
Mizoe, 2009 [44] Case series 33     33 33 
Mizoguchi, 2015[166] Case series     21 21 21 
Rieken, 2012 [167] Case series  7    33 33 
Schulz-Ertner, 2002 [168] Case series 37     37 37 
Schulz-Ertner, 2003 [169] Case series 74     74 74 
Schulz-Ertner, 2007 [43] Case series 54     54 54 
Takahashi, 2009 [170] Case series 32     32 32 
Uhl, 2014 [42] Case series 25     25 25 
Total 299 190 5 14 21 481 701 
 
Table A-20: Tumours in the brain region – identified studies according to study design,  
sample size and specific indications according to the list of potential indications for carbon ion radiotherapy (CIRT)  
Name of first author,  
year of publication 
Study  
design 
Glioma  
Grade II 
Glioma  
Grade III Glioblastoma 
Number of patients enrolled in  
the clinical studies receiving CIRT 
Number of patients enrolled  
in the clinical studies 
Combs, 2013a [163] Case series 51 26 29 84 260 
Hasegawa, 2012 [69] Case series 14   14 14 
Mizoe, 2007 [68] Case series  16 32 48 48 
Rieken, 2012 [167] Case series 5 3 18 26 33 
Total 70 45 79 172 355 
                                                             
126 The number of patients for specific tumour entities in those studies refers to the total number of patients enrolled in the clinical study and not to the CIRT patients.  
In Combs, 2013 [163], for instance, 84 out of 260 patients received CIRT. 
127 In total, 8 studies were identified for chordomas and chondrosarcomas. Some of the studies had only chordomas or chondrosarcomas in their sample. Due to practical reasons, those 
studies were summed up: Mizoe, 2009 [44] had only patients with chordomas in their sample and Schulz-Ertner, 2002 [168] had only patients with chondrosarcomas in their sample. 
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Table A-21: Prostate cancer – identified studies according to study design, sample size and specific indications according to the list of potential indications for carbon ion radiotherapy (CIRT) 
Name of first Author  
and year of publication Study Design 
Number of patients enrolled  
in the clinical studies receiving CIRT 
Number of patients enrolled  
in the clinical studies 
Akakura, 2004 [159] Case series 247 247 
Habl, 2016 [132] RCT 45 92 
Ishikawa, 2006 [139] Case series 175 175 
Ishikawa, 2015 [133] Before-After Study & case series study 76 76 
Maruyama, 2017 [134]128 Before-After Study   
Nikoghosyan, 2011 [136] Case series 14 14 
Nomiya, 2016 [138] Multi-institutional observational 
studies/case series 
2,157 2,157 
Shimazaki, 2010 [160] Case series 254 254 
Shimazaki, 2006 [161] Case series 37 37 
Tsuji, 2005 [137] Case series 201 201 
Wakatsuki, 2008 [135]129 Before-After Study   
Total 3,206 3,253 
Abbreviations: CIRT – carbon ion radiotherapy 
 
  
                                                             
128 417 patients were included in this assessment to assess health related quality of life (HRQoL) before and after CIRT.  
However, those patients are assumed to be included in [138]. Thus, those patients were only counted once in this analysis. 
129 194 patients were included in this assessment to assess health related quality of life (HRQoL) before and after CIRT.  
However, those patients are assumed to be included in [137]. Thus, those patients were only counted once in this analysis. 
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Table A-22: Lung cancer region – identified studies according to study design,  
sample size and specific indications according to the list of potential indications for carbon ion radiotherapy (CIRT)  
Name of first Author and year of publication Study Design Indication CIRT pts enrolled in the clinical study Patients enrolled in the clinical study 
Iwata, 2010 [100] Case-control study NSCLC 23 80 
Iwata, 2013 [99] Case-control study NSCLC 27 70 
Koto, 2004 [30] Case series NSCLC 81 81 
Miyamoto, 2003130 [29] Case series NSCLC   
Miyamoto, 2007a[102] Case series NSCLC 79 79 
Miyamoto, 2007b [101] Case series NSCLC 50 50 
Takahashi, 2015 [98] Case series NSCLC 62 62 
Yamamoto, 2013 [175] Case series Oligo-recurrence in the lung 91 91 
Yamamoto, 2017 [97] Case series NSCLC 218 218 
Total patients 631 731 
Abbreviations: CIRT – carbon ion radiotherapy; NSCLC – non-small cell lung cancer  
 
Table A-23: Cancer in the Ear-Nose-Throat (ENT) region – identified studies according to study design,  
sample size and specific indications according to the list of potential indications for carbon ion radiotherapy (CIRT)  
Name of first author  
and year of publication Study design 
Tumours in the 
nasal cavity and 
paranasal sinus 
Maxillary sinus 
carcinomas 
Pharynx 
carcinoma131 
adenoid cystic 
salivary gland 
tumours 
Sarcomas in 
the head and 
neck region Orbita 
CIRT 
patients 
Patients 
enrolled in the 
clinical study 
Jingu, 2012 [86] Case series 11    27  27 27 
Mizoe, 2004 [32] Case series 10 2 7 4   36 36 
Mizoe, 2012 [33] Case series 116 2 23 15  20 236 236 
Schulz-Ertner, 2005 [87] Case-control study    63   29 63 
Shirai, 2017 [31] Case series 18 9 4 6   35 35 
Yanagi, 2009 [172] Case series 60      72 72 
Jensen, 2015 [85] Case series    54   54 54 
Total 215 13 34 142 27 20 489 523 
                                                             
130 2 studies [29, 30] are assumed to have reported on the same 81 patients in their studies. It was found out considerably late in the assessment and both of the studies  
were excluded for the qualitative synthesis because of high risk of bias. Therefore, those patients were only counted once in the analysis. 
131 Region not specified in the identified studies: may include naso- or oropharynxcarcinoma. 
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Table A-24: Cancer in the bone and soft tissue area – identified studies according to study design,  
sample size and specific indications according to the list of potential indications for carbon ion radiotherapy (CIRT)  
Name of first author  
and year of publication 
Study  
design 
Soft Tissue 
Sarcoma Osteosarcoma 
Sacral 
Chordoma 
Sacral 
Chondrosarcoma 
Number of patients enrolled in  
the clinical studies receiving CIRT 
Number of patients enrolled 
in the clinical studies 
Kamada, 2002 [176] Case series 16 15 11 6 57 57 
Sugahara, 2012[126] Case series 13 3  1 17 17 
Total 29 18 11 7 74 74 
 
Table A-25: Cancer in the gastrointestinal region – identified studies according to study design,  
sample size and specific indications according to the list of potential indications for carbon ion radiotherapy (CIRT)  
Name of first Author  
and year of publication 
Study  
design 
Oesophagus  
carcinoma 
Liver 
carcinoma 
Rectal  
carcinoma 
Number of patients enrolled in  
the clinical studies receiving CIRT 
Number of patients enrolled 
in the clinical studies 
Akutsu, 2012 [106] Case series 31   31 31 
Kasuya, 2017 [173] Case series  124  124 124 
Kato, 2004 [174] Case series  24  24 24 
Yamada, 2016 [107] Case series   184 184 184 
Total 31 148 184 363 363 
 
Table A-26: Cancer in the eye region identified studies according to study design,  
sample size and specific indications according to the list of potential indications for carbon ion radiotherapy (CIRT)  
Name of first Author  
and year of publication 
Study  
Design 
Choroid  
Melanoma 
Number of patients enrolled  
in the clinical studies receiving CIRT 
Number of patients enrolled  
in the clinical studies 
Tsuji, 2007 [171] Case series 59 59 59 
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Table A-27: Cancer in the gynecologic region – identified studies according to study design and sample size  
Name of first Author and year of publication Study design Number of patients enrolled in the clinical studies receiving CIRT Number of patients enrolled in the clinical studies 
Kato 2006 [179] Case series 44 44 
Nakano 2006 [180] Case series 49 49 
Nakano 1999 [181] Case series 31 31 
Wakatsuki 2015a [182] Case series 26 26 
Wakatsuki 2014a [184]132 Case series   
Wakatsuki 2014b [185]133 Case series   
Wakatsuki 2015b [183] Case series 91 91 
Total 241 241 
 
Table A-28: Cancer in the skin region – identified studies according to study design and sample size  
Name of first Author and year of publication Study design Number of patients enrolled in the clinical studies receiving CIRT Number of patients enrolled in the clinical studies 
Zhang 2012 [186] Case series 45 45 
 
 
 
                                                             
132 22 patients were enrolled in this study. Those patients were also included in the dose-escalation, case series study of Wakatsuki 2015b [183]. None of the studies was excluded for 
research question 1, since different outcomes were measured. However, patients were only included once in the estimation of patients having been treated with CIRT in those 
clinical studies. 
133 58 patients were enrolled in this study. Those patients were also included in the dose-escalation, case series study of Wakatsuki 2015b [183]. None of the studies was excluded for 
research question 1, since different outcomes were measured. However, patients were only included once in the estimation of patients having been treated with CIRT in those 
clinical studies. 
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Literature search strategies 
Search strategy for Cochrane 
Search Name: Carbon-Ions in Cancer Therapies 
Search Date: 07/09/2017  
ID Search 
#1 MeSH descriptor: [Heavy Ion Radiotherapy] explode all trees 
#2 MeSH descriptor: [Ions] this term only and with qualifier(s): [Therapeutic use - TU] 
#3 MeSH descriptor: [Heavy Ions] explode all trees and with qualifier(s): [Therapeutic use - TU] 
#4 carbon ion* near (therap* or treat* or radiotherap* or radio-therap* or regimen* or program*) (Word 
variations have been searched) 
#5 #1 or #2 or #3 or #4 
#6 MeSH descriptor: [Neoplasms] explode all trees 
#7 MeSH descriptor: [Carcinoma] explode all trees 
#8 neoplasm* or cancer* or tumor* or tumour* or carcinoma* or oncolog* (Word variations have been 
searched) 
#9 #6 or #7 or #8 
#10 #5 and #9 in Trials 
Total: 44 Hits 
 
 
Search strategy for CRD 
Search Name: Carbon-Ion Therapy 
Search Date: 07/09/2017  
ID Search 
#1 MeSH DESCRIPTOR Heavy Ion Radiotherapy EXPLODE ALL TREES 
#2 MeSH DESCRIPTOR Ions WITH QUALIFIER TU 
#3 MeSH DESCRIPTOR Heavy Ions EXPLODE ALL TREES WITH QUALIFIER TU 
#4 (carbon ion* NEAR (therap* OR treat* OR radiotherap* OR radio-therap* OR regimen* OR program*)) 
#5 #1 OR #2 OR #3 OR #4 
Total: 11 Hits 
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Search strategy for Embase 
Search Name: Carbon-Ions in Cancer Therapies 
Search Date: 07/09/2017 18:01:40.183 
ID Query results Results Date 
#20 ((('carbon ion radiotherapy'/exp OR 'carbon ion radiation'/exp OR 'carbon ion 
irradiation'/exp OR 'ion therapy'/exp OR 'heavy ion radiation'/exp OR 'heavy 
ion'/exp/dd_dt OR 'ion'/mj/dd_dt OR ('carbon ion*' NEAR/3 (therap* OR treat* OR 
radiotherap* OR 'radio therap*' OR regimen* OR program*)):ti,ab) AND 
('malignant neoplasm'/exp OR 'neoplasm'/exp OR 'carcinoma'/exp OR (neoplasm* 
OR cancer* OR tumor* OR tumour* OR carcinoma* OR oncolog*))) AND 
('clinical trial'/de OR 'phase 1 clinical trial'/de OR 'phase 2 clinical trial'/de)) OR 
((('carbon ion radiotherapy'/exp OR 'carbon ion radiation'/exp OR 'carbon ion 
irradiation'/exp OR 'ion therapy'/exp OR 'heavy ion radiation'/exp OR 'heavy 
ion'/exp/dd_dt OR 'ion'/mj/dd_dt OR ('carbon ion*' NEAR/3 (therap* OR treat* OR 
radiotherap* OR 'radio therap*' OR regimen* OR program*)):ti,ab) AND 
('malignant neoplasm'/exp OR 'neoplasm'/exp OR 'carcinoma'/exp OR (neoplasm* 
OR cancer* OR tumor* OR tumour* OR carcinoma* OR oncolog*))) AND 
([controlled clinical trial]/lim OR [randomized controlled trial]/lim)) OR 
((('carbon ion radiotherapy'/exp OR 'carbon ion radiation'/exp OR 'carbon ion 
irradiation'/exp OR 'ion therapy'/exp OR 'heavy ion radiation'/exp OR 'heavy 
ion'/exp/dd_dt OR 'ion'/mj/dd_dt OR ('carbon ion*' NEAR/3 (therap* OR treat* OR 
radiotherap* OR 'radio therap*' OR regimen* OR program*)):ti,ab) AND 
('malignant neoplasm'/exp OR 'neoplasm'/exp OR 'carcinoma'/exp OR (neoplasm* 
OR cancer* OR tumor* OR tumour* OR carcinoma* OR oncolog*))) AND 
('crossover procedure':de OR 'double-blind procedure':de OR 'randomized 
controlled trial':de OR 'single-blind procedure':de OR random*:de,ab,ti OR 
factorial*:de,ab,ti OR crossover*:de,ab,ti OR ((cross NEXT/1 over*):de,ab,ti) OR 
placebo*:de,ab,ti OR ((doubl* NEAR/1 blind*):de,ab,ti) OR ((singl* NEAR/1 
blind*):de,ab,ti) OR assign*:de,ab,ti OR allocat*:de,ab,ti OR volunteer*:de,ab,ti)) 
282 7 Sep 2017 
#19 (('carbon ion radiotherapy'/exp OR 'carbon ion radiation'/exp OR 'carbon ion 
irradiation'/exp OR 'ion therapy'/exp OR 'heavy ion radiation'/exp OR 'heavy 
ion'/exp/dd_dt OR 'ion'/mj/dd_dt OR ('carbon ion*' NEAR/3 (therap* OR treat* OR 
radiotherap* OR 'radio therap*' OR regimen* OR program*)):ti,ab) AND 
('malignant neoplasm'/exp OR 'neoplasm'/exp OR 'carcinoma'/exp OR (neoplasm* 
OR cancer* OR tumor* OR tumour* OR carcinoma* OR oncolog*))) AND 
('crossover procedure':de OR 'double-blind procedure':de OR 'randomized 
controlled trial':de OR 'single-blind procedure':de OR random*:de,ab,ti OR 
factorial*:de,ab,ti OR crossover*:de,ab,ti OR ((cross NEXT/1 over*):de,ab,ti) OR 
placebo*:de,ab,ti OR ((doubl* NEAR/1 blind*):de,ab,ti) OR ((singl* NEAR/1 
blind*):de,ab,ti) OR assign*:de,ab,ti OR allocat*:de,ab,ti OR volunteer*:de,ab,ti) 
134 7 Sep 2017 
#18 'crossover procedure':de OR 'double-blind procedure':de OR 'randomized 
controlled trial':de OR 'single-blind procedure':de OR random*:de,ab,ti OR 
factorial*:de,ab,ti OR crossover*:de,ab,ti OR ((cross NEXT/1 over*):de,ab,ti) OR 
placebo*:de,ab,ti OR ((doubl* NEAR/1 blind*):de,ab,ti) OR ((singl* NEAR/1 
blind*):de,ab,ti) OR assign*:de,ab,ti OR allocat*:de,ab,ti OR volunteer*:de,ab,ti 
2,121,462 7 Sep 2017 
#17 (('carbon ion radiotherapy'/exp OR 'carbon ion radiation'/exp OR 'carbon ion 
irradiation'/exp OR 'ion therapy'/exp OR 'heavy ion radiation'/exp OR 'heavy 
ion'/exp/dd_dt OR 'ion'/mj/dd_dt OR ('carbon ion*' NEAR/3 (therap* OR treat* OR 
radiotherap* OR 'radio therap*' OR regimen* OR program*)):ti,ab) AND 
('malignant neoplasm'/exp OR 'neoplasm'/exp OR 'carcinoma'/exp OR (neoplasm* 
OR cancer* OR tumor* OR tumour* OR carcinoma* OR oncolog*))) AND 
([controlled clinical trial]/lim OR [randomized controlled trial]/lim) 
63 7 Sep 2017 
#16 (('carbon ion radiotherapy'/exp OR 'carbon ion radiation'/exp OR 'carbon ion 
irradiation'/exp OR 'ion therapy'/exp OR 'heavy ion radiation'/exp OR 'heavy 
ion'/exp/dd_dt OR 'ion'/mj/dd_dt OR ('carbon ion*' NEAR/3 (therap* OR treat* OR 
radiotherap* OR 'radio therap*' OR regimen* OR program*)):ti,ab) AND 
('malignant neoplasm'/exp OR 'neoplasm'/exp OR 'carcinoma'/exp OR (neoplasm* 
OR cancer* OR tumor* OR tumour* OR carcinoma* OR oncolog*))) AND 
('clinical trial'/de OR 'phase 1 clinical trial'/de OR 'phase 2 clinical trial'/de) 
172 7 Sep 2017 
#15 ('carbon ion radiotherapy'/exp OR 'carbon ion radiation'/exp OR 'carbon ion 
irradiation'/exp OR 'ion therapy'/exp OR 'heavy ion radiation'/exp OR 'heavy 
ion'/exp/dd_dt OR 'ion'/mj/dd_dt OR ('carbon ion*' NEAR/3 (therap* OR treat* OR 
radiotherap* OR 'radio therap*' OR regimen* OR program*)):ti,ab) AND 
('malignant neoplasm'/exp OR 'neoplasm'/exp OR 'carcinoma'/exp OR (neoplasm* 
OR cancer* OR tumor* OR tumour* OR carcinoma* OR oncolog*)) 
1,872 7 Sep 2017 
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#14 'malignant neoplasm'/exp OR 'neoplasm'/exp OR 'carcinoma'/exp OR (neoplasm* 
OR cancer* OR tumor* OR tumour* OR carcinoma* OR oncolog*) 
5,525,971 7 Sep 2017 
#13 neoplasm* OR cancer* OR tumor* OR tumour* OR carcinoma* OR oncolog* 5,060,901 7 Sep 2017 
#12 'carcinoma'/exp 1,040,879 7 Sep 2017 
#11 'neoplasm'/exp 4,164,393 7 Sep 2017 
#10 'malignant neoplasm'/exp 3,064,172 7 Sep 2017 
#9 'carbon ion radiotherapy'/exp OR 'carbon ion radiation'/exp OR 'carbon ion 
irradiation'/exp OR 'ion therapy'/exp OR 'heavy ion radiation'/exp OR 'heavy 
ion'/exp/dd_dt OR 'ion'/mj/dd_dt OR ('carbon ion*' NEAR/3 (therap* OR treat* OR 
radiotherap* OR 'radio therap*' OR regimen* OR program*)):ti,ab 
2,545 7 Sep 2017 
#8 ('carbon ion*' NEAR/3 (therap* OR treat* OR radiotherap* OR 'radio therap*' OR 
regimen* OR program*)):ti,ab 
1,047 7 Sep 2017 
#7 'ion'/mj/dd_dt 27 7 Sep 2017 
#6 'heavy ion'/exp/dd_dt 68 7 Sep 2017 
#5 'heavy ion radiation'/exp 715 7 Sep 2017 
#4 'ion therapy'/exp 1,456 7 Sep 2017 
#3 'carbon ion irradiation'/exp 17 7 Sep 2017 
#2 'carbon ion radiation'/exp  39 7 Sep 2017 
#1 'carbon ion radiotherapy'/exp 55 7 Sep 2017 
 
 
Search strategy for Medline via OVID 
Database:Ovid MEDLINE(R) <1946 to August Week 5 2017>, Ovid MEDLINE(R) Epub Ahead of Print <September 
06, 2017>, Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations <September 05, 2017>, Ovid MEDLINE(R) 
Daily Update <September 05, 2017 
Search Date: 05/09/2017 18:01:40.183 
ID Search 
1 exp Heavy Ion Radiotherapy/ (436) 
2 *Ions/tu, th [Therapeutic Use, Therapy] (70) 
3 exp *Heavy Ions/tu [Therapeutic Use] (205) 
4 exp Heavy Ion Radiotherapy/ (436) 
5 (carbon ion* adj3 (therap* or treat* or radio?therap* or regimen* or program*)).mp. (800) 
6 1 or 2 or 3 or 4 or 5 (1165) 
7 exp Neoplasms/ (3104407) 
8 exp Carcinoma/ (597801) 
9 (neoplasm* or cancer* or tumo?r* or carcinoma* or oncolog*).mp. (3644138) 
10 7 or 8 or 9 (4011737) 
11 6 and 10 (923) 
12 limit 11 to clinical trial, all (125) 
13 ((randomized controlled trial or controlled clinical trial).pt. or randomi#ed.ab. or placebo.ab. or drug 
therapy.fs. or randomly.ab. or trial.ab. or groups.ab.) not (exp animals/ not humans.sh.) (3693350) 
14 11 and 13 (184) 
15 12 or 14 (226) 
16 remove duplicates from 15 (203) 
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Study selection process: exclusion of full-text studies 
Table A-29: Excluded studies based on full-text evaluation with reasons 
Name Title Exclusion reason 
Akakura 2005 [187] Heavy particle therapy for prostate cancer Wrong language 
Akakura 2004 [159] Phase I/II clinical trials of carbon ion therapy for prostate 
cancer.[Erratum appears in Prostate. 2004 Sep 15;61(1):103] 
High RoB 
Akutsu 2012 [188] Heavy ion radiotherapy for esophageal cancer – To further progress 
in multidisciplinary treatment 
Wrong language 
Akutsu 2012 [189] A phase I/II clinical trial of preoperative short-course carbon-ion 
radiotherapy for patients with squamous cell carcinoma of the 
esophagus 
Only abstract 
Baba 2008 [190] Carbon ion radiotherapy in hypofraction regimen for stage I non-
small cell lung cancer 
Wrong language 
Blattmann 2010 [191] Non-randomized therapy trial to determine the safety and efficacy of 
heavy ion radiotherapy in patients with non-resectable osteosarcoma 
Protocol 
Castro 1980 [192] Radiotherapy with heavy charged particles at Lawrence Berkeley 
Laboratory 
Wrong intervention 
Combs 2010 [193] Carbon ion radiation therapy for high-risk meningiomas ≤10 pts 
Combs 2011 [194] Proton and carbon ion radiotherapy for primary brain tumors amd 
meningeomas delivered with active rasterscanning at the Heidelberg 
Ion Therapy Center (HIT): Initial treatment results and study concepts 
Only abstract 
Combs 2013 [164] Prospective evaluation of early treatment outcome in patients with 
meningiomas treated with particle therapy based on target volume 
definition with MRI and 68Ga-DOTATOC-PET 
High RoB 
Combs 2010 [178] Randomised phase I/II study to evaluate carbon ion radiotherapy 
versus fractionated stereotactic radiotherapy in patients with 
recurrent or progressive gliomas: the CINDERELLA trial 
Protocol 
Combs 2013b [14] Treatment with heavy charged particles: systematic review of 
clinical data and current clinical (comparative) trials 
HTA-Reports/ 
Systematic Reviews. 
Combs 2010 [195] Treatment of patients with atypical meningiomas Simpson grade 4 
and 5 with a carbon ion boost in combination with postoperative 
photon radiotherapy: the MARCIE trial 
Protocol 
Combs 2013 [163] Proton and carbon ion radiotherapy for primary brain tumors and 
tumors of the skull base 
High RoB 
Combs 2012 [196] Phase I/II trial evaluating carbon ion radiotherapy for the treatment 
of recurrent rectal cancer: the PANDORA-01 trial 
Protocol 
Combs 2010 [177] Randomized phase II study evaluating a carbon ion boost applied 
after combined radiochemotherapy with temozolomide versus a 
proton boost after radiochemotherapy with temozolomide in 
patients with primary glioblastoma: the CLEOPATRA trial 
Protocol 
Combs 2009 [162] Carbon ion radiotherapy for pediatric patients and young adults 
treated for tumors of the skull base 
High RoB 
Debus 2000 [165] [Carbon ion irradiation of skull base tumors at GSI. First clinical 
results and future perspectives] 
High RoB 
Fagundes 2016 [197] In Regard to Habl et al Commentary 
Grutters 2010 [12] Comparison of the effectiveness of radiotherapy with photons, protons 
and carbon-ions for non-small cell lung cancer: A meta-analysis 
HTA-Reports/ 
Systematic Reviews. 
Habermehl 2012 [198] Carbon ion therapy applied in raster scanning technique for 
hepatocellular carcinoma-first results from the Heidelberg Ion-Beam 
Therapy Center 
Only abstract 
Habl 2014 [157] Ion Prostate Irradiation (IPI) – a pilot study to establish the safety 
and feasibility of primary hypofractionated irradiation of the prostate 
with protons and carbon ions in a raster scan technique 
Protocol 
Hasegawa 2010 [199] Carbon ion radiotherapy for malignant head-and-neck tumors 
invading the skull base 
Only abstract 
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Hasegawa 2014 [200] Carbon ion radiotherapy for adenoid cystic carcinoma of the head 
and neck 
Only abstract 
Hasegawa 2011 [201] Carbon ion radiotherapy for adenoid cystic carcinoma of the head 
and neck 
Only abstract 
Hasegawa 2016 [202] Carbon ion radiotherapy for adenoid cystic carcinomas invading the 
skull base 
Only abstract 
Huybrechts 2007 [203] Hadronthérapie. KCE reports vol. 67B HTA-Reports/ 
Systematic Reviews. 
Igaki 2017 [15] A systematic review of publications on charged particle therapy for 
hepatocellular carcinoma 
HTA-Reports/ 
Systematic Reviews. 
Imada 2010 [204] Comparison of efficacy and toxicity of short-course carbon ion 
radiotherapy for hepatocellular carcinoma depending on their 
proximity to the porta hepatis 
Wrong study design 
Imai 2010 [205] Effect of carbon ion radiotherapy for sacral chordoma: results of 
Phase I-II and Phase II clinical trials 
Wrong study design 
Imai 2004 [206] Carbon ion radiotherapy for unresectable sacral chordomas Wrong study design 
Ishikawa 2012 [207] Carbon-ion radiation therapy for prostate cancer Wrong study design 
Ishikawa 2005 [208] A phase II trial using carbon ion radiotherapy (C-ion RT) for 
prostate cancer 
Only abstract 
Ishikawa 2006 [209] Clinical experience of carbon ion radiotherapy for malignant tumors Wrong language 
Jensen 2011 [210] Phase II study of induction chemotherapy with TPF followed by 
radioimmunotherapy with Cetuximab and intensity-modulated 
radiotherapy (IMRT) in combination with a carbon ion boost for locally 
advanced tumours of the oro-, hypopharynx and larynx – TPF-C-HIT 
Protocol 
Jensen 2011 [211] Carbon ion therapy for advanced sinonasal malignancies: feasibility 
and acute toxicity 
Wrong study design 
Jensen 2012 [212] IMRT and carbon ion boost for malignant salivary gland tumors: 
interim analysis of the COSMIC trial 
Double-Publication 
(same sample)134 
Kamada 2002 [176] Efficacy and safety of carbon ion radiotherapy in bone and soft 
tissue sarcomas 
published before 
2005 
Jensen 2011 [213] Treatment of malignant sinonasal tumours with intensity-modulated 
radiotherapy (IMRT) and carbon ion boost (C12) 
Protocol 
Jensen 2010 [214] Combined treatment of malignant salivary gland tumours with 
intensity-modulated radiation therapy (IMRT) and carbon ions: 
COSMIC 
Protocol 
Karasawa 2016 [215] A study of radical intent apbi using carbon-ion radiotherapy for 
patients with stage i breast cancer 
Only abstract 
Karasawa 2014 [216] Clinical trial of carbon ion radiotherapy for gynecological melanoma Wrong study design 
Karube 2015 [217] Single fraction carbon ion radiotherapy for 80 year old and over 
patients with stage I peripheral NSCLC 
Only abstract 
Karube 2016 [218] Single-Fraction Carbon-Ion Radiation Therapy for Patients 80 Years 
of Age and Older With Stage I Non-Small Cell Lung Cancer 
Double-Publication 
(same sample)135 
Kasuya 2017 [173] Progressive hypofractionated carbon-ion radiotherapy for 
hepatocellular carcinoma: Combined analyses of 2 prospective trials 
High RoB 
Kato 2001 [219] Charged particle (carbon-ion) therapy Wrong language 
Kato 2004 [174] Results of the first prospective study of carbon ion radiotherapy for 
hepatocellular carcinoma with liver cirrhosis 
published before 
2005 
Kato 2005 [220] Two-fraction carbon ion radiotherapy for hepatocellular carcinoma: 
Preliminary results of a phase I/II clinical trial 
Only abstract 
Kato 2009 [221] Carbon Ion radiotherapy for Hepatocellular Carcinoma Wrong language 
Kato 2006 [179] Dose escalation study of carbon ion radiotherapy for locally 
advanced carcinoma of the uterine cervix 
Wrong indication 
                                                             
134 The sample of this study is judged to be included in [85]. 
135 The sample of this study is judged to be included in [97]. 
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Kong 2016 [222] Phase I/II trial evaluating concurrent carbon-ion radiotherapy plus 
chemotherapy for salvage treatment of locally recurrent 
nasopharyngeal carcinoma 
Protocol 
Kong 2016 [223] Phase I/II Trial Evaluating Carbon Ion Radiotherapy for Salvaging 
Treatment of Locally Recurrent Nasopharyngeal Carcinoma 
Protocol 
Koto 2004 [30] Local control and recurrence of stage I non-small cell lung cancer 
after carbon ion radiotherapy 
High RoB 
Leroy 2015 [19] Hadron therapy in children – an update of the scientific evidence 
for 15 paediatric cancers. Synthesis. 
HTA-Reports/ 
Systematic Reviews 
Miyamoto 2002 [224] Heavy ion therapy for lung cancer Wrong language 
Miyamoto 2002 [225] Heavy-ion therapy for non-small cell lung cancer Wrong language 
Miyamoto 2003 [29] Carbon ion radiotherapy for stage I non-small cell lung cancer High RoB 
Miyawaki 2009 [226] Brain injury after proton therapy or carbon ion therapy for  
head-and-neck cancer and skull base tumors 
Wrong study design 
Mizoe 2005 [227] Carbon ion radiotherapy for brain tumors Wrong language 
Mizoe 2004 [32] Dose escalation study of carbon ion radiotherapy for locally 
advanced head-and-neck cancer 
High RoB 
Mizoguchi 2012 [228] Carbon-ion radiation therapy for locally advanced primary or 
postoperative recurrent epithelial carcinoma of lacrimal gland:  
A phase I/II dose-escalation study 
Only abstract 
Mizoguchi 2015 [166] Carbon-ion radiotherapy for locally advanced primary or 
postoperative recurrent epithelial carcinoma of the lacrimal gland 
High RoB 
Nakano 1999 [181] The phase I/II clinical study of carbon ion therapy for cancer of the 
uterine cervix 
Wrong indication 
Nakano 2006 [180] Carbon beam therapy overcomes the radiation resistance of uterine 
cervical cancer originating from hypoxia 
Wrong indication 
Nakayama 2017 [229] Carbon-ion therapy of lung cancer Only abstract 
Nathan 1995 [230] Weighing the benefits of heavy-ion therapy Commentary 
Nikoghosyan 2010 
[231] 
Randomised trial of proton vs. carbon ion radiation therapy in patients 
with chordoma of the skull base, clinical phase III study HIT-1-Study 
Protocol 
Nikoghosyan 2010 
[232] 
Randomised trial of proton vs. carbon ion radiation therapy in 
patients with low and intermediate grade chondrosarcoma of the 
skull base, clinical phase III study 
Protocol 
Nomiya 2013 [233] Up-to-date results of a clinical trial of carbon-ion radiotherapy for 
prostate cancer: Analysis of 1,144 patients 
Only abstract 
Ogino 2002 [234] Heavy charged particle radiation therapy for prostate cancers Wrong language 
Oonishi 2011 [235] Outcomes after short-course carbon ion radiotherapy for patients 
with hepatocellular carcinoma according to tumor size 
Only abstract 
Pijls-Johannesma 2008 
[11] 
Particle therapy in lung cancer: where do we stand? HTA-Reports/ 
Systematic Reviews 
Pommier 2012 [236] Medico-economical prospective randomized trials of carbon ions 
therapy 
Only abstract 
Ramaekers 2011 [13] Systematic review and meta-analysis of radiotherapy in various head 
and neck cancers: comparing photons, carbon-ions and protons 
HTA-Reports/ 
Systematic Reviews 
Ramaekers 2010 [237] Radiotherapy with photons, carbon-ions and protons in various head 
and neck cancers: A review and metaanalysis of observational studies 
Only abstract 
Rieken 2012 [167] Proton and carbon ion radiotherapy for primary brain tumors 
delivered with active raster scanning at the Heidelberg Ion Therapy 
Center (HIT): early treatment results and study concepts 
High RoB 
Schulz-Ertner 2002 [168] Radiotherapy for chordomas and low-grade chondrosarcomas of 
the skull base with carbon ions 
High RoB 
Schulz-Ertner 2004 [238] Results of carbon ion radiotherapy in 152 patients Wrong study design 
Schulz-Ertner 2003 [169] Carbon ion radiotherapy for chordomas and low-grade 
chondrosarcomas of the skull base. Results in 67 patients 
High RoB 
Serizawa 2009 [239] Carbon Ion Radiotherapy for Unresectable Retroperitoneal Sarcomas Wrong study design 
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Shimazaki 2006 [161] Monotherapy with carbon ion radiation for localized prostate cancer High RoB 
Shimazaki 2010 [160] Carbon ion radiotherapy for treatment of prostate cancer and 
subsequent outcomes after biochemical failure 
High RoB 
Shinoto 2015 [240] A phase II clinical trial of carbon-ion radiotherapy and concurrent S-
1 chemotherapy for locally advanced pancreatic cancer 
Protocol 
Shinoto 2009 [241] A phase I/II clinical trial of carbon ion therapy for patients with locally 
advanced pancreas cancer (protocol 0204, 12 fractions/3 weeks) 
Only abstract 
Sugane 2009 [242] Carbon ion radiotherapy for elderly patients 80 years and older with 
stage I non-small cell lung cancer 
Double-Publication 
(same sample)136 
Sulaiman 2014 [243] Particle beam radiation therapy using carbon ions and protons for 
oligometastatic lung tumors 
Wrong study design 
Takagi 2014 [244] Treatment outcomes of proton or carbon ion radiation therapy for 
chordoma of the skull base 
Only abstract 
Takagi 2013 [245] Treatment outcomes of proton or carbon ion radiation therapy for 
adenoid cystic carcinoma of the head and neck 
Only abstract 
Takahashi 2009 [170] Skull base chordomas: efficacy of surgery followed by carbon ion 
radiotherapy 
High RoB 
Takahashi 2016 [246] Changes in pulmonary function after single-fraction carbon-ion 
radiotherapy for stage I NSCLC 
Only abstract 
Takahashi 2014 [247] Prospective phase 1/2 trial of carbon ion radiation therapy for 
locally advanced non-small cell lung cancer (NSCLC) 
Only abstract 
Tian 2016 [248] Proton and Carbon ion for stage I non-small cell lung cancer: A meta 
analysis 
Only abstract 
Tsuji 2007 [171] Carbon-ion radiotherapy for locally advanced or unfavorably 
located choroidal melanoma: a Phase I/II dose-escalation study 
High RoB 
Tsujii 1999 [249] Current status of heavy ion beam therapy at NIRS Wrong language 
Tsujii 1997 [250] Preliminary results of phase I/II carbon-ion therapy at the National 
Institute of Radiological Sciences 
Wrong study design 
Tsujii 2004 [251] Overview of clinical experiences on carbon ion radiotherapy at NIRS Wrong study design 
Tuan 2013 [252] Initial clinical experience with scanned proton beams at the Italian 
National Center for Hadrontherapy (CNAO) 
Wrong intervention 
Uhl 2014 [253] Randomized phase II trial of hypofractionated proton versus carbon 
ion radiation therapy in patients with sacrococcygeal chordoma-the 
ISAC trial protocol 
Protocol 
Uhl 2014 [254] High control rate in patients with chondrosarcoma of the skull base 
after carbon ion therapy: first report of long-term results 
Wrong study design 
Uhl 2015 [255] Carbon ion beam treatment in patients with primary and recurrent 
sacrococcygeal chordoma 
Wrong study design 
Vitolo 2016 [256] Chordoma of the skull base: Initial results in a series of patients 
treated by particle therapy at the italian national center for 
oncological hadron therapy (CNAO) 
Only abstract 
Wakatsuki 2013 [257] Carbon ion radiation therapy for locally-advanced adenocarcinoma 
of the uterine cervix 
Only abstract 
Wakatsuki 2012 [258] Carbon ion radiotherapy for locally advanced adenocarcinoma of 
the uterine cervix 
Only abstract 
Wakatsuki 2015 [182] Clinical trial of prophylactic extended-field carbon-ion radiotherapy for 
locally advanced uterine cervical cancer (protocol 0508).[Erratum 
appears in PLoS One. 2015;10(11):e0143301; PMID: 26565701] 
Wrong indication 
Wakatsuki 2014 [184] Dose-escalation study of carbon ion radiotherapy for locally 
advanced squamous cell carcinoma of the uterine cervix (9902) 
Wrong indication 
Wakatsuki 2014 [185] Clinical outcomes of carbon ion radiotherapy for locally advanced 
adenocarcinoma of the uterine cervix in phase 1/2 clinical trial 
(protocol 9704) 
Wrong indication 
                                                             
136 The study used a fraction of patients (elderly) enrolled in other included studies [101, 102]. 
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Wakatsuki 2015 [183] Difference in distant failure site between locally advanced squamous 
cell carcinoma and adenocarcinoma of the uterine cervix after C-ion RT 
Wrong indication 
Wang 2016 [259] The preliminarily results of carbon ion radiotherapy in 60 patients Only abstract 
Wang 2016 [260] The clinical study on oligometastases from different tumors treated 
with carbon ions 
Only abstract 
Wild 2015 [261] [Hadron therapy in children: evidence synthesis for 15 paediatric 
tumours. Report based on Belgian (KCE) HTA report] 
HTA-Reports/ 
Systematic Reviews 
Wild 2013 [9] [Hadron therapy: proton and carbon ion therapy – a review of 
clinical evidence of efficacy, ongoing research and reimbursement] 
HTA-Reports/ 
Systematic Reviews 
Yamada 2005 [262] Phase I/II trial of carbon-ion therapy for patients with locally 
recurrent rectal cancer 
Only abstract 
Yamada 2009 [263] [Current status and perspective of heavy ion beam therapy for 
patients with pelvic recurrence after primarily resected rectal cancer] 
Wrong language 
Yamamoto 2013 [175] Carbon ion radiotherapy for oligo-recurrence in the lung High RoB 
Yamamoto 2010 [264] [Particle therapy--carbon ion radiotherapy for non-small cell lung 
cancer] 
Wrong language 
Yamamoto 2009 [265] Particle radiotherapy for malignant gliomas Wrong language 
Yanagi 2007 [266] Concomitant chemoradiotherapy with carbon ion beams for 
hypopharyngeal carcinoma – Preliminary report 
Wrong language 
Yanagi 2009 [172] Mucosal malignant melanoma of the head and neck treated by 
carbon ion radiotherapy 
High RoB 
Yanagi 2003 [267] [Heavy charged particles radiotherapy--mainly carbon ion beams] Wrong language 
Zhang 2012 [186] Results of carbon ion radiotherapy for skin carcinomas in 45 patients Wrong indication 
Zhang 2016 [268] Meta analysis of carbon ion therapy prostatic cancer Only abstract 
Zhang 2016 [269] Carbon ion radiotherapy for stage I non-small cell lung cancer:  
A Meta-analysis of 369 patients 
Only abstract 
 

  
 
